

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1p_wp044

Request ID: cder_mpl1p_wp044_cprd_v01

Request Description: We estimated the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time in the Sentinel Distributed Database (SDD), Canadian Network for Observational Drug Effect Studies (CNODES), Clinical Practice Research Datalink (CPRD), and Danish National Prescription Registry (DNPR). This report will only include the data obtained from CPRD.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) tool, version 10.1.1, with custom programming

Data Source: We distributed this query to CPRD on January 14, 2022. The study period included data from January 1, 2014 through August 25, 2020. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We defined two cohorts—incident and prevalent—to estimate the proportion of ARB utilization over time. For the incident cohort, we identified individuals over 18 years of age with incident use of eight ARB products (azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan) that had no use of any of the eight ARBs in the 183 days prior to index date (first dispensing date of each ARB), and followed them on their exposed time until any of the censoring criteria were met. Using these counts, we estimated the proportion of ARB utilization by age group, monthly and quarterly periods, which is defined as the number of episodes for each individual ARB divided by all ARB episodes occurring during the same month or quarter.

For the prevalent cohort, we identified individuals over 18 years of age with prevalent use of the eight ARBs and estimated the proportion of ARB utilization by age group, monthly, and quarterly periods as described above.

To examine the proportion of switching for patients from any of the eight primary ARBs to another ARB, angiotensin-converting-enzyme inhibitors (ACEi), calcium channel blockers (CCB) or ACEi/CCB combination drugs, we first identified the incident and prevalent cohorts for the eight ARBs as described above. Then, we defined a switch as a dispensing for another ARB; ACEi; CCB; ACEi/CCB combination; or ACEi, CCB or ACEi/CCB combination while the patients were exposed to the index ARB episode (any of the eight ARB products).

We estimated proportion of quarterly switching, which is defined as the number of ARB episodes that resulted in a switch from the index ARB to another ARB; ACEi; CCB; ACEi/CCB combination; or ACEi, CCB, or ACEi/CCB combination drug divided by the total number of all ARB index episodes during a given quarter. We also estimated proportion of total switches for each index ARB defined as total switches for each index ARB to another ARB; ACEi; CCB; ACEi/CCB combination; or ACEi, CCB, or ACEi/CCB combination divided by the total number of switches for all index ARBs.

For monthly and quarterly assessment, the episodes that cross multiple months or quarters were counted in the relevant month and quarter and the proportions for ARB utilization and switching were calculated using custom programming.

This is a Type 2 analysis using the multiple events Type 2 add-on functionality in the Query Request Package (QRP) documentation.

Overview for Request: cder_mpl1p_wp044

Exposures of Interest: For the incident and prevalent cohorts, we captured first qualifying episodes of the exposures of interest (azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, or any of the above ARBs) using Systemized Nomenclature for Medicine (SNOMED) codes within CPRD. Cohort re-entry was allowed.

Please see Appendix B for a list of generic and brand names used to define ARBs in this request.

Cohort Eligibility Criteria: For both incident and prevalent-cohorts, we required members to be enrolled in health plans with medical and drug coverage in the 183 days prior to their index date in order to be included in the cohort. A gap in coverage of up to 45 days was allowed and treated as continuous enrollment. The following age groups were included in the cohort: 18-44, 45-64, and 65+ years. The following sex groups were included in the cohort: male and female.

For the incident cohorts, we excluded patients who were exposed to any of the eight ARBs in the 183 days prior to index date. Additionally, we created prevalent cohorts that did not have this washout requirement.

Follow-up Time: For the incident and prevalent cohorts, we created exposure episodes based on the number of days of product supplied per dispensing in the outpatient pharmacy dispensing data. We bridged together episodes less than 30 days apart and added 30 days to the end of each episode. If dispensings overlapped, we allowed for a maximum of 33% overlap of the previous dispensing's days supply before truncating the previous dispensing's days' supply at the next dispensing date. If there is less than 33% overlap in the dispensings, then the next dispensing date is pushed forward to the end of the previous dispensing.

Follow-up begins on the day of the index dispensing and continues until the first occurrence of any of the following: 1) disenrollment; 2) death; 3) the end of the data provided by each Data Partner; or 4) product discontinuation.

Switching Definitions: Switching is defined using the multiple events Type 2 add-on feature in the QRP, where a "switch" is said to have occurred if a dispensing for the switch product occurs during the length of the incident or prevalent cohorts exposure episodes. The following switches are considered in this request.

For each individual index ARB exposure (azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan or valsartan), we evaluated switching from these to each of the following: 1) individual non-index ARBs (seven for each ARB); 2) any of the seven non-index ARBs; 3) non-combination ACEi drugs; 4) non-combination CCB drugs; 5) combination ACEi/CCB drugs only; and 6) ACEi, CCB or ACEi/CCB combination drugs.

We also obtained counts for exposure to any ARB (azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan or valsartan) for use as a denominator for proportion calculation.

Please see Appendix B for a list of generic and brand names used to define ARBs in this request. Please see Appendix C for a list of generic and brand names used to define ACEi, CCB, and ACEi/CCB combination drugs.

Baseline Characteristics: We assessed the following characteristics in the 183 days prior to and including the index date of the incident or prevalent cohort index dates: age, calendar year, sex, angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, and stroke. These conditions are defined in any care setting and position using Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) codes. Please see Appendix D for a list of diagnosis codes used to define baseline characteristics in this request.

Please see Appendices E and F for the parameter specifications used in the analyses.

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

Table of Contents

<u>Glossary</u>	Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module
<u>Table 1a</u>	Aggregated Baseline Table for Members Dispensed Any Incident Angiotensin Receptor Blocker (ARB)-Containing Product between January 1, 2014 and August 25, 2020
<u>Table 1b</u>	Aggregated Baseline Table for Members Dispensed Incident Azilsartan between January 1, 2014 and August 25, 2020
<u>Table 1c</u>	Aggregated Baseline Table for Members Dispensed Incident Candesartan between January 1, 2014 and August 25, 2020
<u>Table 1d</u>	Aggregated Baseline Table for Members Dispensed Incident Eprosartan between January 1, 2014 and August 25, 2020
<u>Table 1e</u>	Aggregated Baseline Table for Members Dispensed Incident Irbesartan between January 1, 2014 and August 25, 2020
<u>Table 1f</u>	Aggregated Baseline Table for Members Dispensed Incident Losartan between January 1, 2014 and August 25, 2020
<u>Table 1g</u>	Aggregated Baseline Table for Members Dispensed Incident Olmesartan between January 1, 2014 and August 25, 2020
<u>Table 1h</u>	Aggregated Baseline Table for Members Dispensed Incident Telmisartan between January 1, 2014 and August 25, 2020
<u>Table 1i</u>	Aggregated Baseline Table for Members Dispensed Incident Valsartan between January 1, 2014 and August 25, 2020
<u>Table 1j</u>	Aggregated Baseline Table for Members Dispensed Any Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product between January 1, 2014 and August 25, 2020
<u>Table 1k</u>	Aggregated Baseline Table for Members Dispensed Prevalent Azilsartan between January 1, 2014 and August 25, 2020
<u>Table 1l</u>	Aggregated Baseline Table for Members Dispensed Prevalent Candesartan between January 1, 2014 and August 25, 2020
<u>Table 1m</u>	Aggregated Baseline Table for Members Dispensed Prevalent Eprosartan between January 1, 2014 and August 25, 2020
<u>Table 1n</u>	Aggregated Baseline Table for Members Dispensed Prevalent Irbesartan between January 1, 2014 and August 25, 2020
<u>Table 1o</u>	Aggregated Baseline Table for Members Dispensed Prevalent Losartan between January 1, 2014 and August 25, 2020
<u>Table 1p</u>	Aggregated Baseline Table for Members Dispensed Prevalent Olmesartan between January 1, 2014 and August 25, 2020
<u>Table 1q</u>	Aggregated Baseline Table for Members Dispensed Prevalent Telmisartan between January 1, 2014 and August 25, 2020
<u>Table 1r</u>	Aggregated Baseline Table for Members Dispensed Prevalent Valsartan between January 1, 2014 and August 25, 2020
<u>Table 2a</u>	Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020, Overall
<u>Table 2b</u>	Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Age Group

Table of Contents

<u>Table 2c</u>	Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month
<u>Table 2d</u>	Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter
<u>Table 2e</u>	Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020, Overall
<u>Table 2f</u>	Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Age Group
<u>Table 2g</u>	Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month
<u>Table 2h</u>	Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter
<u>Table 3a</u>	Proportion of Switching for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter (Switching per 1,000 ARB Episodes)
<u>Table 3b</u>	Proportion of Switching for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter (Switching per 1,000 ARB Episodes)
<u>Table 4a</u>	Proportion of Total Switches for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Switches Reported by Year and Quarter (Switching per 1,000 ARB Switches)
<u>Table 4b</u>	Proportion of Total Switches for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Switches Reported by Year and Quarter (Switching per 1,000 ARB Switches)
<u>Appendix A</u>	Dates of Available Data for Each Data Partner (DP) as of Request End Date (August 25, 2020)
<u>Appendix B</u>	List of Generic and Brand Names of Medical Products Used to Define Angiotensin Receptor Blockers (ARBs) in this Request
<u>Appendix C</u>	List of Generic and Brand Names of Medical Products Used to Define Angiotensin-Converting-Enzyme Inhibitors (ACEi), Calcium Channel Blockers (CCB), and ACEi/CCB Combination Drugs in this Request
<u>Appendix D</u>	List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request
<u>Appendix E</u>	Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)
<u>Appendix F</u>	Specifications Defining Parameters for this Request (Cohorts used to Define Switches)

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per National Drug Code (NDC) per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Baseline Table for Members Dispensed Any Incident Angiotensin Receptor Blocker (ARB)-Containing Product between January 1, 2014 and August 25, 2020

Characteristic¹	Number	
Number of episodes	513,119	
Number of unique patients	398,450	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	66	13.5
Age	Number	Percent
18-44 years	32,478	6.3%
45-64 years	195,816	38.2%
≥ 65 years	284,825	55.5%
Sex		
Female	210,036	52.7%
Male	188,414	47.3%
Race (Unknown)	398,450	100.0%
Year		
2014	67,745	13.2%
2015	69,632	13.6%
2016	74,729	14.6%
2017	78,370	15.3%
2018	83,639	16.3%
2019	90,051	17.5%
2020	48,953	9.5%
History of Use:		
Angina	4,159	0.8%
Atrial fibrillation	13,499	2.6%
Diabetes	61,735	12.0%
Heart failure	13,114	2.6%
Hyperlipidemia	6,205	1.2%
Hypertension	185,761	36.2%
Myocardial infarction	7,842	1.5%
Renal disorders	15,204	3.0%
Stroke	9,326	1.8%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1b. Aggregated Baseline Table for Members Dispensed Incident Azilsartan between January 1, 2014 and August 25, 2020

Characteristic ¹	Number	
Number of episodes	17	
Number of unique patients	14	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	66.7	10.8
Age	Number	Percent
18-44 years	0	0.0%
45-64 years	5	29.4%
≥ 65 years	12	70.6%
Sex		
Female	9	64.3%
Male	5	35.7%
Race (Unknown)	14	100.0%
Year		
2014	*****	11.8%
2015	*****	17.6%
2016	*****	11.8%
2017	0	0.0%
2018	*****	17.6%
2019	*****	23.5%
2020	*****	17.6%
History of Use:		
Angina	0	0.0%
Atrial fibrillation	*****	11.8%
Diabetes	*****	23.5%
Heart failure	0	0.0%
Hyperlipidemia	*****	5.9%
Hypertension	6	35.3%
Myocardial infarction	0	0.0%
Renal disorders	0	0.0%
Stroke	0	0.0%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1c. Aggregated Baseline Table for Members Dispensed Incident Candesartan between January 1, 2014 and 25, 2020

August

Characteristic¹	Number	
Number of episodes	173,517	
Number of unique patients	139,150	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	66.4	13.8
Age	Number	Percent
18-44 years	11,466	6.6%
45-64 years	63,317	36.5%
≥ 65 years	98,734	56.9%
Sex		
Female	74,807	53.8%
Male	64,343	46.2%
Race (Unknown)	139,150	100.0%
Year		
2014	22,251	12.8%
2015	23,666	13.6%
2016	25,139	14.5%
2017	26,297	15.2%
2018	28,070	16.2%
2019	31,350	18.1%
2020	16,744	9.6%
History of Use:		
Angina	1,809	1.0%
Atrial fibrillation	5,632	3.2%
Diabetes	18,942	10.9%
Heart failure	6,587	3.8%
Hyperlipidemia	1,875	1.1%
Hypertension	60,945	35.1%
Myocardial infarction	3,523	2.0%
Renal disorders	4,826	2.8%
Stroke	3,271	1.9%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1d. Aggregated Baseline Table for Members Dispensed Incident Eprosartan between January 1, 2014 and August 25, 2020

Characteristic ¹	Number	
Number of episodes	1,193	
Number of unique patients	957	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	71.8	11.6
Age	Number	Percent
18-44 years	19	1.6%
45-64 years	268	22.5%
≥ 65 years	906	75.9%
Sex		
Female	527	55.1%
Male	430	44.9%
Race (Unknown)	957	100.0%
Year		
2014	202	16.9%
2015	231	19.4%
2016	175	14.7%
2017	250	21.0%
2018	131	11.0%
2019	125	10.5%
2020	79	6.6%
History of Use:		
Angina	6	0.5%
Atrial fibrillation	28	2.3%
Diabetes	141	11.8%
Heart failure	12	1.0%
Hyperlipidemia	8	0.7%
Hypertension	309	25.9%
Myocardial infarction	5	0.4%
Renal disorders	19	1.6%
Stroke	24	2.0%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1e. Aggregated Baseline Table for Members Dispensed Incident Irbesartan between January 1, 2014 and August 25, 2020

Characteristic ¹	Number	
Number of episodes	45,189	
Number of unique patients	33,923	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	65.6	13.5
Age	Number	Percent
18-44 years	3,221	7.1%
45-64 years	17,337	38.4%
≥ 65 years	24,631	54.5%
Sex		
Female	17,216	50.8%
Male	16,707	49.2%
Race (Unknown)	33,923	100.0%
Year		
2014	6,424	14.2%
2015	6,733	14.9%
2016	6,726	14.9%
2017	6,924	15.3%
2018	7,453	16.5%
2019	7,046	15.6%
2020	3,883	8.6%
History of Use:		
Angina	253	0.6%
Atrial fibrillation	879	1.9%
Diabetes	6,773	15.0%
Heart failure	488	1.1%
Hyperlipidemia	511	1.1%
Hypertension	12,848	28.4%
Myocardial infarction	322	0.7%
Renal disorders	2,079	4.6%
Stroke	713	1.6%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1f. Aggregated Baseline Table for Members Dispensed Incident Losartan between January 1, 2014 and August 25, 2020

Characteristic¹	Number	
Number of episodes	262,016	
Number of unique patients	205,513	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	65.8	13.3
	Number	Percent
Age		
18-44 years	16,346	6.2%
45-64 years	103,517	39.5%
≥ 65 years	142,153	54.3%
Sex		
Female	108,625	52.9%
Male	96,888	47.1%
Race (Unknown)	205,513	100.0%
Year		
2014	33,864	12.9%
2015	34,840	13.3%
2016	37,956	14.5%
2017	40,594	15.5%
2018	43,083	16.4%
2019	46,351	17.7%
2020	25,328	9.7%
History of Use:		
Angina	1,836	0.7%
Atrial fibrillation	6,115	2.3%
Diabetes	32,316	12.3%
Heart failure	4,514	1.7%
Hyperlipidemia	3,504	1.3%
Hypertension	102,567	39.1%
Myocardial infarction	3,644	1.4%
Renal disorders	7,506	2.9%
Stroke	4,802	1.8%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1g. Aggregated Baseline Table for Members Dispensed Incident Olmesartan between January 1, 2014 and August 25, 2020

Characteristic¹	Number	
Number of episodes	7,584	
Number of unique patients	6,154	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	67	12.4
Age	Number	Percent
18-44 years	313	4.1%
45-64 years	2,864	37.8%
≥ 65 years	4,407	58.1%
Sex		
Female	3,035	49.3%
Male	3,119	50.7%
Race (Unknown)	6,154	100.0%
Year		
2014	1,285	16.9%
2015	1,122	14.8%
2016	1,119	14.8%
2017	1,071	14.1%
2018	1,052	13.9%
2019	1,294	17.1%
2020	641	8.5%
History of Use:		
Angina	49	0.6%
Atrial fibrillation	149	2.0%
Diabetes	759	10.0%
Heart failure	57	0.8%
Hyperlipidemia	65	0.9%
Hypertension	2,511	33.1%
Myocardial infarction	49	0.6%
Renal disorders	211	2.8%
Stroke	111	1.5%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1h. Aggregated Baseline Table for Members Dispensed Incident Telmisartan between January 1, 2014 and August 25, 2020

Characteristic ¹	Number	
Number of episodes	7,901	
Number of unique patients	5,927	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	67.3	12.9
Age	Number	Percent
18-44 years	417	5.3%
45-64 years	2,786	35.3%
≥ 65 years	4,698	59.5%
Sex		
Female	3,041	51.3%
Male	2,886	48.7%
Race (Unknown)	5,927	100.0%
Year		
2014	1,142	14.5%
2015	1,104	14.0%
2016	1,159	14.7%
2017	1,175	14.9%
2018	1,355	17.1%
2019	1,205	15.3%
2020	761	9.6%
History of Use:		
Angina	64	0.8%
Atrial fibrillation	148	1.9%
Diabetes	913	11.6%
Heart failure	76	1.0%
Hyperlipidemia	87	1.1%
Hypertension	2,252	28.5%
Myocardial infarction	56	0.7%
Renal disorders	178	2.3%
Stroke	103	1.3%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1i. Aggregated Baseline Table for Members Dispensed Incident Valsartan between January 1, 2014 and August 25, 2020

Characteristic¹	Number	
Number of episodes	15,768	
Number of unique patients	12,742	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	67.1	12.6
Age	Number	Percent
18-44 years	700	4.4%
45-64 years	5,744	36.4%
≥ 65 years	9,324	59.1%
Sex		
Female	5,931	46.5%
Male	6,811	53.5%
Race (Unknown)	12,742	100.0%
Year		
2014	2,594	16.5%
2015	1,938	12.3%
2016	2,464	15.6%
2017	2,066	13.1%
2018	2,501	15.9%
2019	2,689	17.1%
2020	1,516	9.6%
History of Use:		
Angina	142	0.9%
Atrial fibrillation	547	3.5%
Diabetes	1,896	12.0%
Heart failure	1,382	8.8%
Hyperlipidemia	157	1.0%
Hypertension	4,352	27.6%
Myocardial infarction	246	1.6%
Renal disorders	387	2.5%
Stroke	302	1.9%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1j. Aggregated Baseline Table for Members Dispensed Any Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product between January 1, 2014 and August 25, 2020

Characteristic ¹	Number	
Number of episodes	3,270,823	
Number of unique patients	578,652	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	68.7	12.6
Age	Number	Percent
18-44 years	117,058	3.6%
45-64 years	1,071,346	32.8%
≥ 65 years	2,082,419	63.7%
Sex		
Female	309,543	53.5%
Male	269,109	46.5%
Race (Unknown)	578,652	100.0%
Year		
2014	379,521	11.6%
2015	422,710	12.9%
2016	467,836	14.3%
2017	504,800	15.4%
2018	545,882	16.7%
2019	577,031	17.6%
2020	373,043	11.4%
History of Use:		
Angina	26,174	0.8%
Atrial fibrillation	77,151	2.4%
Diabetes	431,132	13.2%
Heart failure	52,749	1.6%
Hyperlipidemia	29,395	0.9%
Hypertension	828,737	25.3%
Myocardial infarction	22,347	0.7%
Renal disorders	90,614	2.8%
Stroke	51,325	1.6%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1k. Aggregated Baseline Table for Members Dispensed Prevalent Azilsartan between January 1, 2014 and August 25, 2020

Characteristic ¹	Number	
Number of episodes	171	
Number of unique patients	30	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	68.6	13.8
Age	Number	Percent
18-44 years	6	3.5%
45-64 years	60	35.1%
≥ 65 years	105	61.4%
Sex		
Female	23	76.7%
Male	7	23.3%
Race (Unknown)	30	100.0%
Year		
2014	18	10.5%
2015	29	17.0%
2016	32	18.7%
2017	23	13.5%
2018	29	17.0%
2019	20	11.7%
2020	20	11.7%
History of Use:		
Angina	0	0.0%
Atrial fibrillation	6	3.5%
Diabetes	34	19.9%
Heart failure	*****	0.6%
Hyperlipidemia	*****	1.8%
Hypertension	61	35.7%
Myocardial infarction	*****	1.2%
Renal disorders	8	4.7%
Stroke	*****	2.3%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1I. Aggregated Baseline Table for Members Dispensed Prevalent Candesartan between January 1, 2014 and August 25, 2020

Characteristic¹	Number	
Number of episodes	1,117,827	
Number of unique patients	207,004	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	69.3	12.6
Age	Number	Percent
18-44 years	37,216	3.3%
45-64 years	347,749	31.1%
≥ 65 years	732,862	65.6%
Sex		
Female	112,627	54.4%
Male	94,377	45.6%
Race (Unknown)	207,004	100.0%
Year		
2014	127,683	11.4%
2015	143,687	12.9%
2016	159,827	14.3%
2017	172,737	15.5%
2018	186,220	16.7%
2019	199,146	17.8%
2020	128,527	11.5%
History of Use:		
Angina	10,951	1.0%
Atrial fibrillation	30,924	2.8%
Diabetes	137,381	12.3%
Heart failure	25,635	2.3%
Hyperlipidemia	9,411	0.8%
Hypertension	280,049	25.1%
Myocardial infarction	9,545	0.9%
Renal disorders	30,122	2.7%
Stroke	18,325	1.6%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1m. Aggregated Baseline Table for Members Dispensed Prevalent Eprosartan between January 1, 2014 and August 25, 2020

Characteristic ¹	Number	
Number of episodes	12,957	
Number of unique patients	2,215	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	72.8	10.7
Age	Number	Percent
18-44 years	83	0.6%
45-64 years	2,755	21.3%
≥ 65 years	10,119	78.1%
Sex		
Female	1,250	56.4%
Male	965	43.6%
Race (Unknown)	2,215	100.0%
Year		
2014	2,317	17.9%
2015	2,286	17.6%
2016	2,291	17.7%
2017	1,981	15.3%
2018	1,639	12.6%
2019	1,515	11.7%
2020	928	7.2%
History of Use:		
Angina	84	0.6%
Atrial fibrillation	302	2.3%
Diabetes	1,780	13.7%
Heart failure	75	0.6%
Hyperlipidemia	78	0.6%
Hypertension	3,371	26.0%
Myocardial infarction	43	0.3%
Renal disorders	348	2.7%
Stroke	202	1.6%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1n. Aggregated Baseline Table for Members Dispensed Prevalent Irbesartan between January 1, 2014 and August 25, 2020

Characteristic ¹	Number	
Number of episodes	334,601	
Number of unique patients	56,805	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	68.3	12.6
Age	Number	Percent
18-44 years	13,706	4.1%
45-64 years	111,651	33.4%
≥ 65 years	209,244	62.5%
Sex		
Female	29,510	51.9%
Male	27,295	48.1%
Race (Unknown)	56,805	100.0%
Year		
2014	44,272	13.2%
2015	47,129	14.1%
2016	49,839	14.9%
2017	51,904	15.5%
2018	53,526	16.0%
2019	54,042	16.2%
2020	33,889	10.1%
History of Use:		
Angina	2,434	0.7%
Atrial fibrillation	6,847	2.0%
Diabetes	55,494	16.6%
Heart failure	3,264	1.0%
Hyperlipidemia	3,082	0.9%
Hypertension	73,058	21.8%
Myocardial infarction	1,417	0.4%
Renal disorders	12,891	3.9%
Stroke	5,234	1.6%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1o. Aggregated Baseline Table for Members Dispensed Prevalent Losartan between January 1, 2014 and August 25, 2020

Characteristic¹	Number	
Number of episodes	1,580,156	
Number of unique patients	293,039	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	68.2	12.7
Age	Number	Percent
18-44 years	60,010	3.8%
45-64 years	539,152	34.1%
≥ 65 years	980,994	62.1%
Sex		
Female	157,027	53.6%
Male	136,012	46.4%
Race (Unknown)	293,039	100.0%
Year		
2014	173,389	11.0%
2015	196,540	12.4%
2016	221,778	14.0%
2017	245,504	15.5%
2018	269,536	17.1%
2019	286,912	18.2%
2020	186,497	11.8%
History of Use:		
Angina	11,104	0.7%
Atrial fibrillation	34,140	2.2%
Diabetes	208,642	13.2%
Heart failure	19,356	1.2%
Hyperlipidemia	15,034	1.0%
Hypertension	420,265	26.6%
Myocardial infarction	10,305	0.7%
Renal disorders	41,537	2.6%
Stroke	24,307	1.5%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1p. Aggregated Baseline Table for Members Dispensed Prevalent Olmesartan between January 1, 2014 and August 25, 2020

Characteristic¹	Number	
Number of episodes	75,319	
Number of unique patients	13,067	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	69.3	11.6
Age	Number	Percent
18-44 years	1,635	2.2%
45-64 years	24,021	31.9%
≥ 65 years	49,663	65.9%
Sex		
Female	6,706	51.3%
Male	6,361	48.7%
Race (Unknown)	13,067	100.0%
Year		
2014	11,981	15.9%
2015	11,409	15.1%
2016	11,056	14.7%
2017	10,863	14.4%
2018	11,075	14.7%
2019	11,705	15.5%
2020	7,230	9.6%
History of Use:		
Angina	376	0.5%
Atrial fibrillation	1,315	1.7%
Diabetes	8,502	11.3%
Heart failure	379	0.5%
Hyperlipidemia	609	0.8%
Hypertension	19,234	25.5%
Myocardial infarction	218	0.3%
Renal disorders	2,031	2.7%
Stroke	890	1.2%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1q. Aggregated Baseline Table for Members Dispensed Prevalent Telmisartan between January 1, 2014 and August 25, 2020

Characteristic ¹	Number	
Number of episodes	61,814	
Number of unique patients	10,865	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	69.9	11.9
Age	Number	Percent
18-44 years	1,744	2.8%
45-64 years	17,896	29.0%
≥ 65 years	42,174	68.2%
Sex		
Female	5,711	52.6%
Male	5,154	47.4%
Race (Unknown)	10,865	100.0%
Year		
2014	8,549	13.8%
2015	8,817	14.3%
2016	9,125	14.8%
2017	9,452	15.3%
2018	9,929	16.1%
2019	9,669	15.6%
2020	6,273	10.1%
History of Use:		
Angina	447	0.7%
Atrial fibrillation	1,291	2.1%
Diabetes	7,859	12.7%
Heart failure	513	0.8%
Hyperlipidemia	525	0.8%
Hypertension	13,483	21.8%
Myocardial infarction	249	0.4%
Renal disorders	1,493	2.4%
Stroke	829	1.3%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1r. Aggregated Baseline Table for Members Dispensed Prevalent Valsartan between January 1, 2014 and August 25, 2020

Characteristic ¹	Number	
Number of episodes	100,075	
Number of unique patients	23,580	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	69.1	12
	Number	Percent
18-44 years	2,928	2.9%
45-64 years	31,268	31.2%
≥ 65 years	65,879	65.8%
Sex		
Female	11,688	49.6%
Male	11,892	50.4%
Race (Unknown)	23,580	100.0%
Year		
2014	16,362	16.3%
2015	13,960	13.9%
2016	15,103	15.1%
2017	13,588	13.6%
2018	15,238	15.2%
2019	15,697	15.7%
2020	10,127	10.1%
History of Use:		
Angina	920	0.9%
Atrial fibrillation	2,750	2.7%
Diabetes	13,115	13.1%
Heart failure	3,920	3.9%
Hyperlipidemia	755	0.8%
Hypertension	23,967	23.9%
Myocardial infarction	750	0.7%
Renal disorders	2,647	2.6%
Stroke	1,764	1.8%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 2a. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020, Overall

	New Users	Eligible Members ¹	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ¹	Eligible Member Years ¹	Proportion of All ARB Use ²
ARB												
<i>Incident ARB episodes</i>												
	398,450	4,307,021	513,119	78,569,803	215,112.4	1,734,541	1,773,218	58,313,065	61,543,826	7,426,648,251	20,333,054.8	1.00
Azilsartan												
<i>Incident Azilsartan episodes</i>												
	14	4,307,021	17	2,145	5.9	37	37	1,541	1,681	7,426,648,251	20,333,054.8	0.00
Candesartan												
<i>Incident Candesartan episodes</i>												
	139,150	4,307,021	173,517	26,925,844	73,718.9	605,903	627,149	20,003,564	21,077,192	7,426,648,251	20,333,054.8	0.34
Eprosartan												
<i>Incident Eprosartan episodes</i>												
	957	4,307,021	1,193	169,297	463.5	4,003	4,013	120,864	143,188	7,426,648,251	20,333,054.8	0.00
Irbesartan												
<i>Incident Irbesartan episodes</i>												
	33,923	4,307,021	45,189	6,766,617	18,526.0	142,152	143,114	5,007,562	5,406,222	7,426,648,251	20,333,054.8	0.09
Losartan												
<i>Incident Losartan episodes</i>												
	205,513	4,307,021	262,016	39,822,040	109,026.8	870,572	885,421	29,513,681	30,610,982	7,426,648,251	20,333,054.8	0.51
Olmesartan												
<i>Incident Olmesartan episodes</i>												
	6,154	4,307,021	7,584	1,132,047	3,099.4	26,233	26,522	818,799	841,420	7,426,648,251	20,333,054.8	0.01
Telmisartan												
<i>Incident Telmisartan episodes</i>												
	5,927	4,307,021	7,901	1,154,510	3,160.9	22,749	22,886	857,398	913,476	7,426,648,251	20,333,054.8	0.02
Valsartan												
<i>Incident Valsartan episodes</i>												
	12,742	4,307,021	15,768	2,133,976	5,842.5	46,101	46,816	1,537,822	2,076,256	7,426,648,251	20,333,054.8	0.03

¹Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on

²Proportion of ARB use estimated as number of episodes for each individual ARB divided by all ARB episodes

Table 2b. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Age Group

Age Group	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
<i>Incident ARB episodes</i>												
18-44 years	26,063	713,415	32,478	4,302,941	11,780.8	82,538	84,545	3,132,905	3,358,564	941,889,989	2,578,754.2	1.00
45-64 years	150,633	1,961,830	195,816	29,140,407	79,782.1	567,166	579,225	21,755,444	23,019,310	2,956,250,836	8,093,773.7	1.00
More than 65 years	229,971	2,364,963	284,825	45,126,455	123,549.5	1,084,837	1,109,448	33,424,716	35,165,951	3,528,507,426	9,660,526.8	1.00
Azilsartan												
<i>Incident Azilsartan episodes</i>												
18-44 years	0	713,415	0	0	0.0	0	0	0	0	941,889,989	2,578,754.2	0.00
45-64 years	*****	1,961,830	*****	493	1.3	12	12	310	338	2,956,250,836	8,093,773.7	0.00
More than 65 years	*****	2,364,963	12	1,652	4.5	25	25	1,231	1,343	3,528,507,426	9,660,526.8	0.00
Candesartan												
<i>Incident Candesartan episodes</i>												
18-44 years	9,663	713,415	11,466	1,506,790	4,125.4	30,265	31,564	1,092,158	1,208,277	941,889,989	2,578,754.2	0.35
45-64 years	50,193	1,961,830	63,317	9,584,849	26,241.9	190,938	197,584	7,170,226	7,562,130	2,956,250,836	8,093,773.7	0.32
More than 65 years	81,652	2,364,963	98,734	15,834,205	43,351.7	384,700	398,001	11,741,180	12,306,784	3,528,507,426	9,660,526.8	0.35
Eprosartan												
<i>Incident Eprosartan episodes</i>												
18-44 years	17	713,415	19	2,607	7.1	50	50	1,863	2,828	941,889,989	2,578,754.2	0.00
45-64 years	207	1,961,830	268	39,245	107.4	738	739	28,538	34,412	2,956,250,836	8,093,773.7	0.00
More than 65 years	747	2,364,963	906	127,445	348.9	3,215	3,224	90,463	105,948	3,528,507,426	9,660,526.8	0.00
Irbesartan												
<i>Incident Irbesartan episodes</i>												
18-44 years	2,426	713,415	3,221	429,790	1,176.7	8,074	8,107	311,882	348,410	941,889,989	2,578,754.2	0.10
45-64 years	12,873	1,961,830	17,337	2,545,105	6,968.1	47,253	47,539	1,893,842	2,058,343	2,956,250,836	8,093,773.7	0.09
More than 65 years	19,464	2,364,963	24,631	3,791,722	10,381.2	86,825	87,468	2,801,838	2,999,470	3,528,507,426	9,660,526.8	0.09
Losartan												
<i>Incident Losartan episodes</i>												
18-44 years	13,063	713,415	16,346	2,173,939	5,951.9	40,285	40,884	1,586,384	1,633,081	941,889,989	2,578,754.2	0.50
45-64 years	80,306	1,961,830	103,517	15,256,142	41,769.0	293,567	298,241	11,370,590	11,838,079	2,956,250,836	8,093,773.7	0.53
More than 65 years	116,199	2,364,963	142,153	22,391,959	61,305.8	536,720	546,296	16,556,707	17,139,822	3,528,507,426	9,660,526.8	0.50
Olmesartan												
<i>Incident Olmesartan episodes</i>												
18-44 years	254	713,415	313	37,147	101.7	711	727	25,832	28,028	941,889,989	2,578,754.2	0.01
45-64 years	2,315	1,961,830	2,864	410,418	1,123.7	8,142	8,225	297,751	313,469	2,956,250,836	8,093,773.7	0.01
More than 65 years	3,693	2,364,963	4,407	684,482	1,874.0	17,380	17,570	495,216	499,923	3,528,507,426	9,660,526.8	0.02

Table 2b. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Age Group

Age Group	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Telmisartan												
<i>Incident Telmisartan episodes</i>												
18-44 years	337	713,415	417	50,802	139.1	842	848	36,588	38,930	941,889,989	2,578,754.2	0.01
45-64 years	2,074	1,961,830	2,786	397,703	1,088.9	6,752	6,787	297,924	311,349	2,956,250,836	8,093,773.7	0.01
More than 65 years	3,666	2,364,963	4,698	706,005	1,932.9	15,155	15,251	522,886	563,197	3,528,507,426	9,660,526.8	0.02
Valsartan												
<i>Incident Valsartan episodes</i>												
18-44 years	599	713,415	700	81,271	222.5	1,528	1,558	57,065	76,435	941,889,989	2,578,754.2	0.02
45-64 years	4,638	1,961,830	5,744	756,355	2,070.8	15,017	15,248	547,173	743,370	2,956,250,836	8,093,773.7	0.03
More than 65 years	7,722	2,364,963	9,324	1,296,350	3,549.2	29,556	30,010	933,584	1,256,451	3,528,507,426	9,660,526.8	0.03

¹Total number of users by age group may not sum up to total patients in Table 1 because cohort re-entry was allowed, enabling multiple counts for patients with multiple ARB episodes during the study period

²Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

³Proportion of ARB use estimated as number of episodes for each individual ARB in specified age group divided by all ARB episodes in the same age group

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
<i>Incident ARB episodes</i>												
2014												
January	5,723	3,297,185	5,723	978,824	2,679.9	21,775	22,304	736,237	740,719	101,664,226	278,341.5	1.00
February	11,148	3,289,812	11,148	911,141	2,494.6	19,601	20,325	682,214	696,910	91,672,932	250,986.8	1.00
March	17,333	3,286,611	17,333	1,049,926	2,874.5	22,427	22,782	783,449	789,729	101,333,877	277,437.0	1.00
April	21,836	3,281,387	21,836	1,004,912	2,751.3	21,776	22,497	758,610	754,901	97,930,055	268,117.9	1.00
May	24,986	3,278,790	24,986	998,062	2,732.5	21,359	21,769	755,327	730,436	101,099,410	276,795.1	1.00
June	26,821	3,272,221	26,821	958,484	2,624.2	20,503	20,937	724,538	714,793	97,720,653	267,544.6	1.00
July	28,738	3,270,908	28,738	984,428	2,695.2	21,126	21,469	741,484	721,530	100,807,406	275,995.6	1.00
August	29,045	3,268,948	29,045	875,459	2,396.9	19,626	20,010	659,316	647,797	100,787,406	275,940.9	1.00
September	29,977	3,266,769	29,977	999,629	2,736.8	23,465	23,944	754,952	718,188	97,500,274	266,941.2	1.00
October	30,898	3,265,787	30,898	1,005,525	2,753.0	22,395	22,913	764,950	722,660	100,655,643	275,580.1	1.00
November	31,071	3,262,170	31,071	939,799	2,573.0	21,538	21,840	711,029	668,017	97,331,354	266,478.7	1.00
December	32,125	3,260,343	32,125	1,008,518	2,761.2	22,180	22,691	757,896	746,102	100,477,755	275,093.1	1.00
2015												
January	32,657	3,257,558	32,657	962,708	2,635.8	21,419	22,184	724,702	732,488	100,370,700	274,800.0	1.00
February	32,537	3,250,942	32,537	901,657	2,468.6	20,358	20,888	672,817	677,666	90,530,323	247,858.5	1.00
March	33,944	3,247,072	33,944	1,001,063	2,740.8	22,433	22,967	736,580	766,400	100,090,395	274,032.6	1.00
April	34,347	3,243,212	34,347	907,253	2,483.9	20,657	21,273	672,897	699,731	96,768,486	264,937.7	1.00
May	34,310	3,240,539	34,310	898,725	2,460.6	20,569	20,999	666,731	689,891	99,920,089	273,566.3	1.00
June	34,816	3,235,765	34,816	1,018,819	2,789.4	23,897	24,534	754,980	773,779	96,605,138	264,490.5	1.00
July	35,816	3,233,520	35,816	998,742	2,734.4	22,181	22,788	741,190	768,550	99,654,079	272,838.0	1.00
August	35,408	3,229,783	35,408	892,663	2,444.0	20,398	20,787	661,864	691,406	99,592,205	272,668.6	1.00
September	35,927	3,227,540	35,927	1,002,585	2,744.9	22,616	23,336	747,250	776,579	96,308,333	263,677.8	1.00
October	36,103	3,223,729	36,103	987,156	2,702.7	22,920	23,443	728,560	762,353	99,353,099	272,014.0	1.00
November	36,428	3,216,466	36,428	1,001,962	2,743.2	23,179	23,719	739,408	772,712	95,985,749	262,794.7	1.00
December	37,608	3,211,593	37,608	1,010,903	2,767.7	23,173	23,817	746,168	772,653	98,996,173	271,036.8	1.00

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
2016												
January	37,385	3,206,673	37,385	948,555	2,597.0	21,093	21,641	705,820	733,234	98,859,950	270,663.8	1.00
February	37,506	3,200,849	37,506	988,471	2,706.3	22,090	22,599	729,377	759,411	92,325,977	252,774.7	1.00
March	38,460	3,198,010	38,460	1,066,643	2,920.3	23,914	24,463	790,062	829,173	98,506,902	269,697.2	1.00
April	38,388	3,191,342	38,388	1,008,548	2,761.3	21,560	21,930	747,472	776,243	95,181,466	260,592.7	1.00
May	38,432	3,185,415	38,432	996,014	2,726.9	21,796	22,217	737,863	777,686	98,227,543	268,932.4	1.00
June	38,782	3,180,394	38,782	1,046,516	2,865.2	23,395	23,995	778,525	815,925	94,918,361	259,872.3	1.00
July	38,785	3,175,382	38,785	1,015,882	2,781.3	22,708	23,277	753,923	790,151	97,900,577	268,037.2	1.00
August	39,149	3,173,558	39,149	1,050,445	2,876.0	23,372	23,953	779,576	814,335	97,828,414	267,839.6	1.00
September	39,145	3,168,107	39,145	1,021,523	2,796.8	23,424	23,961	753,993	800,175	94,515,334	258,768.9	1.00
October	39,136	3,160,553	39,136	993,925	2,721.2	22,874	23,432	732,080	783,710	97,450,754	266,805.6	1.00
November	39,708	3,154,494	39,708	1,077,295	2,949.5	24,737	25,309	797,283	847,606	94,118,283	257,681.8	1.00
December	39,513	3,149,605	39,513	971,550	2,660.0	22,295	22,879	717,878	753,366	97,040,729	265,683.0	1.00
2017												
January	39,394	3,143,891	39,394	1,040,645	2,849.1	23,428	24,157	773,996	812,336	96,903,658	265,307.8	1.00
February	39,280	3,135,363	39,280	936,273	2,563.4	21,004	21,459	686,382	728,399	87,322,336	239,075.5	1.00
March	40,431	3,131,348	40,431	1,123,655	3,076.4	25,125	25,732	827,929	875,803	96,465,809	264,109.0	1.00
April	39,764	3,123,891	39,764	970,660	2,657.5	21,497	21,978	718,824	759,873	93,219,115	255,220.0	1.00
May	40,669	3,120,599	40,669	1,103,013	3,019.9	23,893	24,429	815,163	860,734	96,167,020	263,291.0	1.00
June	40,838	3,111,883	40,838	1,076,431	2,947.1	23,552	24,049	795,024	843,997	92,881,687	254,296.2	1.00
July	41,037	3,105,920	41,037	1,033,836	2,830.5	22,565	23,030	762,812	810,826	95,751,818	262,154.2	1.00
August	41,466	3,101,932	41,466	1,044,086	2,858.6	23,199	23,760	767,697	820,721	95,590,652	261,712.9	1.00
September	40,890	3,096,663	40,890	1,015,076	2,779.1	22,966	23,518	749,294	800,327	92,355,306	252,855.0	1.00
October	41,305	3,090,326	41,305	1,084,127	2,968.2	24,305	24,942	799,485	851,993	95,247,522	260,773.5	1.00
November	41,866	3,083,437	41,866	1,089,899	2,984.0	24,310	24,815	802,874	854,221	91,972,641	251,807.4	1.00
December	41,355	3,075,872	41,355	999,139	2,735.5	21,728	22,270	738,131	790,674	94,796,824	259,539.6	1.00

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
2018												
January	42,289	3,071,078	42,289	1,162,423	3,182.5	25,072	25,763	855,532	933,540	94,581,266	258,949.4	1.00
February	41,846	3,059,869	41,846	1,031,133	2,823.1	23,514	23,961	756,387	818,535	85,186,366	233,227.6	1.00
March	42,711	3,052,381	42,711	1,116,339	3,056.4	24,014	24,544	821,663	882,817	94,003,330	257,367.1	1.00
April	42,396	3,043,656	42,396	1,064,395	2,914.2	22,485	22,983	784,674	846,228	90,739,857	248,432.2	1.00
May	43,583	3,036,173	43,583	1,157,441	3,168.9	25,501	26,093	855,702	916,433	93,544,468	256,110.8	1.00
June	43,097	3,027,432	43,097	1,090,900	2,986.7	23,638	24,208	807,291	868,069	90,334,252	247,321.7	1.00
July	43,131	3,020,706	43,131	1,089,432	2,982.7	24,303	24,855	802,684	866,188	93,109,745	254,920.6	1.00
August	43,515	3,015,323	43,515	1,062,507	2,909.0	22,274	22,768	783,964	853,749	92,902,777	254,353.9	1.00
September	42,500	3,006,456	42,500	995,626	2,725.9	21,326	21,857	737,603	796,318	89,696,384	245,575.3	1.00
October	43,329	3,000,750	43,329	1,142,991	3,129.3	24,688	25,184	837,969	912,973	92,446,983	253,106.0	1.00
November	43,309	2,987,121	43,309	1,118,742	3,062.9	24,264	24,825	823,978	894,113	88,963,329	243,568.3	1.00
December	43,053	2,969,626	43,053	1,006,049	2,754.4	21,213	21,665	739,353	813,771	91,530,460	250,596.7	1.00
2019												
January	44,192	2,965,054	44,192	1,163,898	3,186.6	24,648	25,112	858,885	939,266	91,327,091	250,039.9	1.00
February	43,499	2,953,382	43,499	1,017,931	2,786.9	21,895	22,568	751,598	817,809	81,759,088	223,844.2	1.00
March	45,359	2,927,088	45,359	1,336,871	3,660.2	30,186	30,891	978,550	1,056,109	90,115,768	246,723.5	1.00
April	46,398	2,917,535	46,398	1,234,495	3,379.9	26,543	27,119	911,055	987,148	86,969,965	238,110.8	1.00
May	47,546	2,910,874	47,546	1,188,585	3,254.2	24,880	25,333	876,263	950,602	89,637,349	245,413.7	1.00
June	46,683	2,899,491	46,683	1,021,676	2,797.2	21,134	21,457	751,000	820,304	86,212,923	236,038.1	1.00
July	47,018	2,879,468	47,018	1,165,076	3,189.8	24,634	25,098	864,658	944,938	88,558,118	242,458.9	1.00
August	46,437	2,863,402	46,437	1,028,480	2,815.8	21,756	22,083	759,544	825,417	88,137,267	241,306.7	1.00
September	45,491	2,850,741	45,491	1,024,471	2,804.8	21,331	21,686	759,453	830,514	84,844,147	232,290.6	1.00
October	46,286	2,832,757	46,286	1,075,035	2,943.3	22,867	23,355	790,588	864,474	87,147,743	238,597.5	1.00
November	45,849	2,818,207	45,849	998,000	2,732.4	21,103	21,541	737,219	809,128	83,892,433	229,685.0	1.00
December	45,531	2,801,822	45,531	927,464	2,539.3	19,576	19,877	682,410	750,114	86,316,754	236,322.4	1.00

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
<i>2020</i>												
January	46,385	2,795,508	46,385	969,299	2,653.8	20,259	20,570	720,292	795,548	86,071,408	235,650.7	1.00
February	45,515	2,782,568	45,515	827,716	2,266.2	17,753	17,987	611,815	684,386	79,850,616	218,619.1	1.00
March	46,583	2,750,794	46,583	944,411	2,585.7	19,616	19,823	698,341	784,937	84,378,043	231,014.5	1.00
April	44,970	2,720,142	44,970	539,690	1,477.6	11,621	11,730	403,342	452,046	80,929,734	221,573.5	1.00
May	42,833	2,703,358	42,833	440,650	1,206.4	9,773	9,860	334,983	376,875	83,331,436	228,149.0	1.00
June	40,863	2,696,022	40,863	369,447	1,011.5	9,284	9,361	294,288	341,447	80,421,992	220,183.4	1.00
July	39,280	2,689,586	39,280	213,394	584.2	7,035	7,076	193,555	229,124	82,588,413	226,114.8	1.00
August	36,382	2,664,992	36,382	44,086	120.7	3,954	3,974	43,814	53,994	58,413,396	159,927.2	1.00
Azilsartan												
<i>Incident Azilsartan episodes</i>												
<i>2014</i>												
January	0	3,297,185	0	0	0.0	0	0	0	0	101,664,226	278,341.5	0.00
February	0	3,289,812	0	0	0.0	0	0	0	0	91,672,932	250,986.8	0.00
March	0	3,286,611	0	0	0.0	0	0	0	0	101,333,877	277,437.0	0.00
April	0	3,281,387	0	0	0.0	0	0	0	0	97,930,055	268,117.9	0.00
May	0	3,278,790	0	0	0.0	0	0	0	0	101,099,410	276,795.1	0.00
June	0	3,272,221	0	0	0.0	0	0	0	0	97,720,653	267,544.6	0.00
July	0	3,270,908	0	0	0.0	0	0	0	0	100,807,406	275,995.6	0.00
August	0	3,268,948	0	0	0.0	0	0	0	0	100,787,406	275,940.9	0.00
September	*****	3,266,769	*****	58	0.2	*****	*****	28	56	97,500,274	266,941.2	0.00
October	*****	3,265,787	*****	0	0.0	0	0	0	0	100,655,643	275,580.1	0.00
November	*****	3,262,170	*****	58	0.2	*****	*****	28	28	97,331,354	266,478.7	0.00
December	*****	3,260,343	*****	0	0.0	0	0	0	0	100,477,755	275,093.1	0.00

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Azilsartan												
2015												
January	*****	3,257,558	*****	0	0.0	0	0	0	0	100,370,700	274,800.0	0.00
February	0	3,250,942	0	0	0.0	0	0	0	0	90,530,323	247,858.5	0.00
March	*****	3,247,072	*****	246	0.7	6	6	168	168	100,090,395	274,032.6	0.00
April	*****	3,243,212	*****	0	0.0	0	0	0	0	96,768,486	264,937.7	0.00
May	*****	3,240,539	*****	0	0.0	0	0	0	0	99,920,089	273,566.3	0.00
June	*****	3,235,765	*****	0	0.0	0	0	0	0	96,605,138	264,490.5	0.00
July	*****	3,233,520	*****	86	0.2	*****	*****	56	56	99,654,079	272,838.0	0.00
August	*****	3,229,783	*****	0	0.0	0	0	0	0	99,592,205	272,668.6	0.00
September	*****	3,227,540	*****	0	0.0	0	0	0	0	96,308,333	263,677.8	0.00
October	*****	3,223,729	*****	0	0.0	0	0	0	0	99,353,099	272,014.0	0.00
November	0	3,216,466	0	0	0.0	0	0	0	0	95,985,749	262,794.7	0.00
December	0	3,211,593	0	0	0.0	0	0	0	0	98,996,173	271,036.8	0.00
2016												
January	0	3,206,673	0	0	0.0	0	0	0	0	98,859,950	270,663.8	0.00
February	0	3,200,849	0	0	0.0	0	0	0	0	92,325,977	252,774.7	0.00
March	0	3,198,010	0	0	0.0	0	0	0	0	98,506,902	269,697.2	0.00
April	0	3,191,342	0	0	0.0	0	0	0	0	95,181,466	260,592.7	0.00
May	*****	3,185,415	*****	86	0.2	*****	*****	56	56	98,227,543	268,932.4	0.00
June	*****	3,180,394	*****	0	0.0	0	0	0	0	94,918,361	259,872.3	0.00
July	*****	3,175,382	*****	0	0.0	0	0	0	0	97,900,577	268,037.2	0.00
August	*****	3,173,558	*****	0	0.0	0	0	0	0	97,828,414	267,839.6	0.00
September	*****	3,168,107	*****	66	0.2	*****	*****	36	36	94,515,334	258,768.9	0.00
October	*****	3,160,553	*****	0	0.0	0	0	0	0	97,450,754	266,805.6	0.00
November	*****	3,154,494	*****	0	0.0	0	0	0	0	94,118,283	257,681.8	0.00
December	0	3,149,605	0	0	0.0	0	0	0	0	97,040,729	265,683.0	0.00

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Azilsartan												
2017												
January	0	3,143,891	0	0	0.0	0	0	0	0	96,903,658	265,307.8	0.00
February	0	3,135,363	0	0	0.0	0	0	0	0	87,322,336	239,075.5	0.00
March	0	3,131,348	0	0	0.0	0	0	0	0	96,465,809	264,109.0	0.00
April	0	3,123,891	0	0	0.0	0	0	0	0	93,219,115	255,220.0	0.00
May	0	3,120,599	0	0	0.0	0	0	0	0	96,167,020	263,291.0	0.00
June	0	3,111,883	0	0	0.0	0	0	0	0	92,881,687	254,296.2	0.00
July	0	3,105,920	0	0	0.0	0	0	0	0	95,751,818	262,154.2	0.00
August	0	3,101,932	0	0	0.0	0	0	0	0	95,590,652	261,712.9	0.00
September	0	3,096,663	0	0	0.0	0	0	0	0	92,355,306	252,855.0	0.00
October	0	3,090,326	0	0	0.0	0	0	0	0	95,247,522	260,773.5	0.00
November	0	3,083,437	0	0	0.0	0	0	0	0	91,972,641	251,807.4	0.00
December	0	3,075,872	0	0	0.0	0	0	0	0	94,796,824	259,539.6	0.00
2018												
January	0	3,071,078	0	0	0.0	0	0	0	0	94,581,266	258,949.4	0.00
February	0	3,059,869	0	0	0.0	0	0	0	0	85,186,366	233,227.6	0.00
March	*****	3,052,381	*****	502	1.4	*****	*****	420	420	94,003,330	257,367.1	0.00
April	*****	3,043,656	*****	0	0.0	0	0	0	0	90,739,857	248,432.2	0.00
May	*****	3,036,173	*****	0	0.0	0	0	0	0	93,544,468	256,110.8	0.00
June	*****	3,027,432	*****	0	0.0	0	0	0	0	90,334,252	247,321.7	0.00
July	*****	3,020,706	*****	0	0.0	0	0	0	0	93,109,745	254,920.6	0.00
August	*****	3,015,323	*****	0	0.0	0	0	0	0	92,902,777	254,353.9	0.00
September	*****	3,006,456	*****	0	0.0	0	0	0	0	89,696,384	245,575.3	0.00
October	*****	3,000,750	*****	200	0.5	*****	*****	140	140	92,446,983	253,106.0	0.00
November	*****	2,987,121	*****	0	0.0	0	0	0	0	88,963,329	243,568.3	0.00
December	*****	2,969,626	*****	0	0.0	0	0	0	0	91,530,460	250,596.7	0.00

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Azilsartan												
2019												
January	*****	2,965,054	*****	0	0.0	0	0	0	0	91,327,091	250,039.9	0.00
February	*****	2,953,382	*****	0	0.0	0	0	0	0	81,759,088	223,844.2	0.00
March	*****	2,927,088	*****	0	0.0	0	0	0	0	90,115,768	246,723.5	0.00
April	*****	2,917,535	*****	0	0.0	0	0	0	0	86,969,965	238,110.8	0.00
May	*****	2,910,874	*****	58	0.2	*****	*****	28	56	89,637,349	245,413.7	0.00
June	*****	2,899,491	*****	0	0.0	0	0	0	0	86,212,923	236,038.1	0.00
July	*****	2,879,468	*****	0	0.0	0	0	0	0	88,558,118	242,458.9	0.00
August	*****	2,863,402	*****	142	0.4	*****	*****	112	112	88,137,267	241,306.7	0.00
September	*****	2,850,741	*****	338	0.9	6	6	299	299	84,844,147	232,290.6	0.00
October	*****	2,832,757	*****	192	0.5	*****	*****	112	112	87,147,743	238,597.5	0.00
November	*****	2,818,207	*****	0	0.0	0	0	0	0	83,892,433	229,685.0	0.00
December	*****	2,801,822	*****	0	0.0	0	0	0	0	86,316,754	236,322.4	0.00
2020												
January	*****	2,795,508	*****	0	0.0	0	0	0	0	86,071,408	235,650.7	0.00
February	*****	2,782,568	*****	0	0.0	0	0	0	0	79,850,616	218,619.1	0.00
March	*****	2,750,794	*****	58	0.2	*****	*****	28	112	84,378,043	231,014.5	0.00
April	*****	2,720,142	*****	0	0.0	0	0	0	0	80,929,734	221,573.5	0.00
May	*****	2,703,358	*****	0	0.0	0	0	0	0	83,331,436	228,149.0	0.00
June	*****	2,696,022	*****	0	0.0	0	0	0	0	80,421,992	220,183.4	0.00
July	*****	2,689,586	*****	53	0.1	*****	*****	28	28	82,588,413	226,114.8	0.00
August	*****	2,664,992	*****	2	0.0	*****	*****	2	2	58,413,396	159,927.2	0.00

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Candesartan												
<i>Incident Candesartan episodes</i>												
2014												
January	1,817	3,297,185	1,817	318,723	872.6	7,234	7,527	241,529	230,342	101,664,226	278,341.5	0.32
February	3,432	3,289,812	3,432	281,598	771.0	6,114	6,472	213,328	209,772	91,672,932	250,986.8	0.31
March	5,395	3,286,611	5,395	337,889	925.1	7,576	7,783	249,516	250,508	101,333,877	277,437.0	0.31
April	6,884	3,281,387	6,884	336,087	920.2	7,030	7,347	255,352	251,393	97,930,055	268,117.9	0.32
May	7,936	3,278,790	7,936	345,179	945.0	7,523	7,744	263,842	241,134	101,099,410	276,795.1	0.32
June	8,681	3,272,221	8,681	340,446	932.1	7,311	7,538	260,152	249,274	97,720,653	267,544.6	0.32
July	9,251	3,270,908	9,251	321,188	879.4	6,925	7,080	243,363	230,443	100,807,406	275,995.6	0.32
August	9,440	3,268,948	9,440	310,112	849.0	6,953	7,106	235,577	225,984	100,787,406	275,940.9	0.33
September	9,920	3,266,769	9,920	360,534	987.1	8,696	9,037	273,573	258,899	97,500,274	266,941.2	0.33
October	10,282	3,265,787	10,282	354,271	969.9	8,252	8,520	270,287	254,369	100,655,643	275,580.1	0.33
November	10,433	3,262,170	10,433	317,787	870.1	7,277	7,436	239,506	226,127	97,331,354	266,478.7	0.34
December	10,832	3,260,343	10,832	348,867	955.1	7,589	7,856	263,416	255,409	100,477,755	275,093.1	0.34
2015												
January	11,110	3,257,558	11,110	345,994	947.3	7,947	8,450	263,124	263,160	100,370,700	274,800.0	0.34
February	11,117	3,250,942	11,117	299,093	818.9	7,185	7,485	221,424	229,221	90,530,323	247,858.5	0.34
March	11,509	3,247,072	11,509	325,323	890.7	7,105	7,374	240,430	248,984	100,090,395	274,032.6	0.34
April	11,603	3,243,212	11,603	300,383	822.4	6,802	7,021	223,887	235,415	96,768,486	264,937.7	0.34
May	11,548	3,240,539	11,548	308,554	844.8	6,824	7,075	229,727	243,616	99,920,089	273,566.3	0.34
June	11,801	3,235,765	11,801	358,515	981.6	8,363	8,661	267,688	274,678	96,605,138	264,490.5	0.34
July	12,185	3,233,520	12,185	353,747	968.5	8,156	8,561	265,006	274,553	99,654,079	272,838.0	0.34
August	12,155	3,229,783	12,155	322,271	882.3	7,282	7,482	240,636	248,499	99,592,205	272,668.6	0.34
September	12,458	3,227,540	12,458	346,375	948.3	7,750	8,086	258,161	267,945	96,308,333	263,677.8	0.35
October	12,492	3,223,729	12,492	332,907	911.4	7,890	8,112	243,841	258,629	99,353,099	272,014.0	0.35
November	12,628	3,216,466	12,628	353,668	968.3	8,507	8,824	260,110	275,988	95,985,749	262,794.7	0.35
December	13,121	3,211,593	13,121	347,757	952.1	8,280	8,651	256,031	264,901	98,996,173	271,036.8	0.35

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Candesartan												
<i>2016</i>												
January	12,968	3,206,673	12,968	331,720	908.2	7,222	7,571	247,459	257,629	98,859,950	270,663.8	0.35
February	13,055	3,200,849	13,055	349,201	956.1	8,131	8,343	257,440	265,716	92,325,977	252,774.7	0.35
March	13,284	3,198,010	13,284	360,391	986.7	8,099	8,386	267,462	282,778	98,506,902	269,697.2	0.35
April	13,232	3,191,342	13,232	325,729	891.8	6,883	7,029	239,588	250,848	95,181,466	260,592.7	0.34
May	13,149	3,185,415	13,149	342,832	938.6	7,390	7,668	256,592	267,859	98,227,543	268,932.4	0.34
June	13,269	3,180,394	13,269	359,167	983.3	8,816	9,144	265,933	280,403	94,918,361	259,872.3	0.34
July	13,186	3,175,382	13,186	341,027	933.7	7,788	8,067	252,383	263,008	97,900,577	268,037.2	0.34
August	13,296	3,173,558	13,296	358,766	982.2	8,082	8,346	264,877	275,143	97,828,414	267,839.6	0.34
September	13,335	3,168,107	13,335	346,993	950.0	7,992	8,275	255,989	269,986	94,515,334	258,768.9	0.34
October	13,297	3,160,553	13,297	333,375	912.7	7,695	7,920	245,296	262,818	97,450,754	266,805.6	0.34
November	13,515	3,154,494	13,515	370,911	1,015.5	8,548	8,809	275,683	292,719	94,118,283	257,681.8	0.34
December	13,429	3,149,605	13,429	330,445	904.7	7,920	8,282	243,737	257,086	97,040,729	265,683.0	0.34
<i>2017</i>												
January	13,345	3,143,891	13,345	348,718	954.7	8,336	8,812	259,311	270,066	96,903,658	265,307.8	0.34
February	13,271	3,135,363	13,271	312,042	854.3	7,297	7,535	228,707	241,144	87,322,336	239,075.5	0.34
March	13,721	3,131,348	13,721	389,802	1,067.2	8,988	9,367	287,600	302,951	96,465,809	264,109.0	0.34
April	13,518	3,123,891	13,518	326,905	895.0	7,136	7,413	241,484	258,587	93,219,115	255,220.0	0.34
May	13,866	3,120,599	13,866	377,863	1,034.5	8,101	8,384	278,700	291,211	96,167,020	263,291.0	0.34
June	13,971	3,111,883	13,971	369,884	1,012.7	8,251	8,581	273,997	292,250	92,881,687	254,296.2	0.34
July	14,009	3,105,920	14,009	348,137	953.1	7,464	7,760	259,038	271,202	95,751,818	262,154.2	0.34
August	14,119	3,101,932	14,119	355,897	974.4	8,018	8,299	261,560	279,763	95,590,652	261,712.9	0.34
September	13,880	3,096,663	13,880	341,777	935.7	7,925	8,227	252,241	269,807	92,355,306	252,855.0	0.34
October	14,048	3,090,326	14,048	361,956	991.0	8,061	8,365	266,977	283,526	95,247,522	260,773.5	0.34
November	14,141	3,083,437	14,141	372,195	1,019.0	8,438	8,722	275,546	293,604	91,972,641	251,807.4	0.34
December	14,012	3,075,872	14,012	340,493	932.2	7,779	8,069	251,100	271,524	94,796,824	259,539.6	0.34

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Candesartan												
<i>2018</i>												
January	14,252	3,071,078	14,252	396,575	1,085.8	8,861	9,257	292,629	318,140	94,581,266	258,949.4	0.34
February	14,123	3,059,869	14,123	356,167	975.1	8,826	9,122	264,122	279,081	85,186,366	233,227.6	0.34
March	14,415	3,052,381	14,415	385,276	1,054.8	8,321	8,676	284,700	305,458	94,003,330	257,367.1	0.34
April	14,311	3,043,656	14,311	350,562	959.8	7,319	7,588	258,981	282,486	90,739,857	248,432.2	0.34
May	14,699	3,036,173	14,699	389,185	1,065.5	8,789	9,080	287,513	308,235	93,544,468	256,110.8	0.34
June	14,620	3,027,432	14,620	383,674	1,050.4	8,609	8,954	285,792	305,345	90,334,252	247,321.7	0.34
July	14,687	3,020,706	14,687	375,749	1,028.7	8,595	8,925	277,157	298,578	93,109,745	254,920.6	0.34
August	14,793	3,015,323	14,793	353,160	966.9	7,674	7,945	261,462	282,789	92,902,777	254,353.9	0.34
September	14,448	3,006,456	14,448	338,233	926.0	7,693	8,049	250,281	272,365	89,696,384	245,575.3	0.34
October	14,758	3,000,750	14,758	395,418	1,082.6	8,953	9,165	289,716	318,262	92,446,983	253,106.0	0.34
November	14,737	2,987,121	14,737	376,922	1,032.0	8,152	8,489	277,537	303,439	88,963,329	243,568.3	0.34
December	14,689	2,969,626	14,689	345,949	947.2	7,437	7,696	252,783	282,148	91,530,460	250,596.7	0.34
<i>2019</i>												
January	15,196	2,965,054	15,196	399,566	1,094.0	8,535	8,771	294,108	326,504	91,327,091	250,039.9	0.34
February	15,040	2,953,382	15,040	361,442	989.6	7,966	8,345	268,080	293,839	81,759,088	223,844.2	0.35
March	15,864	2,927,088	15,864	485,939	1,330.4	11,057	11,463	354,310	386,349	90,115,768	246,723.5	0.35
April	16,278	2,917,535	16,278	437,329	1,197.3	9,781	10,133	319,927	347,840	86,969,965	238,110.8	0.35
May	16,705	2,910,874	16,705	420,508	1,151.3	9,013	9,276	310,496	336,989	89,637,349	245,413.7	0.35
June	16,408	2,899,491	16,408	358,004	980.2	7,547	7,738	262,486	286,089	86,212,923	236,038.1	0.35
July	16,584	2,879,468	16,584	418,379	1,145.5	9,033	9,332	310,554	336,593	88,558,118	242,458.9	0.35
August	16,308	2,863,402	16,308	348,349	953.7	7,940	8,123	255,957	278,769	88,137,267	241,306.7	0.35
September	15,994	2,850,741	15,994	359,133	983.3	7,577	7,754	266,158	293,288	84,844,147	232,290.6	0.35
October	16,237	2,832,757	16,237	375,139	1,027.1	8,207	8,489	275,589	302,916	87,147,743	238,597.5	0.35
November	16,097	2,818,207	16,097	351,136	961.4	7,539	7,806	259,947	287,453	83,892,433	229,685.0	0.35
December	15,928	2,801,822	15,928	310,764	850.8	6,848	7,041	227,095	249,084	86,316,754	236,322.4	0.35
<i>2020</i>												
January	16,197	2,795,508	16,197	333,552	913.2	7,162	7,356	248,796	276,865	86,071,408	235,650.7	0.35
February	15,963	2,782,568	15,963	299,494	820.0	6,670	6,795	220,703	245,349	79,850,616	218,619.1	0.35
March	16,276	2,750,794	16,276	321,269	879.6	6,724	6,835	236,853	266,103	84,378,043	231,014.5	0.35
April	15,702	2,720,142	15,702	174,615	478.1	3,821	3,880	129,124	145,744	80,929,734	221,573.5	0.35
May	14,878	2,703,358	14,878	145,538	398.5	3,269	3,318	110,786	125,372	83,331,436	228,149.0	0.35
June	14,144	2,696,022	14,144	125,188	342.7	3,191	3,238	99,218	115,481	80,421,992	220,183.4	0.35
July	13,596	2,689,586	13,596	74,472	203.9	2,466	2,499	66,944	80,228	82,588,413	226,114.8	0.35
August	12,744	2,664,992	12,744	15,664	42.9	1,397	1,409	15,554	19,141	58,413,396	159,927.2	0.35
Eprosartan												
<i>Incident Eprosartan episodes</i>												

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
2014												
January	16	3,297,185	16	3,032	8.3	113	113	2,479	1,887	101,664,226	278,341.5	0.00
February	33	3,289,812	33	4,644	12.7	99	99	3,739	2,682	91,672,932	250,986.8	0.00
March	53	3,286,611	53	2,617	7.2	48	48	1,786	2,178	101,333,877	277,437.0	0.00
April	67	3,281,387	67	3,297	9.0	63	63	2,536	2,560	97,930,055	268,117.9	0.00
May	70	3,278,790	70	2,539	7.0	76	76	1,782	2,483	101,099,410	276,795.1	0.00
June	78	3,272,221	78	2,435	6.7	49	49	1,776	2,387	97,720,653	267,544.6	0.00
July	84	3,270,908	84	1,753	4.8	29	29	1,245	1,756	100,807,406	275,995.6	0.00
August	93	3,268,948	93	2,886	7.9	61	61	2,041	2,235	100,787,406	275,940.9	0.00
September	94	3,266,769	94	1,986	5.4	30	30	1,418	1,313	97,500,274	266,941.2	0.00
October	94	3,265,787	94	2,608	7.1	51	51	2,042	3,011	100,655,643	275,580.1	0.00
November	90	3,262,170	90	1,739	4.8	29	29	1,253	1,425	97,331,354	266,478.7	0.00
December	91	3,260,343	91	2,308	6.3	45	45	1,494	2,606	100,477,755	275,093.1	0.00
2015												
January	90	3,257,558	90	1,816	5.0	55	55	1,271	1,407	100,370,700	274,800.0	0.00
February	87	3,250,942	87	2,601	7.1	42	42	1,981	2,065	90,530,323	247,858.5	0.00
March	88	3,247,072	88	3,592	9.8	73	73	2,430	2,906	100,090,395	274,032.6	0.00
April	95	3,243,212	95	2,246	6.1	44	44	1,557	1,790	96,768,486	264,937.7	0.00
May	104	3,240,539	104	2,728	7.5	53	53	1,861	2,197	99,920,089	273,566.3	0.00
June	117	3,235,765	117	3,371	9.2	116	116	2,133	3,037	96,605,138	264,490.5	0.00
July	122	3,233,520	122	4,218	11.5	95	95	2,939	3,178	99,654,079	272,838.0	0.00
August	115	3,229,783	115	2,182	6.0	85	85	1,639	1,307	99,592,205	272,668.6	0.00
September	106	3,227,540	106	3,101	8.5	146	146	2,104	2,654	96,308,333	263,677.8	0.00
October	111	3,223,729	111	3,161	8.7	62	62	2,365	2,227	99,353,099	272,014.0	0.00
November	115	3,216,466	115	3,956	10.8	108	108	2,782	2,994	95,985,749	262,794.7	0.00
December	119	3,211,593	119	3,562	9.8	126	126	2,378	2,627	98,996,173	271,036.8	0.00

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Eprosartan												
2016												
January	118	3,206,673	118	3,013	8.2	121	122	2,336	2,136	98,859,950	270,663.8	0.00
February	112	3,200,849	112	1,857	5.1	36	36	1,282	1,372	92,325,977	252,774.7	0.00
March	108	3,198,010	108	1,436	3.9	26	26	992	1,461	98,506,902	269,697.2	0.00
April	105	3,191,342	105	1,833	5.0	37	37	1,226	1,338	95,181,466	260,592.7	0.00
May	105	3,185,415	105	3,320	9.1	65	65	2,592	2,940	98,227,543	268,932.4	0.00
June	99	3,180,394	99	3,247	8.9	111	111	2,190	2,524	94,918,361	259,872.3	0.00
July	98	3,175,382	98	3,133	8.6	66	66	2,258	2,788	97,900,577	268,037.2	0.00
August	101	3,173,558	101	3,703	10.1	100	100	2,862	2,556	97,828,414	267,839.6	0.00
September	98	3,168,107	98	2,168	5.9	43	43	1,501	2,380	94,515,334	268,768.9	0.00
October	98	3,160,553	98	1,931	5.3	31	31	1,370	1,538	97,450,754	266,805.6	0.00
November	93	3,154,494	93	2,147	5.9	25	25	1,751	1,680	94,118,283	257,681.8	0.00
December	88	3,149,605	88	901	2.5	17	17	616	728	97,040,729	265,683.0	0.00
2017												
January	88	3,143,891	88	1,277	3.5	27	28	878	1,092	96,903,658	265,307.8	0.00
February	100	3,135,363	100	2,531	6.9	53	53	1,675	2,351	87,322,336	239,075.5	0.00
March	111	3,131,348	111	3,715	10.2	72	72	2,726	3,234	96,465,809	264,109.0	0.00
April	121	3,123,891	121	3,148	8.6	60	60	2,309	2,980	93,219,115	255,220.0	0.00
May	122	3,120,599	122	3,204	8.8	58	58	2,415	2,959	96,167,020	263,291.0	0.00
June	115	3,111,883	115	1,923	5.3	43	43	1,258	1,817	92,881,687	254,296.2	0.00
July	145	3,105,920	145	5,896	16.1	199	205	3,958	5,783	95,751,818	262,154.2	0.00
August	143	3,101,932	143	1,939	5.3	42	42	1,316	2,014	95,590,652	261,712.9	0.00
September	134	3,096,663	134	2,345	6.4	74	74	1,607	1,935	92,355,306	252,855.0	0.00
October	96	3,090,326	96	1,651	4.5	26	26	1,113	1,700	95,247,522	260,773.5	0.00
November	89	3,083,437	89	2,121	5.8	30	31	1,673	1,649	91,972,641	251,807.4	0.00
December	80	3,075,872	80	1,565	4.3	28	28	1,064	1,204	94,796,824	259,539.6	0.00

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Eprosartan												
January	77	3,071,078	77	1,166	3.2	33	33	778	1,100	94,581,266	258,949.4	0.00
February	79	3,059,869	79	2,289	6.3	44	44	1,707	2,542	85,186,366	233,227.6	0.00
March	74	3,052,381	74	1,221	3.3	19	19	873	907	94,003,330	257,367.1	0.00
April	76	3,043,656	76	1,631	4.5	22	22	1,246	1,526	90,739,857	248,432.2	0.00
May	74	3,036,173	74	1,273	3.5	32	32	906	888	93,544,468	256,110.8	0.00
June	70	3,027,432	70	774	2.1	14	14	448	896	90,334,252	247,321.7	0.00
July	65	3,020,706	65	683	1.9	14	14	426	700	93,109,745	254,920.6	0.00
August	61	3,015,323	61	1,558	4.3	28	28	1,015	1,435	92,902,777	254,353.9	0.00
September	66	3,006,456	66	2,006	5.5	36	37	1,291	1,690	89,696,384	245,575.3	0.00
October	71	3,000,750	71	1,722	4.7	36	36	1,166	1,534	92,446,983	253,106.0	0.00
November	66	2,987,121	66	1,206	3.3	19	19	840	980	88,963,329	243,568.3	0.00
December	60	2,969,626	60	837	2.3	20	20	560	679	91,530,460	250,596.7	0.00
2019												
January	56	2,965,054	56	1,935	5.3	56	56	1,369	1,481	91,327,091	250,039.9	0.00
February	58	2,953,382	58	1,696	4.6	62	62	1,198	1,019	81,759,088	223,844.2	0.00
March	56	2,927,088	56	1,626	4.5	50	50	1,062	1,246	90,115,768	246,723.5	0.00
April	55	2,917,535	55	663	1.8	9	9	423	701	86,969,965	238,110.8	0.00
May	56	2,910,874	56	1,697	4.6	36	36	1,340	2,007	89,637,349	245,413.7	0.00
June	59	2,899,491	59	1,227	3.4	16	16	950	1,354	86,212,923	236,038.1	0.00
July	54	2,879,468	54	1,082	3.0	20	20	728	868	88,558,118	242,458.9	0.00
August	55	2,863,402	55	1,428	3.9	29	29	1,136	1,268	88,137,267	241,306.7	0.00
September	64	2,850,741	64	2,564	7.0	75	75	1,678	2,017	84,844,147	232,290.6	0.00
October	68	2,832,757	68	1,472	4.0	30	30	952	1,152	87,147,743	238,597.5	0.00
November	63	2,818,207	63	1,084	3.0	15	15	873	942	83,892,433	229,685.0	0.00
December	63	2,801,822	63	1,290	3.5	22	22	863	954	86,316,754	236,322.4	0.00
2020												
January	61	2,795,508	61	1,626	4.5	34	34	1,191	1,262	86,071,408	235,650.7	0.00
February	63	2,782,568	63	1,227	3.4	21	21	860	1,196	79,850,616	218,619.1	0.00
March	57	2,750,794	57	845	2.3	17	17	595	735	84,378,043	231,014.5	0.00
April	58	2,720,142	58	892	2.4	26	26	659	713	80,929,734	221,573.5	0.00
May	64	2,703,358	64	950	2.6	36	36	754	764	83,331,436	228,149.0	0.00
June	62	2,696,022	62	978	2.7	33	33	756	1,256	80,421,992	220,183.4	0.00
July	59	2,689,586	59	216	0.6	6	6	171	255	82,588,413	226,114.8	0.00
August	54	2,664,992	54	51	0.1	5	5	51	51	58,413,396	159,927.2	0.00

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Irbesartan												
<i>Incident Irbesartan episodes</i>												
2014												
January	575	3,297,185	575	98,319	269.2	1,945	1,964	75,020	73,180	101,664,226	278,341.5	0.10
February	1,036	3,289,812	1,036	74,962	205.2	1,497	1,507	55,871	57,062	91,672,932	250,986.8	0.09
March	1,580	3,286,611	1,580	87,974	240.9	1,765	1,784	65,090	68,591	101,333,877	277,437.0	0.09
April	2,006	3,281,387	2,006	92,040	252.0	1,707	1,713	70,219	68,400	97,930,055	268,117.9	0.09
May	2,305	3,278,790	2,305	87,022	238.3	1,596	1,606	66,147	63,976	101,099,410	276,795.1	0.09
June	2,457	3,272,221	2,457	86,925	238.0	1,957	1,960	64,265	66,976	97,720,653	267,544.6	0.09
July	2,710	3,270,908	2,710	99,564	272.6	1,964	1,973	74,490	75,588	100,807,406	275,995.6	0.09
August	2,752	3,268,948	2,752	72,413	198.3	1,475	1,480	53,362	56,209	100,787,406	275,940.9	0.09
September	2,813	3,266,769	2,813	82,766	226.6	1,740	1,742	61,519	62,943	97,500,274	266,941.2	0.09
October	2,882	3,265,787	2,882	93,096	254.9	1,973	1,985	71,044	66,358	100,655,643	275,580.1	0.09
November	2,883	3,262,170	2,883	84,639	231.7	1,806	1,822	63,222	62,058	97,331,354	266,478.7	0.09
December	3,023	3,260,343	3,023	102,164	279.7	2,303	2,327	76,823	79,285	100,477,755	275,093.1	0.09
2015												
January	3,117	3,257,558	3,117	91,346	250.1	1,774	1,786	68,943	70,024	100,370,700	274,800.0	0.10
February	3,141	3,250,942	3,141	95,576	261.7	2,028	2,044	70,997	68,372	90,530,323	247,858.5	0.10
March	3,283	3,247,072	3,283	99,645	272.8	1,855	1,857	73,976	76,652	100,090,395	274,032.6	0.10
April	3,337	3,243,212	3,337	89,722	245.6	2,109	2,114	65,869	69,618	96,768,486	264,937.7	0.10
May	3,341	3,240,539	3,341	89,158	244.1	1,993	1,998	66,032	69,586	99,920,089	273,566.3	0.10
June	3,334	3,235,765	3,334	97,441	266.8	2,562	2,587	70,522	73,334	96,605,138	264,490.5	0.10
July	3,420	3,233,520	3,420	84,662	231.8	1,653	1,662	63,065	66,223	99,654,079	272,838.0	0.10
August	3,339	3,229,783	3,339	80,595	220.7	1,652	1,660	59,012	64,888	99,592,205	272,668.6	0.09
September	3,401	3,227,540	3,401	93,431	255.8	1,903	1,911	69,666	74,307	96,308,333	263,677.8	0.09
October	3,415	3,223,729	3,415	94,358	258.3	2,094	2,095	68,995	74,373	99,353,099	272,014.0	0.09
November	3,403	3,216,466	3,403	88,934	243.5	2,232	2,250	66,122	69,349	95,985,749	262,794.7	0.09
December	3,540	3,211,593	3,540	102,041	279.4	2,463	2,482	75,298	78,973	98,996,173	271,036.8	0.09

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Irbesartan												
2016												
January	3,539	3,206,673	3,539	90,732	248.4	1,798	1,804	67,746	70,988	98,859,950	270,663.8	0.09
February	3,516	3,200,849	3,516	87,687	240.1	1,867	1,872	65,667	67,609	92,325,977	252,774.7	0.09
March	3,567	3,198,010	3,567	83,908	229.7	1,654	1,664	61,364	66,716	98,506,902	269,697.2	0.09
April	3,537	3,191,342	3,537	91,494	250.5	1,804	1,822	68,273	71,377	95,181,466	260,592.7	0.09
May	3,491	3,185,415	3,491	87,465	239.5	1,944	1,954	64,064	77,281	98,227,543	268,932.4	0.09
June	3,469	3,180,394	3,469	87,099	238.5	1,720	1,725	64,962	68,577	94,918,361	259,872.3	0.09
July	3,460	3,175,382	3,460	81,340	222.7	1,737	1,754	59,413	63,766	97,900,577	268,037.2	0.09
August	3,479	3,173,558	3,479	95,965	262.7	2,042	2,061	71,218	73,737	97,828,414	267,839.6	0.09
September	3,431	3,168,107	3,431	85,545	234.2	2,092	2,098	61,657	66,612	94,515,334	258,768.9	0.09
October	3,420	3,160,553	3,420	83,590	228.9	1,774	1,810	61,334	65,371	97,450,754	266,805.6	0.09
November	3,421	3,154,494	3,421	86,015	235.5	1,745	1,761	63,534	68,530	94,118,283	257,681.8	0.09
December	3,367	3,149,605	3,367	89,784	245.8	1,989	2,001	65,854	68,716	97,040,729	265,683.0	0.09
2017												
January	3,379	3,143,891	3,379	95,757	262.2	2,085	2,105	72,299	76,569	96,903,658	265,307.8	0.09
February	3,368	3,135,363	3,368	83,079	227.5	1,733	1,735	60,890	65,852	87,322,336	239,075.5	0.09
March	3,438	3,131,348	3,438	93,840	256.9	2,013	2,014	69,198	73,863	96,465,809	264,109.0	0.09
April	3,390	3,123,891	3,390	86,151	235.9	1,849	1,870	63,538	66,718	93,219,115	255,220.0	0.09
May	3,434	3,120,599	3,434	89,289	244.5	2,069	2,083	65,048	71,290	96,167,020	263,291.0	0.08
June	3,455	3,111,883	3,455	95,653	261.9	1,973	1,983	70,984	78,485	92,881,687	254,296.2	0.08
July	3,483	3,105,920	3,483	87,972	240.9	1,772	1,772	65,277	72,227	95,751,818	262,154.2	0.08
August	3,470	3,101,932	3,470	82,568	226.1	1,784	1,797	60,267	63,952	95,590,652	261,712.9	0.08
September	3,451	3,096,663	3,451	92,111	252.2	1,935	1,949	68,054	74,296	92,355,306	252,855.0	0.08
October	3,526	3,090,326	3,526	102,163	279.7	1,938	1,964	76,335	80,665	95,247,522	260,773.5	0.09
November	3,649	3,083,437	3,649	101,024	276.6	2,114	2,119	75,107	81,053	91,972,641	251,807.4	0.09
December	3,650	3,075,872	3,650	83,436	228.4	1,756	1,778	60,649	69,239	94,796,824	259,539.6	0.09

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Irbesartan												
2018												
January	3,920	3,071,078	3,920	111,989	306.6	2,292	2,308	79,778	99,759	94,581,266	258,949.4	0.09
February	4,057	3,059,869	4,057	96,724	264.8	2,019	2,035	68,622	88,005	85,186,366	233,227.6	0.10
March	4,128	3,052,381	4,128	101,775	278.6	2,185	2,191	73,273	84,867	94,003,330	257,367.1	0.10
April	3,950	3,043,656	3,950	90,003	246.4	1,825	1,833	65,958	72,208	90,739,857	248,432.2	0.09
May	3,947	3,036,173	3,947	103,705	283.9	2,452	2,483	76,630	82,311	93,544,468	256,110.8	0.09
June	3,758	3,027,432	3,758	82,727	226.5	1,633	1,640	60,839	66,777	90,334,252	247,321.7	0.09
July	3,668	3,020,706	3,668	89,640	245.4	1,890	1,906	66,600	71,425	93,109,745	254,920.6	0.09
August	3,662	3,015,323	3,662	84,960	232.6	1,744	1,786	62,486	68,552	92,902,777	254,353.9	0.08
September	3,522	3,006,456	3,522	77,640	212.6	1,513	1,530	57,422	61,727	89,696,384	245,575.3	0.08
October	3,599	3,000,750	3,599	94,560	258.9	1,891	1,900	69,102	78,895	92,446,983	253,106.0	0.08
November	3,624	2,987,121	3,624	89,031	243.8	1,789	1,790	64,697	71,764	88,963,329	243,568.3	0.08
December	3,575	2,969,626	3,575	77,162	211.3	1,498	1,499	57,300	64,242	91,530,460	250,596.7	0.08
2019												
January	3,617	2,965,054	3,617	90,523	247.8	1,901	1,908	67,065	73,018	91,327,091	250,039.9	0.08
February	3,496	2,953,382	3,496	81,196	222.3	1,637	1,677	60,365	68,025	81,759,088	223,844.2	0.08
March	3,633	2,927,088	3,633	110,494	302.5	2,553	2,593	81,332	88,518	90,115,768	246,723.5	0.08
April	3,696	2,917,535	3,696	105,425	288.6	2,285	2,308	79,004	87,695	86,969,965	238,110.8	0.08
May	3,736	2,910,874	3,736	87,355	239.2	1,771	1,781	63,947	71,932	89,637,349	245,413.7	0.08
June	3,648	2,899,491	3,648	76,344	209.0	1,456	1,460	56,683	63,542	86,212,923	236,038.1	0.08
July	3,631	2,879,468	3,631	81,784	223.9	1,553	1,557	59,725	65,503	88,558,118	242,458.9	0.08
August	3,589	2,863,402	3,589	76,165	208.5	1,483	1,499	55,576	63,672	88,137,267	241,306.7	0.08
September	3,526	2,850,741	3,526	82,265	225.2	1,730	1,756	60,998	69,358	84,844,147	232,290.6	0.08
October	3,564	2,832,757	3,564	78,710	215.5	1,502	1,514	58,068	65,627	87,147,743	238,597.5	0.08
November	3,538	2,818,207	3,538	75,919	207.9	1,498	1,501	55,715	63,076	83,892,433	229,685.0	0.08
December	3,507	2,801,822	3,507	70,199	192.2	1,430	1,432	51,354	57,125	86,316,754	236,322.4	0.08
2020												
January	3,560	2,795,508	3,560	72,264	197.8	1,426	1,432	53,812	60,595	86,071,408	235,650.7	0.08
February	3,448	2,782,568	3,448	61,524	168.4	1,217	1,227	45,429	52,009	79,850,616	218,619.1	0.08
March	3,501	2,750,794	3,501	69,537	190.4	1,357	1,363	51,546	59,512	84,378,043	231,014.5	0.08
April	3,410	2,720,142	3,410	44,289	121.3	921	926	33,041	38,609	80,929,734	221,573.5	0.08
May	3,339	2,703,358	3,339	40,202	110.1	864	865	30,215	35,285	83,331,436	228,149.0	0.08
June	3,195	2,696,022	3,195	29,167	79.9	707	713	23,364	28,402	80,421,992	220,183.4	0.08
July	3,083	2,689,586	3,083	17,292	47.3	577	577	15,740	19,770	82,588,413	226,114.8	0.08
August	2,859	2,664,992	2,859	3,587	9.8	320	320	3,575	4,606	58,413,396	159,927.2	0.08

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Losartan												
<i>Incident Losartan episodes</i>												
2014												
January	2,660	3,297,185	2,660	447,023	1,223.9	9,615	9,792	333,676	334,510	101,664,226	278,341.5	0.46
February	5,321	3,289,812	5,321	441,361	1,208.4	9,442	9,750	329,262	328,298	91,672,932	250,986.8	0.48
March	8,419	3,286,611	8,419	524,087	1,434.9	10,802	10,896	392,964	382,943	101,333,877	277,437.0	0.49
April	10,779	3,281,387	10,779	499,836	1,368.5	11,326	11,691	371,657	369,993	97,930,055	268,117.9	0.49
May	12,518	3,278,790	12,518	498,416	1,364.6	10,402	10,557	373,606	368,326	101,099,410	276,795.1	0.50
June	13,534	3,272,221	13,534	469,042	1,284.2	9,892	10,068	352,240	346,572	97,720,653	267,544.6	0.50
July	14,616	3,270,908	14,616	498,269	1,364.2	10,765	10,925	373,777	364,304	100,807,406	275,995.6	0.51
August	14,703	3,268,948	14,703	434,686	1,190.1	9,767	9,977	326,404	323,527	100,787,406	275,940.9	0.51
September	15,080	3,266,769	15,080	496,379	1,359.0	11,468	11,595	375,989	349,643	97,500,274	266,941.2	0.50
October	15,506	3,265,787	15,506	490,032	1,341.6	10,785	11,007	370,325	351,819	100,655,643	275,580.1	0.50
November	15,554	3,262,170	15,554	470,789	1,289.0	10,858	10,972	357,044	334,502	97,331,354	266,478.7	0.50
December	15,989	3,260,343	15,989	486,787	1,332.8	10,861	11,056	364,472	356,483	100,477,755	275,093.1	0.50
2015												
January	16,134	3,257,558	16,134	468,888	1,283.7	10,558	10,793	350,333	353,970	100,370,700	274,800.0	0.49
February	16,086	3,250,942	16,086	450,470	1,233.3	10,011	10,213	336,690	337,666	90,530,323	247,858.5	0.49
March	16,886	3,247,072	16,886	507,986	1,390.8	12,031	12,286	371,587	384,693	100,090,395	274,032.6	0.50
April	17,124	3,243,212	17,124	451,346	1,235.7	10,284	10,651	333,493	343,772	96,768,486	264,937.7	0.50
May	17,093	3,240,539	17,093	445,006	1,218.4	10,473	10,644	330,140	330,395	99,920,089	273,566.3	0.50
June	17,319	3,235,765	17,319	490,096	1,341.8	11,126	11,396	361,463	367,408	96,605,138	264,490.5	0.50
July	17,767	3,233,520	17,767	488,347	1,337.0	10,816	10,976	359,849	370,442	99,654,079	272,838.0	0.50
August	17,537	3,229,783	17,537	436,532	1,195.2	10,023	10,197	322,642	334,310	99,592,205	272,668.6	0.50
September	17,658	3,227,540	17,658	496,462	1,359.2	11,450	11,816	369,611	382,304	96,308,333	263,677.8	0.49
October	17,777	3,223,729	17,777	503,134	1,377.5	11,672	11,930	373,101	383,333	99,353,099	272,014.0	0.49
November	17,959	3,216,466	17,959	496,742	1,360.0	11,009	11,180	366,748	374,709	95,985,749	262,794.7	0.49
December	18,519	3,211,593	18,519	502,781	1,376.5	10,986	11,218	371,813	381,963	98,996,173	271,036.8	0.49

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Losartan												
2016												
January	18,505	3,206,673	18,505	470,222	1,287.4	10,655	10,786	348,552	356,917	98,859,950	270,663.8	0.49
February	18,585	3,200,849	18,585	488,419	1,337.2	10,593	10,812	359,384	373,070	92,325,977	252,774.7	0.50
March	19,199	3,198,010	19,199	552,186	1,511.8	12,525	12,762	408,262	422,112	98,506,902	269,697.2	0.50
April	19,217	3,191,342	19,217	529,395	1,449.4	11,478	11,679	393,531	402,891	95,181,466	260,592.7	0.50
May	19,349	3,185,415	19,349	498,595	1,365.1	10,791	10,912	366,135	377,876	98,227,543	268,932.4	0.50
June	19,578	3,180,394	19,578	531,633	1,455.5	11,309	11,555	395,711	409,081	94,918,361	259,872.3	0.50
July	19,615	3,175,382	19,615	522,465	1,430.4	11,672	11,915	387,913	400,044	97,900,577	268,037.2	0.51
August	19,756	3,173,558	19,756	520,913	1,426.2	11,504	11,778	386,591	396,677	97,828,414	267,839.6	0.50
September	19,696	3,168,107	19,696	518,403	1,419.3	11,780	12,016	383,791	396,891	94,515,334	258,768.9	0.50
October	19,697	3,160,553	19,697	502,745	1,376.4	11,566	11,849	369,992	390,202	97,450,754	266,805.6	0.50
November	20,028	3,154,494	20,028	552,261	1,512.0	12,861	13,127	407,146	426,723	94,118,283	257,681.8	0.50
December	20,081	3,149,605	20,081	495,032	1,355.3	11,052	11,258	366,024	377,536	97,040,729	265,683.0	0.51
2017												
January	20,097	3,143,891	20,097	536,235	1,468.1	11,646	11,867	396,600	413,981	96,903,658	265,307.8	0.51
February	20,139	3,135,363	20,139	486,466	1,331.9	10,796	10,990	355,273	374,751	87,322,336	239,075.5	0.51
March	20,755	3,131,348	20,755	579,953	1,587.8	12,601	12,811	427,373	447,084	96,465,809	264,109.0	0.51
April	20,420	3,123,891	20,420	493,086	1,350.0	11,074	11,248	365,424	378,796	93,219,115	255,220.0	0.51
May	20,935	3,120,599	20,935	572,703	1,568.0	12,365	12,568	424,601	443,088	96,167,020	263,291.0	0.51
June	20,965	3,111,883	20,965	540,973	1,481.1	11,695	11,836	397,510	412,830	92,881,687	254,296.2	0.51
July	21,068	3,105,920	21,068	532,738	1,458.6	11,861	12,006	390,225	409,438	95,751,818	262,154.2	0.51
August	21,365	3,101,932	21,365	546,333	1,495.8	12,009	12,248	401,039	424,248	95,590,652	261,712.9	0.52
September	21,061	3,096,663	21,061	515,414	1,411.1	11,201	11,435	380,692	399,055	92,355,306	252,855.0	0.52
October	21,222	3,090,326	21,222	548,669	1,502.2	12,472	12,732	403,762	423,638	95,247,522	260,773.5	0.51
November	21,558	3,083,437	21,558	560,770	1,535.3	12,549	12,748	411,300	430,295	91,972,641	251,807.4	0.51
December	21,209	3,075,872	21,209	512,257	1,402.5	10,739	10,908	379,069	395,115	94,796,824	259,539.6	0.51

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Losartan												
2018												
January	21,606	3,071,078	21,606	583,678	1,598.0	12,478	12,738	429,812	453,161	94,581,266	258,949.4	0.51
February	21,181	3,059,869	21,181	514,618	1,408.9	11,224	11,350	375,885	392,781	85,186,366	233,227.6	0.51
March	21,670	3,052,381	21,670	569,295	1,558.6	12,294	12,457	418,841	438,312	94,003,330	257,367.1	0.51
April	21,618	3,043,656	21,618	560,521	1,534.6	12,008	12,204	412,541	433,908	90,739,857	248,432.2	0.51
May	22,332	3,036,173	22,332	596,402	1,632.9	12,664	12,908	441,171	464,846	93,544,468	256,110.8	0.51
June	22,160	3,027,432	22,160	562,104	1,539.0	11,914	12,113	414,600	438,298	90,334,252	247,321.7	0.51
July	22,174	3,020,706	22,174	552,565	1,512.8	12,011	12,182	406,329	428,009	93,109,745	254,920.6	0.51
August	22,386	3,015,323	22,386	552,298	1,512.1	11,328	11,486	406,246	432,987	92,902,777	254,353.9	0.51
September	21,845	3,006,456	21,845	513,556	1,406.0	10,833	10,961	380,309	399,695	89,696,384	245,575.3	0.51
October	22,265	3,000,750	22,265	587,091	1,607.4	12,384	12,638	431,034	455,996	92,446,983	253,106.0	0.51
November	22,263	2,987,121	22,263	587,650	1,608.9	12,909	13,118	433,739	458,664	88,963,329	243,568.3	0.51
December	22,105	2,969,626	22,105	517,426	1,416.6	10,814	10,987	380,436	405,449	91,530,460	250,596.7	0.51
2019												
January	22,692	2,965,054	22,692	604,157	1,654.1	12,419	12,616	446,335	474,717	91,327,091	250,039.9	0.51
February	22,326	2,953,382	22,326	515,105	1,410.3	10,861	11,102	378,629	401,285	81,759,088	223,844.2	0.51
March	23,185	2,927,088	23,185	664,617	1,819.6	14,811	15,027	485,777	511,314	90,115,768	246,723.5	0.51
April	23,666	2,917,535	23,666	619,898	1,697.2	12,921	13,106	457,859	482,334	86,969,965	238,110.8	0.51
May	24,275	2,910,874	24,275	611,897	1,675.3	12,657	12,817	450,843	474,925	89,637,349	245,413.7	0.51
June	23,821	2,899,491	23,821	527,931	1,445.4	10,817	10,930	388,408	411,940	86,212,923	236,038.1	0.51
July	23,950	2,879,468	23,950	595,512	1,630.4	12,467	12,611	442,556	473,423	88,558,118	242,458.9	0.51
August	23,761	2,863,402	23,761	547,277	1,498.4	11,098	11,216	406,144	431,125	88,137,267	241,306.7	0.51
September	23,271	2,850,741	23,271	525,790	1,439.5	10,761	10,913	391,143	413,608	84,844,147	232,290.6	0.51
October	23,741	2,832,757	23,741	556,956	1,524.9	11,840	12,027	410,587	436,556	87,147,743	238,597.5	0.51
November	23,531	2,818,207	23,531	512,157	1,402.2	10,836	10,992	377,852	401,934	83,892,433	229,685.0	0.51
December	23,388	2,801,822	23,388	484,854	1,327.5	9,990	10,093	358,014	383,276	86,316,754	236,322.4	0.51
2020												
January	23,896	2,795,508	23,896	508,155	1,391.3	10,475	10,575	375,789	402,949	86,071,408	235,650.7	0.52
February	23,416	2,782,568	23,416	417,186	1,142.2	8,760	8,849	309,091	334,145	79,850,616	218,619.1	0.51
March	24,044	2,750,794	24,044	494,084	1,352.7	10,281	10,361	365,281	399,396	84,378,043	231,014.5	0.52
April	23,132	2,720,142	23,132	284,907	780.0	6,094	6,133	214,533	234,389	80,929,734	221,573.5	0.51
May	22,032	2,703,358	22,032	230,234	630.3	5,085	5,119	175,430	192,102	83,331,436	228,149.0	0.51
June	21,027	2,696,022	21,027	191,459	524.2	4,784	4,807	153,079	172,456	80,421,992	220,183.4	0.51
July	20,161	2,689,586	20,161	108,102	296.0	3,546	3,554	98,546	112,524	82,588,413	226,114.8	0.51
August	18,516	2,664,992	18,516	22,195	60.8	1,992	1,999	22,056	26,259	58,413,396	159,927.2	0.51

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Olmesartan												
<i>Incident Olmesartan episodes</i>												
2014												
January	116	3,297,185	116	19,437	53.2	626	628	13,868	13,415	101,664,226	278,341.5	0.02
February	236	3,289,812	236	17,659	48.3	397	399	12,549	13,786	91,672,932	250,986.8	0.02
March	350	3,286,611	350	16,354	44.8	367	373	11,384	12,103	101,333,877	277,437.0	0.02
April	417	3,281,387	417	14,258	39.0	278	278	10,045	10,218	97,930,055	268,117.9	0.02
May	469	3,278,790	469	16,883	46.2	499	512	12,019	11,764	101,099,410	276,795.1	0.02
June	458	3,272,221	458	14,275	39.1	433	437	9,866	10,037	97,720,653	267,544.6	0.02
July	501	3,270,908	501	18,278	50.0	448	452	13,151	13,241	100,807,406	275,995.6	0.02
August	505	3,268,948	505	20,018	54.8	531	534	15,482	12,113	100,787,406	275,940.9	0.02
September	507	3,266,769	507	15,023	41.1	401	401	10,813	11,598	97,500,274	266,941.2	0.02
October	529	3,265,787	529	15,610	42.7	334	334	11,377	10,263	100,655,643	275,580.1	0.02
November	567	3,262,170	567	22,557	61.8	586	586	16,596	14,459	97,331,354	266,478.7	0.02
December	612	3,260,343	612	23,876	65.4	544	564	18,125	17,036	100,477,755	275,093.1	0.02
2015												
January	636	3,257,558	636	18,386	50.3	374	382	13,623	12,937	100,370,700	274,800.0	0.02
February	612	3,250,942	612	13,834	37.9	295	299	10,541	9,122	90,530,323	247,858.5	0.02
March	626	3,247,072	626	17,873	48.9	468	468	12,442	13,080	100,090,395	274,032.6	0.02
April	611	3,243,212	611	14,219	38.9	325	331	9,836	9,738	96,768,486	264,937.7	0.02
May	628	3,240,539	628	14,225	38.9	377	377	9,919	10,272	99,920,089	273,566.3	0.02
June	629	3,235,765	629	16,967	46.5	397	410	12,851	11,699	96,605,138	264,490.5	0.02
July	620	3,233,520	620	18,583	50.9	421	424	13,389	13,765	99,654,079	272,838.0	0.02
August	593	3,229,783	593	11,939	32.7	293	293	8,294	8,914	99,592,205	272,668.6	0.02
September	587	3,227,540	587	12,790	35.0	320	320	8,951	9,807	96,308,333	263,677.8	0.02
October	575	3,223,729	575	15,267	41.8	378	401	11,677	11,630	99,353,099	272,014.0	0.02
November	581	3,216,466	581	15,253	41.8	366	368	10,762	11,801	95,985,749	262,794.7	0.02
December	567	3,211,593	567	11,779	32.2	261	261	8,699	8,387	98,996,173	271,036.8	0.02

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Olmesartan												
2016												
January	549	3,206,673	549	9,063	24.8	177	177	6,325	6,696	98,859,950	270,663.8	0.01
February	540	3,200,849	540	14,639	40.1	314	315	10,464	11,285	92,325,977	252,774.7	0.01
March	585	3,198,010	585	18,176	49.8	357	358	13,038	14,039	98,506,902	269,697.2	0.02
April	578	3,191,342	578	14,898	40.8	345	345	10,929	10,605	95,181,466	260,592.7	0.02
May	585	3,185,415	585	16,103	44.1	407	412	12,333	10,858	98,227,543	268,932.4	0.02
June	586	3,180,394	586	14,050	38.5	335	341	10,118	10,683	94,918,361	259,872.3	0.02
July	579	3,175,382	579	16,649	45.6	408	409	12,622	12,102	97,900,577	268,037.2	0.01
August	566	3,173,558	566	11,067	30.3	210	210	7,695	8,096	97,828,414	267,839.6	0.01
September	568	3,168,107	568	12,328	33.8	238	238	8,760	9,613	94,515,334	258,768.9	0.01
October	561	3,160,553	561	16,904	46.3	453	453	11,756	12,274	97,450,754	266,805.6	0.01
November	577	3,154,494	577	15,108	41.4	379	379	11,317	10,599	94,118,283	257,681.8	0.01
December	571	3,149,605	571	11,466	31.4	213	213	8,367	8,095	97,040,729	265,683.0	0.01
2017												
January	554	3,143,891	554	13,708	37.5	317	323	10,248	10,489	96,903,658	265,307.8	0.01
February	539	3,135,363	539	12,895	35.3	245	248	9,333	9,302	87,322,336	239,075.5	0.01
March	543	3,131,348	543	11,431	31.3	413	414	7,851	8,328	96,465,809	264,109.0	0.01
April	523	3,123,891	523	12,797	35.0	258	259	9,382	9,717	93,219,115	255,220.0	0.01
May	518	3,120,599	518	13,481	36.9	260	263	9,744	10,099	96,167,020	263,291.0	0.01
June	521	3,111,883	521	17,296	47.4	387	388	13,067	11,947	92,881,687	254,296.2	0.01
July	539	3,105,920	539	12,872	35.2	316	317	9,081	9,790	95,751,818	262,154.2	0.01
August	548	3,101,932	548	11,035	30.2	280	281	7,791	8,262	95,590,652	261,712.9	0.01
September	541	3,096,663	541	14,621	40.0	361	362	10,460	10,950	92,355,306	252,855.0	0.01
October	569	3,090,326	569	22,357	61.2	549	582	16,297	17,162	95,247,522	260,773.5	0.01
November	579	3,083,437	579	12,974	35.5	325	326	8,998	9,731	91,972,641	251,807.4	0.01
December	564	3,075,872	564	11,522	31.5	287	295	8,141	8,510	94,796,824	259,539.6	0.01

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Olmesartan												
2018												
January	563	3,071,078	563	14,044	38.5	305	305	10,352	10,284	94,581,266	258,949.4	0.01
February	560	3,059,869	560	12,697	34.8	323	325	9,064	9,098	85,186,366	233,227.6	0.01
March	547	3,052,381	547	10,966	30.0	231	232	7,649	8,845	94,003,330	257,367.1	0.01
April	533	3,043,656	533	13,549	37.1	266	269	9,815	10,373	90,739,857	248,432.2	0.01
May	537	3,036,173	537	13,044	35.7	258	259	9,369	10,101	93,544,468	256,110.8	0.01
June	532	3,027,432	532	11,864	32.5	283	283	8,284	8,673	90,334,252	247,321.7	0.01
July	509	3,020,706	509	13,567	37.1	340	365	10,122	9,994	93,109,745	254,920.6	0.01
August	515	3,015,323	515	13,393	36.7	270	282	9,926	10,191	92,902,777	254,353.9	0.01
September	516	3,006,456	516	13,629	37.3	258	263	10,100	11,274	89,696,384	245,575.3	0.01
October	550	3,000,750	550	16,058	44.0	367	371	11,406	12,055	92,446,983	253,106.0	0.01
November	565	2,987,121	565	14,590	39.9	279	280	10,550	11,170	88,963,329	243,568.3	0.01
December	550	2,969,626	550	10,554	28.9	239	239	7,425	8,156	91,530,460	250,596.7	0.01
2019												
January	564	2,965,054	564	15,302	41.9	334	335	10,977	11,844	91,327,091	250,039.9	0.01
February	560	2,953,382	560	15,087	41.3	308	315	11,065	11,896	81,759,088	223,844.2	0.01
March	599	2,927,088	599	17,461	47.8	394	404	12,326	13,043	90,115,768	246,723.5	0.01
April	606	2,917,535	606	18,394	50.4	401	412	13,992	14,533	86,969,965	238,110.8	0.01
May	639	2,910,874	639	16,639	45.6	359	359	12,108	12,820	89,637,349	245,413.7	0.01
June	625	2,899,491	625	13,266	36.3	259	264	9,232	10,294	86,212,923	236,038.1	0.01
July	653	2,879,468	653	15,749	43.1	313	313	11,271	12,320	88,558,118	242,458.9	0.01
August	657	2,863,402	657	16,093	44.1	361	366	11,429	12,124	88,137,267	241,306.7	0.01
September	638	2,850,741	638	13,149	36.0	290	290	9,190	10,756	84,844,147	232,290.6	0.01
October	672	2,832,757	672	17,573	48.1	389	389	12,119	13,151	87,147,743	238,597.5	0.01
November	657	2,818,207	657	14,136	38.7	296	296	9,945	10,806	83,892,433	229,685.0	0.01
December	651	2,801,822	651	13,698	37.5	337	337	10,252	11,734	86,316,754	236,322.4	0.01
2020												
January	651	2,795,508	651	11,204	30.7	217	219	8,418	8,983	86,071,408	235,650.7	0.01
February	606	2,782,568	606	10,130	27.7	222	222	7,402	8,108	79,850,616	218,619.1	0.01
March	607	2,750,794	607	11,416	31.3	226	233	8,284	8,903	84,378,043	231,014.5	0.01
April	602	2,720,142	602	8,277	22.7	181	181	5,962	7,020	80,929,734	221,573.5	0.01
May	544	2,703,358	544	5,239	14.3	115	115	3,660	4,096	83,331,436	228,149.0	0.01
June	553	2,696,022	553	5,361	14.7	129	129	3,769	4,667	80,421,992	220,183.4	0.01
July	506	2,689,586	506	2,530	6.9	80	80	2,369	2,894	82,588,413	226,114.8	0.01
August	467	2,664,992	467	605	1.7	50	50	591	806	58,413,396	159,927.2	0.01

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Telmisartan												
<i>Incident Telmisartan episodes</i>												
2014												
January	94	3,297,185	94	14,144	38.7	254	254	10,548	11,099	101,664,226	278,341.5	0.02
February	188	3,289,812	188	15,332	42.0	258	265	11,667	11,276	91,672,932	250,986.8	0.02
March	285	3,286,611	285	18,014	49.3	308	308	14,023	12,537	101,333,877	277,437.0	0.02
April	350	3,281,387	350	18,248	50.0	309	309	14,590	11,607	97,930,055	268,117.9	0.02
May	408	3,278,790	408	16,307	44.6	311	312	12,249	12,305	101,099,410	276,795.1	0.02
June	454	3,272,221	454	16,072	44.0	270	276	12,076	12,718	97,720,653	267,544.6	0.02
July	475	3,270,908	475	15,469	42.4	340	342	11,830	11,398	100,807,406	275,995.6	0.02
August	495	3,268,948	495	16,349	44.8	449	454	11,959	11,813	100,787,406	275,940.9	0.02
September	536	3,266,769	536	17,343	47.5	381	381	12,865	13,383	97,500,274	266,941.2	0.02
October	562	3,265,787	562	21,371	58.5	378	380	17,315	13,809	100,655,643	275,580.1	0.02
November	535	3,262,170	535	16,886	46.2	432	432	13,022	10,358	97,331,354	266,478.7	0.02
December	531	3,260,343	531	14,479	39.6	259	260	10,876	11,813	100,477,755	275,093.1	0.02
2015												
January	555	3,257,558	555	14,401	39.4	235	235	10,651	11,954	100,370,700	274,800.0	0.02
February	522	3,250,942	522	13,359	36.6	212	212	10,348	9,070	90,530,323	247,858.5	0.02
March	523	3,247,072	523	11,780	32.3	193	193	8,761	9,477	100,090,395	274,032.6	0.02
April	549	3,243,212	549	19,384	53.1	471	472	14,853	15,008	96,768,486	264,937.7	0.02
May	537	3,240,539	537	11,773	32.2	212	212	8,575	8,946	99,920,089	273,566.3	0.02
June	538	3,235,765	538	18,216	49.9	498	499	13,325	13,111	96,605,138	264,490.5	0.02
July	580	3,233,520	580	16,463	45.1	335	339	12,249	12,816	99,654,079	272,838.0	0.02
August	575	3,229,783	575	14,784	40.5	328	332	10,800	12,424	99,592,205	272,668.6	0.02
September	590	3,227,540	590	18,349	50.2	361	361	14,023	13,537	96,308,333	263,677.8	0.02
October	604	3,223,729	604	15,572	42.6	298	298	11,657	12,490	99,353,099	272,014.0	0.02
November	601	3,216,466	601	12,476	34.2	244	244	9,118	9,844	95,985,749	262,794.7	0.02
December	587	3,211,593	587	13,319	36.5	300	310	9,781	9,566	98,996,173	271,036.8	0.02

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Telmisartan												
2016												
January	555	3,206,673	555	11,176	30.6	191	191	8,084	9,464	98,859,950	270,663.8	0.01
February	555	3,200,849	555	14,224	38.9	271	271	10,179	11,169	92,325,977	252,774.7	0.01
March	579	3,198,010	579	17,955	49.2	365	365	13,873	14,617	98,506,902	269,697.2	0.02
April	573	3,191,342	573	13,824	37.8	309	310	10,325	10,352	95,181,466	260,592.7	0.01
May	575	3,185,415	575	15,008	41.1	332	333	11,101	13,019	98,227,543	268,932.4	0.01
June	575	3,180,394	575	17,007	46.6	326	326	12,698	13,755	94,918,361	259,872.3	0.01
July	590	3,175,382	590	15,537	42.5	260	263	11,960	12,495	97,900,577	268,037.2	0.02
August	593	3,173,558	593	14,529	39.8	283	283	11,089	11,257	97,828,414	267,839.6	0.02
September	588	3,168,107	588	15,208	41.6	376	376	11,085	11,648	94,515,334	258,768.9	0.02
October	604	3,160,553	604	14,921	40.9	399	401	10,874	11,161	97,450,754	266,805.6	0.02
November	620	3,154,494	620	16,235	44.4	381	382	11,761	12,459	94,118,283	257,681.8	0.02
December	616	3,149,605	616	12,569	34.4	239	240	8,991	10,111	97,040,729	265,683.0	0.02
2017												
January	615	3,143,891	615	15,019	41.1	238	239	11,531	11,633	96,903,658	265,307.8	0.02
February	587	3,135,363	587	12,293	33.7	217	217	9,378	9,437	87,322,336	239,075.5	0.01
March	636	3,131,348	636	18,277	50.0	309	312	13,357	14,480	96,465,809	264,109.0	0.02
April	617	3,123,891	617	18,259	50.0	383	383	13,676	14,261	93,219,115	255,220.0	0.02
May	627	3,120,599	627	15,188	41.6	309	314	10,838	11,695	96,167,020	263,291.0	0.02
June	636	3,111,883	636	16,753	45.9	359	359	12,115	13,244	92,881,687	254,296.2	0.02
July	633	3,105,920	633	13,785	37.7	242	242	10,192	11,112	95,751,818	262,154.2	0.02
August	625	3,101,932	625	12,019	32.9	281	281	8,853	9,103	95,590,652	261,712.9	0.02
September	604	3,096,663	604	17,406	47.7	395	395	12,993	13,497	92,355,306	252,855.0	0.01
October	602	3,090,326	602	12,805	35.1	227	228	9,011	10,159	95,247,522	260,773.5	0.01
November	593	3,083,437	593	12,284	33.6	217	217	8,950	10,020	91,972,641	251,807.4	0.01
December	585	3,075,872	585	17,883	49.0	414	427	13,642	14,220	94,796,824	259,539.6	0.01

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Telmisartan												
2018												
January	590	3,071,078	590	16,945	46.4	293	294	12,673	13,509	94,581,266	258,949.4	0.01
February	584	3,059,869	584	13,593	37.2	243	243	10,096	10,461	85,186,366	233,227.6	0.01
March	589	3,052,381	589	13,151	36.0	253	255	9,847	11,044	94,003,330	257,367.1	0.01
April	588	3,043,656	588	14,245	39.0	247	247	9,879	11,433	90,739,857	248,432.2	0.01
May	637	3,036,173	637	18,098	49.5	418	425	13,138	13,871	93,544,468	256,110.8	0.01
June	626	3,027,432	626	13,522	37.0	240	240	9,614	10,516	90,334,252	247,321.7	0.01
July	653	3,020,706	653	17,433	47.7	301	306	12,949	14,624	93,109,745	254,920.6	0.02
August	676	3,015,323	676	18,643	51.0	320	322	13,473	15,729	92,902,777	254,353.9	0.02
September	705	3,006,456	705	19,959	54.6	358	358	14,894	17,590	89,696,384	245,575.3	0.02
October	713	3,000,750	713	15,847	43.4	293	300	11,375	13,910	92,446,983	253,106.0	0.02
November	691	2,987,121	691	16,361	44.8	293	298	11,705	14,174	88,963,329	243,568.3	0.02
December	668	2,969,626	668	14,590	39.9	256	261	10,805	12,205	91,530,460	250,596.7	0.02
2019												
January	644	2,965,054	644	13,913	38.1	304	307	9,826	11,450	91,327,091	250,039.9	0.01
February	627	2,953,382	627	14,785	40.5	354	356	10,720	11,812	81,759,088	223,844.2	0.01
March	611	2,927,088	611	14,442	39.5	315	321	10,581	11,694	90,115,768	246,723.5	0.01
April	634	2,917,535	634	13,759	37.7	221	221	9,966	11,279	86,969,965	238,110.8	0.01
May	647	2,910,874	647	17,078	46.8	292	295	12,381	13,847	89,637,349	245,413.7	0.01
June	616	2,899,491	616	11,722	32.1	180	180	8,577	9,480	86,212,923	236,038.1	0.01
July	614	2,879,468	614	13,796	37.8	249	249	10,372	11,882	88,558,118	242,458.9	0.01
August	574	2,863,402	574	9,399	25.7	182	182	6,817	8,064	88,137,267	241,306.7	0.01
September	558	2,850,741	558	11,960	32.7	203	203	8,537	9,886	84,844,147	232,290.6	0.01
October	558	2,832,757	558	13,208	36.2	225	229	9,417	11,243	87,147,743	238,597.5	0.01
November	550	2,818,207	550	13,275	36.3	256	259	9,967	11,465	83,892,433	229,685.0	0.01
December	559	2,801,822	559	11,759	32.2	196	196	8,415	9,815	86,316,754	236,322.4	0.01
2020												
January	583	2,795,508	583	14,063	38.5	260	261	10,431	11,819	86,071,408	235,650.7	0.01
February	573	2,782,568	573	9,637	26.4	170	170	6,724	8,489	79,850,616	218,619.1	0.01
March	591	2,750,794	591	13,622	37.3	242	244	9,995	11,512	84,378,043	231,014.5	0.01
April	576	2,720,142	576	7,826	21.4	149	152	5,829	6,605	80,929,734	221,573.5	0.01
May	564	2,703,358	564	7,016	19.2	149	149	5,509	6,277	83,331,436	228,149.0	0.01
June	548	2,696,022	548	6,275	17.2	137	137	5,051	6,157	80,421,992	220,183.4	0.01
July	546	2,689,586	546	3,880	10.6	126	126	3,468	4,117	82,588,413	226,114.8	0.01
August	507	2,664,992	507	654	1.8	65	65	650	795	58,413,396	159,927.2	0.01

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
<i>Incident Valsartan episodes</i>												
2014												
January	445	3,297,185	445	50,881	139.3	1,062	1,078	34,867	51,773	101,664,226	278,341.5	0.08
February	903	3,289,812	903	47,712	130.6	921	923	32,228	49,622	91,672,932	250,986.8	0.08
March	1,255	3,286,611	1,255	38,852	106.4	873	876	25,546	37,962	101,333,877	277,437.0	0.07
April	1,280	3,281,387	1,280	24,241	66.4	450	468	17,354	22,372	97,930,055	268,117.9	0.06
May	1,069	3,278,790	1,069	19,443	53.2	398	399	13,760	18,782	101,099,410	276,795.1	0.04
June	831	3,272,221	831	20,727	56.7	383	387	15,507	18,979	97,720,653	267,544.6	0.03
July	748	3,270,908	748	24,238	66.4	488	497	18,361	19,481	100,807,406	275,995.6	0.03
August	677	3,268,948	677	15,409	42.2	267	272	11,220	12,504	100,787,406	275,940.9	0.02
September	662	3,266,769	662	20,721	56.7	536	543	14,626	15,683	97,500,274	266,941.2	0.02
October	718	3,265,787	718	24,285	66.5	447	448	18,054	18,616	100,655,643	275,580.1	0.02
November	723	3,262,170	723	22,961	62.9	426	439	17,499	16,269	97,331,354	266,478.7	0.02
December	786	3,260,343	786	26,973	73.8	481	485	20,036	20,759	100,477,755	275,093.1	0.02
2015												
January	799	3,257,558	799	19,367	53.0	397	403	14,292	16,514	100,370,700	274,800.0	0.02
February	791	3,250,942	791	23,696	64.9	500	508	17,730	18,915	90,530,323	247,858.5	0.02
March	853	3,247,072	853	29,079	79.6	548	556	21,462	25,213	100,090,395	274,032.6	0.03
April	870	3,243,212	870	25,837	70.7	507	525	19,304	20,428	96,768,486	264,937.7	0.03
May	907	3,240,539	907	23,724	65.0	460	463	17,230	21,595	99,920,089	273,566.3	0.03
June	917	3,235,765	917	26,537	72.7	584	591	19,507	22,384	96,605,138	264,490.5	0.03
July	959	3,233,520	959	27,755	76.0	572	595	20,291	22,974	99,654,079	272,838.0	0.03
August	922	3,229,783	922	19,657	53.8	361	364	14,222	15,947	99,592,205	272,668.6	0.03
September	959	3,227,540	959	27,046	74.0	544	549	19,941	21,524	96,308,333	263,677.8	0.03
October	952	3,223,729	952	19,530	53.5	431	450	13,854	16,633	99,353,099	272,014.0	0.03
November	984	3,216,466	984	26,542	72.7	535	559	19,771	23,739	95,985,749	262,794.7	0.03
December	989	3,211,593	989	23,423	64.1	485	486	16,727	20,541	98,996,173	271,036.8	0.03

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
2016												
January	991	3,206,673	991	25,121	68.8	569	613	18,658	21,860	98,859,950	270,663.8	0.03
February	989	3,200,849	989	27,230	74.6	705	776	19,833	23,645	92,325,977	252,774.7	0.03
March	994	3,198,010	994	26,441	72.4	679	691	18,751	21,181	98,506,902	269,697.2	0.03
April	1,006	3,191,342	1,006	28,097	76.9	586	590	20,070	25,244	95,181,466	260,592.7	0.03
May	1,029	3,185,415	1,029	27,031	74.0	633	636	19,330	22,749	98,227,543	268,932.4	0.03
June	1,054	3,180,394	1,054	30,659	83.9	659	670	22,733	26,404	94,918,361	259,872.3	0.03
July	1,104	3,175,382	1,104	31,367	85.9	599	622	22,841	30,855	97,900,577	268,037.2	0.03
August	1,206	3,173,558	1,206	36,913	101.1	843	849	25,990	37,657	97,828,414	267,839.6	0.03
September	1,280	3,168,107	1,280	31,947	87.5	619	621	22,364	33,361	94,515,334	258,768.9	0.03
October	1,300	3,160,553	1,300	30,991	84.8	613	616	22,139	30,462	97,450,754	266,805.6	0.03
November	1,290	3,154,494	1,290	26,521	72.6	546	568	18,627	27,198	94,118,283	257,681.8	0.03
December	1,187	3,149,605	1,187	25,490	69.8	644	645	18,554	23,917	97,040,729	265,683.0	0.03
2017												
January	1,110	3,143,891	1,110	24,115	66.0	534	534	17,140	22,076	96,903,658	265,307.8	0.03
February	1,038	3,135,363	1,038	20,816	57.0	457	464	14,724	18,904	87,322,336	239,075.5	0.03
March	999	3,131,348	999	23,028	63.0	544	551	16,115	22,265	96,465,809	264,109.0	0.02
April	944	3,123,891	944	25,465	69.7	584	592	18,163	23,847	93,219,115	255,220.0	0.02
May	936	3,120,599	936	25,424	69.6	461	479	18,522	24,523	96,167,020	263,291.0	0.02
June	933	3,111,883	933	28,361	77.6	679	692	20,655	27,951	92,881,687	254,296.2	0.02
July	957	3,105,920	957	26,505	72.6	530	547	19,554	25,687	95,751,818	262,154.2	0.02
August	983	3,101,932	983	29,121	79.7	599	607	21,562	28,105	95,590,652	261,712.9	0.02
September	1,001	3,096,663	1,001	24,006	65.7	661	662	16,693	23,407	92,355,306	252,855.0	0.02
October	1,024	3,090,326	1,024	28,510	78.1	698	709	20,101	28,602	95,247,522	260,773.5	0.02
November	1,059	3,083,437	1,059	24,986	68.4	505	514	17,532	23,996	91,972,641	251,807.4	0.03
December	1,063	3,075,872	1,063	25,109	68.7	514	529	18,005	24,091	94,796,824	259,539.6	0.03

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
2018												
January	1,099	3,071,078	1,099	29,627	81.1	554	571	21,402	28,833	94,581,266	258,949.4	0.03
February	1,095	3,059,869	1,095	28,623	78.4	633	640	20,557	29,878	85,186,366	233,227.6	0.03
March	1,124	3,052,381	1,124	30,143	82.5	537	540	22,097	28,617	94,003,330	257,367.1	0.03
April	1,131	3,043,656	1,131	26,696	73.1	561	566	19,272	26,867	90,739,857	248,432.2	0.03
May	1,156	3,036,173	1,156	29,877	81.8	713	714	21,073	29,655	93,544,468	256,110.8	0.03
June	1,146	3,027,432	1,146	31,466	86.1	760	777	23,086	33,157	90,334,252	247,321.7	0.03
July	1,196	3,020,706	1,196	34,665	94.9	996	1,001	24,002	36,818	93,109,745	254,920.6	0.03
August	1,238	3,015,323	1,238	31,619	86.6	663	672	23,045	35,241	92,902,777	254,353.9	0.03
September	1,207	3,006,456	1,207	26,182	71.7	487	497	19,051	27,541	89,696,384	245,575.3	0.03
October	1,185	3,000,750	1,185	28,328	77.6	587	596	20,289	28,227	92,446,983	253,106.0	0.03
November	1,156	2,987,121	1,156	29,249	80.1	697	703	20,942	29,871	88,963,329	243,568.3	0.03
December	1,193	2,969,626	1,193	32,510	89.0	685	696	23,300	33,740	91,530,460	250,596.7	0.03
2019												
January	1,207	2,965,054	1,207	30,911	84.6	785	793	22,120	32,150	91,327,091	250,039.9	0.03
February	1,177	2,953,382	1,177	24,235	66.4	561	563	16,964	24,837	81,759,088	223,844.2	0.03
March	1,199	2,927,088	1,199	35,245	96.5	765	783	25,569	36,269	90,115,768	246,723.5	0.03
April	1,260	2,917,535	1,260	33,011	90.4	738	741	23,340	35,455	86,969,965	238,110.8	0.03
May	1,294	2,910,874	1,294	28,793	78.8	570	579	20,291	32,543	89,637,349	245,413.7	0.03
June	1,298	2,899,491	1,298	29,691	81.3	697	702	20,929	33,743	86,212,923	236,038.1	0.03
July	1,320	2,879,468	1,320	34,361	94.1	825	835	24,735	38,918	88,558,118	242,458.9	0.03
August	1,272	2,863,402	1,272	26,528	72.6	559	563	19,170	27,081	88,137,267	241,306.7	0.03
September	1,200	2,850,741	1,200	26,244	71.9	574	574	18,383	27,849	84,844,147	232,290.6	0.03
October	1,231	2,832,757	1,231	29,373	80.4	601	603	20,917	30,949	87,147,743	238,597.5	0.03
November	1,196	2,818,207	1,196	27,850	76.2	582	589	20,228	30,519	83,892,433	229,685.0	0.03
December	1,241	2,801,822	1,241	32,646	89.4	675	677	23,966	35,283	86,316,754	236,322.4	0.03

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
<i>2020</i>												
January	1,259	2,795,508	1,259	26,644	72.9	590	594	19,889	30,912	86,071,408	235,650.7	0.03
February	1,267	2,782,568	1,267	26,821	73.4	624	632	19,468	32,762	79,850,616	218,619.1	0.03
March	1,325	2,750,794	1,325	31,645	86.6	681	682	23,385	36,074	84,378,043	231,014.5	0.03
April	1,314	2,720,142	1,314	18,670	51.1	413	416	13,877	18,579	80,929,734	221,573.5	0.03
May	1,246	2,703,358	1,246	11,380	31.2	246	249	8,437	12,761	83,331,436	228,149.0	0.03
June	1,179	2,696,022	1,179	10,876	29.8	280	281	8,580	12,529	80,421,992	220,183.4	0.03
July	1,176	2,689,586	1,176	6,849	18.8	224	224	6,101	9,097	82,588,413	226,114.8	0.03
August	1,088	2,664,992	1,088	1,328	3.6	121	122	1,312	2,312	58,413,396	159,927.2	0.03

¹Total number of users by year month may not sum up to total patients in Table 1 because cohort re-entry was allowed, enabling multiple counts for patients with multiple ARB episodes during the study period

²Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

³Proportion of ARB use estimated as number of episodes for each individual ARB in given year month divided by all ARB episodes in the same year month

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
<i>Incident ARB episodes</i>												
2014												
Q1: January - March	17,486	3,327,467	17,486	2,939,891	8,049.0	63,803	65,411	2,201,900	2,227,359	294,671,035	806,765.3	1.00
Q2: April - June	33,265	3,310,698	33,265	2,961,458	8,108.0	63,638	65,203	2,238,475	2,200,130	296,750,118	812,457.5	1.00
Q3: July - September	39,369	3,305,131	39,369	2,859,516	7,828.9	64,217	65,423	2,155,752	2,087,515	299,095,086	818,877.7	1.00
Q4: October - December	41,992	3,300,482	41,992	2,953,842	8,087.2	66,113	67,444	2,233,875	2,136,778	298,464,752	817,152.0	1.00
2015												
Q1: January - March	44,137	3,290,234	44,137	2,865,428	7,845.1	64,210	66,039	2,134,099	2,176,554	290,991,418	796,691.1	1.00
Q2: April - June	45,711	3,274,115	45,711	2,824,797	7,733.9	65,123	66,806	2,094,608	2,163,401	293,293,713	802,994.4	1.00
Q3: July - September	47,156	3,266,963	47,156	2,893,990	7,923.3	65,195	66,911	2,150,304	2,236,535	295,554,617	809,184.4	1.00
Q4: October - December	48,505	3,253,534	48,505	3,000,021	8,213.6	69,272	70,979	2,214,136	2,307,719	294,335,021	805,845.4	1.00
2016												
Q1: January - March	50,037	3,239,003	50,037	3,003,669	8,223.6	67,097	68,703	2,225,259	2,321,818	289,692,829	793,135.7	1.00
Q2: April - June	50,832	3,220,652	50,832	3,051,078	8,353.4	66,751	68,142	2,263,860	2,369,854	288,327,370	789,397.3	1.00
Q3: July - September	51,501	3,206,599	51,501	3,087,850	8,454.1	69,504	71,191	2,287,492	2,404,662	290,244,325	794,645.7	1.00
Q4: October - December	51,787	3,191,942	51,787	3,042,770	8,330.7	69,906	71,620	2,247,241	2,384,682	288,609,766	790,170.5	1.00
2017												
Q1: January - March	52,318	3,175,247	52,318	3,100,573	8,488.9	69,557	71,348	2,288,307	2,416,538	280,691,803	768,492.3	1.00
Q2: April - June	53,354	3,153,114	53,354	3,150,104	8,624.5	68,942	70,456	2,329,011	2,464,604	282,267,822	772,807.2	1.00
Q3: July - September	54,099	3,138,649	54,099	3,092,998	8,468.2	68,730	70,308	2,279,803	2,431,874	283,697,776	776,722.2	1.00
Q4: October - December	54,429	3,120,385	54,429	3,173,165	8,687.7	70,343	72,027	2,340,490	2,496,888	282,016,987	772,120.4	1.00
2018												
Q1: January - March	56,026	3,101,766	56,026	3,309,895	9,062.0	72,600	74,268	2,433,582	2,634,892	273,770,962	749,544.0	1.00
Q2: April - June	56,516	3,073,526	56,516	3,312,736	9,069.8	71,624	73,284	2,447,667	2,630,730	274,618,577	751,864.7	1.00
Q3: July - September	56,402	3,050,011	56,402	3,147,565	8,617.6	67,903	69,480	2,324,251	2,516,255	275,708,906	754,849.8	1.00
Q4: October - December	57,289	3,028,692	57,289	3,267,782	8,946.7	70,165	71,674	2,401,300	2,620,857	272,940,772	747,271.1	1.00
2019												
Q1: January - March	59,468	2,995,725	59,468	3,518,700	9,633.7	76,729	78,571	2,589,033	2,813,184	263,201,947	720,607.7	1.00
Q2: April - June	61,391	2,945,833	61,391	3,444,756	9,431.2	72,557	73,909	2,538,318	2,758,054	262,820,237	719,562.6	1.00
Q3: July - September	61,177	2,908,284	61,177	3,218,027	8,810.5	67,721	68,867	2,383,655	2,600,870	261,539,532	716,056.2	1.00
Q4: October - December	60,691	2,858,894	60,691	3,000,499	8,214.9	63,546	64,773	2,210,217	2,423,716	257,356,930	704,604.9	1.00
2020												
Q1: January - March	61,947	2,822,548	61,947	2,741,426	7,505.6	57,628	58,380	2,030,448	2,264,872	250,300,067	685,284.2	1.00
Q2: April - June	55,698	2,743,898	55,698	1,349,787	3,695.5	30,678	30,951	1,032,613	1,170,368	244,683,162	669,906.0	1.00
Q3: July - September	43,161	2,698,565	43,161	257,480	704.9	10,989	11,050	237,369	283,118	141,001,869	386,042.1	1.00

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Azilsartan												
<i>Incident Azilsartan episodes</i>												
2014												
Q1: January - March	0	3,327,467	0	0	0.0	0	0	0	0	294,671,035	806,765.3	0.00
Q2: April - June	0	3,310,698	0	0	0.0	0	0	0	0	296,750,118	812,457.5	0.00
Q3: July - September	*****	3,305,131	*****	58	0.2	*****	*****	28	56	299,095,086	818,877.7	0.00
Q4: October - December	*****	3,300,482	*****	58	0.2	*****	*****	28	28	298,464,752	817,152.0	0.00
2015												
Q1: January - March	*****	3,290,234	*****	246	0.7	6	6	168	168	290,991,418	796,691.1	0.00
Q2: April - June	*****	3,274,115	*****	0	0.0	0	0	0	0	293,293,713	802,994.4	0.00
Q3: July - September	*****	3,266,963	*****	86	0.2	*****	*****	56	56	295,554,617	809,184.4	0.00
Q4: October - December	*****	3,253,534	*****	0	0.0	0	0	0	0	294,335,021	805,845.4	0.00
2016												
Q1: January - March	0	3,239,003	0	0	0.0	0	0	0	0	289,692,829	793,135.7	0.00
Q2: April - June	*****	3,220,652	*****	86	0.2	*****	*****	56	56	288,327,370	789,397.3	0.00
Q3: July - September	*****	3,206,599	*****	66	0.2	*****	*****	36	36	290,244,325	794,645.7	0.00
Q4: October - December	*****	3,191,942	*****	0	0.0	0	0	0	0	288,609,766	790,170.5	0.00
2017												
Q1: January - March	0	3,175,247	0	0	0.0	0	0	0	0	280,691,803	768,492.3	0.00
Q2: April - June	0	3,153,114	0	0	0.0	0	0	0	0	282,267,822	772,807.2	0.00
Q3: July - September	0	3,138,649	0	0	0.0	0	0	0	0	283,697,776	776,722.2	0.00
Q4: October - December	0	3,120,385	0	0	0.0	0	0	0	0	282,016,987	772,120.4	0.00
2018												
Q1: January - March	*****	3,101,766	*****	502	1.4	8	8	420	420	273,770,962	749,544.0	0.00
Q2: April - June	*****	3,073,526	*****	0	0.0	0	0	0	0	274,618,577	751,864.7	0.00
Q3: July - September	*****	3,050,011	*****	0	0.0	0	0	0	0	275,708,906	754,849.8	0.00
Q4: October - December	*****	3,028,692	*****	200	0.5	*****	*****	140	140	272,940,772	747,271.1	0.00
2019												
Q1: January - March	*****	2,995,725	*****	0	0.0	0	0	0	0	263,201,947	720,607.7	0.00
Q2: April - June	*****	2,945,833	*****	58	0.2	*****	*****	28	56	262,820,237	719,562.6	0.00
Q3: July - September	*****	2,908,284	*****	480	1.3	*****	*****	411	411	261,539,532	716,056.2	0.00
Q4: October - December	*****	2,858,894	*****	192	0.5	*****	*****	112	112	257,356,930	704,604.9	0.00
2020												
Q1: January - March	*****	2,822,548	*****	58	0.2	*****	*****	28	112	250,300,067	685,284.2	0.00
Q2: April - June	*****	2,743,898	*****	0	0.0	0	0	0	0	244,683,162	669,906.0	0.00
Q3: July - September	*****	2,698,565	*****	55	0.2	*****	*****	30	30	141,001,869	386,042.1	0.00

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Candesartan												
<i>Incident Candesartan episodes</i>												
2014												
Q1: January - March	5,453	3,327,467	5,453	938,210	2,568.7	20,924	21,782	704,373	690,623	294,671,035	806,765.3	0.31
Q2: April - June	10,674	3,310,698	10,674	1,021,712	2,797.3	21,864	22,629	779,346	741,801	296,750,118	812,457.5	0.32
Q3: July - September	12,871	3,305,131	12,871	991,834	2,715.5	22,574	23,223	752,513	715,326	299,095,086	818,877.7	0.33
Q4: October - December	14,057	3,300,482	14,057	1,020,925	2,795.1	23,118	23,812	773,209	735,905	298,464,752	817,152.0	0.33
2015												
Q1: January - March	14,887	3,290,234	14,887	970,410	2,656.8	22,237	23,309	724,978	741,364	290,991,418	796,691.1	0.34
Q2: April - June	15,496	3,274,115	15,496	967,452	2,648.7	21,989	22,757	721,302	753,708	293,293,713	802,994.4	0.34
Q3: July - September	16,166	3,266,963	16,166	1,022,393	2,799.2	23,188	24,129	763,803	790,996	295,554,617	809,184.4	0.34
Q4: October - December	16,767	3,253,534	16,767	1,034,332	2,831.8	24,677	25,587	759,982	799,519	294,335,021	805,845.4	0.35
2016												
Q1: January - March	17,269	3,239,003	17,269	1,041,312	2,851.0	23,452	24,300	772,361	806,124	289,692,829	793,135.7	0.35
Q2: April - June	17,401	3,220,652	17,401	1,027,728	2,813.8	23,089	23,841	762,113	799,110	288,327,370	789,397.3	0.34
Q3: July - September	17,443	3,206,599	17,443	1,046,786	2,865.9	23,862	24,688	773,249	808,137	290,244,325	794,645.7	0.34
Q4: October - December	17,570	3,191,942	17,570	1,034,731	2,832.9	24,163	25,011	764,716	812,624	288,609,766	790,170.5	0.34
2017												
Q1: January - March	17,683	3,175,247	17,683	1,050,562	2,876.3	24,621	25,714	775,618	814,161	280,691,803	768,492.3	0.34
Q2: April - June	18,163	3,153,114	18,163	1,074,652	2,942.2	23,488	24,378	794,181	842,047	282,267,822	772,807.2	0.34
Q3: July - September	18,405	3,138,649	18,405	1,045,811	2,863.3	23,407	24,286	772,839	820,772	283,697,776	776,722.2	0.34
Q4: October - December	18,460	3,120,385	18,460	1,074,644	2,942.2	24,278	25,156	793,623	848,654	282,016,987	772,120.4	0.34
2018												
Q1: January - March	18,833	3,101,766	18,833	1,138,018	3,115.7	26,008	27,055	841,451	902,678	273,770,962	749,544.0	0.34
Q2: April - June	19,057	3,073,526	19,057	1,123,421	3,075.8	24,717	25,622	832,286	896,066	274,618,577	751,864.7	0.34
Q3: July - September	19,077	3,050,011	19,077	1,067,142	2,921.7	23,962	24,919	788,900	853,733	275,708,906	754,849.8	0.34
Q4: October - December	19,551	3,028,692	19,551	1,118,289	3,061.7	24,542	25,350	820,036	903,849	272,940,772	747,271.1	0.34
2019												
Q1: January - March	20,635	2,995,725	20,635	1,246,947	3,414.0	27,558	28,579	916,498	1,006,692	263,201,947	720,607.7	0.35
Q2: April - June	21,504	2,945,833	21,504	1,215,841	3,328.8	26,341	27,147	892,909	970,917	262,820,237	719,562.6	0.35
Q3: July - September	21,439	2,908,284	21,439	1,125,861	3,082.4	24,550	25,209	832,669	908,650	261,539,532	716,056.2	0.35
Q4: October - December	21,160	2,858,894	21,160	1,037,039	2,839.3	22,594	23,336	762,631	839,453	257,356,930	704,604.9	0.35
2020												
Q1: January - March	21,620	2,822,548	21,620	954,315	2,612.8	20,556	20,986	706,352	788,316	250,300,067	685,284.2	0.35
Q2: April - June	19,299	2,743,898	19,299	445,341	1,219.3	10,281	10,436	339,128	386,598	244,683,162	669,906.0	0.35
Q3: July - September	14,967	2,698,565	14,967	90,136	246.8	3,863	3,908	82,498	99,368	141,001,869	386,042.1	0.35

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Eprosartan												
<i>Incident Eprosartan episodes</i>												
2014												
Q1: January - March	53	3,327,467	53	10,293	28.2	260	260	8,004	6,746	294,671,035	806,765.3	0.00
Q2: April - June	95	3,310,698	95	8,271	22.6	188	188	6,094	7,430	296,750,118	812,457.5	0.00
Q3: July - September	122	3,305,131	122	6,625	18.1	120	120	4,704	5,304	299,095,086	818,877.7	0.00
Q4: October - December	130	3,300,482	130	6,655	18.2	125	125	4,789	7,042	298,464,752	817,152.0	0.00
2015												
Q1: January - March	128	3,290,234	128	8,009	21.9	170	170	5,682	6,378	290,991,418	796,691.1	0.00
Q2: April - June	139	3,274,115	139	8,345	22.8	213	213	5,551	7,024	293,293,713	802,994.4	0.00
Q3: July - September	150	3,266,963	150	9,501	26.0	326	326	6,682	7,139	295,554,617	809,184.4	0.00
Q4: October - December	155	3,253,534	155	10,679	29.2	296	296	7,525	7,848	294,335,021	805,845.4	0.00
2016												
Q1: January - March	146	3,239,003	146	6,306	17.3	183	184	4,610	4,969	289,692,829	793,135.7	0.00
Q2: April - June	137	3,220,652	137	8,400	23.0	213	213	6,008	6,802	288,327,370	789,397.3	0.00
Q3: July - September	128	3,206,599	128	9,004	24.7	209	209	6,621	7,724	290,244,325	794,645.7	0.00
Q4: October - December	118	3,191,942	118	4,979	13.6	73	73	3,737	3,946	288,609,766	790,170.5	0.00
2017												
Q1: January - March	141	3,175,247	141	7,523	20.6	152	153	5,279	6,677	280,691,803	768,492.3	0.00
Q2: April - June	157	3,153,114	157	8,275	22.7	161	161	5,982	7,756	282,267,822	772,807.2	0.00
Q3: July - September	176	3,138,649	176	10,180	27.9	315	321	6,881	9,732	283,697,776	776,722.2	0.00
Q4: October - December	122	3,120,385	122	5,337	14.6	84	85	3,850	4,553	282,016,987	772,120.4	0.00
2018												
Q1: January - March	101	3,101,766	101	4,676	12.8	96	96	3,358	4,549	273,770,962	749,544.0	0.00
Q2: April - June	92	3,073,526	92	3,678	10.1	68	68	2,600	3,310	274,618,577	751,864.7	0.00
Q3: July - September	94	3,050,011	94	4,247	11.6	78	79	2,732	3,825	275,708,906	754,849.8	0.00
Q4: October - December	88	3,028,692	88	3,765	10.3	75	75	2,566	3,193	272,940,772	747,271.1	0.00
2019												
Q1: January - March	79	2,995,725	79	5,257	14.4	168	168	3,629	3,746	263,201,947	720,607.7	0.00
Q2: April - June	73	2,945,833	73	3,587	9.8	61	61	2,713	4,062	262,820,237	719,562.6	0.00
Q3: July - September	79	2,908,284	79	5,074	13.9	124	124	3,542	4,153	261,539,532	716,056.2	0.00
Q4: October - December	88	2,858,894	88	3,846	10.5	67	67	2,688	3,048	257,356,930	704,604.9	0.00
2020												
Q1: January - March	80	2,822,548	80	3,698	10.1	72	72	2,646	3,193	250,300,067	685,284.2	0.00
Q2: April - June	85	2,743,898	85	2,820	7.7	95	95	2,169	2,733	244,683,162	669,906.0	0.00
Q3: July - September	64	2,698,565	64	267	0.7	11	11	222	306	141,001,869	386,042.1	0.00

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Irbesartan												
<i>Incident Irbesartan episodes</i>												
2014												
Q1: January - March	1,597	3,327,467	1,597	261,255	715.3	5,207	5,255	195,981	198,834	294,671,035	806,765.3	0.09
Q2: April - June	3,063	3,310,698	3,063	265,987	728.2	5,260	5,279	200,631	199,352	296,750,118	812,457.5	0.09
Q3: July - September	3,696	3,305,131	3,696	254,743	697.4	5,179	5,195	189,371	194,741	299,095,086	818,877.7	0.09
Q4: October - December	4,006	3,300,482	4,006	279,899	766.3	6,082	6,134	211,089	207,701	298,464,752	817,152.0	0.10
2015												
Q1: January - March	4,308	3,290,234	4,308	286,567	784.6	5,657	5,687	213,916	215,048	290,991,418	796,691.1	0.10
Q2: April - June	4,425	3,274,115	4,425	276,321	756.5	6,664	6,699	202,423	212,537	293,293,713	802,994.4	0.10
Q3: July - September	4,502	3,266,963	4,502	258,688	708.2	5,208	5,233	191,743	205,418	295,554,617	809,184.4	0.10
Q4: October - December	4,569	3,253,534	4,569	285,333	781.2	6,789	6,827	210,415	222,695	294,335,021	805,845.4	0.09
2016												
Q1: January - March	4,642	3,239,003	4,642	262,327	718.2	5,319	5,340	194,777	205,313	289,692,829	793,135.7	0.09
Q2: April - June	4,622	3,220,652	4,622	266,058	728.4	5,468	5,501	197,299	217,234	288,327,370	789,397.3	0.09
Q3: July - September	4,622	3,206,599	4,622	262,850	719.6	5,871	5,913	192,288	204,115	290,244,325	794,645.7	0.09
Q4: October - December	4,541	3,191,942	4,541	259,389	710.2	5,508	5,572	190,722	202,617	288,609,766	790,170.5	0.09
2017												
Q1: January - March	4,508	3,175,247	4,508	272,676	746.5	5,831	5,854	202,387	216,283	280,691,803	768,492.3	0.09
Q2: April - June	4,578	3,153,114	4,578	271,093	742.2	5,891	5,936	199,570	216,493	282,267,822	772,807.2	0.09
Q3: July - September	4,595	3,138,649	4,595	262,651	719.1	5,491	5,518	193,598	210,475	283,697,776	776,722.2	0.08
Q4: October - December	4,718	3,120,385	4,718	286,623	784.7	5,808	5,861	212,091	230,957	282,016,987	772,120.4	0.09
2018												
Q1: January - March	5,309	3,101,766	5,309	310,488	850.1	6,496	6,534	221,673	272,631	273,770,962	749,544.0	0.09
Q2: April - June	5,132	3,073,526	5,132	276,435	756.8	5,910	5,956	203,427	221,296	274,618,577	751,864.7	0.09
Q3: July - September	4,765	3,050,011	4,765	252,240	690.6	5,147	5,222	186,508	201,704	275,708,906	754,849.8	0.08
Q4: October - December	4,723	3,028,692	4,723	260,753	713.9	5,178	5,189	191,099	214,901	272,940,772	747,271.1	0.08
2019												
Q1: January - March	4,850	2,995,725	4,850	282,213	772.7	6,091	6,178	208,762	229,560	263,201,947	720,607.7	0.08
Q2: April - June	4,822	2,945,833	4,822	269,124	736.8	5,512	5,549	199,634	223,168	262,820,237	719,562.6	0.08
Q3: July - September	4,770	2,908,284	4,770	240,214	657.7	4,766	4,812	176,299	198,534	261,539,532	716,056.2	0.08
Q4: October - December	4,683	2,858,894	4,683	224,828	615.5	4,430	4,447	165,137	185,828	257,356,930	704,604.9	0.08
2020												
Q1: January - March	4,720	2,822,548	4,720	203,325	556.7	4,000	4,022	150,787	172,116	250,300,067	685,284.2	0.08
Q2: April - June	4,326	2,743,898	4,326	113,658	311.2	2,492	2,504	86,620	102,295	244,683,162	669,906.0	0.08
Q3: July - September	3,396	2,698,565	3,396	20,879	57.2	897	897	19,315	24,376	141,001,869	386,042.1	0.08

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Losartan												
<i>Incident Losartan episodes</i>												
2014												
Q1: January - March	8,481	3,327,467	8,481	1,412,471	3,867.1	29,859	30,438	1,055,902	1,045,750	294,671,035	806,765.3	0.49
Q2: April - June	16,650	3,310,698	16,650	1,467,294	4,017.2	31,620	32,316	1,097,503	1,084,891	296,750,118	812,457.5	0.50
Q3: July - September	19,964	3,305,131	19,964	1,429,334	3,913.3	32,000	32,497	1,076,170	1,037,475	299,095,086	818,877.7	0.51
Q4: October - December	20,946	3,300,482	20,946	1,447,608	3,963.3	32,504	33,035	1,091,841	1,042,804	298,464,752	817,152.0	0.50
2015												
Q1: January - March	21,924	3,290,234	21,924	1,427,344	3,907.9	32,600	33,292	1,058,610	1,076,328	290,991,418	796,691.1	0.50
Q2: April - June	22,791	3,274,115	22,791	1,386,448	3,795.9	31,883	32,691	1,025,096	1,041,574	293,293,713	802,994.4	0.50
Q3: July - September	23,334	3,266,963	23,334	1,421,341	3,891.4	32,289	32,989	1,052,102	1,087,056	295,554,617	809,184.4	0.49
Q4: October - December	24,006	3,253,534	24,006	1,502,657	4,114.1	33,667	34,328	1,111,662	1,140,005	294,335,021	805,845.4	0.49
2016												
Q1: January - March	24,941	3,239,003	24,941	1,510,827	4,136.4	33,773	34,360	1,116,198	1,152,099	289,692,829	793,135.7	0.50
Q2: April - June	25,619	3,220,652	25,619	1,559,623	4,270.0	33,578	34,146	1,155,377	1,189,847	288,327,370	789,397.3	0.50
Q3: July - September	25,978	3,206,599	25,978	1,561,781	4,275.9	34,956	35,709	1,158,295	1,193,612	290,244,325	794,645.7	0.50
Q4: October - December	26,173	3,191,942	26,173	1,550,038	4,243.8	35,479	36,234	1,143,162	1,194,460	288,609,766	790,170.5	0.51
2017												
Q1: January - March	26,802	3,175,247	26,802	1,602,654	4,387.8	35,043	35,668	1,179,246	1,235,816	280,691,803	768,492.3	0.51
Q2: April - June	27,410	3,153,114	27,410	1,606,762	4,399.1	35,134	35,652	1,187,535	1,234,714	282,267,822	772,807.2	0.51
Q3: July - September	27,882	3,138,649	27,882	1,594,485	4,365.5	35,071	35,689	1,171,956	1,232,741	283,697,776	776,722.2	0.52
Q4: October - December	27,993	3,120,385	27,993	1,621,696	4,440.0	35,760	36,388	1,194,131	1,249,049	282,016,987	772,120.4	0.51
2018												
Q1: January - March	28,617	3,101,766	28,617	1,667,591	4,565.6	35,996	36,545	1,224,538	1,284,254	273,770,962	749,544.0	0.51
Q2: April - June	29,000	3,073,526	29,000	1,719,027	4,706.4	36,586	37,225	1,268,312	1,337,052	274,618,577	751,864.7	0.51
Q3: July - September	29,060	3,050,011	29,060	1,618,419	4,431.0	34,172	34,629	1,192,884	1,260,691	275,708,906	754,849.8	0.52
Q4: October - December	29,446	3,028,692	29,446	1,692,167	4,632.9	36,107	36,743	1,245,209	1,320,109	272,940,772	747,271.1	0.51
2019												
Q1: January - March	30,433	2,995,725	30,433	1,783,879	4,884.0	38,091	38,745	1,310,741	1,387,316	263,201,947	720,607.7	0.51
Q2: April - June	31,402	2,945,833	31,402	1,759,726	4,817.9	36,395	36,853	1,297,110	1,369,198	262,820,237	719,562.6	0.51
Q3: July - September	31,313	2,908,284	31,313	1,668,579	4,568.3	34,326	34,740	1,239,843	1,318,156	261,539,532	716,056.2	0.51
Q4: October - December	31,214	2,858,894	31,214	1,553,967	4,254.5	32,666	33,112	1,146,453	1,221,766	257,356,930	704,604.9	0.51
2020												
Q1: January - March	31,939	2,822,548	31,939	1,419,425	3,886.2	29,516	29,785	1,050,161	1,136,489	250,300,067	685,284.2	0.52
Q2: April - June	28,698	2,743,898	28,698	706,600	1,934.6	15,963	16,059	543,042	598,947	244,683,162	669,906.0	0.52
Q3: July - September	22,119	2,698,565	22,119	130,297	356.7	5,538	5,553	120,602	138,783	141,001,869	386,042.1	0.51

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Olmesartan												
<i>Incident Olmesartan episodes</i>												
2014												
Q1: January - March	353	3,327,467	353	53,450	146.3	1,390	1,400	37,801	39,304	294,671,035	806,765.3	0.02
Q2: April - June	606	3,310,698	606	45,416	124.3	1,210	1,227	31,930	32,018	296,750,118	812,457.5	0.02
Q3: July - September	689	3,305,131	689	53,319	146.0	1,380	1,387	39,446	36,952	299,095,086	818,877.7	0.02
Q4: October - December	774	3,300,482	774	62,043	169.9	1,464	1,484	46,098	41,758	298,464,752	817,152.0	0.02
2015												
Q1: January - March	834	3,290,234	834	50,093	137.1	1,137	1,149	36,606	35,138	290,991,418	796,691.1	0.02
Q2: April - June	794	3,274,115	794	45,411	124.3	1,099	1,118	32,606	31,709	293,293,713	802,994.4	0.02
Q3: July - September	788	3,266,963	788	43,312	118.6	1,034	1,037	30,634	32,486	295,554,617	809,184.4	0.02
Q4: October - December	759	3,253,534	759	42,299	115.8	1,005	1,030	31,138	31,819	294,335,021	805,845.4	0.02
2016												
Q1: January - March	769	3,239,003	769	41,878	114.7	848	850	29,827	32,020	289,692,829	793,135.7	0.02
Q2: April - June	749	3,220,652	749	45,051	123.3	1,087	1,098	33,380	32,146	288,327,370	789,397.3	0.01
Q3: July - September	762	3,206,599	762	40,044	109.6	856	857	29,077	29,811	290,244,325	794,645.7	0.01
Q4: October - December	744	3,191,942	744	43,478	119.0	1,045	1,045	31,440	30,968	288,609,766	790,170.5	0.01
2017												
Q1: January - March	728	3,175,247	728	38,034	104.1	975	985	27,432	28,119	280,691,803	768,492.3	0.01
Q2: April - June	713	3,153,114	713	43,574	119.3	905	910	32,193	31,762	282,267,822	772,807.2	0.01
Q3: July - September	708	3,138,649	708	38,528	105.5	957	960	27,332	29,001	283,697,776	776,722.2	0.01
Q4: October - December	740	3,120,385	740	46,853	128.3	1,161	1,203	33,436	35,402	282,016,987	772,120.4	0.01
2018												
Q1: January - March	730	3,101,766	730	37,707	103.2	859	862	27,065	28,227	273,770,962	749,544.0	0.01
Q2: April - June	701	3,073,526	701	38,457	105.3	807	811	27,468	29,146	274,618,577	751,864.7	0.01
Q3: July - September	690	3,050,011	690	40,589	111.1	868	910	30,148	31,458	275,708,906	754,849.8	0.01
Q4: October - December	728	3,028,692	728	41,202	112.8	885	890	29,381	31,381	272,940,772	747,271.1	0.01
2019												
Q1: January - March	775	2,995,725	775	47,850	131.0	1,036	1,054	34,368	36,782	263,201,947	720,607.7	0.01
Q2: April - June	825	2,945,833	825	48,299	132.2	1,019	1,035	35,332	37,646	262,820,237	719,562.6	0.01
Q3: July - September	857	2,908,284	857	44,991	123.2	964	969	31,890	35,199	261,539,532	716,056.2	0.01
Q4: October - December	878	2,858,894	878	45,407	124.3	1,022	1,022	32,316	35,691	257,356,930	704,604.9	0.01
2020												
Q1: January - March	845	2,822,548	845	32,750	89.7	665	674	24,104	25,994	250,300,067	685,284.2	0.01
Q2: April - June	748	2,743,898	748	18,877	51.7	425	425	13,391	15,783	244,683,162	669,906.0	0.01
Q3: July - September	555	2,698,565	555	3,135	8.6	130	130	2,960	3,700	141,001,869	386,042.1	0.01

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Telmisartan												
<i>Incident Telmisartan episodes</i>												
2014												
Q1: January - March	288	3,327,467	288	47,490	130.0	820	827	36,238	34,913	294,671,035	806,765.3	0.02
Q2: April - June	560	3,310,698	560	50,627	138.6	890	897	38,915	36,630	296,750,118	812,457.5	0.02
Q3: July - September	679	3,305,131	679	49,161	134.6	1,170	1,177	36,654	36,594	299,095,086	818,877.7	0.02
Q4: October - December	724	3,300,482	724	52,736	144.4	1,069	1,072	41,213	35,980	298,464,752	817,152.0	0.02
2015												
Q1: January - March	705	3,290,234	705	39,540	108.3	640	640	29,760	30,501	290,991,418	796,691.1	0.02
Q2: April - June	723	3,274,115	723	49,373	135.2	1,181	1,183	36,753	37,065	293,293,713	802,994.4	0.02
Q3: July - September	779	3,266,963	779	49,596	135.8	1,024	1,032	37,072	38,777	295,554,617	809,184.4	0.02
Q4: October - December	773	3,253,534	773	41,367	113.3	842	852	30,556	31,899	294,335,021	805,845.4	0.02
2016												
Q1: January - March	761	3,239,003	761	43,355	118.7	827	827	32,136	35,250	289,692,829	793,135.7	0.02
Q2: April - June	776	3,220,652	776	45,839	125.5	967	969	34,124	37,127	288,327,370	789,397.3	0.02
Q3: July - September	782	3,206,599	782	45,274	124.0	919	922	34,134	35,400	290,244,325	794,645.7	0.02
Q4: October - December	800	3,191,942	800	43,725	119.7	1,019	1,023	31,626	33,731	288,609,766	790,170.5	0.02
2017												
Q1: January - March	826	3,175,247	826	45,589	124.8	764	768	34,266	35,550	280,691,803	768,492.3	0.02
Q2: April - June	823	3,153,114	823	50,200	137.4	1,051	1,056	36,629	39,199	282,267,822	772,807.2	0.02
Q3: July - September	823	3,138,649	823	43,210	118.3	918	918	32,038	33,712	283,697,776	776,722.2	0.02
Q4: October - December	778	3,120,385	778	42,972	117.7	858	872	31,603	34,399	282,016,987	772,120.4	0.01
2018												
Q1: January - March	765	3,101,766	765	43,689	119.6	789	792	32,616	35,014	273,770,962	749,544.0	0.01
Q2: April - June	808	3,073,526	808	45,865	125.6	905	912	32,631	35,819	274,618,577	751,864.7	0.01
Q3: July - September	927	3,050,011	927	56,035	153.4	979	986	41,316	47,943	275,708,906	754,849.8	0.02
Q4: October - December	931	3,028,692	931	46,798	128.1	842	859	33,885	40,288	272,940,772	747,271.1	0.02
2019												
Q1: January - March	851	2,995,725	851	43,140	118.1	973	984	31,127	34,955	263,201,947	720,607.7	0.01
Q2: April - June	851	2,945,833	851	42,559	116.5	693	696	30,924	34,605	262,820,237	719,562.6	0.01
Q3: July - September	783	2,908,284	783	35,155	96.2	634	634	25,726	29,832	261,539,532	716,056.2	0.01
Q4: October - December	756	2,858,894	756	38,242	104.7	677	684	27,799	32,523	257,356,930	704,604.9	0.01
2020												
Q1: January - March	797	2,822,548	797	37,322	102.2	672	675	27,150	31,819	250,300,067	685,284.2	0.01
Q2: April - June	752	2,743,898	752	21,117	57.8	435	438	16,389	19,038	244,683,162	669,906.0	0.01
Q3: July - September	611	2,698,565	611	4,534	12.4	191	191	4,118	4,912	141,001,869	386,042.1	0.01

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
<i>Incident Valsartan episodes</i>												
2014												
Q1: January - March	1,267	3,327,467	1,267	137,445	376.3	2,856	2,877	92,641	139,357	294,671,035	806,765.3	0.07
Q2: April - June	1,569	3,310,698	1,569	64,411	176.3	1,231	1,254	46,621	60,132	296,750,118	812,457.5	0.05
Q3: July - September	996	3,305,131	996	60,368	165.3	1,291	1,312	44,207	47,668	299,095,086	818,877.7	0.03
Q4: October - December	1,031	3,300,482	1,031	74,219	203.2	1,354	1,372	55,589	55,644	298,464,752	817,152.0	0.02
2015												
Q1: January - March	1,135	3,290,234	1,135	72,142	197.5	1,445	1,467	53,484	60,641	290,991,418	796,691.1	0.03
Q2: April - June	1,186	3,274,115	1,186	76,098	208.3	1,551	1,579	56,041	64,407	293,293,713	802,994.4	0.03
Q3: July - September	1,275	3,266,963	1,275	74,458	203.9	1,477	1,508	54,454	60,445	295,554,617	809,184.4	0.03
Q4: October - December	1,299	3,253,534	1,299	69,495	190.3	1,451	1,495	50,352	60,912	294,335,021	805,845.4	0.03
2016												
Q1: January - March	1,350	3,239,003	1,350	78,792	215.7	1,953	2,080	57,242	66,685	289,692,829	793,135.7	0.03
Q2: April - June	1,388	3,220,652	1,388	85,787	234.9	1,878	1,896	62,133	74,396	288,327,370	789,397.3	0.03
Q3: July - September	1,635	3,206,599	1,635	100,227	274.4	2,061	2,092	71,195	101,873	290,244,325	794,645.7	0.03
Q4: October - December	1,684	3,191,942	1,684	83,002	227.2	1,803	1,829	59,320	81,577	288,609,766	790,170.5	0.03
2017												
Q1: January - March	1,426	3,175,247	1,426	67,959	186.1	1,535	1,549	47,979	63,245	280,691,803	768,492.3	0.03
Q2: April - June	1,280	3,153,114	1,280	79,250	217.0	1,724	1,763	57,340	76,321	282,267,822	772,807.2	0.02
Q3: July - September	1,308	3,138,649	1,308	79,632	218.0	1,790	1,816	57,809	77,199	283,697,776	776,722.2	0.02
Q4: October - December	1,400	3,120,385	1,400	78,605	215.2	1,717	1,752	55,638	76,688	282,016,987	772,120.4	0.03
2018												
Q1: January - March	1,489	3,101,766	1,489	88,393	242.0	1,724	1,751	64,056	87,327	273,770,962	749,544.0	0.03
Q2: April - June	1,538	3,073,526	1,538	88,039	241.0	2,034	2,057	63,431	89,679	274,618,577	751,864.7	0.03
Q3: July - September	1,611	3,050,011	1,611	92,466	253.2	2,146	2,170	66,098	99,600	275,708,906	754,849.8	0.03
Q4: October - December	1,636	3,028,692	1,636	90,087	246.6	1,969	1,995	64,531	91,837	272,940,772	747,271.1	0.03
2019												
Q1: January - March	1,633	2,995,725	1,633	90,391	247.5	2,111	2,139	64,653	93,256	263,201,947	720,607.7	0.03
Q2: April - June	1,713	2,945,833	1,713	91,495	250.5	2,005	2,022	64,560	101,740	262,820,237	719,562.6	0.03
Q3: July - September	1,723	2,908,284	1,723	87,133	238.6	1,958	1,972	62,288	93,848	261,539,532	716,056.2	0.03
Q4: October - December	1,697	2,858,894	1,697	89,869	246.0	1,858	1,869	65,111	96,751	257,356,930	704,604.9	0.03

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
2020												
Q1: January - March	1,768	2,822,548	1,768	85,110	233.0	1,895	1,908	62,742	99,748	250,300,067	685,284.2	0.03
Q2: April - June	1,614	2,743,898	1,614	40,926	112.0	939	946	30,894	43,868	244,683,162	669,906.0	0.03
Q3: July - September	1,295	2,698,565	1,295	8,177	22.4	345	346	7,413	11,409	141,001,869	386,042.1	0.03

¹Total number of users by year quarter may not sum up to total patients in Table 1 because cohort re-entry was allowed, enabling multiple counts for patients with multiple ARB episodes during the study period

²Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

³Proportion of ARB use estimated as number of episodes for each individual ARB in given year quarter divided by all ARB episodes in the same year quarter

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2e. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020, Overall

	Prevalent Users	Eligible Members ¹	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ¹	Eligible Member Years ¹	Proportion of All ARB Use ²
ARB												
<i>Prevalent ARB episodes</i>												
	578,652	4,474,842	3,270,823	515,493,950	1,411,345.5	11,540,914	11,788,816	380,824,147	405,920,571	8,149,957,919	22,313,368.7	1.00
Azilsartan												
<i>Prevalent Azilsartan episodes</i>												
	30	4,474,842	171	25,732	70.5	525	531	18,772	19,994	8,149,957,919	22,313,368.7	0.00
Candesartan												
<i>Prevalent Candesartan episodes</i>												
	207,004	4,474,842	1,117,827	179,125,501	490,418.9	4,056,031	4,196,780	132,751,604	141,627,242	8,149,957,919	22,313,368.7	0.34
Eprosartan												
<i>Prevalent Eprosartan episodes</i>												
	2,215	4,474,842	12,957	2,037,168	5,577.5	48,428	48,536	1,451,812	1,664,216	8,149,957,919	22,313,368.7	0.00
Irbesartan												
<i>Prevalent Irbesartan episodes</i>												
	56,805	4,474,842	334,601	52,224,639	142,983.3	1,153,707	1,162,615	38,358,907	41,442,047	8,149,957,919	22,313,368.7	0.10
Losartan												
<i>Prevalent Losartan episodes</i>												
	293,039	4,474,842	1,580,156	245,928,491	673,315.5	5,459,076	5,545,142	181,454,185	190,739,886	8,149,957,919	22,313,368.7	0.48
Olmesartan												
<i>Prevalent Olmesartan episodes</i>												
	13,067	4,474,842	75,319	11,735,463	32,129.9	278,728	281,974	8,393,829	8,703,790	8,149,957,919	22,313,368.7	0.02
Telmisartan												
<i>Prevalent Telmisartan episodes</i>												
	10,865	4,474,842	61,814	9,586,794	26,247.2	202,442	204,305	7,088,289	7,527,186	8,149,957,919	22,313,368.7	0.02
Valsartan												
<i>Prevalent Valsartan episodes</i>												
	23,580	4,474,842	100,075	14,764,429	40,422.8	326,194	332,667	10,737,396	13,575,469	8,149,957,919	22,313,368.7	0.03

¹Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

²Proportion of ARB use estimated as number of episodes for each individual ARB divided by all ARB episodes

Table 2f. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Age Group

Age Group	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
<i>Prevalent ARB episodes</i>												
18-44 years	32,927	721,147	117,058	16,241,403	44,466.5	318,136	326,068	11,856,563	12,875,366	965,199,192	2,642,571.4	1.00
45-64 years	213,455	2,028,148	1,071,346	162,985,916	446,231.1	3,296,766	3,367,255	121,026,896	129,338,316	3,182,823,863	8,714,096.8	1.00
More than 65 years	381,030	2,508,179	2,082,419	336,266,631	920,647.9	7,926,012	8,095,493	247,940,688	263,706,889	4,001,934,864	10,956,700.5	1.00
Azilsartan												
<i>Prevalent Azilsartan episodes</i>												
18-44 years	*****	721,147	6	1,031	2.8	25	25	729	729	965,199,192	2,642,571.4	0.00
45-64 years	*****	2,028,148	60	8,719	23.9	163	163	6,484	6,988	3,182,823,863	8,714,096.8	0.00
More than 65 years	20	2,508,179	105	15,982	43.8	337	343	11,559	12,277	4,001,934,864	10,956,700.5	0.00
Candesartan												
<i>Prevalent Candesartan episodes</i>												
18-44 years	11,752	721,147	37,216	5,177,564	14,175.4	104,484	108,913	3,780,654	4,188,109	965,199,192	2,642,571.4	0.32
45-64 years	72,010	2,028,148	347,749	53,894,820	147,556.0	1,103,130	1,142,961	40,176,531	42,925,632	3,182,823,863	8,714,096.8	0.32
More than 65 years	139,108	2,508,179	732,862	120,053,117	328,687.5	2,848,417	2,944,906	88,794,419	94,513,501	4,001,934,864	10,956,700.5	0.35
Eprosartan												
<i>Prevalent Eprosartan episodes</i>												
18-44 years	27	721,147	83	12,061	33.0	229	229	8,991	9,365	965,199,192	2,642,571.4	0.00
45-64 years	522	2,028,148	2,755	426,945	1,168.9	9,298	9,327	304,142	355,927	3,182,823,863	8,714,096.8	0.00
More than 65 years	1,830	2,508,179	10,119	1,598,162	4,375.5	38,901	38,980	1,138,679	1,298,923	4,001,934,864	10,956,700.5	0.00
Irbesartan												
<i>Prevalent Irbesartan episodes</i>												
18-44 years	3,409	721,147	13,706	1,877,056	5,139.1	36,467	36,746	1,355,059	1,546,293	965,199,192	2,642,571.4	0.12
45-64 years	20,995	2,028,148	111,651	16,911,902	46,302.3	339,341	341,843	12,476,036	13,581,199	3,182,823,863	8,714,096.8	0.10
More than 65 years	37,659	2,508,179	209,244	33,435,681	91,541.9	777,899	784,026	24,527,812	26,314,555	4,001,934,864	10,956,700.5	0.10
Losartan												
<i>Prevalent Losartan episodes</i>												
18-44 years	16,699	721,147	60,010	8,339,857	22,833.3	160,655	163,539	6,100,097	6,410,564	965,199,192	2,642,571.4	0.51
45-64 years	111,700	2,028,148	539,152	80,980,318	221,712.0	1,619,949	1,645,147	60,068,287	63,289,255	3,182,823,863	8,714,096.8	0.50
More than 65 years	188,218	2,508,179	980,994	156,608,316	428,770.2	3,678,472	3,736,456	115,285,801	121,040,067	4,001,934,864	10,956,700.5	0.47
Olmesartan												
<i>Prevalent Olmesartan episodes</i>												
18-44 years	465	721,147	1,635	217,973	596.8	4,574	4,659	151,875	164,350	965,199,192	2,642,571.4	0.01
45-64 years	4,664	2,028,148	24,021	3,603,513	9,865.9	78,174	78,901	2,585,499	2,695,857	3,182,823,863	8,714,096.8	0.02
More than 65 years	9,082	2,508,179	49,663	7,913,977	21,667.3	195,980	198,414	5,656,455	5,843,583	4,001,934,864	10,956,700.5	0.02

Table 2f. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Age Group

Age Group	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Telmisartan												
<i>Prevalent Telmisartan episodes</i>												
18-44 years	533	721,147	1,744	230,459	631.0	4,009	4,053	168,043	179,131	965,199,192	2,642,571.4	0.01
45-64 years	3,678	2,028,148	17,896	2,660,326	7,283.6	51,226	51,752	1,970,079	2,102,961	3,182,823,863	8,714,096.8	0.02
More than 65 years	7,554	2,508,179	42,174	6,696,009	18,332.7	147,207	148,500	4,950,167	5,245,094	4,001,934,864	10,956,700.5	0.02
Valsartan												
<i>Prevalent Valsartan episodes</i>												
18-44 years	940	721,147	2,928	382,701	1,047.8	7,520	7,712	275,467	360,017	965,199,192	2,642,571.4	0.03
45-64 years	8,037	2,028,148	31,268	4,437,185	12,148.4	90,150	91,735	3,237,280	4,159,059	3,182,823,863	8,714,096.8	0.03
More than 65 years	15,941	2,508,179	65,879	9,944,543	27,226.7	228,524	233,220	7,224,649	9,056,393	4,001,934,864	10,956,700.5	0.03

¹Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

²Proportion of ARB use estimated as number of episodes for each individual ARB divided by all ARB episodes in the same age group

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
ARB												
<i>Prevalent ARB episodes</i>												
2014												
January	30,598	3,507,846	30,598	5,332,787	14,600.4	120,201	122,899	3,958,305	4,113,283	108,292,422	296,488.5	1.00
February	59,657	3,503,171	59,693	5,071,948	13,886.2	115,186	118,366	3,755,403	3,908,842	97,729,726	267,569.4	1.00
March	89,165	3,502,444	90,494	5,440,540	14,895.4	120,715	123,054	4,037,871	4,164,733	108,131,605	296,048.2	1.00
April	112,511	3,500,386	115,183	5,401,237	14,787.8	120,146	122,946	4,012,430	4,138,152	104,600,874	286,381.6	1.00
May	129,630	3,500,442	132,624	5,380,207	14,730.2	119,377	121,931	3,995,241	4,091,429	108,077,729	295,900.7	1.00
June	142,325	3,496,708	145,762	5,382,938	14,737.7	119,610	121,884	3,997,114	4,111,325	104,552,935	286,250.3	1.00
July	155,077	3,497,621	159,864	5,767,035	15,789.3	126,795	129,218	4,284,481	4,393,348	107,934,819	295,509.4	1.00
August	161,911	3,498,115	166,213	5,207,778	14,258.1	117,544	119,748	3,842,050	3,977,070	107,983,758	295,643.4	1.00
September	170,029	3,497,642	174,826	5,885,907	16,114.7	134,176	137,192	4,358,926	4,465,733	104,529,462	286,186.1	1.00
October	177,454	3,498,776	183,092	5,872,383	16,077.7	133,028	135,884	4,356,788	4,455,880	107,978,970	295,630.3	1.00
November	180,932	3,497,242	185,356	5,306,029	14,527.1	119,083	121,374	3,928,329	4,040,274	104,478,437	286,046.4	1.00
December	187,692	3,497,280	192,666	5,921,743	16,212.8	131,583	134,956	4,384,098	4,542,150	107,940,383	295,524.7	1.00
2015												
January	191,341	3,496,690	197,014	5,728,761	15,684.5	130,093	133,308	4,232,737	4,407,027	107,881,672	295,363.9	1.00
February	192,768	3,492,219	197,901	5,666,438	15,513.9	129,189	132,452	4,178,481	4,344,628	97,372,716	266,592.0	1.00
March	199,605	3,490,152	205,909	6,353,864	17,395.9	141,734	144,904	4,693,999	4,886,544	107,733,931	294,959.4	1.00
April	202,846	3,488,959	209,242	5,800,106	15,879.8	130,692	134,052	4,285,814	4,463,346	104,230,695	285,368.1	1.00
May	204,886	3,488,452	210,491	5,711,454	15,637.1	127,671	130,705	4,219,469	4,414,591	107,700,240	294,867.2	1.00
June	208,402	3,485,548	214,531	6,292,976	17,229.2	141,947	145,036	4,649,353	4,849,874	104,209,432	285,309.9	1.00
July	213,107	3,485,913	220,732	6,337,267	17,350.5	142,266	145,427	4,678,351	4,892,724	107,580,481	294,539.3	1.00
August	213,050	3,485,067	218,621	5,632,547	15,421.1	126,464	129,042	4,144,934	4,352,911	107,600,723	294,594.7	1.00
September	217,218	3,484,792	224,133	6,498,172	17,791.0	145,962	149,488	4,794,168	5,026,639	104,129,782	285,091.8	1.00
October	219,196	3,483,124	225,895	6,209,096	16,999.6	140,549	143,885	4,572,959	4,817,302	107,503,246	294,327.8	1.00
November	220,864	3,478,261	226,766	6,287,221	17,213.5	143,617	147,090	4,631,624	4,849,666	103,945,706	284,587.8	1.00
December	226,007	3,475,769	232,587	6,351,651	17,389.9	141,528	144,782	4,679,759	4,892,080	107,309,180	293,796.5	1.00

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
ARB												
2016												
January	226,016	3,473,355	232,230	6,107,681	16,721.9	138,297	141,416	4,515,263	4,722,895	107,231,746	293,584.5	1.00
February	227,459	3,469,581	234,619	6,621,132	18,127.7	151,527	155,413	4,866,049	5,116,177	100,224,321	274,399.2	1.00
March	232,290	3,468,985	240,435	6,873,905	18,819.7	154,814	158,097	5,071,964	5,330,790	107,021,614	293,009.2	1.00
April	233,072	3,464,889	239,692	6,451,918	17,664.4	145,365	148,850	4,750,587	4,995,576	103,490,698	283,342.1	1.00
May	234,976	3,461,155	241,676	6,605,848	18,085.8	146,372	149,671	4,877,482	5,137,493	106,891,996	292,654.3	1.00
June	238,124	3,458,252	245,422	6,748,169	18,475.5	150,799	154,274	4,979,218	5,246,126	103,368,878	283,008.6	1.00
July	239,062	3,455,547	245,811	6,509,365	17,821.7	145,317	148,771	4,812,536	5,080,298	106,697,888	292,122.9	1.00
August	242,543	3,455,916	249,953	6,999,646	19,164.0	155,915	159,448	5,168,196	5,443,450	106,702,337	292,135.1	1.00
September	244,101	3,452,879	251,530	6,854,288	18,766.0	154,792	158,449	5,052,955	5,344,795	103,169,294	282,462.1	1.00
October	245,278	3,447,391	252,487	6,697,979	18,338.1	151,864	155,377	4,937,448	5,234,213	106,451,503	291,448.3	1.00
November	248,583	3,442,934	256,646	7,065,358	19,343.9	159,903	163,206	5,216,962	5,501,746	102,889,008	281,694.8	1.00
December	249,968	3,440,236	256,469	6,591,678	18,047.0	147,473	150,551	4,859,205	5,123,227	106,173,852	290,688.2	1.00
2017												
January	251,003	3,436,319	258,274	7,043,703	19,284.6	158,757	162,623	5,196,149	5,495,557	106,084,392	290,443.2	1.00
February	250,964	3,429,829	258,987	6,698,684	18,340.0	152,141	155,982	4,925,113	5,227,240	95,664,633	261,915.5	1.00
March	256,399	3,427,335	265,730	7,494,462	20,518.7	167,766	171,500	5,530,289	5,845,858	105,767,800	289,576.5	1.00
April	255,443	3,422,433	261,975	6,527,959	17,872.6	146,242	149,843	4,810,310	5,107,621	102,287,330	280,047.4	1.00
May	259,388	3,420,701	267,427	7,392,546	20,239.7	164,722	168,205	5,447,138	5,773,259	105,599,916	289,116.8	1.00
June	260,836	3,414,139	268,846	7,172,537	19,637.3	160,275	164,221	5,284,568	5,633,947	102,075,503	279,467.5	1.00
July	262,423	3,410,527	270,286	7,076,045	19,373.2	157,159	160,550	5,210,056	5,532,219	105,312,720	288,330.5	1.00
August	265,365	3,408,462	274,268	7,302,714	19,993.7	162,438	166,129	5,373,342	5,716,021	105,217,268	288,069.2	1.00
September	264,739	3,405,273	271,895	6,979,645	19,109.2	156,923	160,552	5,132,728	5,494,669	101,730,015	278,521.6	1.00
October	267,104	3,400,665	275,289	7,547,919	20,665.1	168,656	172,593	5,566,015	5,936,681	104,997,747	287,468.2	1.00
November	269,616	3,395,804	278,011	7,395,863	20,248.8	166,238	170,040	5,436,907	5,830,271	101,467,725	277,803.5	1.00
December	269,849	3,390,282	276,169	6,722,226	18,404.5	148,796	152,226	4,937,657	5,274,600	104,676,070	286,587.5	1.00

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
ARB												
2018												
January	273,457	3,386,976	282,329	7,746,114	21,207.7	173,456	177,614	5,687,082	6,115,383	104,506,931	286,124.4	1.00
February	272,591	3,378,265	281,017	7,137,417	19,541.2	161,018	164,495	5,230,855	5,615,681	94,210,603	257,934.6	1.00
March	276,528	3,372,159	285,397	7,566,461	20,715.8	169,477	173,376	5,558,774	5,934,240	104,048,900	284,870.4	1.00
April	276,602	3,366,021	284,130	7,334,911	20,081.9	160,742	164,566	5,398,222	5,783,925	100,523,173	275,217.4	1.00
May	280,939	3,360,077	290,567	7,797,462	21,348.3	173,454	177,483	5,735,527	6,147,879	103,725,063	283,983.7	1.00
June	280,413	3,353,599	288,426	7,249,991	19,849.4	160,027	163,678	5,325,675	5,724,457	100,253,057	274,477.9	1.00
July	282,433	3,348,920	290,862	7,862,021	21,525.0	173,311	176,861	5,780,551	6,214,182	103,411,558	283,125.4	1.00
August	285,698	3,345,055	295,487	7,619,396	20,860.8	168,002	171,679	5,592,785	6,023,301	103,253,070	282,691.5	1.00
September	283,399	3,337,642	290,675	7,029,476	19,245.7	156,496	160,110	5,171,432	5,563,879	99,758,114	273,122.8	1.00
October	286,945	3,333,041	296,163	8,137,786	22,280.0	180,036	184,092	5,995,938	6,485,119	102,889,905	281,697.2	1.00
November	286,657	3,320,650	295,560	7,500,262	20,534.6	164,269	168,006	5,531,332	6,005,088	99,089,300	271,291.7	1.00
December	286,692	3,304,275	293,898	7,041,356	19,278.2	151,255	154,205	5,171,659	5,608,015	102,043,869	279,380.9	1.00
2019												
January	290,927	3,300,870	300,909	7,791,541	21,332.1	170,584	174,071	5,731,664	6,221,269	101,879,735	278,931.5	1.00
February	288,265	3,290,887	297,115	7,222,290	19,773.6	159,716	163,558	5,303,625	5,760,975	91,267,938	249,878.0	1.00
March	291,018	3,262,310	299,692	7,607,529	20,828.3	166,625	170,394	5,601,442	6,049,100	100,679,246	275,644.8	1.00
April	293,596	3,256,535	302,229	7,733,980	21,174.5	168,374	171,973	5,692,630	6,182,372	97,288,410	266,361.1	1.00
May	297,471	3,252,842	307,462	7,850,694	21,494.0	170,801	174,323	5,777,043	6,301,859	100,383,670	274,835.5	1.00
June	295,718	3,244,286	303,200	6,890,502	18,865.2	150,160	152,905	5,073,219	5,519,158	96,646,185	264,602.8	1.00
July	299,073	3,224,000	308,889	8,165,839	22,356.8	177,459	180,679	6,013,053	6,543,849	99,374,866	272,073.6	1.00
August	299,729	3,209,477	308,827	7,181,991	19,663.2	155,429	158,231	5,279,379	5,770,281	98,994,635	271,032.5	1.00
September	299,068	3,198,349	307,059	7,173,269	19,639.3	155,509	158,271	5,283,293	5,763,186	95,374,854	261,122.1	1.00
October	302,762	3,180,417	313,416	7,437,107	20,361.7	160,871	163,802	5,474,895	5,994,909	98,058,099	268,468.4	1.00
November	301,599	3,167,402	310,272	6,740,199	18,453.7	147,356	149,887	4,966,514	5,452,997	94,489,280	258,697.5	1.00
December	303,063	3,152,259	310,738	6,686,507	18,306.7	144,327	146,593	4,925,665	5,418,004	97,324,920	266,461.1	1.00
2020												
January	306,441	3,147,549	316,863	6,680,081	18,289.1	145,676	147,814	4,952,051	5,487,848	97,124,069	265,911.2	1.00
February	303,569	3,136,667	312,879	5,833,581	15,971.5	131,404	133,280	4,319,780	4,813,582	90,206,705	246,972.5	1.00
March	309,820	3,104,243	320,533	6,530,000	17,878.2	142,495	144,392	4,856,793	5,417,518	95,463,699	261,365.4	1.00
April	307,426	3,074,928	315,835	4,288,259	11,740.6	98,702	99,867	3,218,716	3,575,973	91,650,882	250,926.4	1.00
May	304,235	3,057,216	313,325	3,808,770	10,427.8	89,944	90,916	2,892,912	3,270,470	94,411,304	258,484.1	1.00
June	303,135	3,049,628	313,203	3,276,901	8,971.7	86,207	87,122	2,595,345	2,980,487	91,140,661	249,529.5	1.00
July	302,986	3,042,931	313,046	1,874,706	5,132.7	62,537	63,173	1,682,468	1,975,223	93,615,535	256,305.4	1.00
August	291,903	3,017,723	296,172	376,196	1,030.0	33,488	33,790	373,007	456,083	66,245,593	181,370.5	1.00

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Azilsartan												
<i>Prevalent Azilsartan episodes</i>												
2014												
January	0	3,507,846	0	0	0.0	0	0	0	0	108,292,422	296,488.5	0.00
February	****	3,503,171	****	58	0.2	****	****	28	28	97,729,726	267,569.4	0.00
March	****	3,502,444	****	352	1.0	7	7	226	226	108,131,605	296,048.2	0.00
April	5	3,500,386	5	214	0.6	****	****	168	168	104,600,874	286,381.6	0.00
May	7	3,500,442	7	429	1.2	8	8	336	336	108,077,729	295,900.7	0.00
June	7	3,496,708	7	145	0.4	****	****	112	112	104,552,935	286,250.3	0.00
July	8	3,497,621	8	58	0.2	****	****	28	28	107,934,819	295,509.4	0.00
August	7	3,498,115	7	0	0.0	0	0	0	0	107,983,758	295,643.4	0.00
September	7	3,497,642	7	58	0.2	****	****	28	56	104,529,462	286,186.1	0.00
October	6	3,498,776	7	232	0.6	5	5	140	140	107,978,970	295,630.3	0.00
November	8	3,497,242	9	589	1.6	11	11	392	448	104,478,437	286,046.4	0.00
December	7	3,497,280	7	58	0.2	****	****	28	28	107,940,383	295,524.7	0.00
2015												
January	9	3,496,690	9	172	0.5	****	****	112	112	107,881,672	295,363.9	0.00
February	7	3,492,219	7	254	0.7	6	6	168	168	97,372,716	266,592.0	0.00
March	10	3,490,152	11	397	1.1	10	10	259	308	107,733,931	294,959.4	0.00
April	12	3,488,959	14	947	2.6	18	18	701	981	104,230,695	285,368.1	0.00
May	13	3,488,452	13	254	0.7	7	7	196	196	107,700,240	294,867.2	0.00
June	12	3,485,548	14	405	1.1	8	8	315	315	104,209,432	285,309.9	0.00
July	13	3,485,913	13	191	0.5	****	****	112	168	107,580,481	294,539.3	0.00
August	13	3,485,067	13	0	0.0	0	0	0	0	107,600,723	294,594.7	0.00
September	12	3,484,792	12	58	0.2	****	****	28	28	104,129,782	285,091.8	0.00
October	12	3,483,124	12	523	1.4	10	10	364	364	107,503,246	294,327.8	0.00
November	15	3,478,261	15	994	2.7	23	23	770	770	103,945,706	284,587.8	0.00
December	12	3,475,769	13	58	0.2	****	****	28	28	107,309,180	293,796.5	0.00

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Azilsartan												
2016												
January	14	3,473,355	14	572	1.6	11	11	392	448	107,231,746	293,584.5	0.00
February	13	3,469,581	13	0	0.0	0	0	0	0	100,224,321	274,399.2	0.00
March	13	3,468,985	13	582	1.6	17	17	439	439	107,021,614	293,009.2	0.00
April	15	3,464,889	15	424	1.2	8	8	245	301	103,490,698	283,342.1	0.00
May	16	3,461,155	16	172	0.5	*****	*****	112	112	106,891,996	292,654.3	0.00
June	16	3,458,252	16	1,089	3.0	23	23	812	812	103,368,878	283,008.6	0.00
July	14	3,455,547	16	426	1.2	7	7	280	280	106,697,888	292,122.9	0.00
August	12	3,455,916	12	58	0.2	*****	*****	28	28	106,702,337	292,135.1	0.00
September	14	3,452,879	15	523	1.4	12	12	344	344	103,169,294	282,462.1	0.00
October	15	3,447,391	15	198	0.5	*****	*****	168	168	106,451,503	291,448.3	0.00
November	16	3,442,934	16	615	1.7	12	12	420	532	102,889,008	281,694.8	0.00
December	15	3,440,236	15	291	0.8	5	5	229	229	106,173,852	290,688.2	0.00
2017												
January	13	3,436,319	14	112	0.3	*****	*****	56	56	106,084,392	290,443.2	0.00
February	13	3,429,829	14	565	1.5	12	14	440	608	95,664,633	261,915.5	0.00
March	14	3,427,335	14	198	0.5	*****	*****	168	168	105,767,800	289,576.5	0.00
April	14	3,422,433	14	169	0.5	*****	*****	112	112	102,287,330	280,047.4	0.00
May	14	3,420,701	15	508	1.4	14	14	390	390	105,599,916	289,116.8	0.00
June	15	3,414,139	16	735	2.0	15	15	569	569	102,075,503	279,467.5	0.00
July	15	3,410,527	16	283	0.8	5	8	224	448	105,312,720	288,330.5	0.00
August	14	3,408,462	14	597	1.6	12	12	392	392	105,217,268	288,069.2	0.00
September	14	3,405,273	14	100	0.3	*****	*****	56	56	101,730,015	278,521.6	0.00
October	14	3,400,665	14	1,255	3.4	28	28	1,034	792	104,997,747	287,468.2	0.00
November	13	3,395,804	13	142	0.4	*****	*****	112	112	101,467,725	277,803.5	0.00
December	11	3,390,282	11	992	2.7	31	31	856	856	104,676,070	286,587.5	0.00

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Azilsartan												
2018												
January	12	3,386,976	12	228	0.6	*****	*****	168	168	104,506,931	286,124.4	0.00
February	14	3,378,265	14	214	0.6	5	5	136	136	94,210,603	257,934.6	0.00
March	15	3,372,159	15	560	1.5	9	9	448	448	104,048,900	284,870.4	0.00
April	18	3,366,021	18	682	1.9	11	11	504	504	100,523,173	275,217.4	0.00
May	16	3,360,077	16	0	0.0	0	0	0	0	103,725,063	283,983.7	0.00
June	14	3,353,599	15	743	2.0	16	16	604	604	100,253,057	274,477.9	0.00
July	12	3,348,920	12	298	0.8	6	7	211	366	103,411,558	283,125.4	0.00
August	11	3,345,055	11	107	0.3	*****	*****	56	56	103,253,070	282,691.5	0.00
September	12	3,337,642	12	256	0.7	*****	*****	196	196	99,758,114	273,122.8	0.00
October	16	3,333,041	16	429	1.2	6	6	280	280	102,889,905	281,697.2	0.00
November	16	3,320,650	16	401	1.1	6	6	336	336	99,089,300	271,291.7	0.00
December	17	3,304,275	18	598	1.6	13	13	364	392	102,043,869	279,380.9	0.00
2019												
January	17	3,300,870	17	0	0.0	0	0	0	0	101,879,735	278,931.5	0.00
February	16	3,290,887	16	86	0.2	*****	*****	56	56	91,267,938	249,878.0	0.00
March	14	3,262,310	16	256	0.7	6	6	168	168	100,679,246	275,644.8	0.00
April	12	3,256,535	12	0	0.0	0	0	0	0	97,288,410	266,361.1	0.00
May	12	3,252,842	12	58	0.2	*****	*****	28	56	100,383,670	274,835.5	0.00
June	13	3,244,286	14	831	2.3	15	15	644	644	96,646,185	264,602.8	0.00
July	13	3,224,000	13	0	0.0	0	0	0	0	99,374,866	272,073.6	0.00
August	13	3,209,477	13	228	0.6	*****	*****	168	168	98,994,635	271,032.5	0.00
September	13	3,198,349	13	484	1.3	8	8	411	411	95,374,854	261,122.1	0.00
October	13	3,180,417	13	422	1.2	8	8	252	252	98,058,099	268,468.4	0.00
November	14	3,167,402	14	200	0.5	*****	*****	140	140	94,489,280	258,697.5	0.00
December	14	3,152,259	14	86	0.2	*****	*****	56	56	97,324,920	266,461.1	0.00
2020												
January	12	3,147,549	13	153	0.4	*****	*****	112	112	97,124,069	265,911.2	0.00
February	11	3,136,667	12	317	0.9	8	8	202	202	90,206,705	246,972.5	0.00
March	14	3,104,243	14	430	1.2	7	7	293	377	95,463,699	261,365.4	0.00
April	13	3,074,928	13	0	0.0	0	0	0	0	91,650,882	250,926.4	0.00
May	10	3,057,216	10	226	0.6	*****	*****	166	250	94,411,304	258,484.1	0.00
June	13	3,049,628	13	206	0.6	7	7	204	204	91,140,661	249,529.5	0.00
July	15	3,042,931	16	179	0.5	5	5	150	150	93,615,535	256,305.4	0.00
August	13	3,017,723	13	2	0.0	*****	*****	2	2	66,245,593	181,370.5	0.00

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Candesartan												
<i>Prevalent Candesartan episodes</i>												
2014												
January	9,925	3,507,846	9,925	1,754,099	4,802.5	39,627	41,182	1,306,140	1,332,413	108,292,422	296,488.5	0.32
February	19,413	3,503,171	19,427	1,691,342	4,630.6	38,229	39,965	1,257,308	1,298,170	97,729,726	267,569.4	0.33
March	29,302	3,502,444	29,736	1,844,283	5,049.4	40,801	42,164	1,368,616	1,408,053	108,131,605	296,048.2	0.33
April	37,521	3,500,386	38,372	1,885,298	5,161.7	42,333	43,863	1,402,541	1,438,021	104,600,874	286,381.6	0.33
May	43,541	3,500,442	44,519	1,901,814	5,206.9	42,906	44,334	1,419,008	1,428,103	108,077,729	295,900.7	0.34
June	48,145	3,496,708	49,318	1,913,922	5,240.0	43,004	44,427	1,429,677	1,457,752	104,552,935	286,250.3	0.34
July	52,504	3,497,621	54,054	1,987,268	5,440.8	43,741	45,001	1,485,934	1,502,396	107,934,819	295,509.4	0.34
August	54,896	3,498,115	56,403	1,817,025	4,974.7	41,741	42,842	1,344,597	1,385,793	107,983,758	295,643.4	0.34
September	57,747	3,497,642	59,406	2,027,735	5,551.6	46,298	48,038	1,509,151	1,541,154	104,529,462	286,186.1	0.34
October	60,245	3,498,776	62,125	2,005,171	5,489.9	45,702	47,298	1,498,046	1,528,326	107,978,970	295,630.3	0.34
November	61,581	3,497,242	63,080	1,847,813	5,059.0	40,913	42,231	1,374,764	1,413,792	104,478,437	286,046.4	0.34
December	63,766	3,497,280	65,400	2,007,289	5,495.7	45,467	47,336	1,490,207	1,546,630	107,940,383	295,524.7	0.34
2015												
January	65,053	3,496,690	66,972	1,982,297	5,427.2	44,976	46,756	1,473,091	1,531,557	107,881,672	295,363.9	0.34
February	65,628	3,492,219	67,394	1,930,627	5,285.8	45,281	47,007	1,420,098	1,488,506	97,372,716	266,592.0	0.34
March	67,990	3,490,152	70,151	2,208,330	6,046.1	49,206	50,991	1,644,459	1,707,910	107,733,931	294,959.4	0.34
April	69,125	3,488,959	71,381	2,002,159	5,481.6	45,617	47,460	1,485,735	1,554,737	104,230,695	285,368.1	0.34
May	69,776	3,488,452	71,680	1,966,488	5,384.0	44,011	45,744	1,459,984	1,537,578	107,700,240	294,867.2	0.34
June	71,351	3,485,548	73,451	2,225,896	6,094.2	50,568	52,170	1,651,972	1,726,241	104,209,432	285,309.9	0.34
July	72,987	3,485,913	75,589	2,229,757	6,104.7	51,427	53,236	1,655,358	1,735,422	107,580,481	294,539.3	0.34
August	73,105	3,485,067	75,019	1,974,438	5,405.7	45,167	46,466	1,457,878	1,526,004	107,600,723	294,594.7	0.34
September	74,593	3,484,792	76,963	2,190,480	5,997.2	49,264	51,161	1,616,574	1,707,814	104,129,782	285,091.8	0.34
October	75,262	3,483,124	77,518	2,169,754	5,940.5	50,003	51,967	1,604,681	1,697,845	107,503,246	294,327.8	0.34
November	76,074	3,478,261	78,083	2,189,241	5,993.8	50,590	52,434	1,620,990	1,698,203	103,945,706	284,587.8	0.34
December	77,794	3,475,769	80,106	2,212,888	6,058.6	50,596	52,571	1,637,149	1,711,961	107,309,180	293,796.5	0.34

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Candesartan												
<i>2016</i>												
January	77,880	3,473,355	80,061	2,129,247	5,829.6	48,546	50,371	1,578,989	1,654,159	107,231,746	293,584.5	0.34
February	78,530	3,469,581	81,090	2,326,413	6,369.4	54,535	56,574	1,717,036	1,804,758	100,224,321	274,399.2	0.35
March	80,197	3,468,985	82,995	2,370,722	6,490.7	54,590	56,573	1,756,872	1,845,846	107,021,614	293,009.2	0.35
April	80,532	3,464,889	82,893	2,275,990	6,231.3	51,840	53,735	1,678,648	1,775,985	103,490,698	283,342.1	0.35
May	81,030	3,461,155	83,344	2,298,036	6,291.7	50,698	52,637	1,708,714	1,795,397	106,891,996	292,654.3	0.34
June	82,130	3,458,252	84,641	2,339,390	6,404.9	52,953	54,793	1,729,033	1,823,102	103,368,878	283,008.6	0.34
July	82,528	3,455,547	84,823	2,268,525	6,210.9	50,632	52,671	1,686,969	1,778,273	106,697,888	292,122.9	0.35
August	83,732	3,455,916	86,299	2,448,573	6,703.8	55,111	57,192	1,814,088	1,906,216	106,702,337	292,135.1	0.35
September	84,368	3,452,879	86,919	2,386,536	6,534.0	54,193	56,195	1,766,105	1,872,743	103,169,294	282,462.1	0.35
October	84,814	3,447,391	87,300	2,321,645	6,356.3	52,460	54,316	1,715,977	1,812,620	106,451,503	291,448.3	0.35
November	86,061	3,442,934	88,806	2,434,727	6,665.9	55,896	57,760	1,804,315	1,898,747	102,889,008	281,694.8	0.35
December	86,741	3,440,236	88,954	2,323,022	6,360.1	52,428	54,141	1,717,567	1,815,157	106,173,852	290,688.2	0.35
<i>2017</i>												
January	87,178	3,436,319	89,701	2,458,761	6,731.7	56,607	58,730	1,818,910	1,927,104	106,084,392	290,443.2	0.35
February	87,065	3,429,829	89,948	2,358,015	6,455.9	55,616	57,953	1,736,768	1,850,598	95,664,633	261,915.5	0.35
March	88,997	3,427,335	92,244	2,615,835	7,161.8	59,077	61,298	1,936,952	2,052,552	105,767,800	289,576.5	0.35
April	88,767	3,422,433	91,065	2,288,398	6,265.3	50,896	52,852	1,692,911	1,810,835	102,287,330	280,047.4	0.35
May	90,083	3,420,701	92,795	2,555,934	6,997.8	56,876	58,801	1,892,293	2,004,205	105,599,916	289,116.8	0.35
June	90,678	3,414,139	93,483	2,548,603	6,977.7	58,085	60,509	1,889,536	2,018,230	102,075,503	279,467.5	0.35
July	91,168	3,410,527	93,902	2,435,043	6,666.8	54,159	56,170	1,799,344	1,912,975	105,312,720	288,330.5	0.35
August	92,161	3,408,462	95,288	2,535,034	6,940.5	57,233	59,298	1,868,622	1,989,408	105,217,268	288,069.2	0.35
September	91,928	3,405,273	94,308	2,407,834	6,592.3	54,559	56,556	1,772,893	1,905,165	101,730,015	278,521.6	0.35
October	92,771	3,400,665	95,684	2,608,166	7,140.8	58,759	60,995	1,925,701	2,057,984	104,997,747	287,468.2	0.35
November	93,646	3,395,804	96,584	2,577,755	7,057.5	58,048	60,371	1,902,276	2,049,997	101,467,725	277,803.5	0.35
December	93,788	3,390,282	95,987	2,345,287	6,421.0	53,085	55,084	1,728,671	1,851,947	104,676,070	286,587.5	0.35

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Candesartan												
2018												
January	95,045	3,386,976	98,181	2,740,528	7,503.2	62,460	64,810	2,022,777	2,171,853	104,506,931	286,124.4	0.35
February	94,809	3,378,265	97,802	2,530,251	6,927.4	58,093	60,102	1,867,846	2,005,443	94,210,603	257,934.6	0.35
March	96,193	3,372,159	99,326	2,668,001	7,304.6	60,405	62,700	1,965,678	2,100,120	104,048,900	284,870.4	0.35
April	96,250	3,366,021	98,918	2,545,459	6,969.1	57,170	59,386	1,878,725	2,020,613	100,523,173	275,217.4	0.35
May	97,639	3,360,077	100,956	2,699,598	7,391.1	60,412	62,701	1,997,925	2,135,559	103,725,063	283,983.7	0.35
June	97,528	3,353,599	100,238	2,494,512	6,829.6	55,954	58,028	1,837,296	1,976,383	100,253,057	274,477.9	0.35
July	98,266	3,348,920	101,205	2,720,113	7,447.3	60,445	62,445	2,005,068	2,162,426	103,411,558	283,125.4	0.35
August	99,349	3,345,055	102,786	2,611,213	7,149.1	57,756	59,722	1,917,855	2,063,946	103,253,070	282,691.5	0.35
September	98,704	3,337,642	101,244	2,426,132	6,642.4	55,067	57,150	1,791,412	1,935,516	99,758,114	273,122.8	0.35
October	99,744	3,333,041	102,960	2,856,974	7,822.0	64,917	67,165	2,112,246	2,296,470	102,889,905	281,697.2	0.35
November	99,240	3,320,650	102,225	2,579,182	7,061.4	57,068	59,330	1,908,495	2,071,934	99,089,300	271,291.7	0.35
December	99,437	3,304,275	101,864	2,445,895	6,696.5	53,050	54,773	1,797,510	1,953,328	102,043,869	279,380.9	0.35
2019												
January	101,163	3,300,870	104,516	2,674,876	7,323.4	59,186	61,294	1,971,511	2,147,543	101,879,735	278,931.5	0.35
February	100,475	3,290,887	103,654	2,543,819	6,964.6	56,814	59,043	1,876,521	2,038,336	91,267,938	249,878.0	0.35
March	101,669	3,262,310	104,777	2,681,549	7,341.7	59,534	61,694	1,973,591	2,138,409	100,679,246	275,644.8	0.35
April	102,432	3,256,535	105,445	2,730,997	7,477.1	60,645	62,725	2,017,535	2,193,682	97,288,410	266,361.1	0.35
May	103,926	3,252,842	107,297	2,734,885	7,487.7	60,001	62,035	2,019,871	2,197,939	100,383,670	274,835.5	0.35
June	103,300	3,244,286	105,893	2,377,991	6,510.6	52,859	54,380	1,748,252	1,908,657	96,646,185	264,602.8	0.35
July	104,836	3,224,000	108,255	2,882,319	7,891.4	63,764	65,719	2,129,998	2,319,321	99,374,866	272,073.6	0.35
August	105,156	3,209,477	108,336	2,499,583	6,843.5	55,389	56,992	1,839,737	2,016,952	98,994,635	271,032.5	0.35
September	105,029	3,198,349	107,839	2,500,882	6,847.0	54,543	56,119	1,843,723	2,023,613	95,374,854	261,122.1	0.35
October	106,168	3,180,417	109,907	2,602,369	7,124.9	56,997	58,670	1,916,788	2,109,696	98,058,099	268,468.4	0.35
November	105,821	3,167,402	108,791	2,330,163	6,379.6	51,591	53,035	1,724,873	1,904,971	94,489,280	258,697.5	0.35
December	106,171	3,152,259	108,868	2,324,233	6,363.4	50,954	52,282	1,713,949	1,889,453	97,324,920	266,461.1	0.35
2020												
January	107,311	3,147,549	110,914	2,322,140	6,357.7	51,432	52,694	1,725,566	1,924,870	97,124,069	265,911.2	0.35
February	106,575	3,136,667	109,874	2,058,664	5,636.3	47,172	48,240	1,527,030	1,703,541	90,206,705	246,972.5	0.35
March	108,824	3,104,243	112,489	2,251,468	6,164.2	49,649	50,727	1,678,806	1,877,524	95,463,699	261,365.4	0.35
April	107,928	3,074,928	110,797	1,449,910	3,969.6	33,822	34,425	1,086,295	1,210,346	91,650,882	250,926.4	0.35
May	106,898	3,057,216	110,051	1,304,946	3,572.7	30,997	31,566	993,377	1,129,500	94,411,304	258,484.1	0.35
June	106,361	3,049,628	109,911	1,133,918	3,104.5	30,222	30,754	898,091	1,035,964	91,140,661	249,529.5	0.35
July	106,370	3,042,931	109,863	650,043	1,779.7	21,708	22,091	581,115	687,709	93,615,535	256,305.4	0.35
August	102,809	3,017,723	104,301	129,983	355.9	11,605	11,764	128,994	157,246	66,245,593	181,370.5	0.35

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Eprosartan												
<i>Prevalent Eprosartan episodes</i>												
2014												
January	203	3,507,846	203	35,805	98.0	915	930	26,179	26,810	108,292,422	296,488.5	0.01
February	385	3,503,171	385	31,995	87.6	715	715	23,269	24,515	97,729,726	267,569.4	0.01
March	562	3,502,444	571	34,036	93.2	830	831	24,662	27,391	108,131,605	296,048.2	0.01
April	694	3,500,386	704	28,913	79.2	651	651	21,046	23,848	104,600,874	286,381.6	0.01
May	789	3,500,442	807	31,777	87.0	704	704	22,689	26,324	108,077,729	295,900.7	0.01
June	864	3,496,708	896	33,423	91.5	727	727	24,160	25,418	104,552,935	286,250.3	0.01
July	942	3,497,621	980	32,180	88.1	719	719	23,037	25,762	107,934,819	295,509.4	0.01
August	980	3,498,115	1,002	28,077	76.9	642	643	20,103	22,462	107,983,758	295,643.4	0.01
September	1,016	3,497,642	1,044	29,927	81.9	657	658	21,743	22,460	104,529,462	286,186.1	0.01
October	1,054	3,498,776	1,101	32,792	89.8	738	738	23,446	28,146	107,978,970	295,630.3	0.01
November	1,078	3,497,242	1,106	29,481	80.7	706	709	21,425	23,368	104,478,437	286,046.4	0.01
December	1,107	3,497,280	1,140	38,900	106.5	845	845	28,281	30,722	107,940,383	295,524.7	0.01
2015												
January	1,091	3,496,690	1,125	30,251	82.8	754	758	21,962	24,546	107,881,672	295,363.9	0.01
February	1,111	3,492,219	1,143	35,941	98.4	813	829	25,910	28,999	97,372,716	266,592.0	0.01
March	1,139	3,490,152	1,174	36,258	99.3	962	962	25,794	28,379	107,733,931	294,959.4	0.01
April	1,144	3,488,959	1,190	31,729	86.9	754	754	23,047	25,337	104,230,695	285,368.1	0.01
May	1,150	3,488,452	1,178	28,507	78.0	746	746	20,018	21,548	107,700,240	294,867.2	0.01
June	1,167	3,485,548	1,217	38,666	105.9	1,085	1,085	26,768	29,356	104,209,432	285,309.9	0.01
July	1,180	3,485,913	1,217	26,825	73.4	571	571	18,800	20,747	107,580,481	294,539.3	0.01
August	1,153	3,485,067	1,184	27,886	76.3	734	734	20,139	21,673	107,600,723	294,594.7	0.01
September	1,162	3,484,792	1,195	27,184	74.4	693	693	18,895	20,933	104,129,782	285,091.8	0.01
October	1,164	3,483,124	1,202	30,581	83.7	682	682	21,349	24,949	107,503,246	294,327.8	0.01
November	1,161	3,478,261	1,196	32,470	88.9	777	783	22,574	25,248	103,945,706	284,587.8	0.01
December	1,182	3,475,769	1,219	29,148	79.8	736	741	20,111	22,332	107,309,180	293,796.5	0.01

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Eprosartan												
<i>2016</i>												
January	1,187	3,473,355	1,225	31,318	85.7	758	759	21,991	25,639	107,231,746	293,584.5	0.01
February	1,156	3,469,581	1,193	30,159	82.6	684	684	21,472	24,200	100,224,321	274,399.2	0.01
March	1,175	3,468,985	1,234	33,162	90.8	750	750	23,105	27,372	107,021,614	293,009.2	0.01
April	1,157	3,464,889	1,195	32,791	89.8	758	758	23,256	25,868	103,490,698	283,342.1	0.00
May	1,170	3,461,155	1,212	33,696	92.3	748	750	24,326	27,696	106,891,996	292,654.3	0.01
June	1,178	3,458,252	1,221	32,310	88.5	740	740	23,071	25,505	103,368,878	283,008.6	0.00
July	1,156	3,455,547	1,183	30,002	82.1	727	729	20,957	25,185	106,697,888	292,122.9	0.00
August	1,187	3,455,916	1,227	37,339	102.2	978	984	27,895	30,334	106,702,337	292,135.1	0.00
September	1,181	3,452,879	1,213	34,219	93.7	883	888	24,109	27,595	103,169,294	282,462.1	0.00
October	1,178	3,447,391	1,223	28,894	79.1	639	639	20,405	24,341	106,451,503	291,448.3	0.00
November	1,191	3,442,934	1,232	27,394	75.0	610	610	19,298	21,687	102,889,008	281,694.8	0.00
December	1,174	3,440,236	1,207	27,118	74.2	645	646	19,340	22,334	106,173,852	290,688.2	0.00
<i>2017</i>												
January	1,159	3,436,319	1,193	26,795	73.4	625	628	18,912	20,883	106,084,392	290,443.2	0.00
February	1,144	3,429,829	1,193	27,604	75.6	724	726	19,043	23,942	95,664,633	261,915.5	0.00
March	1,175	3,427,335	1,222	32,624	89.3	726	727	22,781	27,200	105,767,800	289,576.5	0.00
April	1,178	3,422,433	1,212	26,245	71.9	596	598	18,809	22,905	102,287,330	280,047.4	0.00
May	1,172	3,420,701	1,213	27,039	74.0	602	605	19,199	22,837	105,599,916	289,116.8	0.00
June	1,137	3,414,139	1,177	28,732	78.7	673	677	20,455	23,730	102,075,503	279,467.5	0.00
July	1,135	3,410,527	1,154	28,593	78.3	722	729	20,152	24,366	105,312,720	288,330.5	0.00
August	1,105	3,408,462	1,131	22,362	61.2	472	472	16,485	20,302	105,217,268	288,069.2	0.00
September	1,016	3,405,273	1,049	24,684	67.6	564	564	18,089	21,251	101,730,015	278,521.6	0.00
October	969	3,400,665	1,006	25,038	68.6	582	582	17,363	21,548	104,997,747	287,468.2	0.00
November	936	3,395,804	955	18,665	51.1	397	400	13,391	15,355	101,467,725	277,803.5	0.00
December	900	3,390,282	931	20,811	57.0	484	485	14,869	18,357	104,676,070	286,587.5	0.00

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Eprosartan												
2018												
January	922	3,386,976	956	28,716	78.6	701	704	19,926	25,506	104,506,931	286,124.4	0.00
February	919	3,378,265	950	24,735	67.7	586	586	17,239	20,948	94,210,603	257,934.6	0.00
March	901	3,372,159	926	18,991	52.0	426	426	13,374	14,879	104,048,900	284,870.4	0.00
April	880	3,366,021	910	24,267	66.4	522	522	17,215	19,937	100,523,173	275,217.4	0.00
May	864	3,360,077	907	23,479	64.3	584	584	16,484	18,558	103,725,063	283,983.7	0.00
June	875	3,353,599	900	26,471	72.5	617	617	19,119	23,255	100,253,057	274,477.9	0.00
July	857	3,348,920	881	21,252	58.2	546	546	14,887	17,556	103,411,558	283,125.4	0.00
August	847	3,345,055	870	23,574	64.5	559	559	16,886	18,700	103,253,070	282,691.5	0.00
September	851	3,337,642	882	20,745	56.8	486	490	14,424	16,743	99,758,114	273,122.8	0.00
October	863	3,333,041	886	26,535	72.6	746	746	18,987	22,124	102,889,905	281,697.2	0.00
November	864	3,320,650	891	18,740	51.3	401	401	12,924	15,441	99,089,300	271,291.7	0.00
December	827	3,304,275	841	14,038	38.4	308	308	9,833	11,431	102,043,869	279,380.9	0.00
2019												
January	837	3,300,870	864	21,183	58.0	526	526	14,774	17,163	101,879,735	278,931.5	0.00
February	815	3,290,887	844	21,139	57.9	506	506	15,016	16,277	91,267,938	249,878.0	0.00
March	814	3,262,310	834	19,394	53.1	481	481	13,659	15,854	100,679,246	275,644.8	0.00
April	799	3,256,535	833	22,476	61.5	512	512	16,081	19,693	97,288,410	266,361.1	0.00
May	808	3,252,842	827	20,482	56.1	453	453	14,575	17,878	100,383,670	274,835.5	0.00
June	785	3,244,286	805	14,579	39.9	336	337	10,275	13,155	96,646,185	264,602.8	0.00
July	784	3,224,000	813	21,836	59.8	502	502	15,437	17,971	99,374,866	272,073.6	0.00
August	788	3,209,477	808	18,688	51.2	416	418	13,419	15,079	98,994,635	271,032.5	0.00
September	801	3,198,349	819	20,966	57.4	507	507	15,293	18,529	95,374,854	261,122.1	0.00
October	801	3,180,417	830	21,090	57.7	498	498	15,078	18,489	98,058,099	268,468.4	0.00
November	799	3,167,402	816	17,309	47.4	429	429	12,167	14,118	94,489,280	258,697.5	0.00
December	788	3,152,259	800	13,908	38.1	304	304	9,560	11,437	97,324,920	266,461.1	0.00
2020												
January	802	3,147,549	828	18,410	50.4	472	472	13,298	14,766	97,124,069	265,911.2	0.00
February	787	3,136,667	813	14,078	38.5	367	367	10,328	12,766	90,206,705	246,972.5	0.00
March	792	3,104,243	821	16,048	43.9	383	383	11,583	13,117	95,463,699	261,365.4	0.00
April	777	3,074,928	795	9,647	26.4	243	243	7,123	8,083	91,650,882	250,926.4	0.00
May	763	3,057,216	790	10,201	27.9	268	270	7,513	9,158	94,411,304	258,484.1	0.00
June	769	3,049,628	800	8,845	24.2	256	257	6,564	8,342	91,140,661	249,529.5	0.00
July	761	3,042,931	787	4,098	11.2	156	156	3,709	4,499	93,615,535	256,305.4	0.00
August	734	3,017,723	748	902	2.5	88	88	882	1,060	66,245,593	181,370.5	0.00

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Irbesartan												
<i>Prevalent Irbesartan episodes</i>												
2014												
January	3,649	3,507,846	3,649	638,533	1,748.2	14,113	14,316	473,601	491,525	108,292,422	296,488.5	0.12
February	6,887	3,503,171	6,891	559,400	1,531.6	12,195	12,283	412,297	428,520	97,729,726	267,569.4	0.12
March	10,426	3,502,444	10,577	632,629	1,732.0	13,650	13,707	465,321	489,779	108,131,605	296,048.2	0.12
April	13,317	3,500,386	13,626	635,932	1,741.1	13,754	13,819	466,981	488,314	104,600,874	286,381.6	0.12
May	15,407	3,500,442	15,755	620,308	1,698.3	13,344	13,432	457,207	474,087	108,077,729	295,900.7	0.12
June	16,797	3,496,708	17,176	602,053	1,648.3	13,551	13,600	439,793	467,479	104,552,935	286,250.3	0.12
July	18,223	3,497,621	18,757	656,845	1,798.3	14,412	14,475	484,773	508,869	107,934,819	295,509.4	0.12
August	19,007	3,498,115	19,472	587,482	1,608.4	12,632	12,747	430,094	454,814	107,983,758	295,643.4	0.12
September	19,775	3,497,642	20,319	672,941	1,842.4	15,551	15,640	495,198	518,228	104,529,462	286,186.1	0.12
October	20,554	3,498,776	21,190	658,522	1,802.9	15,275	15,388	482,581	500,189	107,978,970	295,630.3	0.12
November	20,846	3,497,242	21,350	602,663	1,650.0	13,860	13,961	441,703	461,082	104,478,437	286,046.4	0.12
December	21,551	3,497,280	22,129	667,316	1,827.0	14,501	14,599	491,674	511,482	107,940,383	295,524.7	0.11
2015												
January	21,969	3,496,690	22,616	642,288	1,758.5	14,210	14,324	472,799	496,467	107,881,672	295,363.9	0.11
February	22,063	3,492,219	22,608	642,881	1,760.1	14,292	14,457	474,781	490,985	97,372,716	266,592.0	0.11
March	22,652	3,490,152	23,399	691,420	1,893.0	15,125	15,180	505,111	530,699	107,733,931	294,959.4	0.11
April	22,960	3,488,959	23,654	638,812	1,749.0	14,223	14,318	471,740	489,627	104,230,695	285,368.1	0.11
May	23,169	3,488,452	23,785	630,184	1,725.3	13,459	13,558	463,068	490,088	107,700,240	294,867.2	0.11
June	23,354	3,485,548	24,028	668,649	1,830.7	15,092	15,200	491,269	514,477	104,209,432	285,309.9	0.11
July	23,717	3,485,913	24,509	668,657	1,830.7	14,791	14,897	490,251	515,868	107,580,481	294,539.3	0.11
August	23,652	3,485,067	24,273	602,530	1,649.6	12,695	12,809	440,517	470,829	107,600,723	294,594.7	0.11
September	24,127	3,484,792	24,895	744,002	2,037.0	16,715	16,813	547,336	579,239	104,129,782	285,091.8	0.11
October	24,327	3,483,124	25,084	675,525	1,849.5	14,955	15,065	493,828	524,902	107,503,246	294,327.8	0.11
November	24,397	3,478,261	25,007	671,419	1,838.2	15,606	15,736	491,324	516,984	103,945,706	284,587.8	0.11
December	24,938	3,475,769	25,665	699,922	1,916.3	15,710	15,770	510,805	533,699	107,309,180	293,796.5	0.11

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Irbesartan												
2016												
January	24,870	3,473,355	25,505	655,605	1,794.9	13,715	13,813	486,076	508,512	107,231,746	293,584.5	0.11
February	24,898	3,469,581	25,667	707,418	1,936.8	16,426	16,648	515,224	540,547	100,224,321	274,399.2	0.11
March	25,323	3,468,985	26,157	735,237	2,013.0	15,932	16,078	541,909	570,527	107,021,614	293,009.2	0.11
April	25,290	3,464,889	25,985	679,609	1,860.7	14,776	14,926	500,617	529,848	103,490,698	283,342.1	0.11
May	25,355	3,461,155	26,055	684,109	1,873.0	15,087	15,170	501,694	544,609	106,891,996	292,654.3	0.11
June	25,546	3,458,252	26,345	692,011	1,894.6	14,938	15,026	507,526	536,211	103,368,878	283,008.6	0.11
July	25,533	3,455,547	26,248	674,463	1,846.6	14,655	14,792	494,402	526,971	106,697,888	292,122.9	0.11
August	25,803	3,455,916	26,563	737,497	2,019.2	16,383	16,529	541,219	576,068	106,702,337	292,135.1	0.11
September	25,806	3,452,879	26,573	720,989	1,974.0	16,642	16,795	529,595	558,894	103,169,294	282,462.1	0.11
October	25,821	3,447,391	26,577	692,281	1,895.4	15,304	15,479	507,870	543,658	106,451,503	291,448.3	0.11
November	26,029	3,442,934	26,843	719,038	1,968.6	15,647	15,781	529,448	561,183	102,889,008	281,694.8	0.10
December	26,112	3,440,236	26,811	696,068	1,905.7	15,009	15,100	512,376	542,265	106,173,852	290,688.2	0.10
2017												
January	26,167	3,436,319	26,899	725,580	1,986.5	16,481	16,645	533,524	569,562	106,084,392	290,443.2	0.10
February	26,226	3,429,829	27,056	697,854	1,910.6	15,204	15,351	511,165	549,754	95,664,633	261,915.5	0.10
March	26,622	3,427,335	27,531	746,904	2,044.9	16,493	16,592	549,838	584,022	105,767,800	289,576.5	0.10
April	26,330	3,422,433	27,018	650,362	1,780.6	14,681	14,856	472,516	506,367	102,287,330	280,047.4	0.10
May	26,623	3,420,701	27,399	724,976	1,984.9	16,371	16,480	524,877	569,468	105,599,916	289,116.8	0.10
June	26,827	3,414,139	27,623	711,722	1,948.6	15,628	15,741	519,685	564,431	102,075,503	279,467.5	0.10
July	26,894	3,410,527	27,722	720,634	1,973.0	15,767	15,857	526,739	569,397	105,312,720	288,330.5	0.10
August	27,013	3,408,462	27,878	704,436	1,928.6	15,253	15,317	514,928	556,917	105,217,268	288,069.2	0.10
September	26,804	3,405,273	27,567	715,042	1,957.7	16,282	16,433	522,319	569,413	101,730,015	278,521.6	0.10
October	26,921	3,400,665	27,725	767,559	2,101.5	16,840	17,008	564,902	608,498	104,997,747	287,468.2	0.10
November	27,148	3,395,804	27,969	750,378	2,054.4	16,628	16,762	552,059	604,814	101,467,725	277,803.5	0.10
December	27,185	3,390,282	27,839	680,443	1,863.0	15,030	15,172	497,109	548,080	104,676,070	286,587.5	0.10

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Irbesartan												
2018												
January	27,643	3,386,976	28,506	733,669	2,008.7	16,109	16,281	530,995	606,162	104,506,931	286,124.4	0.10
February	27,600	3,378,265	28,382	673,464	1,843.8	14,739	14,827	487,424	547,962	94,210,603	257,934.6	0.10
March	27,819	3,372,159	28,677	730,576	2,000.2	16,323	16,436	532,980	589,926	104,048,900	284,870.4	0.10
April	27,381	3,366,021	28,112	694,272	1,900.8	15,204	15,298	506,848	557,305	100,523,173	275,217.4	0.10
May	27,609	3,360,077	28,517	773,247	2,117.0	17,253	17,443	566,893	616,689	103,725,063	283,983.7	0.10
June	27,262	3,353,599	28,034	681,212	1,865.1	14,523	14,609	498,399	545,678	100,253,057	274,477.9	0.10
July	27,288	3,348,920	28,079	737,114	2,018.1	15,938	16,082	538,554	587,833	103,411,558	283,125.4	0.10
August	27,589	3,345,055	28,515	730,422	1,999.8	16,213	16,367	533,042	582,325	103,253,070	282,691.5	0.10
September	27,114	3,337,642	27,802	660,237	1,807.6	14,636	14,766	482,913	527,242	99,758,114	273,122.8	0.10
October	27,500	3,333,041	28,364	775,521	2,123.3	16,677	16,807	567,453	630,345	102,889,905	281,697.2	0.10
November	27,577	3,320,650	28,389	710,717	1,945.8	15,521	15,595	520,407	573,469	99,089,300	271,291.7	0.10
December	27,536	3,304,275	28,250	681,068	1,864.7	14,808	14,906	497,304	552,330	102,043,869	279,380.9	0.10
2019												
January	27,661	3,300,870	28,590	739,344	2,024.2	16,176	16,311	542,077	593,281	101,879,735	278,931.5	0.10
February	27,314	3,290,887	28,139	698,820	1,913.3	15,302	15,445	507,739	559,755	91,267,938	249,878.0	0.09
March	27,585	3,262,310	28,380	705,648	1,932.0	15,478	15,644	519,090	565,247	100,679,246	275,644.8	0.09
April	27,643	3,256,535	28,438	699,144	1,914.2	14,882	15,017	510,585	570,139	97,288,410	266,361.1	0.09
May	27,825	3,252,842	28,739	711,081	1,946.8	15,271	15,391	518,686	594,375	100,383,670	274,835.5	0.09
June	27,558	3,244,286	28,262	645,282	1,766.7	13,707	13,825	475,591	522,157	96,646,185	264,602.8	0.09
July	27,796	3,224,000	28,684	747,058	2,045.3	15,815	15,900	545,998	602,371	99,374,866	272,073.6	0.09
August	27,781	3,209,477	28,623	654,969	1,793.2	13,860	13,984	477,955	535,255	98,994,635	271,032.5	0.09
September	27,729	3,198,349	28,414	665,757	1,822.7	14,450	14,590	489,676	541,222	95,374,854	261,122.1	0.09
October	28,058	3,180,417	29,051	685,332	1,876.3	14,584	14,727	502,600	559,118	98,058,099	268,468.4	0.09
November	27,837	3,167,402	28,624	611,429	1,674.0	12,965	13,043	447,769	504,575	94,489,280	258,697.5	0.09
December	27,853	3,152,259	28,573	607,504	1,663.3	12,999	13,104	444,612	496,576	97,324,920	266,461.1	0.09
2020												
January	28,024	3,147,549	28,942	606,879	1,661.5	13,086	13,149	449,396	505,374	97,124,069	265,911.2	0.09
February	27,663	3,136,667	28,546	535,738	1,466.8	11,913	11,977	395,472	449,401	90,206,705	246,972.5	0.09
March	28,143	3,104,243	29,121	592,608	1,622.5	12,784	12,884	441,943	502,482	95,463,699	261,365.4	0.09
April	27,832	3,074,928	28,613	392,364	1,074.2	9,023	9,064	294,612	332,279	91,650,882	250,926.4	0.09
May	27,492	3,057,216	28,351	351,675	962.8	8,348	8,381	267,260	309,305	94,411,304	258,484.1	0.09
June	27,265	3,049,628	28,152	290,439	795.2	7,670	7,712	229,413	271,887	91,140,661	249,529.5	0.09
July	27,160	3,042,931	28,029	166,089	454.7	5,514	5,535	149,063	179,109	93,615,535	256,305.4	0.09
August	26,050	3,017,723	26,411	34,832	95.4	3,053	3,070	34,489	42,626	66,245,593	181,370.5	0.09

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Losartan												
<i>Prevalent Losartan episodes</i>												
2014												
January	12,861	3,507,846	12,861	2,209,947	6,050.5	48,879	49,565	1,634,572	1,684,665	108,292,422	296,488.5	0.42
February	25,369	3,503,171	25,386	2,149,424	5,884.8	48,816	49,869	1,583,757	1,624,984	97,729,726	267,569.4	0.43
March	39,175	3,502,444	39,697	2,502,737	6,852.1	56,383	57,187	1,846,068	1,870,744	108,131,605	296,048.2	0.44
April	50,600	3,500,386	51,741	2,535,926	6,943.0	57,257	58,447	1,871,185	1,904,702	104,600,874	286,381.6	0.45
May	59,196	3,500,442	60,483	2,488,681	6,813.6	54,553	55,407	1,841,617	1,879,961	108,077,729	295,900.7	0.46
June	65,288	3,496,708	66,805	2,431,804	6,657.9	53,908	54,609	1,797,204	1,832,680	104,552,935	286,250.3	0.46
July	71,112	3,497,621	73,283	2,621,256	7,176.6	57,479	58,450	1,941,327	1,985,360	107,934,819	295,509.4	0.46
August	74,055	3,498,115	75,942	2,351,132	6,437.0	52,774	53,617	1,735,051	1,786,722	107,983,758	295,643.4	0.46
September	77,599	3,497,642	79,700	2,655,428	7,270.2	60,211	61,250	1,963,525	1,993,423	104,529,462	286,186.1	0.46
October	80,945	3,498,776	83,460	2,683,052	7,345.8	59,981	60,869	1,987,976	2,020,376	107,978,970	295,630.3	0.46
November	82,494	3,497,242	84,476	2,400,489	6,572.2	53,908	54,683	1,776,538	1,811,272	104,478,437	286,046.4	0.46
December	85,791	3,497,280	88,093	2,729,590	7,473.2	60,200	61,502	2,018,910	2,074,396	107,940,383	295,524.7	0.46
2015												
January	87,441	3,496,690	90,000	2,603,217	7,127.2	59,297	60,496	1,917,392	1,983,046	107,881,672	295,363.9	0.46
February	88,180	3,492,219	90,474	2,587,143	7,083.2	58,234	59,287	1,911,694	1,968,090	97,372,716	266,592.0	0.46
March	91,490	3,490,152	94,292	2,898,377	7,935.3	64,728	65,912	2,136,466	2,209,493	107,733,931	294,959.4	0.46
April	93,098	3,488,959	95,933	2,648,894	7,252.3	59,315	60,469	1,952,568	2,018,777	104,230,695	285,368.1	0.46
May	94,085	3,488,452	96,610	2,635,272	7,215.0	59,334	60,443	1,946,948	2,004,034	107,700,240	294,867.2	0.46
June	95,647	3,485,548	98,438	2,875,611	7,873.0	64,033	65,192	2,122,405	2,193,338	104,209,432	285,309.9	0.46
July	98,107	3,485,913	101,673	2,911,936	7,972.4	64,375	65,494	2,144,640	2,221,496	107,580,481	294,539.3	0.46
August	98,192	3,485,067	100,692	2,592,729	7,098.5	57,625	58,560	1,906,797	1,985,343	107,600,723	294,594.7	0.46
September	100,115	3,484,792	103,268	3,026,816	8,287.0	67,926	69,294	2,237,007	2,319,107	104,129,782	285,091.8	0.46
October	101,151	3,483,124	104,211	2,864,879	7,843.6	64,519	65,558	2,106,269	2,191,383	107,503,246	294,327.8	0.46
November	101,991	3,478,261	104,742	2,921,613	7,998.9	66,164	67,492	2,146,292	2,225,504	103,945,706	284,587.8	0.46
December	104,706	3,475,769	107,671	2,940,200	8,049.8	64,198	65,218	2,164,483	2,256,063	107,309,180	293,796.5	0.46

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Losartan												
2016												
January	104,802	3,473,355	107,661	2,837,600	7,768.9	64,699	65,706	2,094,666	2,170,457	107,231,746	293,584.5	0.46
February	105,558	3,469,581	108,736	3,032,123	8,301.5	67,215	68,527	2,226,789	2,320,139	100,224,321	274,399.2	0.46
March	107,981	3,468,985	111,753	3,221,815	8,820.8	72,118	73,100	2,372,283	2,472,120	107,021,614	293,009.2	0.46
April	108,451	3,464,889	111,459	2,998,048	8,208.2	67,010	68,205	2,205,730	2,288,750	103,490,698	283,342.1	0.47
May	109,649	3,461,155	112,726	3,110,892	8,517.2	68,958	70,037	2,287,567	2,378,034	106,891,996	292,654.3	0.47
June	111,361	3,458,252	114,714	3,170,141	8,679.4	70,464	71,751	2,335,441	2,435,578	103,368,878	283,008.6	0.47
July	111,833	3,455,547	114,961	3,028,578	8,291.8	67,667	68,794	2,233,424	2,331,459	106,697,888	292,122.9	0.47
August	113,621	3,455,916	117,039	3,258,094	8,920.2	71,972	73,077	2,401,002	2,495,689	106,702,337	292,135.1	0.47
September	114,448	3,452,879	117,889	3,214,781	8,801.6	71,707	73,010	2,365,863	2,464,807	103,169,294	282,462.1	0.47
October	115,279	3,447,391	118,622	3,173,205	8,687.8	71,918	73,258	2,333,988	2,449,609	106,451,503	291,448.3	0.47
November	117,138	3,442,934	120,885	3,369,834	9,226.1	76,025	77,220	2,479,882	2,592,272	102,889,008	281,694.8	0.47
December	117,988	3,440,236	121,050	3,111,289	8,518.2	69,747	70,956	2,285,916	2,380,484	106,173,852	290,688.2	0.47
2017												
January	118,805	3,436,319	122,208	3,368,166	9,221.5	74,486	75,928	2,478,580	2,594,721	106,084,392	290,443.2	0.47
February	119,128	3,429,829	122,770	3,168,857	8,675.9	70,359	71,495	2,326,615	2,438,746	95,664,633	261,915.5	0.47
March	122,133	3,427,335	126,511	3,625,605	9,926.4	80,652	81,926	2,671,364	2,794,344	105,767,800	289,576.5	0.48
April	121,925	3,422,433	124,948	3,132,148	8,575.4	69,922	71,231	2,308,615	2,418,594	102,287,330	280,047.4	0.48
May	124,082	3,420,701	127,964	3,591,534	9,833.1	79,777	81,039	2,647,951	2,765,653	105,599,916	289,116.8	0.48
June	124,701	3,414,139	128,483	3,398,803	9,305.4	75,111	76,373	2,494,966	2,632,675	102,075,503	279,467.5	0.48
July	125,660	3,410,527	129,369	3,423,770	9,373.8	76,090	77,212	2,517,759	2,637,453	105,312,720	288,330.5	0.48
August	127,310	3,408,462	131,546	3,550,898	9,721.8	78,312	79,686	2,611,805	2,746,294	105,217,268	288,069.2	0.48
September	127,308	3,405,273	130,739	3,377,649	9,247.5	74,770	76,128	2,487,067	2,620,834	101,730,015	278,521.6	0.48
October	128,673	3,400,665	132,510	3,646,802	9,984.4	81,018	82,305	2,689,656	2,830,425	104,997,747	287,468.2	0.48
November	130,032	3,395,804	134,058	3,584,564	9,814.0	80,707	81,929	2,629,157	2,770,143	101,467,725	277,803.5	0.48
December	130,086	3,390,282	133,060	3,243,760	8,880.9	70,293	71,447	2,381,187	2,503,343	104,676,070	286,587.5	0.48

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Losartan												
2018												
January	131,876	3,386,976	136,064	3,742,324	10,245.9	83,063	84,562	2,743,030	2,887,264	104,506,931	286,124.4	0.48
February	131,534	3,378,265	135,512	3,448,523	9,441.5	77,049	78,294	2,518,741	2,648,317	94,210,603	257,934.6	0.48
March	133,788	3,372,159	138,031	3,687,379	10,095.5	81,933	83,250	2,706,404	2,845,822	104,048,900	284,870.4	0.48
April	134,106	3,366,021	137,667	3,604,636	9,869.0	77,578	78,904	2,653,145	2,793,624	100,523,173	275,217.4	0.48
May	136,498	3,360,077	141,160	3,804,036	10,414.9	84,007	85,398	2,791,474	2,957,941	103,725,063	283,983.7	0.49
June	136,459	3,353,599	140,351	3,568,921	9,771.2	78,012	79,372	2,615,585	2,767,017	100,253,057	274,477.9	0.49
July	137,601	3,348,920	141,651	3,841,932	10,518.6	83,956	85,181	2,823,796	2,979,901	103,411,558	283,125.4	0.49
August	139,242	3,345,055	143,989	3,755,759	10,282.7	82,245	83,616	2,757,750	2,923,869	103,253,070	282,691.5	0.49
September	138,280	3,337,642	141,780	3,474,760	9,513.4	76,249	77,481	2,554,075	2,697,047	99,758,114	273,122.8	0.49
October	140,225	3,333,041	144,667	3,956,267	10,831.7	86,088	87,583	2,912,518	3,088,456	102,889,905	281,697.2	0.49
November	140,487	3,320,650	144,874	3,699,343	10,128.2	79,934	81,183	2,724,160	2,909,170	99,089,300	271,291.7	0.49
December	140,478	3,304,275	144,018	3,440,355	9,419.2	72,969	73,967	2,524,852	2,688,330	102,043,869	279,380.9	0.49
2019												
January	142,728	3,300,870	147,675	3,861,811	10,573.1	83,472	84,572	2,838,526	3,024,414	101,879,735	278,931.5	0.49
February	141,277	3,290,887	145,467	3,491,723	9,559.8	76,358	77,652	2,560,060	2,729,487	91,267,938	249,878.0	0.49
March	142,353	3,262,310	146,499	3,713,120	10,166.0	80,267	81,553	2,730,963	2,897,701	100,679,246	275,644.8	0.49
April	143,897	3,256,535	148,091	3,794,757	10,389.5	81,442	82,675	2,788,581	2,965,365	97,288,410	266,361.1	0.49
May	145,879	3,252,842	150,846	3,889,418	10,648.6	84,107	85,321	2,858,081	3,048,013	100,383,670	274,835.5	0.49
June	145,229	3,244,286	148,848	3,422,980	9,371.6	73,557	74,591	2,520,345	2,684,140	96,646,185	264,602.8	0.49
July	146,787	3,224,000	151,560	4,020,978	11,008.8	86,399	87,499	2,958,280	3,155,123	99,374,866	272,073.6	0.49
August	147,298	3,209,477	151,721	3,599,396	9,854.6	76,673	77,626	2,649,523	2,837,556	98,994,635	271,032.5	0.49
September	146,942	3,198,349	150,824	3,542,026	9,697.5	76,066	76,995	2,609,322	2,781,840	95,374,854	261,122.1	0.49
October	149,021	3,180,417	154,168	3,678,754	10,071.9	78,911	79,886	2,709,190	2,905,378	98,058,099	268,468.4	0.49
November	148,644	3,167,402	152,946	3,381,133	9,257.0	73,463	74,373	2,489,584	2,668,806	94,489,280	258,697.5	0.49
December	149,553	3,152,259	153,285	3,315,986	9,078.7	70,698	71,446	2,444,853	2,635,786	97,324,920	266,461.1	0.49
2020												
January	151,418	3,147,549	156,551	3,327,661	9,110.6	71,404	72,119	2,463,744	2,669,920	97,124,069	265,911.2	0.49
February	149,917	3,136,667	154,364	2,874,749	7,870.6	63,777	64,470	2,131,100	2,324,278	90,206,705	246,972.5	0.49
March	152,958	3,104,243	158,250	3,244,212	8,882.2	69,960	70,571	2,408,489	2,626,883	95,463,699	261,365.4	0.49
April	151,980	3,074,928	156,142	2,171,411	5,945.0	49,355	49,829	1,632,776	1,779,055	91,650,882	250,926.4	0.49
May	150,335	3,057,216	154,746	1,903,883	5,212.5	44,626	44,967	1,445,999	1,593,280	94,411,304	258,484.1	0.49
June	150,012	3,049,628	154,937	1,639,269	4,488.1	42,545	42,848	1,301,303	1,458,026	91,140,661	249,529.5	0.49
July	149,894	3,042,931	154,922	938,659	2,569.9	31,162	31,371	844,525	968,007	93,615,535	256,305.4	0.49
August	144,282	3,017,723	146,372	187,221	512.6	16,657	16,777	185,447	222,488	66,245,593	181,370.5	0.49

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Olmesartan												
<i>Prevalent Olmesartan episodes</i>												
2014												
January	996	3,507,846	996	169,219	463.3	4,457	4,510	120,604	121,228	108,292,422	296,488.5	0.03
February	2,018	3,503,171	2,018	157,936	432.4	3,611	3,623	110,756	114,726	97,729,726	267,569.4	0.03
March	2,972	3,502,444	3,035	170,243	466.1	4,061	4,150	120,335	122,597	108,131,605	296,048.2	0.03
April	3,670	3,500,386	3,751	154,398	422.7	3,505	3,521	109,352	112,431	104,600,874	286,381.6	0.03
May	4,136	3,500,442	4,259	160,294	438.9	3,995	4,044	113,929	111,744	108,077,729	295,900.7	0.03
June	4,447	3,496,708	4,578	166,913	457.0	4,076	4,126	120,129	121,702	104,552,935	286,250.3	0.03
July	4,829	3,497,621	4,999	175,714	481.1	4,077	4,102	125,494	127,975	107,934,819	295,509.4	0.03
August	4,977	3,498,115	5,122	157,858	432.2	3,743	3,806	113,356	112,602	107,983,758	295,643.4	0.03
September	5,178	3,497,642	5,348	173,592	475.3	4,164	4,176	122,688	126,546	104,529,462	286,186.1	0.03
October	5,381	3,498,776	5,591	163,759	448.3	3,939	3,959	115,452	118,599	107,978,970	295,630.3	0.03
November	5,470	3,497,242	5,625	152,983	418.8	3,846	3,875	107,349	108,783	104,478,437	286,046.4	0.03
December	5,652	3,497,280	5,821	174,957	479.0	4,094	4,134	127,195	126,430	107,940,383	295,524.7	0.03
2015												
January	5,711	3,496,690	5,907	156,815	429.3	3,569	3,586	111,485	114,593	107,881,672	295,363.9	0.03
February	5,672	3,492,219	5,856	152,397	417.2	3,590	3,650	108,105	110,917	97,372,716	266,592.0	0.03
March	5,852	3,490,152	6,046	178,466	488.6	4,247	4,257	127,316	129,124	107,733,931	294,959.4	0.03
April	5,854	3,488,959	6,059	156,969	429.8	3,611	3,668	110,696	113,589	104,230,695	285,368.1	0.03
May	5,877	3,488,452	6,064	155,054	424.5	3,698	3,754	110,918	115,029	107,700,240	294,867.2	0.03
June	5,889	3,485,548	6,066	157,015	429.9	3,767	3,857	112,777	112,731	104,209,432	285,309.9	0.03
July	5,893	3,485,913	6,118	165,223	452.4	3,846	3,878	117,984	121,531	107,580,481	294,539.3	0.03
August	5,751	3,485,067	5,918	140,406	384.4	3,361	3,426	100,278	103,228	107,600,723	294,594.7	0.03
September	5,787	3,484,792	6,002	167,968	459.9	4,102	4,155	118,647	123,149	104,129,782	285,091.8	0.03
October	5,735	3,483,124	5,934	155,002	424.4	3,636	3,709	111,926	115,479	107,503,246	294,327.8	0.03
November	5,707	3,478,261	5,892	157,986	432.5	3,772	3,789	112,489	116,666	103,945,706	284,587.8	0.03
December	5,692	3,475,769	5,878	149,579	409.5	3,287	3,323	107,745	106,470	107,309,180	293,796.5	0.03

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Olmesartan												
<i>2016</i>												
January	5,577	3,473,355	5,759	151,923	415.9	3,779	3,897	108,914	112,115	107,231,746	293,584.5	0.02
February	5,565	3,469,581	5,781	167,975	459.9	4,183	4,329	120,001	123,768	100,224,321	274,399.2	0.02
March	5,690	3,468,985	5,928	161,988	443.5	3,795	3,845	114,739	120,387	107,021,614	293,009.2	0.02
April	5,693	3,464,889	5,880	148,858	407.6	3,536	3,585	106,291	108,570	103,490,698	283,342.1	0.02
May	5,695	3,461,155	5,869	135,358	370.6	3,114	3,178	96,335	98,454	106,891,996	292,654.3	0.02
June	5,714	3,458,252	5,910	154,562	423.2	3,728	3,782	110,605	111,713	103,368,878	283,008.6	0.02
July	5,667	3,455,547	5,859	158,799	434.8	3,758	3,801	115,722	114,439	106,697,888	292,122.9	0.02
August	5,669	3,455,916	5,870	158,545	434.1	3,599	3,633	112,726	116,695	106,702,337	292,135.1	0.02
September	5,695	3,452,879	5,894	152,857	418.5	3,658	3,690	108,002	111,936	103,169,294	282,462.1	0.02
October	5,643	3,447,391	5,842	155,672	426.2	3,737	3,770	110,289	115,889	106,451,503	291,448.3	0.02
November	5,673	3,442,934	5,902	166,669	456.3	3,937	3,988	120,131	121,970	102,889,008	281,694.8	0.02
December	5,685	3,440,236	5,835	141,196	386.6	3,201	3,225	100,854	105,084	106,173,852	290,688.2	0.02
<i>2017</i>												
January	5,632	3,436,319	5,822	149,796	410.1	3,537	3,565	108,060	110,587	106,084,392	290,443.2	0.02
February	5,567	3,429,829	5,767	141,685	387.9	3,396	3,452	100,118	104,748	95,664,633	261,915.5	0.02
March	5,605	3,427,335	5,859	152,406	417.3	3,764	3,781	107,965	112,092	105,767,800	289,576.5	0.02
April	5,604	3,422,433	5,745	138,804	380.0	3,085	3,102	99,792	102,187	102,287,330	280,047.4	0.02
May	5,646	3,420,701	5,877	163,346	447.2	3,758	3,812	117,135	121,410	105,599,916	289,116.8	0.02
June	5,664	3,414,139	5,848	151,560	414.9	3,641	3,684	109,463	110,264	102,075,503	279,467.5	0.02
July	5,697	3,410,527	5,893	156,710	429.0	3,780	3,863	112,649	116,339	105,312,720	288,330.5	0.02
August	5,769	3,408,462	5,974	151,632	415.1	3,648	3,710	108,094	111,986	105,217,268	288,069.2	0.02
September	5,699	3,405,273	5,900	152,158	416.6	3,720	3,791	108,373	111,966	101,730,015	278,521.6	0.02
October	5,746	3,400,665	5,957	167,108	457.5	4,021	4,099	119,890	123,048	104,997,747	287,468.2	0.02
November	5,767	3,395,804	5,978	145,984	399.7	3,408	3,426	103,230	109,635	101,467,725	277,803.5	0.02
December	5,727	3,390,282	5,871	128,986	353.1	3,045	3,079	90,678	95,213	104,676,070	286,587.5	0.02

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Olmesartan												
2018												
January	5,767	3,386,976	5,996	156,754	429.2	3,613	3,622	112,233	115,163	104,506,931	286,124.4	0.02
February	5,674	3,378,265	5,881	151,781	415.6	3,715	3,771	108,499	112,982	94,210,603	257,934.6	0.02
March	5,699	3,372,159	5,892	152,926	418.7	3,680	3,736	109,007	113,865	104,048,900	284,870.4	0.02
April	5,692	3,366,021	5,867	140,449	384.5	3,190	3,225	99,047	103,899	100,523,173	275,217.4	0.02
May	5,724	3,360,077	5,966	152,772	418.3	3,564	3,601	107,867	113,554	103,725,063	283,983.7	0.02
June	5,706	3,353,599	5,915	140,376	384.3	3,292	3,317	100,640	106,764	100,253,057	274,477.9	0.02
July	5,685	3,348,920	5,898	170,527	466.9	4,106	4,184	122,772	126,177	103,411,558	283,125.4	0.02
August	5,743	3,345,055	5,947	155,451	425.6	3,574	3,606	113,054	116,436	103,253,070	282,691.5	0.02
September	5,658	3,337,642	5,835	134,025	366.9	3,073	3,146	96,128	101,295	99,758,114	273,122.8	0.02
October	5,760	3,333,041	5,983	170,773	467.6	3,834	3,884	123,347	128,533	102,889,905	281,697.2	0.02
November	5,746	3,320,650	5,983	153,145	419.3	3,663	3,677	108,535	114,165	99,089,300	271,291.7	0.02
December	5,763	3,304,275	5,909	134,417	368.0	3,016	3,028	95,534	101,302	102,043,869	279,380.9	0.02
2019												
January	5,854	3,300,870	6,098	154,685	423.5	3,614	3,649	110,380	116,175	101,879,735	278,931.5	0.02
February	5,807	3,290,887	5,989	145,984	399.7	3,424	3,468	103,608	109,193	91,267,938	249,878.0	0.02
March	5,877	3,262,310	6,069	150,071	410.9	3,390	3,412	106,387	110,768	100,679,246	275,644.8	0.02
April	5,931	3,256,535	6,123	159,635	437.1	3,684	3,727	114,888	120,819	97,288,410	266,361.1	0.02
May	6,021	3,252,842	6,263	157,464	431.1	3,627	3,637	111,838	117,930	100,383,670	274,835.5	0.02
June	5,969	3,244,286	6,156	136,985	375.0	3,185	3,200	97,731	103,805	96,646,185	264,602.8	0.02
July	6,010	3,224,000	6,246	163,346	447.2	3,799	3,819	116,243	123,723	99,374,866	272,073.6	0.02
August	5,989	3,209,477	6,200	141,698	387.9	3,285	3,339	101,463	107,793	98,994,635	271,032.5	0.02
September	5,955	3,198,349	6,160	143,637	393.3	3,441	3,474	102,354	109,994	95,374,854	261,122.1	0.02
October	6,025	3,180,417	6,273	150,223	411.3	3,492	3,537	108,616	115,146	98,058,099	268,468.4	0.02
November	5,960	3,167,402	6,167	128,589	352.1	3,055	3,079	91,485	98,837	94,489,280	258,697.5	0.02
December	5,960	3,152,259	6,124	132,219	362.0	3,174	3,201	95,682	103,539	97,324,920	266,461.1	0.02
2020												
January	5,971	3,147,549	6,233	127,000	347.7	3,014	3,043	92,588	98,593	97,124,069	265,911.2	0.02
February	5,877	3,136,667	6,106	113,538	310.9	2,702	2,726	81,525	89,455	90,206,705	246,972.5	0.02
March	5,986	3,104,243	6,218	130,083	356.1	3,126	3,156	94,843	102,926	95,463,699	261,365.4	0.02
April	5,935	3,074,928	6,116	82,972	227.2	2,028	2,040	60,647	65,467	91,650,882	250,926.4	0.02
May	5,837	3,057,216	6,039	73,423	201.0	1,855	1,856	54,226	60,336	94,411,304	258,484.1	0.02
June	5,843	3,049,628	6,054	62,962	172.4	1,743	1,751	47,455	53,034	91,140,661	249,529.5	0.02
July	5,830	3,042,931	6,046	34,915	95.6	1,254	1,263	30,924	34,922	93,615,535	256,305.4	0.02
August	5,630	3,017,723	5,729	7,315	20.0	634	635	7,222	8,842	66,245,593	181,370.5	0.02

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Telmisartan												
<i>Prevalent Telmisartan episodes</i>												
2014												
January	681	3,507,846	681	112,980	309.3	2,303	2,319	83,693	88,116	108,292,422	296,488.5	0.02
February	1,350	3,503,171	1,350	113,490	310.7	2,487	2,515	84,092	86,879	97,729,726	267,569.4	0.02
March	2,004	3,502,444	2,034	116,414	318.7	2,410	2,434	86,841	88,532	108,131,605	296,048.2	0.02
April	2,564	3,500,386	2,621	124,059	339.7	2,422	2,429	92,893	91,401	104,600,874	286,381.6	0.02
May	2,952	3,500,442	3,004	112,618	308.3	2,369	2,386	83,999	85,057	108,077,729	295,900.7	0.02
June	3,238	3,496,708	3,319	117,797	322.5	2,481	2,509	87,483	91,118	104,552,935	286,250.3	0.02
July	3,516	3,497,621	3,624	129,114	353.5	2,841	2,879	95,835	96,724	107,934,819	295,509.4	0.02
August	3,643	3,498,115	3,739	114,927	314.7	2,600	2,618	84,846	85,702	107,983,758	295,643.4	0.02
September	3,839	3,497,642	3,941	134,448	368.1	2,910	2,930	99,720	102,579	104,529,462	286,186.1	0.02
October	4,008	3,498,776	4,148	140,344	384.2	3,139	3,229	105,869	103,868	107,978,970	295,630.3	0.02
November	4,030	3,497,242	4,121	115,094	315.1	2,572	2,580	85,574	85,004	104,478,437	286,046.4	0.02
December	4,158	3,497,280	4,253	123,322	337.6	2,496	2,515	90,560	94,548	107,940,383	295,524.7	0.02
2015												
January	4,233	3,496,690	4,346	121,411	332.4	2,701	2,723	90,252	94,077	107,881,672	295,363.9	0.02
February	4,163	3,492,219	4,287	118,065	323.2	2,344	2,368	87,461	86,782	97,372,716	266,592.0	0.02
March	4,262	3,490,152	4,404	123,566	338.3	2,487	2,495	91,181	95,989	107,733,931	294,959.4	0.02
April	4,341	3,488,959	4,467	124,692	341.4	2,687	2,699	92,676	95,919	104,230,695	285,368.1	0.02
May	4,350	3,488,452	4,485	103,131	282.4	2,025	2,033	75,032	79,331	107,700,240	294,867.2	0.02
June	4,380	3,485,548	4,487	126,865	347.3	2,790	2,833	93,480	97,270	104,209,432	285,309.9	0.02
July	4,500	3,485,913	4,648	128,539	351.9	2,827	2,840	94,053	97,510	107,580,481	294,539.3	0.02
August	4,484	3,485,067	4,594	117,013	320.4	2,428	2,449	86,433	91,771	107,600,723	294,594.7	0.02
September	4,563	3,484,792	4,709	137,430	376.3	2,881	2,916	101,958	104,759	104,129,782	285,091.8	0.02
October	4,635	3,483,124	4,769	131,034	358.8	2,880	2,922	96,814	100,431	107,503,246	294,327.8	0.02
November	4,620	3,478,261	4,735	128,682	352.3	2,674	2,698	96,285	99,546	103,945,706	284,587.8	0.02
December	4,638	3,475,769	4,774	126,150	345.4	2,591	2,611	93,467	95,439	107,309,180	293,796.5	0.02

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Telmisartan												
2016												
January	4,578	3,473,355	4,697	116,612	319.3	2,451	2,477	85,545	90,123	107,231,746	293,584.5	0.02
February	4,585	3,469,581	4,716	126,622	346.7	2,636	2,637	93,305	97,819	100,224,321	274,399.2	0.02
March	4,647	3,468,985	4,798	132,173	361.9	2,693	2,722	98,312	104,405	107,021,614	293,009.2	0.02
April	4,632	3,464,889	4,736	118,825	325.3	2,497	2,531	88,645	91,132	103,490,698	283,342.1	0.02
May	4,667	3,461,155	4,803	127,446	348.9	2,674	2,695	94,528	98,980	106,891,996	292,654.3	0.02
June	4,701	3,458,252	4,844	133,243	364.8	2,850	2,879	99,592	104,562	103,368,878	283,008.6	0.02
July	4,738	3,455,547	4,883	131,987	361.4	2,864	2,887	98,075	100,724	106,697,888	292,122.9	0.02
August	4,794	3,455,916	4,941	126,300	345.8	2,415	2,432	94,345	97,762	106,702,337	292,135.1	0.02
September	4,771	3,452,879	4,925	121,119	331.6	2,491	2,510	88,973	94,196	103,169,294	282,462.1	0.02
October	4,731	3,447,391	4,839	123,408	337.9	2,832	2,842	91,414	96,898	106,451,503	291,448.3	0.02
November	4,777	3,442,934	4,941	138,477	379.1	2,956	2,964	102,301	107,836	102,889,008	281,694.8	0.02
December	4,827	3,440,236	4,941	130,894	358.4	2,750	2,756	96,801	101,652	106,173,852	290,688.2	0.02
2017												
January	4,870	3,436,319	5,010	131,070	358.9	2,682	2,701	96,417	99,129	106,084,392	290,443.2	0.02
February	4,826	3,429,829	4,968	125,900	344.7	2,847	2,884	93,032	96,331	95,664,633	261,915.5	0.02
March	4,930	3,427,335	5,111	136,139	372.7	2,769	2,793	100,363	104,633	105,767,800	289,576.5	0.02
April	4,844	3,422,433	4,968	122,739	336.0	2,710	2,734	90,155	94,345	102,287,330	280,047.4	0.02
May	4,922	3,420,701	5,068	141,650	387.8	2,945	2,978	104,558	110,679	105,599,916	289,116.8	0.02
June	4,909	3,414,139	5,038	134,299	367.7	2,879	2,922	99,474	102,411	102,075,503	279,467.5	0.02
July	4,906	3,410,527	5,049	122,674	335.9	2,555	2,570	90,096	96,073	105,312,720	288,330.5	0.02
August	4,949	3,408,462	5,120	137,764	377.2	2,864	2,897	102,620	105,424	105,217,268	288,069.2	0.02
September	4,928	3,405,273	5,058	123,650	338.5	2,559	2,567	90,813	96,432	101,730,015	278,521.6	0.02
October	4,922	3,400,665	5,051	122,475	335.3	2,530	2,573	88,765	97,114	104,997,747	287,468.2	0.02
November	4,950	3,395,804	5,091	121,980	334.0	2,695	2,717	88,675	94,450	101,467,725	277,803.5	0.02
December	4,944	3,390,282	5,085	132,131	361.8	2,972	3,007	97,225	102,392	104,676,070	286,587.5	0.02

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Telmisartan												
2018												
January	4,959	3,386,976	5,107	133,837	366.4	2,729	2,779	97,647	105,812	104,506,931	286,124.4	0.02
February	4,925	3,378,265	5,076	129,942	355.8	2,709	2,732	95,421	102,646	94,210,603	257,934.6	0.02
March	4,929	3,372,159	5,070	121,578	332.9	2,501	2,558	90,619	94,547	104,048,900	284,870.4	0.02
April	4,954	3,366,021	5,072	125,467	343.5	2,376	2,402	90,947	97,652	100,523,173	275,217.4	0.02
May	5,013	3,360,077	5,177	142,656	390.6	3,010	3,048	105,690	111,935	103,725,063	283,983.7	0.02
June	4,987	3,353,599	5,137	133,763	366.2	2,786	2,791	99,572	106,899	100,253,057	274,477.9	0.02
July	5,061	3,348,920	5,217	149,751	410.0	3,172	3,199	110,847	122,234	103,411,558	283,125.4	0.02
August	5,141	3,345,055	5,305	138,922	380.3	3,020	3,072	101,551	114,359	103,253,070	282,691.5	0.02
September	5,119	3,337,642	5,250	124,843	341.8	2,634	2,646	91,754	102,841	99,758,114	273,122.8	0.02
October	5,149	3,333,041	5,292	135,997	372.3	2,843	2,876	99,796	110,612	102,889,905	281,697.2	0.02
November	5,096	3,320,650	5,257	129,465	354.5	2,649	2,688	95,384	107,301	99,089,300	271,291.7	0.02
December	5,032	3,304,275	5,162	118,989	325.8	2,385	2,408	87,818	97,239	102,043,869	279,380.9	0.02
2019												
January	5,062	3,300,870	5,237	131,960	361.3	2,797	2,809	95,839	105,505	101,879,735	278,931.5	0.02
February	4,964	3,290,887	5,112	121,645	333.0	2,635	2,659	88,004	97,349	91,267,938	249,878.0	0.02
March	4,964	3,262,310	5,098	129,046	353.3	2,713	2,756	97,246	103,850	100,679,246	275,644.8	0.02
April	4,960	3,256,535	5,105	119,996	328.5	2,389	2,407	86,869	94,986	97,288,410	266,361.1	0.02
May	5,030	3,252,842	5,202	134,549	368.4	2,649	2,672	98,711	107,664	100,383,670	274,835.5	0.02
June	4,966	3,244,286	5,096	111,693	305.8	2,288	2,306	82,507	91,410	96,646,185	264,602.8	0.02
July	4,988	3,224,000	5,140	126,305	345.8	2,558	2,580	92,313	101,728	99,374,866	272,073.6	0.02
August	4,913	3,209,477	5,054	99,055	271.2	2,043	2,068	71,362	79,162	98,994,635	271,032.5	0.02
September	4,863	3,198,349	4,998	117,933	322.9	2,414	2,425	86,273	96,235	95,374,854	261,122.1	0.02
October	4,942	3,180,417	5,122	123,337	337.7	2,499	2,517	90,557	100,015	98,058,099	268,468.4	0.02
November	4,852	3,167,402	4,983	106,608	291.9	2,217	2,234	78,469	89,128	94,489,280	258,697.5	0.02
December	4,898	3,152,259	5,015	111,592	305.5	2,179	2,206	82,121	88,843	97,324,920	266,461.1	0.02
2020												
January	4,937	3,147,549	5,107	114,444	313.3	2,453	2,469	84,754	95,207	97,124,069	265,911.2	0.02
February	4,877	3,136,667	5,016	92,194	252.4	2,030	2,038	67,972	77,840	90,206,705	246,972.5	0.02
March	4,989	3,104,243	5,186	113,168	309.8	2,352	2,366	83,673	94,066	95,463,699	261,365.4	0.02
April	4,906	3,074,928	5,051	68,332	187.1	1,524	1,539	51,774	58,125	91,650,882	250,926.4	0.02
May	4,845	3,057,216	5,012	66,088	180.9	1,484	1,494	50,039	56,407	94,411,304	258,484.1	0.02
June	4,853	3,049,628	5,024	55,524	152.0	1,395	1,403	44,039	51,013	91,140,661	249,529.5	0.02
July	4,878	3,042,931	5,015	30,986	84.8	998	1,001	27,895	32,790	93,615,535	256,305.4	0.02
August	4,671	3,017,723	4,738	6,367	17.4	550	552	6,300	7,932	66,245,593	181,370.5	0.02

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Valsartan												
<i>Prevalent Valsartan episodes</i>												
2014												
January	2,373	3,507,846	2,373	292,708	801.4	6,226	6,288	202,954	256,707	108,292,422	296,488.5	0.08
February	4,582	3,503,171	4,583	266,802	730.5	5,497	5,578	184,326	233,321	97,729,726	267,569.4	0.08
March	6,251	3,502,444	6,320	214,983	588.6	4,412	4,498	147,914	182,087	108,131,605	296,048.2	0.07
April	6,741	3,500,386	6,861	167,414	458.4	3,361	3,432	118,612	144,395	104,600,874	286,381.6	0.06
May	6,186	3,500,442	6,286	167,481	458.5	3,672	3,778	121,986	139,916	108,077,729	295,900.7	0.05
June	5,512	3,496,708	5,592	168,712	461.9	3,594	3,651	125,064	137,624	104,552,935	286,250.3	0.04
July	5,387	3,497,621	5,561	192,730	527.7	4,018	4,108	140,926	160,287	107,934,819	295,509.4	0.03
August	5,270	3,498,115	5,415	166,806	456.7	3,736	3,815	121,616	137,469	107,983,758	295,643.4	0.03
September	5,474	3,497,642	5,638	196,132	537.0	4,191	4,301	145,150	160,095	104,529,462	286,186.1	0.03
October	5,750	3,498,776	5,938	195,634	535.6	4,295	4,398	145,093	157,100	107,978,970	295,630.3	0.03
November	5,802	3,497,242	5,948	160,365	439.1	3,315	3,379	118,362	136,120	104,478,437	286,046.4	0.03
December	6,003	3,497,280	6,140	180,166	493.3	4,036	4,156	132,792	153,021	107,940,383	295,524.7	0.03
2015												
January	6,132	3,496,690	6,314	187,298	512.8	4,279	4,349	137,208	154,751	107,881,672	295,363.9	0.03
February	6,189	3,492,219	6,368	198,117	542.4	4,584	4,766	145,804	165,004	97,372,716	266,592.0	0.03
March	6,428	3,490,152	6,639	206,582	565.6	4,490	4,601	151,861	172,998	107,733,931	294,959.4	0.03
April	6,549	3,488,959	6,752	185,744	508.5	4,065	4,182	136,467	153,864	104,230,695	285,368.1	0.03
May	6,635	3,488,452	6,826	182,612	500.0	3,890	3,940	133,115	156,294	107,700,240	294,867.2	0.03
June	6,763	3,485,548	6,979	191,755	525.0	3,980	4,050	139,543	162,574	104,209,432	285,309.9	0.03
July	6,906	3,485,913	7,128	201,152	550.7	4,339	4,446	148,805	171,557	107,580,481	294,539.3	0.03
August	6,845	3,485,067	7,047	169,848	465.0	3,637	3,710	122,589	143,552	107,600,723	294,594.7	0.03
September	7,003	3,484,792	7,207	198,939	544.7	4,240	4,307	145,375	164,640	104,129,782	285,091.8	0.03
October	7,043	3,483,124	7,270	188,924	517.2	4,200	4,340	138,396	162,006	107,503,246	294,327.8	0.03
November	7,047	3,478,261	7,211	190,233	520.8	4,187	4,275	139,445	164,626	103,945,706	284,587.8	0.03
December	7,162	3,475,769	7,353	190,479	521.5	4,088	4,215	139,242	160,060	107,309,180	293,796.5	0.03

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Valsartan												
2016												
January	7,155	3,473,355	7,339	179,276	490.8	3,931	4,034	130,281	152,927	107,231,746	293,584.5	0.03
February	7,179	3,469,581	7,421	216,085	591.6	4,994	5,153	156,791	189,200	100,224,321	274,399.2	0.03
March	7,317	3,468,985	7,582	207,915	569.2	4,563	4,621	151,459	174,481	107,021,614	293,009.2	0.03
April	7,330	3,464,889	7,544	189,004	517.5	4,398	4,540	136,777	164,362	103,490,698	283,342.1	0.03
May	7,418	3,461,155	7,653	202,305	553.9	4,617	4,683	147,133	177,082	106,891,996	292,654.3	0.03
June	7,499	3,458,252	7,727	208,574	571.0	4,436	4,590	154,386	188,606	103,368,878	283,008.6	0.03
July	7,598	3,455,547	7,819	200,844	549.9	4,370	4,463	145,619	184,499	106,697,888	292,122.9	0.03
August	7,760	3,455,916	8,011	218,566	598.4	4,864	4,958	157,344	199,817	106,702,337	292,135.1	0.03
September	7,869	3,452,879	8,134	201,659	552.1	4,381	4,490	144,933	186,008	103,169,294	282,462.1	0.03
October	7,877	3,447,391	8,105	189,090	517.7	4,145	4,258	136,557	170,934	106,451,503	291,448.3	0.03
November	7,829	3,442,934	8,099	201,129	550.7	4,383	4,496	146,693	181,407	102,889,008	281,694.8	0.03
December	7,612	3,440,236	7,790	173,328	474.5	3,778	3,833	126,012	152,747	106,173,852	290,688.2	0.03
2017												
January	7,325	3,436,319	7,514	182,443	499.5	4,087	4,157	132,468	163,606	106,084,392	290,443.2	0.03
February	7,000	3,429,829	7,226	178,218	487.9	3,939	4,050	130,381	155,043	95,664,633	261,915.5	0.03
March	6,925	3,427,335	7,169	186,755	511.3	4,041	4,109	136,204	166,625	105,767,800	289,576.5	0.03
April	6,664	3,422,433	6,849	167,430	458.4	4,051	4,196	121,887	146,912	102,287,330	280,047.4	0.03
May	6,703	3,420,701	6,903	186,047	509.4	4,144	4,224	135,506	172,950	105,599,916	289,116.8	0.03
June	6,707	3,414,139	6,932	196,943	539.2	4,345	4,415	145,449	175,676	102,075,503	279,467.5	0.03
July	6,772	3,410,527	6,972	185,362	507.5	4,000	4,063	136,436	168,143	105,312,720	288,330.5	0.03
August	6,876	3,408,462	7,111	195,341	534.8	4,315	4,388	142,809	177,114	105,217,268	288,069.2	0.03
September	6,853	3,405,273	7,041	171,334	469.1	3,934	3,985	124,505	158,933	101,730,015	278,521.6	0.03
October	6,921	3,400,665	7,141	200,404	548.7	4,359	4,474	146,755	185,123	104,997,747	287,468.2	0.03
November	6,992	3,395,804	7,203	184,796	505.9	3,898	3,961	133,927	170,823	101,467,725	277,803.5	0.03
December	7,064	3,390,282	7,217	159,307	436.2	3,321	3,364	113,630	140,342	104,676,070	286,587.5	0.03

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Valsartan												
January	7,209	3,386,976	7,439	200,825	549.8	4,462	4,543	145,261	187,393	104,506,931	286,124.4	0.03
February	7,191	3,378,265	7,435	184,157	504.2	4,120	4,190	133,358	175,408	94,210,603	257,934.6	0.03
March	7,256	3,372,159	7,489	193,971	531.1	4,191	4,271	141,178	174,405	104,048,900	284,870.4	0.03
April	7,263	3,366,021	7,474	196,185	537.1	4,384	4,486	142,054	178,581	100,523,173	275,217.4	0.03
May	7,429	3,360,077	7,690	191,333	523.8	4,254	4,319	136,605	179,583	103,725,063	283,983.7	0.03
June	7,441	3,353,599	7,669	191,799	525.1	4,272	4,355	139,253	183,393	100,253,057	274,477.9	0.03
July	7,560	3,348,920	7,794	216,490	592.7	4,882	4,968	155,878	207,828	103,411,558	283,125.4	0.03
August	7,684	3,345,055	7,948	198,846	544.4	4,302	4,418	143,722	194,200	103,253,070	282,691.5	0.03
September	7,568	3,337,642	7,749	177,827	486.9	3,894	3,952	127,347	169,358	99,758,114	273,122.8	0.03
October	7,604	3,333,041	7,873	206,041	564.1	4,555	4,624	148,506	193,440	102,889,905	281,697.2	0.03
November	7,588	3,320,650	7,836	197,509	540.8	4,407	4,478	144,129	194,983	99,089,300	271,291.7	0.03
December	7,601	3,304,275	7,794	196,210	537.2	4,205	4,291	141,975	186,298	102,043,869	279,380.9	0.03
2019												
January	7,690	3,300,870	7,953	205,990	564.0	4,535	4,598	148,219	207,829	101,879,735	278,931.5	0.03
February	7,632	3,290,887	7,885	197,102	539.6	4,483	4,578	141,951	199,384	91,267,938	249,878.0	0.03
March	7,714	3,262,310	7,949	203,372	556.8	4,472	4,553	148,307	204,872	100,679,246	275,644.8	0.03
April	7,854	3,256,535	8,076	200,534	549.0	4,472	4,545	145,569	203,415	97,288,410	266,361.1	0.03
May	7,912	3,252,842	8,181	198,046	542.2	4,368	4,471	143,331	204,339	100,383,670	274,835.5	0.03
June	7,846	3,244,286	8,039	184,230	504.4	4,183	4,246	133,785	190,140	96,646,185	264,602.8	0.03
July	7,924	3,224,000	8,185	214,094	586.2	4,837	4,899	154,538	222,098	99,374,866	272,073.6	0.03
August	7,766	3,209,477	8,012	176,722	483.8	3,868	3,924	127,601	180,467	98,994,635	271,032.5	0.03
September	7,570	3,198,349	7,774	186,255	509.9	4,126	4,203	136,064	191,306	95,374,854	261,122.1	0.03
October	7,537	3,180,417	7,808	181,989	498.3	3,965	4,050	133,060	188,310	98,058,099	268,468.4	0.02
November	7,443	3,167,402	7,660	169,055	462.8	3,646	3,700	122,707	173,457	94,489,280	258,697.5	0.02
December	7,595	3,152,259	7,791	183,313	501.9	3,966	4,001	133,073	190,452	97,324,920	266,461.1	0.03

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Valsartan												
2020												
January	7,776	3,147,549	8,053	166,507	455.9	3,782	3,831	121,682	177,311	97,124,069	265,911.2	0.03
February	7,678	3,136,667	7,929	147,567	404.0	3,475	3,500	106,221	156,602	90,206,705	246,972.5	0.03
March	7,963	3,104,243	8,251	187,245	512.6	4,282	4,349	138,593	202,428	95,463,699	261,365.4	0.03
April	7,904	3,074,928	8,130	116,994	320.3	2,710	2,733	87,105	124,282	91,650,882	250,926.4	0.03
May	7,898	3,057,216	8,147	100,823	276.0	2,397	2,413	75,126	112,789	94,411,304	258,484.1	0.03
June	7,871	3,049,628	8,144	87,712	240.1	2,358	2,380	68,579	102,457	91,140,661	249,529.5	0.03
July	7,967	3,042,931	8,239	51,633	141.4	1,767	1,778	45,863	68,868	93,615,535	256,305.4	0.03
August	7,651	3,017,723	7,782	10,282	28.2	948	952	10,169	16,363	66,245,593	181,370.5	0.03

¹Total number of users by year month may not sum up to total patients in Table 1 because cohort re-entry was allowed, enabling multiple counts for patients with multiple ARB episodes during the study period

²Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

³Proportion of ARB use estimated as number of episodes for each individual ARB in given year month divided by all ARB episodes in the same year month

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
<i>Prevalent ARB episodes</i>												
2014												
Q1: January - March	89,635	3,534,217	91,255	15,845,275	43,382.0	356,102	364,319	11,751,579	12,186,857	314,153,753	860,106.1	1.00
Q2: April - June	155,112	3,525,479	177,053	16,164,382	44,255.7	359,133	366,761	12,004,785	12,340,906	317,231,538	868,532.6	1.00
Q3: July - September	188,749	3,527,453	223,552	16,860,720	46,162.1	378,515	386,158	12,485,457	12,836,151	320,448,039	877,338.9	1.00
Q4: October - December	208,261	3,528,829	248,177	17,100,155	46,817.7	383,694	392,214	12,669,215	13,038,304	320,397,790	877,201.3	1.00
2015												
Q1: January - March	221,710	3,525,026	266,247	17,749,063	48,594.3	401,016	410,664	13,105,217	13,638,199	312,988,319	856,915.3	1.00
Q2: April - June	231,994	3,515,392	278,394	17,804,536	48,746.2	400,310	409,793	13,154,636	13,727,811	316,140,367	865,545.2	1.00
Q3: July - September	241,513	3,515,081	291,452	18,467,986	50,562.6	414,692	423,957	13,617,453	14,272,274	319,310,986	874,225.8	1.00
Q4: October - December	249,987	3,508,084	300,182	18,847,968	51,602.9	425,694	435,757	13,884,342	14,559,049	318,758,132	872,712.2	1.00
2016												
Q1: January - March	257,622	3,500,679	310,362	19,602,718	53,669.3	444,638	454,926	14,453,276	15,169,862	314,477,681	860,993.0	1.00
Q2: April - June	264,736	3,488,739	317,543	19,805,935	54,225.7	442,536	452,795	14,607,287	15,379,195	313,751,572	859,005.0	1.00
Q3: July - September	271,747	3,481,151	326,873	20,363,299	55,751.7	456,024	466,668	15,033,687	15,868,543	316,569,519	866,720.1	1.00
Q4: October - December	278,012	3,472,733	333,023	20,355,015	55,729.0	459,240	469,134	15,013,615	15,859,185	315,514,363	863,831.2	1.00
2017												
Q1: January - March	283,917	3,461,908	341,293	21,236,849	58,143.3	478,664	490,105	15,651,551	16,568,655	307,516,825	841,935.2	1.00
Q2: April - June	290,444	3,445,212	348,000	21,093,042	57,749.6	471,239	482,269	15,542,016	16,514,828	309,962,749	848,631.8	1.00
Q3: July - September	296,262	3,437,026	355,363	21,358,404	58,476.1	476,520	487,231	15,716,126	16,742,909	312,260,003	854,921.3	1.00
Q4: October - December	301,405	3,424,194	359,901	21,666,008	59,318.3	483,690	494,859	15,940,579	17,041,552	311,141,542	851,859.1	1.00
2018												
Q1: January - March	308,225	3,411,275	370,433	22,449,992	61,464.7	503,951	515,485	16,476,711	17,665,305	302,766,434	828,929.3	1.00
Q2: April - June	313,491	3,388,786	374,750	22,382,364	61,279.6	494,223	505,727	16,459,424	17,656,261	304,501,293	833,679.1	1.00
Q3: July - September	318,018	3,370,606	379,970	22,510,893	61,631.5	497,809	508,650	16,544,768	17,801,362	306,422,742	838,939.7	1.00
Q4: October - December	322,735	3,353,519	386,618	22,679,404	62,092.8	495,560	506,303	16,698,929	18,098,221	304,023,074	832,369.8	1.00
2019												
Q1: January - March	327,546	3,323,199	392,718	22,621,360	61,933.9	496,925	508,023	16,636,731	18,031,344	293,826,919	804,454.3	1.00
Q2: April - June	332,015	3,277,731	396,140	22,475,176	61,533.7	489,335	499,201	16,542,892	18,003,389	294,318,265	805,799.5	1.00
Q3: July - September	336,387	3,245,578	403,818	22,521,099	61,659.4	488,397	497,181	16,575,725	18,077,316	293,744,355	804,228.2	1.00
Q4: October - December	339,917	3,199,218	409,515	20,863,813	57,122.0	452,554	460,282	15,367,074	16,865,909	289,872,299	793,627.1	1.00
2020												
Q1: January - March	345,914	3,167,756	420,927	19,043,662	52,138.7	419,575	425,486	14,128,624	15,718,947	282,794,473	774,249.1	1.00
Q2: April - June	340,459	3,091,261	409,491	11,373,930	31,140.1	274,853	277,905	8,706,973	9,826,930	277,202,847	758,940.0	1.00
Q3: July - September	318,967	3,049,156	345,958	2,250,902	6,162.6	96,025	96,963	2,055,475	2,431,306	159,861,188	437,676.1	1.00

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Azilsartan												
<i>Prevalent Azilsartan episodes</i>												
2014												
Q1: January - March	*****	3,534,217	*****	410	1.1	*****	*****	254	254	314,153,753	860,106.1	0.00
Q2: April - June	*****	3,525,479	*****	788	2.2	15	15	616	616	317,231,538	868,532.6	0.00
Q3: July - September	9	3,527,453	9	116	0.3	*****	*****	56	84	320,448,039	877,338.9	0.00
Q4: October - December	9	3,528,829	12	879	2.4	17	17	560	616	320,397,790	877,201.3	0.00
2015												
Q1: January - March	11	3,525,026	14	823	2.3	*****	*****	539	588	312,988,319	856,915.3	0.00
Q2: April - June	13	3,515,392	18	1,606	4.4	33	33	1,212	1,492	316,140,367	865,545.2	0.00
Q3: July - September	14	3,515,081	14	249	0.7	*****	*****	140	196	319,310,986	874,225.8	0.00
Q4: October - December	15	3,508,084	18	1,575	4.3	34	34	1,162	1,162	318,758,132	872,712.2	0.00
2016												
Q1: January - March	14	3,500,679	15	1,154	3.2	28	28	831	887	314,477,681	860,993.0	0.00
Q2: April - June	16	3,488,739	21	1,685	4.6	33	33	1,169	1,225	313,751,572	859,005.0	0.00
Q3: July - September	17	3,481,151	22	1,007	2.8	20	20	652	652	316,569,519	866,720.1	0.00
Q4: October - December	17	3,472,733	20	1,104	3.0	20	20	817	929	315,514,363	863,831.2	0.00
2017												
Q1: January - March	14	3,461,908	19	875	2.4	17	19	664	832	307,516,825	841,935.2	0.00
Q2: April - June	15	3,445,212	20	1,412	3.9	33	33	1,071	1,071	309,962,749	848,631.8	0.00
Q3: July - September	15	3,437,026	20	980	2.7	19	22	672	896	312,260,003	854,921.3	0.00
Q4: October - December	14	3,424,194	16	2,389	6.5	61	61	2,002	1,760	311,141,542	851,859.1	0.00
2018												
Q1: January - March	15	3,411,275	16	1,002	2.7	18	18	752	752	302,766,434	828,929.3	0.00
Q2: April - June	18	3,388,786	21	1,425	3.9	27	27	1,108	1,108	304,501,293	833,679.1	0.00
Q3: July - September	14	3,370,606	15	661	1.8	12	13	463	618	306,422,742	838,939.7	0.00
Q4: October - December	17	3,353,519	22	1,428	3.9	25	25	980	1,008	304,023,074	832,369.8	0.00
2019												
Q1: January - March	17	3,323,199	20	342	0.9	7	7	224	224	293,826,919	804,454.3	0.00
Q2: April - June	14	3,277,731	18	889	2.4	16	16	672	700	294,318,265	805,799.5	0.00
Q3: July - September	15	3,245,578	17	712	1.9	10	10	579	579	293,744,355	804,228.2	0.00
Q4: October - December	15	3,199,218	16	708	1.9	12	12	448	448	289,872,299	793,627.1	0.00
2020												
Q1: January - March	16	3,167,756	20	900	2.5	19	19	607	691	282,794,473	774,249.1	0.00
Q2: April - June	15	3,091,261	20	432	1.2	11	11	370	454	277,202,847	758,940.0	0.00
Q3: July - September	16	3,049,156	17	181	0.5	6	6	152	152	159,861,188	437,676.1	0.00

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Candesartan												
<i>Prevalent Candesartan episodes</i>												
2014												
Q1: January - March	29,436	3,534,217	29,959	5,289,724	14,482.5	118,657	123,311	3,932,064	4,038,636	314,153,753	860,106.1	0.33
Q2: April - June	52,349	3,525,479	59,584	5,701,034	15,608.6	128,243	132,624	4,251,226	4,323,876	317,231,538	868,532.6	0.34
Q3: July - September	64,016	3,527,453	75,681	5,832,028	15,967.2	131,780	135,881	4,339,682	4,429,343	320,448,039	877,338.9	0.34
Q4: October - December	70,748	3,528,829	84,158	5,860,273	16,044.6	132,082	136,865	4,363,017	4,488,749	320,397,790	877,201.3	0.34
2015												
Q1: January - March	75,307	3,525,026	90,367	6,121,254	16,759.1	139,463	144,754	4,537,648	4,727,973	312,988,319	856,915.3	0.34
Q2: April - June	79,099	3,515,392	94,985	6,194,543	16,959.7	140,196	145,374	4,597,691	4,818,556	316,140,367	865,545.2	0.34
Q3: July - September	82,690	3,515,081	99,611	6,394,675	17,507.7	145,858	150,863	4,729,810	4,969,240	319,310,986	874,225.8	0.34
Q4: October - December	85,780	3,508,084	102,863	6,571,883	17,992.8	151,189	156,972	4,862,820	5,108,010	318,758,132	872,712.2	0.34
2016												
Q1: January - March	88,544	3,500,679	106,705	6,826,382	18,689.6	157,671	163,518	5,052,897	5,304,763	314,477,681	860,993.0	0.34
Q2: April - June	91,054	3,488,739	109,401	6,913,416	18,927.9	155,491	161,165	5,116,395	5,394,484	313,751,572	859,005.0	0.34
Q3: July - September	93,626	3,481,151	112,447	7,103,634	19,448.7	159,936	166,058	5,267,162	5,557,232	316,569,519	866,720.1	0.34
Q4: October - December	96,106	3,472,733	114,902	7,079,394	19,382.3	160,784	166,217	5,237,859	5,526,524	315,514,363	863,831.2	0.35
2017												
Q1: January - March	98,262	3,461,908	118,247	7,432,611	20,349.4	171,300	177,981	5,492,630	5,830,254	307,516,825	841,935.2	0.35
Q2: April - June	100,663	3,445,212	120,530	7,392,935	20,240.8	165,857	172,162	5,474,740	5,833,270	309,962,749	848,631.8	0.35
Q3: July - September	102,611	3,437,026	122,975	7,377,911	20,199.6	165,951	172,024	5,440,859	5,807,547	312,260,003	854,921.3	0.35
Q4: October - December	104,313	3,424,194	124,647	7,531,208	20,619.3	169,892	176,450	5,556,648	5,959,928	311,141,542	851,859.1	0.35
2018												
Q1: January - March	106,776	3,411,275	128,493	7,938,780	21,735.2	180,958	187,612	5,856,301	6,277,416	302,766,434	828,929.3	0.35
Q2: April - June	108,665	3,388,786	129,606	7,739,569	21,189.8	173,536	180,115	5,713,946	6,132,554	304,501,293	833,679.1	0.35
Q3: July - September	110,187	3,370,606	131,420	7,757,458	21,238.8	173,268	179,317	5,714,335	6,161,887	306,422,742	838,939.7	0.35
Q4: October - December	111,964	3,353,519	133,789	7,882,051	21,579.9	175,035	181,268	5,818,251	6,321,732	304,023,074	832,369.8	0.35
2019												
Q1: January - March	113,896	3,323,199	136,447	7,900,244	21,629.7	175,534	182,031	5,821,623	6,324,288	293,826,919	804,454.3	0.35
Q2: April - June	115,705	3,277,731	137,706	7,843,873	21,475.4	173,505	179,140	5,785,658	6,300,278	294,318,265	805,799.5	0.35
Q3: July - September	117,681	3,245,578	141,093	7,882,784	21,581.9	173,696	178,830	5,813,458	6,359,887	293,744,355	804,228.2	0.35
Q4: October - December	118,831	3,199,218	142,871	7,256,765	19,867.9	159,542	163,987	5,355,610	5,904,120	289,872,299	793,627.1	0.35
2020												
Q1: January - March	120,925	3,167,756	146,942	6,632,272	18,158.2	148,253	151,661	4,931,402	5,505,935	282,794,473	774,249.1	0.35
Q2: April - June	119,083	3,091,261	143,041	3,888,774	10,646.9	95,041	96,745	2,977,763	3,375,810	277,202,847	758,940.0	0.35
Q3: July - September	111,916	3,049,156	121,265	780,026	2,135.6	33,313	33,855	710,109	844,956	159,861,188	437,676.1	0.35

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Eprosartan												
<i>Prevalent Eprosartan episodes</i>												
2014												
Q1: January - March	567	3,534,217	578	101,836	278.8	2,460	2,476	74,110	78,717	314,153,753	860,106.1	0.01
Q2: April - June	942	3,525,479	1,092	94,113	257.7	2,082	2,082	67,895	75,591	317,231,538	868,532.6	0.01
Q3: July - September	1,121	3,527,453	1,351	90,184	246.9	2,018	2,020	64,883	70,685	320,448,039	877,338.9	0.01
Q4: October - December	1,220	3,528,829	1,500	101,173	277.0	2,289	2,292	73,152	82,236	320,397,790	877,201.3	0.01
2015												
Q1: January - March	1,256	3,525,026	1,532	102,450	280.5	2,529	2,549	73,666	81,924	312,988,319	856,915.3	0.01
Q2: April - June	1,278	3,515,392	1,580	98,902	270.8	2,585	2,585	69,833	76,241	316,140,367	865,545.2	0.01
Q3: July - September	1,298	3,515,081	1,569	81,895	224.2	1,998	1,998	57,834	63,353	319,310,986	874,225.8	0.01
Q4: October - December	1,312	3,508,084	1,607	92,199	252.4	2,195	2,206	64,034	72,529	318,758,132	872,712.2	0.01
2016												
Q1: January - March	1,302	3,500,679	1,624	94,639	259.1	2,192	2,193	66,568	77,211	314,477,681	860,993.0	0.01
Q2: April - June	1,297	3,488,739	1,580	98,797	270.5	2,246	2,248	70,653	79,069	313,751,572	859,005.0	0.00
Q3: July - September	1,298	3,481,151	1,584	101,560	278.1	2,588	2,601	72,961	83,113	316,569,519	866,720.1	0.00
Q4: October - December	1,284	3,472,733	1,580	83,406	228.4	1,894	1,895	59,043	68,362	315,514,363	863,831.2	0.00
2017												
Q1: January - March	1,287	3,461,908	1,580	87,023	238.3	2,075	2,081	60,736	72,026	307,516,825	841,935.2	0.00
Q2: April - June	1,295	3,445,212	1,570	82,016	224.5	1,871	1,880	58,463	69,472	309,962,749	848,631.8	0.00
Q3: July - September	1,229	3,437,026	1,433	75,639	207.1	1,758	1,765	54,726	65,918	312,260,003	854,921.3	0.00
Q4: October - December	1,063	3,424,194	1,255	64,514	176.6	1,463	1,467	45,623	55,260	311,141,542	851,859.1	0.00
2018												
Q1: January - March	1,007	3,411,275	1,215	72,442	198.3	1,713	1,716	50,539	61,332	302,766,434	828,929.3	0.00
Q2: April - June	972	3,388,786	1,204	74,217	203.2	1,723	1,723	52,818	61,751	304,501,293	833,679.1	0.00
Q3: July - September	945	3,370,606	1,145	65,571	179.5	1,591	1,595	46,197	52,999	306,422,742	838,939.7	0.00
Q4: October - December	941	3,353,519	1,110	59,313	162.4	1,455	1,455	41,744	48,995	304,023,074	832,369.8	0.00
2019												
Q1: January - March	923	3,323,199	1,114	61,716	169.0	1,513	1,513	43,449	49,295	293,826,919	804,454.3	0.00
Q2: April - June	880	3,277,731	1,050	57,537	157.5	1,301	1,302	40,931	50,726	294,318,265	805,799.5	0.00
Q3: July - September	876	3,245,578	1,072	61,490	168.4	1,425	1,427	44,149	51,579	293,744,355	804,228.2	0.00
Q4: October - December	882	3,199,218	1,066	52,307	143.2	1,231	1,231	36,805	44,044	289,872,299	793,627.1	0.00
2020												
Q1: January - March	876	3,167,756	1,075	48,536	132.9	1,222	1,222	35,209	40,649	282,794,473	774,249.1	0.00
Q2: April - June	855	3,091,261	1,047	28,693	78.6	767	770	21,200	25,583	277,202,847	758,940.0	0.00
Q3: July - September	799	3,049,156	874	5,000	13.7	244	244	4,591	5,558	159,861,188	437,676.1	0.00

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Irbesartan												
<i>Prevalent Irbesartan episodes</i>												
2014												
Q1: January - March	10,487	3,534,217	10,673	1,830,562	5,011.8	39,958	40,306	1,351,219	1,409,824	314,153,753	860,106.1	0.12
Q2: April - June	18,323	3,525,479	20,879	1,858,293	5,087.7	40,649	40,851	1,363,981	1,429,880	317,231,538	868,532.6	0.12
Q3: July - September	22,110	3,527,453	26,141	1,917,268	5,249.2	42,595	42,862	1,410,065	1,481,911	320,448,039	877,338.9	0.12
Q4: October - December	24,056	3,528,829	28,690	1,928,501	5,279.9	43,636	43,948	1,415,958	1,472,753	320,397,790	877,201.3	0.12
2015												
Q1: January - March	25,359	3,525,026	30,475	1,976,589	5,411.6	43,627	43,961	1,452,691	1,518,151	312,988,319	856,915.3	0.11
Q2: April - June	26,208	3,515,392	31,332	1,937,645	5,305.0	42,774	43,076	1,426,077	1,494,192	316,140,367	865,545.2	0.11
Q3: July - September	26,948	3,515,081	32,526	2,015,189	5,517.3	44,201	44,519	1,478,104	1,565,936	319,310,986	874,225.8	0.11
Q4: October - December	27,671	3,508,084	33,242	2,046,866	5,604.0	46,271	46,571	1,495,957	1,575,585	318,758,132	872,712.2	0.11
2016												
Q1: January - March	28,194	3,500,679	33,921	2,098,260	5,744.7	46,073	46,539	1,543,209	1,619,586	314,477,681	860,993.0	0.11
Q2: April - June	28,566	3,488,739	34,201	2,055,729	5,628.3	44,801	45,122	1,509,837	1,610,667	313,751,572	859,005.0	0.11
Q3: July - September	28,945	3,481,151	34,851	2,132,949	5,839.7	47,680	48,116	1,565,216	1,661,932	316,569,519	866,720.1	0.11
Q4: October - December	29,254	3,472,733	35,037	2,107,387	5,769.7	45,960	46,360	1,549,694	1,647,106	315,514,363	863,831.2	0.11
2017												
Q1: January - March	29,572	3,461,908	35,558	2,170,338	5,942.1	48,178	48,588	1,594,527	1,703,338	307,516,825	841,935.2	0.10
Q2: April - June	29,990	3,445,212	35,910	2,087,060	5,714.1	46,680	47,077	1,517,078	1,640,266	309,962,749	848,631.8	0.10
Q3: July - September	30,264	3,437,026	36,301	2,140,112	5,859.3	47,302	47,607	1,563,986	1,695,727	312,260,003	854,921.3	0.10
Q4: October - December	30,498	3,424,194	36,399	2,198,380	6,018.8	48,498	48,942	1,614,070	1,761,392	311,141,542	851,859.1	0.10
2018												
Q1: January - March	31,254	3,411,275	37,275	2,137,709	5,852.7	47,171	47,544	1,551,399	1,744,050	302,766,434	828,929.3	0.10
Q2: April - June	30,960	3,388,786	36,956	2,148,731	5,882.9	46,980	47,350	1,572,140	1,719,672	304,501,293	833,679.1	0.10
Q3: July - September	30,769	3,370,606	36,743	2,127,773	5,825.5	46,787	47,215	1,554,509	1,697,400	306,422,742	838,939.7	0.10
Q4: October - December	30,958	3,353,519	37,088	2,167,306	5,933.8	47,006	47,308	1,585,164	1,756,145	304,023,074	832,369.8	0.10
2019												
Q1: January - March	31,107	3,323,199	37,391	2,143,812	5,869.4	46,956	47,400	1,568,906	1,718,283	293,826,919	804,454.3	0.10
Q2: April - June	31,111	3,277,731	37,208	2,055,507	5,627.7	43,860	44,233	1,504,862	1,686,671	294,318,265	805,799.5	0.09
Q3: July - September	31,276	3,245,578	37,533	2,067,784	5,661.3	44,125	44,474	1,513,629	1,678,847	293,744,355	804,228.2	0.09
Q4: October - December	31,400	3,199,218	37,922	1,904,265	5,213.6	40,548	40,874	1,394,981	1,560,270	289,872,299	793,627.1	0.09
2020												
Q1: January - March	31,622	3,167,756	38,469	1,735,225	4,750.8	37,783	38,010	1,286,811	1,457,257	282,794,473	774,249.1	0.09
Q2: April - June	30,812	3,091,261	37,108	1,034,478	2,832.2	25,041	25,157	791,285	913,470	277,202,847	758,940.0	0.09
Q3: July - September	28,635	3,049,156	31,015	200,921	550.1	8,567	8,605	183,552	221,735	159,861,188	437,676.1	0.09

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Losartan												
<i>Prevalent Losartan episodes</i>												
2014												
Q1: January - March	39,390	3,534,217	40,038	6,862,108	18,787.4	154,078	156,621	5,064,397	5,180,394	314,153,753	860,106.1	0.44
Q2: April - June	71,181	3,525,479	80,608	7,456,411	20,414.5	165,718	168,463	5,510,006	5,617,343	317,231,538	868,532.6	0.46
Q3: July - September	86,699	3,527,453	102,296	7,627,816	20,883.8	170,464	173,317	5,639,903	5,765,505	320,448,039	877,338.9	0.46
Q4: October - December	95,354	3,528,829	113,353	7,813,131	21,391.2	174,089	177,054	5,783,424	5,906,043	320,397,790	877,201.3	0.46
2015												
Q1: January - March	101,836	3,525,026	121,889	8,088,737	22,145.8	182,259	185,695	5,965,552	6,160,628	312,988,319	856,915.3	0.46
Q2: April - June	106,931	3,515,392	128,002	8,159,777	22,340.3	182,682	186,104	6,021,921	6,216,149	316,140,367	865,545.2	0.46
Q3: July - September	111,625	3,515,081	134,493	8,531,481	23,357.9	189,926	193,348	6,288,444	6,525,945	319,310,986	874,225.8	0.46
Q4: October - December	116,086	3,508,084	139,119	8,726,692	23,892.4	194,881	198,268	6,417,044	6,672,950	318,758,132	872,712.2	0.46
2016												
Q1: January - March	120,249	3,500,679	144,425	9,091,538	24,891.3	204,032	207,333	6,693,738	6,962,716	314,477,681	860,993.0	0.47
Q2: April - June	124,151	3,488,739	148,482	9,279,081	25,404.7	206,432	209,993	6,828,738	7,102,361	313,751,572	859,005.0	0.47
Q3: July - September	127,808	3,481,151	153,344	9,501,453	26,013.6	211,346	214,881	7,000,289	7,291,956	316,569,519	866,720.1	0.47
Q4: October - December	131,581	3,472,733	157,308	9,654,328	26,432.1	217,690	221,434	7,099,786	7,422,365	315,514,363	863,831.2	0.47
2017												
Q1: January - March	135,628	3,461,908	162,350	10,162,628	27,823.8	225,497	229,349	7,476,559	7,827,812	307,516,825	841,935.2	0.48
Q2: April - June	139,365	3,445,212	166,589	10,122,485	27,713.9	224,810	228,643	7,451,532	7,816,922	309,962,749	848,631.8	0.48
Q3: July - September	142,714	3,437,026	170,955	10,352,317	28,343.1	229,172	233,026	7,616,631	8,004,580	312,260,003	854,921.3	0.48
Q4: October - December	145,840	3,424,194	173,764	10,475,126	28,679.3	232,018	235,681	7,700,000	8,103,911	311,141,542	851,859.1	0.48
2018												
Q1: January - March	149,596	3,411,275	179,433	10,878,226	29,783.0	242,045	246,106	7,968,175	8,381,404	302,766,434	828,929.3	0.48
Q2: April - June	152,840	3,388,786	182,588	10,977,593	30,055.0	239,597	243,674	8,060,204	8,518,582	304,501,293	833,679.1	0.49
Q3: July - September	155,643	3,370,606	185,870	11,072,451	30,314.7	242,450	246,278	8,135,621	8,600,817	306,422,742	838,939.7	0.49
Q4: October - December	158,471	3,353,519	189,613	11,095,965	30,379.1	238,991	242,733	8,161,530	8,685,956	304,023,074	832,369.8	0.49
2019												
Q1: January - March	161,212	3,323,199	192,758	11,066,654	30,298.8	240,097	243,777	8,129,549	8,651,602	293,826,919	804,454.3	0.49
Q2: April - June	163,551	3,277,731	194,912	11,107,155	30,409.7	239,106	242,587	8,167,007	8,697,519	294,318,265	805,799.5	0.49
Q3: July - September	165,948	3,245,578	198,926	11,162,400	30,561.0	239,138	242,120	8,217,125	8,774,519	293,744,355	804,228.2	0.49
Q4: October - December	168,088	3,199,218	202,242	10,375,873	28,407.6	223,072	225,705	7,643,627	8,209,970	289,872,299	793,627.1	0.49
2020												
Q1: January - March	171,479	3,167,756	208,284	9,446,622	25,863.4	205,141	207,160	7,003,333	7,621,081	282,794,473	774,249.1	0.49
Q2: April - June	168,912	3,091,261	202,924	5,714,563	15,645.6	136,526	137,644	4,380,078	4,830,360	277,202,847	758,940.0	0.50
Q3: July - September	157,936	3,049,156	171,352	1,125,880	3,082.5	47,819	48,148	1,029,972	1,190,495	159,861,188	437,676.1	0.50

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Olmesartan												
<i>Prevalent Olmesartan episodes</i>												
2014												
Q1: January - March	2,984	3,534,217	3,054	497,398	1,361.8	12,129	12,283	351,695	358,552	314,153,753	860,106.1	0.03
Q2: April - June	4,892	3,525,479	5,702	481,605	1,318.6	11,576	11,691	343,410	345,876	317,231,538	868,532.6	0.03
Q3: July - September	5,778	3,527,453	6,965	507,164	1,388.5	11,984	12,084	361,538	367,123	320,448,039	877,338.9	0.03
Q4: October - December	6,232	3,528,829	7,577	491,699	1,346.2	11,879	11,968	349,996	353,812	320,397,790	877,201.3	0.03
2015												
Q1: January - March	6,472	3,525,026	7,943	487,678	1,335.2	11,406	11,493	346,906	354,633	312,988,319	856,915.3	0.03
Q2: April - June	6,525	3,515,392	7,926	469,038	1,284.2	11,076	11,279	334,391	341,348	316,140,367	865,545.2	0.03
Q3: July - September	6,531	3,515,081	7,976	473,597	1,296.6	11,309	11,459	336,909	347,908	319,310,986	874,225.8	0.03
Q4: October - December	6,386	3,508,084	7,783	462,567	1,266.4	10,695	10,821	332,160	338,615	318,758,132	872,712.2	0.03
2016												
Q1: January - March	6,253	3,500,679	7,709	481,886	1,319.3	11,757	12,071	343,654	356,270	314,477,681	860,993.0	0.02
Q2: April - June	6,304	3,488,739	7,676	438,778	1,201.3	10,378	10,545	313,231	318,737	313,751,572	859,005.0	0.02
Q3: July - September	6,295	3,481,151	7,784	470,201	1,287.3	11,015	11,124	336,450	343,070	316,569,519	866,720.1	0.02
Q4: October - December	6,284	3,472,733	7,694	463,537	1,269.1	10,875	10,983	331,274	342,942	315,514,363	863,831.2	0.02
2017												
Q1: January - March	6,211	3,461,908	7,606	443,887	1,215.3	10,697	10,798	316,143	327,427	307,516,825	841,935.2	0.02
Q2: April - June	6,261	3,445,212	7,611	453,710	1,242.2	10,484	10,598	326,390	333,861	309,962,749	848,631.8	0.02
Q3: July - September	6,296	3,437,026	7,717	460,500	1,260.8	11,148	11,364	329,116	340,291	312,260,003	854,921.3	0.02
Q4: October - December	6,357	3,424,194	7,728	442,078	1,210.3	10,474	10,604	313,798	327,895	311,141,542	851,859.1	0.02
2018												
Q1: January - March	6,333	3,411,275	7,784	461,461	1,263.4	11,008	11,129	329,739	342,010	302,766,434	828,929.3	0.02
Q2: April - June	6,315	3,388,786	7,689	433,597	1,187.1	10,046	10,143	307,554	324,216	304,501,293	833,679.1	0.02
Q3: July - September	6,297	3,370,606	7,656	460,003	1,259.4	10,753	10,936	331,954	343,908	306,422,742	838,939.7	0.02
Q4: October - December	6,364	3,353,519	7,801	458,335	1,254.9	10,513	10,589	327,416	344,000	304,023,074	832,369.8	0.02
2019												
Q1: January - March	6,506	3,323,199	7,974	450,740	1,234.1	10,428	10,529	320,375	336,136	293,826,919	804,454.3	0.02
Q2: April - June	6,627	3,277,731	8,069	454,084	1,243.2	10,496	10,564	324,457	342,553	294,318,265	805,799.5	0.02
Q3: July - September	6,624	3,245,578	8,161	448,681	1,228.4	10,525	10,632	320,060	341,510	293,744,355	804,228.2	0.02
Q4: October - December	6,636	3,199,218	8,164	411,031	1,125.3	9,721	9,817	295,783	317,522	289,872,299	793,627.1	0.02
2020												
Q1: January - March	6,601	3,167,756	8,290	370,621	1,014.7	8,842	8,925	268,956	290,974	282,794,473	774,249.1	0.02
Q2: April - June	6,483	3,091,261	7,936	219,357	600.6	5,626	5,647	162,328	178,837	277,202,847	758,940.0	0.02
Q3: July - September	6,112	3,049,156	6,666	42,230	115.6	1,888	1,898	38,146	43,764	159,861,188	437,676.1	0.02

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Telmisartan												
<i>Prevalent Telmisartan episodes</i>												
2014												
Q1: January - March	2,014	3,534,217	2,048	342,884	938.8	7,200	7,268	254,626	263,526	314,153,753	860,106.1	0.02
Q2: April - June	3,543	3,525,479	4,005	354,474	970.5	7,272	7,324	264,375	267,576	317,231,538	868,532.6	0.02
Q3: July - September	4,285	3,527,453	5,076	378,489	1,036.2	8,351	8,427	280,401	285,005	320,448,039	877,338.9	0.02
Q4: October - December	4,644	3,528,829	5,542	378,760	1,037.0	8,207	8,324	282,003	283,421	320,397,790	877,201.3	0.02
2015												
Q1: January - March	4,817	3,525,026	5,793	363,042	994.0	7,532	7,586	268,894	276,847	312,988,319	856,915.3	0.02
Q2: April - June	4,920	3,515,392	5,861	354,688	971.1	7,502	7,565	261,188	272,520	316,140,367	865,545.2	0.02
Q3: July - September	5,129	3,515,081	6,177	382,982	1,048.5	8,136	8,205	282,444	294,040	319,310,986	874,225.8	0.02
Q4: October - December	5,240	3,508,084	6,242	385,866	1,056.4	8,145	8,231	286,566	295,417	318,758,132	872,712.2	0.02
2016												
Q1: January - March	5,204	3,500,679	6,220	375,407	1,027.8	7,780	7,836	277,162	292,347	314,477,681	860,993.0	0.02
Q2: April - June	5,269	3,488,739	6,276	379,514	1,039.1	8,021	8,105	282,765	294,674	313,751,572	859,005.0	0.02
Q3: July - September	5,336	3,481,151	6,432	379,406	1,038.8	7,770	7,829	281,393	292,682	316,569,519	866,720.1	0.02
Q4: October - December	5,390	3,472,733	6,435	392,779	1,075.4	8,538	8,562	290,516	306,386	315,514,363	863,831.2	0.02
Q1: January - March	5,478	3,461,908	6,567	393,109	1,076.3	8,298	8,378	289,812	300,092	307,516,825	841,935.2	0.02
Q2: April - June	5,507	3,445,212	6,616	398,688	1,091.5	8,534	8,634	294,187	307,435	309,962,749	848,631.8	0.02
Q3: July - September	5,541	3,437,026	6,647	384,088	1,051.6	7,978	8,034	283,529	297,929	312,260,003	854,921.3	0.02
Q4: October - December	5,519	3,424,194	6,606	376,586	1,031.0	8,197	8,297	274,665	293,956	311,141,542	851,859.1	0.02
2018												
Q1: January - March	5,532	3,411,275	6,629	385,357	1,055.0	7,939	8,069	283,687	303,006	302,766,434	828,929.3	0.02
Q2: April - June	5,631	3,388,786	6,756	401,886	1,100.3	8,172	8,241	296,209	316,486	304,501,293	833,679.1	0.02
Q3: July - September	5,776	3,370,606	6,887	413,516	1,132.1	8,826	8,917	304,152	339,434	306,422,742	838,939.7	0.02
Q4: October - December	5,773	3,353,519	6,874	384,451	1,052.6	7,877	7,972	282,998	315,153	304,023,074	832,369.8	0.02
2019												
Q1: January - March	5,693	3,323,199	6,793	382,651	1,047.6	8,145	8,224	281,089	306,705	293,826,919	804,454.3	0.02
Q2: April - June	5,640	3,277,731	6,731	366,238	1,002.7	7,326	7,385	268,087	294,060	294,318,265	805,799.5	0.02
Q3: July - September	5,585	3,245,578	6,658	343,293	939.9	7,015	7,073	249,948	277,126	293,744,355	804,228.2	0.02
Q4: October - December	5,582	3,199,218	6,716	341,537	935.1	6,895	6,957	251,147	277,985	289,872,299	793,627.1	0.02
2020												
Q1: January - March	5,612	3,167,756	6,854	319,806	875.6	6,835	6,873	236,399	267,112	282,794,473	774,249.1	0.02
Q2: April - June	5,494	3,091,261	6,660	189,944	520.0	4,403	4,436	145,852	165,544	277,202,847	758,940.0	0.02
Q3: July - September	5,149	3,049,156	5,557	37,353	102.3	1,548	1,553	34,195	40,722	159,861,188	437,676.1	0.02

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
<i>Prevalent Valsartan episodes</i>												
2014												
Q1: January - March	6,297	3,534,217	6,387	774,493	2,120.4	16,135	16,364	535,194	672,115	314,153,753	860,106.1	0.07
Q2: April - June	8,244	3,525,479	8,979	503,607	1,378.8	10,627	10,861	365,662	421,936	317,231,538	868,532.6	0.05
Q3: July - September	6,680	3,527,453	7,795	555,668	1,521.3	11,945	12,224	407,692	457,850	320,448,039	877,338.9	0.03
Q4: October - December	6,826	3,528,829	8,025	536,165	1,467.9	11,646	11,933	396,247	446,242	320,397,790	877,201.3	0.03
2015												
Q1: January - March	7,201	3,525,026	8,683	591,997	1,620.8	13,353	13,716	434,873	492,754	312,988,319	856,915.3	0.03
Q2: April - June	7,540	3,515,392	9,072	560,111	1,533.5	11,935	12,172	409,125	472,732	316,140,367	865,545.2	0.03
Q3: July - September	7,838	3,515,081	9,444	569,939	1,560.4	12,216	12,463	416,769	479,749	319,310,986	874,225.8	0.03
Q4: October - December	8,029	3,508,084	9,625	569,636	1,559.6	12,475	12,830	417,083	486,692	318,758,132	872,712.2	0.03
2016												
Q1: January - March	8,179	3,500,679	9,903	603,276	1,651.7	13,488	13,808	438,531	516,608	314,477,681	860,993.0	0.03
Q2: April - June	8,384	3,488,739	10,053	599,883	1,642.4	13,451	13,813	438,296	530,050	313,751,572	859,005.0	0.03
Q3: July - September	8,822	3,481,151	10,612	621,069	1,700.4	13,615	13,911	447,896	570,324	316,569,519	866,720.1	0.03
Q4: October - December	8,893	3,472,733	10,502	563,547	1,542.9	12,306	12,587	409,262	505,088	315,514,363	863,831.2	0.03
2017												
Q1: January - March	8,259	3,461,908	9,761	547,416	1,498.7	12,067	12,316	399,053	485,274	307,516,825	841,935.2	0.03
Q2: April - June	7,690	3,445,212	9,188	550,420	1,507.0	12,540	12,835	402,842	495,538	309,962,749	848,631.8	0.03
Q3: July - September	7,768	3,437,026	9,256	552,037	1,511.4	12,249	12,436	403,750	504,190	312,260,003	854,921.3	0.03
Q4: October - December	7,936	3,424,194	9,415	544,507	1,490.8	11,578	11,799	394,312	496,288	311,141,542	851,859.1	0.03
2018												
Q1: January - March	8,190	3,411,275	9,808	578,953	1,585.1	12,773	13,004	419,797	537,206	302,766,434	828,929.3	0.03
Q2: April - June	8,351	3,388,786	9,969	579,317	1,586.1	12,910	13,160	417,912	541,558	304,501,293	833,679.1	0.03
Q3: July - September	8,631	3,370,606	10,276	593,163	1,624.0	13,078	13,338	426,947	571,385	306,422,742	838,939.7	0.03
Q4: October - December	8,716	3,353,519	10,478	599,760	1,642.1	13,167	13,393	434,610	574,720	304,023,074	832,369.8	0.03
2019												
Q1: January - March	8,790	3,323,199	10,545	606,464	1,660.4	13,490	13,729	438,477	612,085	293,826,919	804,454.3	0.03
Q2: April - June	8,972	3,277,731	10,651	582,810	1,595.6	13,023	13,262	422,685	597,894	294,318,265	805,799.5	0.03
Q3: July - September	8,978	3,245,578	10,630	577,071	1,579.9	12,831	13,026	418,203	593,871	293,744,355	804,228.2	0.03
Q4: October - December	8,687	3,199,218	10,427	534,357	1,463.0	11,577	11,751	388,840	552,219	289,872,299	793,627.1	0.03

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Clinical Practice Research Datalink (CPRD) Database between January 1, 2014 and August 25, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted dispensings	Raw dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
Q1: January - March	8,919	3,167,756	10,904	501,319	1,372.5	11,539	11,680	366,496	536,342	282,794,473	774,249.1	0.03
Q2: April - June	8,843	3,091,261	10,645	305,529	836.5	7,465	7,526	230,810	339,528	277,202,847	758,940.0	0.03
Q3: July - September	8,410	3,049,156	9,157	61,915	169.5	2,715	2,730	56,032	85,232	159,861,188	437,676.1	0.03

¹Total number of users by year quarter may not sum up to total patients in Table 1 because cohort re-entry was allowed, enabling multiple counts for patients with multiple ARB episodes during the study period

²Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

³Proportion of ARB use estimated as number of episodes for each individual ARB in given year quarter divided by all ARB episodes in the same year quarter

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Proportion of Switching for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter¹ (Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB															
	Azilsartan				Candesartan				Eprosartan				Irbesartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2014																
Azilsartan	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.03	0.00	0.06	0.06	0.05	0.07
Eprosartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	-	-	-	-	0.00	0.00	0.00	0.00
Irbesartan	0.00	0.00	0.00	0.00	0.06	0.18	0.08	0.10	0.00	0.00	0.03	0.00	-	-	-	-
Losartan	0.00	0.00	0.00	0.00	0.92	0.90	0.41	0.26	0.00	0.06	0.00	0.02	0.11	0.09	0.15	0.10
Olmesartan	0.00	0.00	0.00	0.00	0.11	0.03	0.03	0.02	0.00	0.03	0.00	0.00	0.00	0.00	0.00	0.02
Telmisartan	0.00	0.00	0.00	0.00	0.00	0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Valsartan	0.00	0.00	0.00	0.00	0.06	0.99	0.38	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.07
Non-index-defining ARB	0.00	0.00	0.00	0.00	1.14	2.10	0.89	0.48	0.00	0.09	0.05	0.02	0.17	0.15	0.25	0.26
Angiotensin-converting-enzyme inhibitors (ACEi)	0.00	0.00	0.00	0.00	5.60	4.39	3.25	2.91	0.06	0.03	0.05	0.00	2.57	2.19	1.98	1.26
Calcium channel blockers (CCB)	0.00	0.00	0.00	0.00	6.41	5.68	4.57	4.31	0.06	0.00	0.10	0.02	2.34	2.01	1.22	1.52
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	0.00	0.00	0.00	0.00	11.84	9.89	7.72	7.17	0.11	0.03	0.13	0.02	4.86	4.18	3.02	2.69
2015																
Azilsartan	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.00	0.00	0.00	0.00	-	-	-	-	0.02	0.00	0.00	0.00	0.07	0.04	0.02	0.10
Eprosartan	0.00	0.00	0.00	0.00	0.02	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.00	0.00
Irbesartan	0.00	0.00	0.00	0.00	0.09	0.00	0.08	0.08	0.00	0.00	0.00	0.00	-	-	-	-
Losartan	0.00	0.00	0.00	0.00	0.39	0.44	0.28	0.29	0.02	0.00	0.02	0.04	0.02	0.20	0.08	0.02
Olmesartan	0.00	0.00	0.00	0.00	0.05	0.02	0.25	0.14	0.00	0.00	0.00	0.00	0.02	0.00	0.00	0.00
Telmisartan	0.00	0.00	0.00	0.00	0.02	0.02	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.02	0.00
Valsartan	0.00	0.00	0.00	0.00	0.02	0.02	0.13	0.02	0.00	0.00	0.00	0.00	0.02	0.00	0.00	0.00
Non-index-defining ARB	0.00	0.00	0.00	0.00	0.59	0.50	0.76	0.54	0.05	0.00	0.02	0.04	0.11	0.26	0.13	0.12
ACEi	0.00	0.00	0.00	0.00	3.33	2.93	2.74	3.11	0.02	0.02	0.04	0.04	1.45	1.60	1.15	1.20
CCB	0.00	0.00	0.00	0.02	3.99	3.17	4.20	3.42	0.09	0.09	0.11	0.00	1.50	1.29	1.29	1.24
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	0.00	0.00	0.00	0.02	7.07	5.84	6.83	6.41	0.11	0.11	0.13	0.04	2.85	2.84	2.40	2.33

Table 3a. Proportion of Switching for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter¹ (Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB															
	Azilsartan				Candesartan				Eprosartan				Irbesartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2016																
Azilsartan	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.00	0.00	0.04	0.04	0.08	0.08
Eprosartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.02	0.00
Irbesartan	0.00	0.00	0.00	0.00	0.12	0.18	0.14	0.06	0.00	0.00	0.00	0.00	-	-	-	-
Losartan	0.00	0.00	0.00	0.00	0.62	0.59	0.29	0.35	0.00	0.02	0.00	0.00	0.08	0.06	0.16	0.02
Olmesartan	0.00	0.00	0.00	0.00	0.06	0.08	0.04	0.06	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.02
Telmisartan	0.00	0.00	0.00	0.00	0.02	0.02	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Valsartan	0.00	0.00	0.00	0.00	0.08	0.12	0.02	0.04	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.04
Non-index-defining ARB	0.00	0.00	0.00	0.00	0.90	0.96	0.49	0.48	0.02	0.02	0.00	0.00	0.12	0.12	0.25	0.15
ACEi	0.00	0.00	0.00	0.00	2.44	2.66	2.54	2.70	0.02	0.02	0.04	0.02	1.02	0.98	0.87	1.02
CCB	0.00	0.00	0.00	0.00	3.44	3.21	3.42	3.55	0.02	0.02	0.00	0.00	1.12	1.12	1.18	1.26
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	0.00	0.00	0.00	0.00	5.78	5.78	5.83	6.20	0.04	0.04	0.04	0.02	2.10	2.03	1.98	2.28
2017																
Azilsartan	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.02	0.00	0.02	0.08	0.15	0.11	0.07
Eprosartan	0.00	0.00	0.00	0.00	0.00	0.02	0.02	0.00	-	-	-	-	0.00	0.00	0.04	0.00
Irbesartan	0.00	0.00	0.00	0.00	0.17	0.07	0.13	0.06	0.00	0.02	0.00	0.00	-	-	-	-
Losartan	0.00	0.00	0.00	0.00	0.46	0.49	0.55	0.44	0.00	0.19	0.11	0.09	0.10	0.09	0.02	0.02
Olmesartan	0.00	0.00	0.00	0.00	0.02	0.02	0.04	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00
Telmisartan	0.00	0.00	0.00	0.00	0.00	0.02	0.02	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Valsartan	0.00	0.00	0.00	0.00	0.15	0.09	0.02	0.06	0.00	0.00	0.00	0.00	0.00	0.02	0.04	0.00
Non-index-defining ARB	0.00	0.00	0.00	0.00	0.78	0.67	0.78	0.62	0.00	0.22	0.11	0.11	0.17	0.26	0.22	0.09
ACEi	0.00	0.00	0.00	0.00	2.79	2.98	2.40	2.99	0.00	0.02	0.02	0.00	0.88	0.81	0.74	0.83
CCB	0.00	0.00	0.00	0.00	3.38	3.06	2.85	3.03	0.04	0.04	0.04	0.06	1.24	1.31	0.98	1.08
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	0.00	0.00	0.00	0.00	6.12	5.90	5.21	5.95	0.04	0.06	0.06	0.06	2.10	2.02	1.66	1.84

Table 3a. Proportion of Switching for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter¹ (Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB															
	Azilsartan				Candesartan				Eprosartan				Irbesartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2018																
Azilsartan	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.00	0.02	0.39	0.05	0.11	0.03
Eprosartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	-	-	-	-	0.02	0.00	0.00	0.00
Irbesartan	0.00	0.00	0.00	0.00	0.09	0.07	0.07	0.10	0.00	0.00	0.00	0.00	-	-	-	-
Losartan	0.00	0.00	0.00	0.00	0.32	0.50	0.41	0.59	0.00	0.00	0.00	0.03	0.91	0.14	0.05	0.07
Olmesartan	0.00	0.00	0.00	0.00	0.02	0.04	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Telmisartan	0.00	0.00	0.00	0.00	0.02	0.04	0.00	0.02	0.00	0.00	0.00	0.00	0.04	0.00	0.00	0.00
Valsartan	0.00	0.00	0.00	0.00	0.05	0.02	0.07	0.12	0.00	0.00	0.00	0.00	0.04	0.02	0.02	0.00
Non-index-defining ARB	0.00	0.00	0.00	0.00	0.50	0.65	0.53	0.87	0.00	0.00	0.00	0.05	1.39	0.21	0.18	0.10
ACEi	0.00	0.00	0.00	0.00	2.50	2.51	2.46	2.51	0.00	0.04	0.02	0.00	0.89	0.92	0.73	0.72
CCB	0.00	0.00	0.00	0.00	3.55	3.15	2.87	2.79	0.05	0.00	0.02	0.03	1.20	1.01	1.05	0.96
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00
ACEi or CCB*	0.00	0.00	0.00	0.00	6.00	5.57	5.30	5.18	0.05	0.04	0.04	0.03	2.05	1.89	1.74	1.66
2019																
Azilsartan	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.03	0.00	0.07	0.11	0.15	0.03
Eprosartan	0.00	0.00	0.00	0.00	0.00	0.02	0.02	0.00	-	-	-	-	0.00	0.00	0.00	0.00
Irbesartan	0.00	0.00	0.00	0.00	0.08	0.20	0.03	0.10	0.00	0.00	0.00	0.00	-	-	-	-
Losartan	0.00	0.00	0.00	0.00	0.39	0.47	0.42	0.35	0.02	0.00	0.00	0.00	0.08	0.05	0.08	0.05
Olmesartan	0.00	0.00	0.00	0.00	0.10	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.00
Telmisartan	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.03	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.00
Valsartan	0.00	0.00	0.00	0.00	0.13	0.07	0.05	0.07	0.00	0.00	0.00	0.00	0.02	0.02	0.00	0.00
Non-index-defining ARB	0.00	0.00	0.00	0.00	0.71	0.77	0.52	0.54	0.02	0.00	0.03	0.00	0.17	0.21	0.23	0.08
ACEi	0.00	0.00	0.00	0.00	2.39	2.64	2.53	2.83	0.02	0.03	0.02	0.00	0.62	0.65	0.49	0.69
CCB	0.00	0.00	0.00	0.00	3.41	2.92	2.70	2.52	0.02	0.03	0.00	0.02	0.91	0.85	0.64	0.96
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	0.00	0.00	0.00	0.00	5.73	5.44	5.17	5.27	0.03	0.07	0.02	0.02	1.48	1.45	1.11	1.63

Table 3a. Proportion of Switching for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter¹ (Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB															
	Azilsartan				Candesartan				Eprosartan				Irbesartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2020																
Azilsartan	-	-	-	-	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.00	0.00	0.08	0.02	0.00	0.00
Eprosartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.00	0.00
Irbesartan	0.00	0.00	0.00	0.00	0.05	0.04	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-
Losartan	0.00	0.00	0.00	0.00	0.32	0.20	0.14	0.00	0.00	0.00	0.00	0.00	0.10	0.02	0.05	0.00
Olmesartan	0.00	0.00	0.00	0.00	0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Telmisartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Valsartan	0.00	0.00	0.00	0.00	0.00	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.02	0.00
Non-index-defining ARB	0.00	0.00	0.00	0.00	0.40	0.27	0.14	0.00	0.00	0.00	0.00	0.00	0.16	0.05	0.07	0.00
ACEi	0.00	0.00	0.00	0.00	2.73	2.06	1.60	0.00	0.00	0.00	0.00	0.00	0.68	0.48	0.21	0.00
CCB	0.00	0.00	0.00	0.00	2.42	2.15	1.23	0.00	0.06	0.04	0.00	0.00	0.73	0.95	0.35	0.00
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	0.00	0.00	0.00	0.00	5.12	4.17	2.78	0.00	0.06	0.04	0.00	0.00	1.40	1.40	0.56	0.00

¹We estimated proportion of switching per 1,000 ARB episodes as the number of ARB episodes that resulted in the switch from the index ARB to another ARB, ACEi only, CCB only, ACEi/CCB combination drugs only, or ACEi or CCB or ACEi/CCB combination drugs in a given year and quarter divided by the total number of all ARB index episodes during the same year and quarter.

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

*ACEi or CCB: only ACEi, only CCB or ACEi/CCB combination drugs

Table 3a. Proportion of Switching for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter¹ (Switching per 1,000 ARB Episodes)(Continued)

ARB Switch	Index ARB															
	Losartan				Olmesartan				Telmisartan				Valsartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2014																
Azilsartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.74	1.32	0.91	0.55	0.06	0.06	0.10	0.00	0.00	0.00	0.00	0.02	2.80	3.04	0.20	0.05
Eprosartan	0.06	0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Irbesartan	0.34	0.24	0.20	0.14	0.06	0.06	0.00	0.00	0.00	0.00	0.00	0.00	0.40	0.48	0.10	0.00
Losartan	-	-	-	-	0.06	0.06	0.00	0.10	0.00	0.09	0.03	0.02	7.03	5.95	0.30	0.10
Olmesartan	0.06	0.00	0.05	0.02	-	-	-	-	0.00	0.00	0.00	0.00	0.11	0.12	0.00	0.00
Telmisartan	0.17	0.00	0.03	0.02	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.06	0.03	0.02
Valsartan	0.46	0.96	0.84	0.19	0.00	0.03	0.00	0.02	0.00	0.03	0.00	0.00	-	-	-	-
Non-index-defining ARB	1.83	2.43	2.03	0.93	0.17	0.21	0.10	0.12	0.00	0.12	0.03	0.05	10.35	9.53	0.58	0.17
ACEi	7.83	6.07	5.51	4.76	0.40	0.09	0.08	0.12	0.17	0.15	0.28	0.12	0.97	0.60	0.10	0.38
CCB	8.92	6.67	5.36	5.52	0.29	0.39	0.25	0.33	0.29	0.24	0.20	0.29	1.83	0.78	0.18	0.31
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	16.70	12.54	10.69	10.24	0.69	0.48	0.33	0.43	0.46	0.39	0.46	0.40	2.75	1.32	0.28	0.69
2015																
Azilsartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.68	0.77	0.89	0.45	0.02	0.15	0.23	0.23	0.00	0.04	0.04	0.02	0.00	0.02	0.04	0.04
Eprosartan	0.00	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Irbesartan	0.09	0.28	0.15	0.23	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02
Losartan	-	-	-	-	0.07	0.00	0.04	0.04	0.02	0.02	0.02	0.00	0.05	0.00	0.00	0.04
Olmesartan	0.02	0.00	0.04	0.02	-	-	-	-	0.00	0.00	0.02	0.00	0.00	0.00	0.00	0.00
Telmisartan	0.02	0.04	0.04	0.02	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.00	0.00
Valsartan	0.14	0.04	0.04	0.06	0.00	0.00	0.00	0.00	0.02	0.02	0.00	0.00	-	-	-	-
Non-index-defining ARB	0.93	1.12	1.17	0.78	0.11	0.15	0.28	0.27	0.05	0.09	0.08	0.02	0.05	0.02	0.04	0.10
ACEi	4.21	4.99	4.50	4.99	0.20	0.09	0.08	0.10	0.07	0.07	0.04	0.14	0.25	0.22	0.25	0.27
CCB	5.66	5.01	4.77	4.76	0.36	0.20	0.11	0.16	0.20	0.31	0.30	0.25	0.43	0.28	0.32	0.39
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	9.65	9.87	9.12	9.57	0.57	0.28	0.19	0.27	0.27	0.35	0.34	0.35	0.68	0.48	0.57	0.66

Table 3a. Proportion of Switching for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter¹ (Switching per 1,000 ARB Episodes)(Continued)

ARB Switch	Index ARB															
	Losartan				Olmesartan				Telmisartan				Valsartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2016																
Azilsartan	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.84	0.83	0.68	0.77	0.04	0.00	0.00	0.02	0.00	0.00	0.00	0.02	0.06	0.04	0.43	0.83
Eprosartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Irbesartan	0.14	0.14	0.17	0.29	0.00	0.00	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.06
Losartan	-	-	-	-	0.00	0.00	0.00	0.04	0.02	0.02	0.04	0.00	0.00	0.10	0.43	1.51
Olmesartan	0.04	0.12	0.10	0.02	-	-	-	-	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.04
Telmisartan	0.08	0.04	0.04	0.02	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.00	0.02
Valsartan	0.12	0.20	0.08	0.23	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-
Non-index-defining ARB	1.22	1.32	1.07	1.33	0.04	0.00	0.00	0.08	0.04	0.02	0.04	0.02	0.06	0.14	0.89	2.39
ACEi	4.24	4.70	4.08	4.56	0.06	0.08	0.14	0.08	0.10	0.04	0.08	0.08	0.18	0.14	0.25	0.37
CCB	4.42	4.62	4.64	4.81	0.18	0.04	0.12	0.10	0.34	0.16	0.16	0.17	0.38	0.39	0.39	0.35
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	8.53	9.13	8.56	9.27	0.22	0.12	0.23	0.17	0.42	0.20	0.23	0.25	0.56	0.51	0.64	0.71
2017																
Azilsartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.76	0.81	0.72	0.86	0.06	0.04	0.00	0.00	0.00	0.00	0.06	0.02	0.29	0.04	0.04	0.00
Eprosartan	0.00	0.02	0.04	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Irbesartan	0.17	0.19	0.18	0.13	0.00	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.10	0.00	0.02	0.00
Losartan	-	-	-	-	0.04	0.02	0.02	0.02	0.02	0.04	0.02	0.04	0.99	0.17	0.09	0.02
Olmesartan	0.02	0.04	0.06	0.00	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Telmisartan	0.08	0.04	0.00	0.04	0.00	0.00	0.00	0.00	-	-	-	-	0.02	0.00	0.00	0.00
Valsartan	0.29	0.15	0.17	0.07	0.02	0.00	0.00	0.00	0.00	0.02	0.00	0.00	-	-	-	-
Non-index-defining ARB	1.30	1.24	1.15	1.08	0.11	0.06	0.04	0.02	0.02	0.06	0.07	0.06	1.36	0.21	0.15	0.02
ACEi	4.61	4.29	5.01	4.01	0.15	0.07	0.09	0.11	0.06	0.07	0.09	0.06	0.15	0.26	0.18	0.28
CCB	4.72	4.70	5.60	4.52	0.11	0.04	0.13	0.15	0.17	0.17	0.26	0.13	0.23	0.26	0.24	0.29
ACEi/CCB combination	0.02	0.00	0.00	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	9.21	8.79	10.39	8.40	0.27	0.11	0.22	0.26	0.23	0.24	0.35	0.18	0.38	0.51	0.41	0.57

Table 3a. Proportion of Switching for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter¹ (Switching per 1,000 ARB Episodes)(Continued)

ARB Switch	Index ARB															
	Losartan				Olmesartan				Telmisartan				Valsartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2018																
Azilsartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.52	0.51	0.82	0.94	0.02	0.02	0.02	0.02	0.00	0.00	0.04	0.07	0.02	0.04	0.14	0.10
Eprosartan	0.00	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Irbesartan	0.23	0.14	0.11	0.14	0.00	0.00	0.00	0.00	0.02	0.02	0.00	0.00	0.00	0.02	0.02	0.02
Losartan	-	-	-	-	0.00	0.00	0.04	0.03	0.02	0.00	0.07	0.14	0.04	0.04	0.43	0.07
Olmesartan	0.02	0.04	0.05	0.00	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Telmisartan	0.00	0.05	0.02	0.09	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.07	0.03
Valsartan	0.09	0.09	0.11	0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.02	-	-	-	-
Non-index-defining ARB	0.86	0.87	1.10	1.27	0.02	0.02	0.05	0.05	0.04	0.02	0.12	0.23	0.05	0.09	0.60	0.23
ACEi	4.00	4.41	4.26	4.07	0.11	0.04	0.04	0.03	0.07	0.05	0.04	0.07	0.23	0.09	0.23	0.17
CCB	4.52	4.23	4.77	4.33	0.11	0.09	0.05	0.09	0.12	0.23	0.21	0.17	0.20	0.16	0.25	0.23
ACEi/CCB combination	0.00	0.00	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	8.34	8.51	8.94	8.33	0.20	0.12	0.09	0.12	0.20	0.28	0.25	0.24	0.43	0.25	0.48	0.40
2019																
Azilsartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.91	0.86	0.57	0.77	0.02	0.03	0.02	0.03	0.05	0.00	0.02	0.03	0.17	0.36	0.36	0.03
Eprosartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Irbesartan	0.27	0.15	0.15	0.15	0.00	0.02	0.00	0.02	0.00	0.02	0.00	0.00	0.02	0.05	0.00	0.00
Losartan	-	-	-	-	0.00	0.07	0.02	0.03	0.08	0.03	0.02	0.02	0.20	0.37	0.47	0.03
Olmesartan	0.07	0.07	0.05	0.07	-	-	-	-	0.02	0.00	0.00	0.00	0.00	0.03	0.00	0.00
Telmisartan	0.02	0.00	0.03	0.02	0.00	0.00	0.00	0.00	-	-	-	-	0.02	0.02	0.02	0.00
Valsartan	0.13	0.15	0.18	0.12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-
Non-index-defining ARB	1.31	1.22	0.96	1.07	0.02	0.11	0.03	0.07	0.15	0.05	0.03	0.03	0.40	0.83	0.83	0.07
ACEi	4.30	4.28	4.27	4.63	0.05	0.15	0.08	0.16	0.03	0.07	0.05	0.03	0.17	0.26	0.16	0.21
CCB	4.24	4.25	3.55	3.74	0.12	0.08	0.13	0.12	0.12	0.18	0.08	0.15	0.24	0.23	0.16	0.18
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	8.51	8.44	7.65	8.16	0.17	0.21	0.21	0.28	0.15	0.24	0.11	0.18	0.40	0.49	0.33	0.40

Table 3a. Proportion of Switching for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter¹ (Switching per 1,000 ARB Episodes)(Continued)

ARB Switch	Index ARB															
	Losartan				Olmesartan				Telmisartan				Valsartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2020																
Azilsartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.56	0.45	0.25	0.00	0.03	0.02	0.02	0.00	0.02	0.02	0.02	0.00	0.00	0.02	0.21	0.00
Eprosartan	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Irbesartan	0.15	0.09	0.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.02	0.00
Losartan	-	-	-	-	0.03	0.02	0.00	0.00	0.02	0.04	0.02	0.00	0.05	0.11	0.28	0.00
Olmesartan	0.02	0.02	0.00	0.00	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00
Telmisartan	0.02	0.02	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.00	0.00
Valsartan	0.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00	-	-	-	-
Non-index-defining ARB	0.84	0.57	0.30	0.00	0.06	0.04	0.02	0.00	0.03	0.05	0.07	0.00	0.06	0.13	0.53	0.00
ACEi	4.23	3.21	2.27	0.00	0.15	0.04	0.02	0.00	0.08	0.02	0.05	0.00	0.21	0.27	0.09	0.00
CCB	3.81	3.21	2.29	0.00	0.13	0.05	0.00	0.00	0.15	0.04	0.09	0.00	0.15	0.16	0.05	0.00
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	7.93	6.36	4.56	0.00	0.27	0.09	0.02	0.00	0.23	0.05	0.14	0.00	0.36	0.41	0.14	0.00

¹We estimated proportion of switching per 1,000 ARB episodes as the number of ARB episodes that resulted in the switch from the index ARB to another ARB, ACEi only, CCB only, ACEi/CCB combination drugs only, or ACEi or CCB or ACEi/CCB combination drugs in a given year and quarter divided by the total number of all ARB index episodes during the same year and quarter.

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

*ACEi or CCB: only ACEi, only CCB or ACEi/CCB combination drugs

Table 3b. Proportion of Switching for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter¹ (Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB															
	Azilsartan				Candesartan				Eprosartan				Irbesartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2014																
Azilsartan	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.00	0.00	0.00	0.00	-	-	-	-	0.01	0.03	0.01	0.00	0.01	0.07	0.03	0.03
Eprosartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.00	0.00
Irbesartan	0.00	0.00	0.00	0.00	0.04	0.08	0.04	0.03	0.00	0.00	0.00	0.01	-	-	-	-
Losartan	0.00	0.00	0.00	0.00	0.37	0.41	0.21	0.19	0.02	0.03	0.02	0.02	0.08	0.07	0.08	0.04
Olmesartan	0.00	0.00	0.00	0.00	0.03	0.03	0.03	0.02	0.00	0.01	0.00	0.00	0.00	0.03	0.01	0.01
Telmisartan	0.00	0.00	0.00	0.00	0.01	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Valsartan	0.00	0.00	0.00	0.00	0.36	1.06	0.57	0.20	0.00	0.00	0.00	0.00	0.11	0.18	0.10	0.04
Non-index-defining ARB	0.00	0.00	0.00	0.00	0.82	1.58	0.85	0.45	0.03	0.06	0.04	0.03	0.20	0.34	0.22	0.12
Angiotensin-converting-enzyme inhibitors (ACEi)	0.00	0.00	0.00	0.00	4.76	3.35	2.58	2.31	0.13	0.07	0.08	0.06	3.92	2.59	2.12	1.68
Calcium channel blockers (CCB)	0.00	0.01	0.00	0.00	10.24	7.01	5.92	5.11	0.24	0.19	0.16	0.17	4.53	3.28	2.40	2.19
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	0.00	0.01	0.01	0.00	14.74	10.14	8.36	7.28	0.37	0.24	0.23	0.22	8.20	5.74	4.34	3.72
2015																
Azilsartan	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.00	0.00	0.00	0.00	-	-	-	-	0.01	0.01	0.01	0.01	0.04	0.05	0.02	0.04
Eprosartan	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	-	-	-	-	0.00	0.00	0.00	0.00
Irbesartan	0.00	0.00	0.00	0.00	0.05	0.03	0.04	0.03	0.00	0.00	0.00	0.01	-	-	-	-
Losartan	0.00	0.00	0.00	0.00	0.16	0.17	0.19	0.14	0.01	0.00	0.01	0.03	0.05	0.08	0.05	0.06
Olmesartan	0.00	0.00	0.00	0.00	0.02	0.02	0.10	0.08	0.00	0.00	0.00	0.00	0.01	0.00	0.01	0.00
Telmisartan	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Valsartan	0.00	0.00	0.00	0.00	0.09	0.05	0.06	0.03	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.01
Non-index-defining ARB	0.00	0.00	0.00	0.00	0.33	0.28	0.40	0.29	0.03	0.01	0.02	0.04	0.11	0.14	0.09	0.12
ACEi	0.00	0.00	0.00	0.00	2.08	1.91	1.96	1.85	0.06	0.04	0.04	0.05	1.48	1.51	1.37	1.30
CCB	0.00	0.00	0.00	0.01	5.18	4.40	4.90	4.66	0.13	0.14	0.13	0.10	2.07	1.95	1.92	1.89
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	0.00	0.00	0.01	0.01	7.12	6.19	6.71	6.40	0.18	0.18	0.16	0.15	3.44	3.34	3.19	3.09

Table 3b. Proportion of Switching for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter¹ (Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB															
	Azilsartan				Candesartan				Eprosartan				Irbesartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2016																
Azilsartan	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.00	0.00	0.03	0.05	0.03	0.02
Eprosartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.00	0.00
Irbesartan	0.00	0.00	0.00	0.00	0.05	0.04	0.03	0.02	0.00	0.00	0.00	0.00	-	-	-	-
Losartan	0.00	0.00	0.00	0.00	0.22	0.19	0.13	0.17	0.03	0.02	0.00	0.00	0.06	0.06	0.08	0.05
Olmesartan	0.00	0.00	0.00	0.00	0.03	0.03	0.03	0.04	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01
Telmisartan	0.00	0.00	0.00	0.00	0.02	0.00	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
Valsartan	0.00	0.00	0.00	0.00	0.04	0.06	0.02	0.11	0.01	0.00	0.00	0.00	0.01	0.01	0.01	0.02
Non-index-defining ARB	0.00	0.00	0.00	0.00	0.35	0.32	0.23	0.33	0.04	0.02	0.00	0.00	0.10	0.13	0.13	0.09
ACEi	0.00	0.00	0.00	0.00	1.66	1.58	1.46	1.49	0.05	0.03	0.05	0.04	1.16	1.12	1.07	1.01
CCB	0.01	0.00	0.00	0.00	4.65	4.62	4.41	4.40	0.11	0.09	0.13	0.07	1.88	1.78	1.79	1.69
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	0.01	0.01	0.00	0.00	6.20	6.09	5.76	5.80	0.15	0.11	0.18	0.11	2.94	2.82	2.79	2.65
2017																
Azilsartan	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.05	0.05	0.05	0.03	0.05	0.05	0.04
Eprosartan	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	-	-	-	-	0.00	0.00	0.02	0.00
Irbesartan	0.00	0.00	0.00	0.00	0.06	0.04	0.04	0.03	0.00	0.01	0.03	0.01	-	-	-	-
Losartan	0.00	0.00	0.00	0.00	0.19	0.17	0.20	0.14	0.01	0.20	0.12	0.09	0.06	0.04	0.04	0.05
Olmesartan	0.00	0.00	0.00	0.00	0.03	0.01	0.01	0.02	0.00	0.00	0.00	0.00	0.01	0.01	0.00	0.00
Telmisartan	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Valsartan	0.00	0.00	0.00	0.00	0.14	0.08	0.04	0.03	0.00	0.00	0.01	0.00	0.01	0.01	0.01	0.00
Non-index-defining ARB	0.00	0.00	0.00	0.00	0.42	0.31	0.29	0.23	0.01	0.26	0.21	0.15	0.11	0.11	0.13	0.10
ACEi	0.00	0.00	0.00	0.00	1.36	1.42	1.20	1.24	0.03	0.04	0.03	0.02	0.92	0.91	0.84	0.75
CCB	0.00	0.00	0.00	0.00	4.22	4.25	4.11	4.12	0.11	0.09	0.08	0.08	1.78	1.73	1.54	1.58
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	0.00	0.00	0.00	0.00	5.51	5.59	5.26	5.31	0.13	0.14	0.10	0.10	2.63	2.58	2.33	2.28

Table 3b. Proportion of Switching for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter¹ (Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB															
	Azilsartan				Candesartan				Eprosartan				Irbesartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2018																
Azilsartan	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.00	0.00	0.00	0.00	-	-	-	-	0.01	0.01	0.00	0.01	0.41	0.04	0.04	0.03
Eprosartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	0.01	0.00	0.00	0.00
Irbesartan	0.00	0.00	0.00	0.00	0.07	0.06	0.04	0.03	0.00	0.00	0.00	0.00	-	-	-	-
Losartan	0.00	0.00	0.00	0.00	0.18	0.14	0.13	0.27	0.02	0.01	0.01	0.04	0.97	0.14	0.05	0.06
Olmesartan	0.00	0.00	0.00	0.00	0.01	0.01	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
Telmisartan	0.00	0.00	0.00	0.00	0.01	0.01	0.00	0.01	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00
Valsartan	0.00	0.00	0.00	0.00	0.02	0.02	0.05	0.04	0.00	0.00	0.00	0.00	0.02	0.01	0.01	0.01
Non-index-defining ARB	0.00	0.00	0.00	0.00	0.30	0.24	0.23	0.36	0.03	0.01	0.01	0.05	1.41	0.19	0.11	0.11
ACEi	0.00	0.00	0.00	0.00	1.29	1.17	1.12	1.01	0.01	0.02	0.02	0.02	0.75	0.74	0.70	0.68
CCB	0.00	0.00	0.00	0.00	4.26	4.03	4.08	3.91	0.06	0.04	0.06	0.05	1.43	1.45	1.45	1.47
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	0.00	0.00	0.00	0.00	5.49	5.15	5.16	4.87	0.08	0.07	0.07	0.07	2.12	2.14	2.12	2.10
2019																
Azilsartan	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.00	0.00	0.07	0.05	0.07	0.04
Eprosartan	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	-	-	-	-	0.00	0.00	0.00	0.00
Irbesartan	0.00	0.00	0.00	0.00	0.05	0.06	0.03	0.04	0.00	0.00	0.00	0.00	-	-	-	-
Losartan	0.00	0.00	0.00	0.00	0.43	0.26	0.21	0.17	0.01	0.00	0.00	0.00	0.10	0.05	0.09	0.07
Olmesartan	0.00	0.00	0.00	0.00	0.22	0.05	0.01	0.01	0.00	0.00	0.00	0.00	0.01	0.01	0.00	0.00
Telmisartan	0.00	0.00	0.00	0.00	0.02	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Valsartan	0.00	0.00	0.00	0.00	0.07	0.07	0.10	0.06	0.00	0.00	0.00	0.00	0.01	0.02	0.01	0.01
Non-index-defining ARB	0.00	0.00	0.00	0.00	0.76	0.45	0.36	0.29	0.02	0.00	0.01	0.00	0.19	0.13	0.17	0.13
ACEi	0.00	0.00	0.00	0.00	0.96	0.99	1.04	1.08	0.02	0.02	0.01	0.01	0.61	0.54	0.55	0.52
CCB	0.00	0.00	0.00	0.00	3.90	3.66	3.59	3.26	0.04	0.03	0.04	0.04	1.42	1.34	1.37	1.22
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	0.00	0.00	0.00	0.00	4.82	4.60	4.59	4.31	0.06	0.05	0.05	0.05	2.00	1.85	1.90	1.71

Table 3b. Proportion of Switching for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter¹ (Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB															
	Azilsartan				Candesartan				Eprosartan				Irbesartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2020																
Azilsartan	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.01	0.01	0.00	0.04	0.01	0.01	0.00
Eprosartan	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	-	-	-	-	0.00	0.00	0.00	0.00
Irbesartan	0.00	0.00	0.00	0.00	0.03	0.03	0.01	0.00	0.00	0.00	0.00	0.00	-	-	-	-
Losartan	0.00	0.00	0.00	0.00	0.15	0.09	0.06	0.00	0.01	0.02	0.01	0.00	0.05	0.03	0.03	0.00
Olmesartan	0.00	0.00	0.00	0.00	0.02	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Telmisartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Valsartan	0.00	0.00	0.00	0.00	0.03	0.02	0.02	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.02	0.00
Non-index-defining ARB	0.00	0.00	0.00	0.00	0.23	0.14	0.10	0.00	0.01	0.03	0.01	0.00	0.09	0.04	0.05	0.00
ACEi	0.00	0.00	0.00	0.00	0.99	0.78	0.52	0.00	0.01	0.01	0.01	0.00	0.50	0.46	0.26	0.00
CCB	0.00	0.00	0.00	0.00	3.45	2.87	1.90	0.00	0.04	0.04	0.03	0.00	1.12	1.09	0.76	0.00
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	0.00	0.00	0.00	0.00	4.41	3.63	2.40	0.00	0.05	0.05	0.03	0.00	1.61	1.52	0.99	0.00

¹We estimated proportion of switching per 1,000 ARB episodes as the number of ARB episodes that resulted in the switch from the index ARB to another ARB, ACEi only, CCB only, ACEi/CCB combination drugs only, or ACEi or CCB or ACEi/CCB combination drugs in a given year and quarter divided by the total number of all ARB index episodes during the same year and quarter.

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

*ACEi or CCB: only ACEi, only CCB or ACEi/CCB combination drugs

Table 3b. Proportion of Switching for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter¹ (Continued)
(Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB															
	Losartan				Olmesartan				Telmisartan				Valsartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2014																
Azilsartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.37	0.71	0.38	0.30	0.04	0.07	0.06	0.06	0.01	0.03	0.00	0.01	2.99	3.58	0.44	0.10
Eprosartan	0.01	0.02	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.00	0.00
Irbesartan	0.19	0.16	0.14	0.09	0.24	0.06	0.00	0.02	0.01	0.01	0.00	0.00	0.54	0.66	0.08	0.02
Losartan	-	-	-	-	0.03	0.10	0.08	0.20	0.02	0.04	0.02	0.02	5.71	6.51	0.53	0.17
Olmesartan	0.01	0.05	0.03	0.02	-	-	-	-	0.00	0.00	0.00	0.00	0.07	0.08	0.00	0.00
Telmisartan	0.05	0.03	0.04	0.01	0.00	0.00	0.00	0.00	-	-	-	-	0.03	0.05	0.01	0.02
Valsartan	0.84	1.73	0.99	0.30	0.03	0.04	0.01	0.00	0.00	0.02	0.00	0.01	-	-	-	-
Non-index-defining ARB	1.47	2.62	1.57	0.73	0.35	0.26	0.15	0.28	0.03	0.10	0.04	0.04	9.35	10.71	1.04	0.30
ACEi	6.45	4.44	3.72	3.30	0.54	0.38	0.25	0.24	0.44	0.32	0.18	0.16	1.25	0.55	0.27	0.30
CCB	12.57	9.13	7.40	6.74	1.08	0.63	0.62	0.51	0.71	0.52	0.38	0.42	2.61	1.06	0.63	0.61
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	18.76	13.37	10.89	9.88	1.61	1.01	0.86	0.74	1.13	0.84	0.55	0.57	3.77	1.58	0.87	0.90
2015																
Azilsartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.32	0.30	0.32	0.23	0.02	0.20	0.31	0.30	0.02	0.03	0.03	0.02	0.06	0.05	0.04	0.02
Eprosartan	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Irbesartan	0.11	0.10	0.09	0.10	0.02	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.02	0.00	0.00	0.01
Losartan	-	-	-	-	0.11	0.06	0.07	0.14	0.02	0.01	0.03	0.02	0.10	0.06	0.08	0.06
Olmesartan	0.02	0.01	0.01	0.03	-	-	-	-	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00
Telmisartan	0.01	0.02	0.03	0.01	0.00	0.02	0.02	0.00	-	-	-	-	0.00	0.00	0.00	0.00
Valsartan	0.20	0.09	0.10	0.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-
Non-index-defining ARB	0.65	0.53	0.54	0.46	0.14	0.30	0.42	0.46	0.05	0.04	0.07	0.04	0.18	0.11	0.12	0.10
ACEi	2.61	2.79	2.43	2.49	0.24	0.14	0.16	0.14	0.20	0.12	0.09	0.15	0.23	0.19	0.21	0.18
CCB	6.73	6.35	6.29	6.03	0.53	0.45	0.42	0.37	0.37	0.35	0.31	0.41	0.56	0.54	0.49	0.53
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	9.19	8.99	8.61	8.36	0.77	0.58	0.58	0.51	0.57	0.46	0.40	0.56	0.77	0.72	0.69	0.69

Table 3b. Proportion of Switching for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter¹ (Continued)
(Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB															
	Losartan				Olmesartan				Telmisartan				Valsartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2016																
Azilsartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.28	0.29	0.30	0.33	0.02	0.02	0.13	0.03	0.01	0.01	0.02	0.02	0.03	0.05	0.27	0.76
Eprosartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Irbesartan	0.08	0.09	0.10	0.09	0.04	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.05	0.07
Losartan	-	-	-	-	0.02	0.03	0.03	0.10	0.01	0.01	0.02	0.01	0.04	0.14	0.32	1.35
Olmesartan	0.03	0.03	0.02	0.02	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
Telmisartan	0.03	0.02	0.02	0.02	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.01	0.02
Valsartan	0.08	0.09	0.06	0.19	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	-	-	-	-
Non-index-defining ARB	0.50	0.52	0.50	0.65	0.08	0.04	0.17	0.13	0.03	0.02	0.04	0.04	0.07	0.20	0.64	2.17
ACEi	2.39	2.31	2.19	1.96	0.17	0.13	0.10	0.10	0.09	0.10	0.08	0.09	0.16	0.17	0.20	0.18
CCB	6.01	6.05	5.60	5.64	0.38	0.31	0.34	0.32	0.33	0.31	0.33	0.30	0.54	0.49	0.50	0.47
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	8.26	8.23	7.68	7.49	0.54	0.43	0.44	0.42	0.42	0.40	0.40	0.38	0.69	0.66	0.68	0.63
2017																
Azilsartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.28	0.27	0.32	0.28	0.03	0.01	0.01	0.01	0.02	0.01	0.02	0.01	0.40	0.05	0.02	0.02
Eprosartan	0.00	0.02	0.02	0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Irbesartan	0.12	0.09	0.05	0.06	0.01	0.00	0.01	0.01	0.00	0.00	0.00	0.00	0.07	0.01	0.01	0.00
Losartan	-	-	-	-	0.04	0.05	0.04	0.04	0.03	0.02	0.01	0.02	1.04	0.17	0.07	0.04
Olmesartan	0.03	0.02	0.01	0.01	-	-	-	-	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00
Telmisartan	0.03	0.01	0.01	0.01	0.00	0.00	0.00	0.00	-	-	-	-	0.02	0.01	0.00	0.00
Valsartan	0.30	0.16	0.09	0.08	0.01	0.01	0.00	0.00	0.00	0.01	0.00	0.00	-	-	-	-
Non-index-defining ARB	0.72	0.57	0.50	0.47	0.08	0.07	0.06	0.06	0.05	0.03	0.03	0.04	1.49	0.23	0.10	0.06
ACEi	1.97	1.89	1.99	1.73	0.09	0.10	0.09	0.08	0.09	0.10	0.07	0.07	0.15	0.16	0.10	0.13
CCB	5.66	5.63	5.91	5.75	0.27	0.27	0.30	0.28	0.30	0.30	0.28	0.31	0.40	0.43	0.34	0.43
ACEi/CCB combination	0.01	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	7.54	7.39	7.78	7.41	0.36	0.36	0.39	0.36	0.38	0.39	0.34	0.37	0.53	0.59	0.43	0.56

Table 3b. Proportion of Switching for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter¹ (Continued)
(Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB															
	Losartan				Olmesartan				Telmisartan				Valsartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2018																
Azilsartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.20	0.23	0.24	0.81	0.01	0.01	0.01	0.01	0.01	0.00	0.06	0.09	0.01	0.02	0.19	0.08
Eprosartan	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Irbesartan	0.24	0.16	0.08	0.09	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.01	0.01	0.01	0.02	0.02
Losartan	-	-	-	-	0.02	0.02	0.02	0.02	0.01	0.01	0.07	0.13	0.03	0.05	0.28	0.10
Olmesartan	0.02	0.02	0.03	0.01	-	-	-	-	0.00	0.00	0.00	0.01	0.00	0.00	0.01	0.00
Telmisartan	0.01	0.02	0.02	0.05	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.02	0.01
Valsartan	0.06	0.05	0.05	0.08	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	-	-	-	-
Non-index-defining ARB	0.53	0.48	0.42	1.03	0.05	0.03	0.03	0.03	0.02	0.01	0.15	0.23	0.05	0.08	0.51	0.21
ACEi	1.61	1.76	1.67	1.61	0.08	0.06	0.05	0.07	0.09	0.09	0.09	0.07	0.11	0.12	0.10	0.14
CCB	5.59	5.52	5.42	5.37	0.27	0.23	0.24	0.21	0.25	0.25	0.24	0.23	0.39	0.37	0.36	0.36
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	7.11	7.19	7.02	6.93	0.35	0.29	0.29	0.28	0.33	0.33	0.32	0.29	0.49	0.47	0.46	0.49
2019																
Azilsartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.62	0.36	0.29	0.30	0.07	0.05	0.06	0.01	0.04	0.01	0.01	0.01	0.12	0.37	0.39	0.04
Eprosartan	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Irbesartan	0.10	0.08	0.06	0.10	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.02	0.06	0.06	0.00
Losartan	-	-	-	-	0.04	0.06	0.02	0.02	0.08	0.04	0.02	0.02	0.18	0.54	0.65	0.07
Olmesartan	0.08	0.06	0.02	0.02	-	-	-	-	0.01	0.00	0.00	0.00	0.01	0.03	0.01	0.00
Telmisartan	0.04	0.03	0.01	0.01	0.01	0.01	0.00	0.00	-	-	-	-	0.01	0.01	0.01	0.00
Valsartan	0.07	0.13	0.19	0.07	0.00	0.01	0.00	0.00	0.01	0.00	0.01	0.00	-	-	-	-
Non-index-defining ARB	0.87	0.65	0.57	0.50	0.12	0.11	0.09	0.04	0.14	0.06	0.04	0.03	0.33	0.99	1.09	0.11
ACEi	1.62	1.54	1.54	1.57	0.06	0.09	0.06	0.08	0.06	0.07	0.05	0.06	0.13	0.12	0.10	0.08
CCB	5.11	5.05	4.77	4.80	0.25	0.26	0.23	0.20	0.21	0.20	0.22	0.21	0.30	0.33	0.28	0.27
ACEi/CCB combination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	6.70	6.54	6.25	6.29	0.30	0.34	0.29	0.27	0.27	0.28	0.27	0.27	0.43	0.44	0.38	0.35

Table 3b. Proportion of Switching for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter¹ (Continued)
(Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB															
	Losartan				Olmesartan				Telmisartan				Valsartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2020																
Azilsartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	0.21	0.14	0.10	0.00	0.03	0.02	0.01	0.00	0.01	0.01	0.01	0.00	0.02	0.02	0.22	0.00
Eprosartan	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Irbesartan	0.06	0.04	0.01	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.04	0.00
Losartan	-	-	-	-	0.04	0.02	0.01	0.00	0.02	0.02	0.01	0.00	0.03	0.05	0.27	0.00
Olmesartan	0.02	0.01	0.00	0.00	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00
Telmisartan	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.00	0.00
Valsartan	0.05	0.02	0.03	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.01	0.00	-	-	-	-
Non-index-defining ARB	0.36	0.21	0.16	0.00	0.08	0.05	0.03	0.00	0.04	0.03	0.03	0.00	0.06	0.07	0.54	0.00
ACEi	1.47	1.14	0.79	0.00	0.08	0.05	0.04	0.00	0.06	0.06	0.03	0.00	0.09	0.09	0.07	0.00
CCB	4.82	4.21	2.84	0.00	0.18	0.16	0.13	0.00	0.20	0.17	0.12	0.00	0.24	0.24	0.19	0.00
ACEi/CCB combination	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ACEi or CCB*	6.26	5.31	3.60	0.00	0.25	0.21	0.17	0.00	0.26	0.23	0.15	0.00	0.33	0.33	0.27	0.00

¹We estimated proportion of switching per 1,000 ARB episodes as the number of ARB episodes that resulted in the switch from the index ARB to another ARB, ACEi only, CCB only, ACEi/CCB combination drugs only, or ACEi or CCB or ACEi/CCB combination drugs in a given year and quarter divided by the total number of all ARB index episodes during the same year and quarter.

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

*ACEi or CCB: only ACEi, only CCB or ACEi/CCB combination drugs

Table 4a. Proportion of Total Switches for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Switches Reported by Year and Quarter¹
(Switching per 1,000 ARB Switches)

Index ARB	2014				2015				2016			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Azilsartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.94	0.00	0.00	0.00	0.00
Candesartan	255.84	276.00	321.16	322.03	333.65	294.63	344.37	321.76	332.68	329.55	312.97	286.42
Eprosartan	2.22	2.72	7.49	1.99	6.69	4.88	7.57	3.75	2.94	2.84	1.88	0.82
Irbesartan	99.00	98.57	127.34	127.62	130.02	140.49	114.47	116.32	110.89	107.01	111.84	103.11
Losartan	361.51	346.02	475.66	469.59	456.98	496.59	466.41	479.36	485.77	512.31	473.68	453.36
Olmesartan	16.69	15.64	15.92	23.93	28.68	19.51	20.81	24.39	13.74	5.68	12.22	10.64
Telmisartan	8.90	11.56	18.73	18.94	13.38	20.49	18.92	18.76	23.55	10.42	13.16	11.46
Valsartan	255.84	249.49	33.71	35.89	30.59	23.41	27.44	34.71	30.42	32.20	74.25	134.21

¹We estimated the proportion of total switches per 1,000 ARB switches as total switches for each index ARB to another ARB, ACEi only, CCB only, ACEi/CCB combination drugs only, or ACEi or CCB or ACEi/CCB combination drugs, divided by the total number of switches for all index ARBs.

Table 4a. Proportion of Total Switches for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Switches Reported by Year and Quarter¹
(Switching per 1,000 ARB Switches) (Continued)

Index ARB	2017				2018				2019				2020		
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Azilsartan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Candesartan	311.70	324.35	284.72	339.27	321.08	336.48	299.37	325.07	333.91	319.64	328.05	324.28	325.47	325.10	316.05
Eprosartan	1.71	13.48	7.86	8.43	2.62	1.89	1.80	4.59	2.59	3.29	2.80	0.91	3.77	2.60	0.00
Irbesartan	102.48	114.11	91.70	102.16	170.60	114.04	100.09	93.66	87.14	86.28	77.35	95.11	92.45	107.93	66.67
Losartan	476.52	490.57	556.33	493.91	459.32	506.13	514.88	509.64	509.92	492.19	501.40	521.74	518.87	507.15	518.52
Olmesartan	17.08	8.09	12.23	14.06	11.37	7.54	7.21	9.18	9.49	17.26	13.98	19.93	19.81	9.10	4.94
Telmisartan	11.10	14.38	20.09	12.18	11.37	16.02	18.94	24.79	15.53	14.79	9.32	12.68	15.09	7.80	22.22
Valsartan	79.42	35.04	27.07	29.99	23.62	17.91	57.71	33.06	41.42	66.56	67.10	25.36	24.53	40.31	71.60

¹We estimated the proportion of total switches per 1,000 ARB switches as total switches for each index ARB to another ARB, ACEi only, CCB only, ACEi/CCB combination drugs only, or ACEi or CCB or ACEi/CCB combination drugs, divided by the total number of switches for all index ARBs.

Table 4b. Proportion of Total Switches for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Switches Reported by Year and Quarter¹
(Switching per 1,000 ARB Switches)

Index ARB	2014				2015				2016			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Azilsartan	0.00	0.11	0.29	0.16	0.00	0.16	0.31	0.31	0.31	0.31	0.15	0.14
Candesartan	256.12	241.75	304.94	305.36	316.61	295.43	324.05	313.86	320.50	320.74	305.41	293.29
Eprosartan	6.57	6.51	8.90	10.31	9.09	8.70	8.42	8.91	9.47	6.81	9.19	5.37
Irbesartan	140.04	125.44	154.59	154.56	152.82	161.24	151.23	152.94	151.48	148.61	149.79	131.87
Losartan	332.09	328.73	414.18	418.03	417.40	433.96	413.90	414.08	428.84	436.53	414.92	388.27
Olmesartan	31.95	25.91	33.40	40.16	38.09	39.79	44.54	44.57	30.58	23.53	30.79	26.15
Telmisartan	19.35	19.06	19.69	24.22	25.71	22.87	20.97	28.13	21.88	21.05	22.67	20.35
Valsartan	213.88	252.48	64.02	47.19	40.28	37.85	36.58	37.20	36.94	42.41	67.09	134.56

¹We estimated the proportion of total switches per 1,000 ARB switches as total switches for each index ARB to another ARB, ACEi only, CCB only, ACEi/CCB combination drugs only, or ACEi or CCB or ACEi/CCB combination drugs, divided by the total number of switches for all index ARBs.

**Table 4b. Proportion of Total Switches for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Switches Reported by Year and Quarter¹
(Switching per 1,000 ARB Switches) (Continued)**

Index ARB	2017				2018				2019				2020		
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Azilsartan	0.00	0.00	0.15	0.16	0.00	0.16	0.00	0.30	0.00	0.15	0.00	0.17	0.17	0.00	0.00
Candesartan	295.98	316.13	307.87	315.75	314.47	321.61	318.19	306.30	328.40	306.46	307.50	319.18	330.37	317.81	293.01
Eprosartan	7.36	21.40	17.78	14.13	5.95	4.89	5.08	7.18	4.73	3.18	3.97	3.71	3.69	6.74	5.04
Irbesartan	138.61	145.09	137.47	137.70	193.44	140.85	132.91	130.63	129.53	120.56	129.19	128.58	121.71	133.78	124.66
Losartan	412.38	427.08	461.26	449.84	415.76	459.31	439.55	464.31	443.29	434.73	423.73	473.71	471.21	465.07	439.52
Olmesartan	21.78	23.52	25.05	23.71	21.33	18.93	19.10	18.55	24.84	27.83	23.49	22.08	23.50	21.45	22.85
Telmisartan	21.78	22.92	20.41	23.08	19.45	20.82	28.03	31.42	24.25	20.12	19.22	20.56	21.32	21.65	20.83
Valsartan	102.12	43.86	30.00	35.64	29.60	33.44	57.14	41.30	44.95	86.98	92.89	32.02	28.03	33.50	94.09

¹We estimated the proportion of total switches per 1,000 ARB switches as total switches for each index ARB to another ARB, ACEi only, CCB only, ACEi/CCB combination drugs only, or ACEi or CCB or ACEi/CCB combination drugs, divided by the total number of switches for all index ARBs.

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request End Date (August 25, 2020)

DP ID	Start Date ¹	End Date ¹
DP01	01/01/2000	08/25/2020

¹The start date is based on the minimum date within each DP. Data included in this report are those received and processed by August 25, 2020. Approximately 90% of the provided data is available through August 21, 2022.

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Angiotensin Receptor Blockers (ARBs) in this Request

Generic Name	Brand Name
Azilsartan	
azilsartan medoxomil	azilsartan medoxomil
azilsartan medoxomil	edarbi
Candesartan	
candesartan cilexetil	amias
candesartan cilexetil	candesartan
Candesartan/hydrochlorothiazide	atacand
Eprosartan	
eprosartan mesilate	eprosartan
eprosartan mesilate	teveten
Eprosartan/hydrochlorothiazide	teveten
Irbesartan	
hydrochlorothiazide/ irbesartan	coaprovel
hydrochlorothiazide/ irbesartan	irbesartan / hydrochlorothiazide
irbesartan	aprovel
irbesartan	ifirmasta
irbesartan	irbesartan
irbesartan	sabervel
Losartan	
hydrochlorothiazide/ losartan potassium	cozaar-comp
hydrochlorothiazide/ losartan potassium	losartan / hydrochlorothiazide
Losartan / Hydrochlorothiazide	hyzaar
losartan potassium	cozaar
losartan potassium	losartan
Olmesartan	
amlodipine besilate/ hydrochlorothiazide/ olmesartan medoxomil	sevikar
amlodipine besilate/ olmesartan medoxomil	olmesartan medoxomil
amlodipine besilate/ olmesartan medoxomil	sevikar
hydrochlorothiazide/ olmesartan medoxomil	olmesartan medoxomil
hydrochlorothiazide/ olmesartan medoxomil	olmetec
olmesartan medoxomil	olmesartan medoxomil
olmesartan medoxomil	olmetec
Telmisartan	
hydrochlorothiazide/ telmisartan	actelsar
hydrochlorothiazide/ telmisartan	micardisplus
hydrochlorothiazide/ telmisartan	telmisartan / hydrochlorothiazide
Telmisartan	
hydrochlorothiazide/ telmisartan	tolucombi
telmisartan	micardis
telmisartan	telmisartan
telmisartan	tolura

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Angiotensin Receptor Blockers (ARBs) in this Request

Generic Name	Brand Name
	Valsartan
amlodipine besilate/ valsartan	amlodipine/valsartan
amlodipine besilate/ valsartan	exforge
amlodipine/valsartan	exforge
amlodipine/valsartan/hydrochlorothiazide	exforge
hydrochlorothiazide/ valsartan	co-diovan
hydrochlorothiazide/ valsartan	valsartan / hydrochlorothiazide
sacubitril/ valsartan	entresto
sacubitril/ valsartan	sacubitril
valsartan	diovan
valsartan	valsartan

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Angiotensin-Converting-Enzyme Inhibitors (ACEi), Calcium Channel Blockers (CCB), and ACEi/CCB Combination Drugs in this Request

Generic Name	Brand Name
ACEi	
captopril	acepril
captopril	acezide
captopril	capoten
captopril	capozide
captopril	captopril
captopril	ecopace
captopril	kaplon
captopril/ hydrochlorothiazide	co-zidocapt
captopril	noyada
enalapril maleate	enalapril
enalapril maleate	innovace
enalapril maleate	pralenal
enalapril maleate/ hydrochlorothiazide	innozide
fosinopril sodium	fosinopril
fosinopril sodium	staril
indapamide/ perindopril arginine	indapamide/ perindopril arginine
indapamide/ perindopril arginine	coversyl arginine plus
lisinopril	carace
lisinopril	lisinopril
lisinopril	zestril
lisinopril/hydrochlorothiazide	carace
lisinopril/hydrochlorothiazide	caraalpha
lisinopril/hydrochlorothiazide	lisicostad
lisinopril/hydrochlorothiazide	lisinopril/hydrochlorothiazide
lisinopril/hydrochlorothiazide	zestoretic
moexipril hydrochloride	moexipril
moexipril hydrochloride	perdix
perindopril arginine	perindopril arginine
perindopril erbumine	perindopril erbumine
perindopril erbumine	perindopril arginine
perindopril erbumine/indapamide	perindopril arginine / indapamide
perindopril erbumine/indapamide	perindopril erbumine
quinapril hydrochloride	accupro
quinapril hydrochloride	quinil
quinapril hydrochloride	quinapril
quinapril hydrochloride/hydrochlorothiazide	quinapril / hydrochlorothiazide

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Angiotensin-Converting-Enzyme Inhibitors (ACEi), Calcium Channel Blockers (CCB), and ACEi/CCB Combination Drugs in this Request

Generic Name	Brand Name
ACEi	
ramipril	ramipril
ramipril	lopace
ramipril	tritace
ramipril/hydrochlorthiazide	ramipril/hydrochlorthiazide
trandolapril	gopten
trandolapril	odrik
trandolapril	trandolapril
CCB	
amlodipine	amlodipine
amlodipine	amlodipine besilate
amlodipine	amlostin
amlodipine	istin
diltiazem hydrochloride	adizem
diltiazem hydrochloride	adizem-60
diltiazem hydrochloride	adizem-sr
diltiazem hydrochloride	adizem-xl
diltiazem hydrochloride	angiozem
diltiazem hydrochloride	angitil
diltiazem hydrochloride	bi-carzem
diltiazem hydrochloride	calcicard
diltiazem hydrochloride	dilcardia
diltiazem hydrochloride	diltiazem
diltiazem hydrochloride	diltiazem hydrochloride
diltiazem hydrochloride	dilzem
diltiazem hydrochloride	disogram
diltiazem hydrochloride	horizem
diltiazem hydrochloride	kenzem
diltiazem hydrochloride	optil
diltiazem hydrochloride	retalzem
diltiazem hydrochloride	slozem
diltiazem hydrochloride	tildiem
diltiazem hydrochloride	viazem
diltiazem hydrochloride	zemret
diltiazem hydrochloride	zemtard
diltiazem hydrochloride	zildil
felodipine	cabren
felodipine	cardioplén
felodipine	felodipine
felodipine	felogen

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Angiotensin-Converting-Enzyme Inhibitors (ACEi), Calcium Channel Blockers (CCB), and ACEi/CCB Combination Drugs in this Request

Generic Name	Brand Name
	CCB
felodipine	felotens
felodipine	folpik
felodipine	neofel
felodipine	parmid
felodipine	plendil
felodipine	vascalpha
indapamide/ perindopril tosilate	prindopril tosilate / indapamide
isradipine	isradipine
isradipine	prescal
nicardipine hydrochloride	cardene
nicardipine hydrochloride	nicardipine
nifedipine	adalat
nifedipine	adanif
nifedipine	adipine
nifedipine	angiopine
nifedipine	calchan
nifedipine	cardilate
nifedipine	coracten
nifedipine	coroday
nifedipine	fortipine
nifedipine	hypolar
nifedipine	neozipine
nifedipine	nidef
nifedipine	nifedipine
nifedipine	nifedipress
nifedipine	nifopress
nifedipine	nimodrel
nifedipine	slofedipine
nifedipine	tensipine
nifedipine	valni
nimodipine	nimodipine
nimodipine	nimotop
nisoldipine	nisoldipine
nisoldipine	syscor
perindopril tosilate	prindopril tosilate
verapamil	cordilox
verapamil hydrochloride	cordilox mr
verapamil hydrochloride	ethimil
verapamil hydrochloride	half securon sr
verapamil hydrochloride	ranvera
verapamil hydrochloride	securon

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Angiotensin-Converting-Enzyme Inhibitors (ACEi), Calcium Channel Blockers (CCB), and ACEi/CCB Combination Drugs in this Request

Generic Name	Brand Name
CCB	
verapamil hydrochloride	univer
verapamil hydrochloride	verapamil
verapamil hydrochloride	verapamil hydrochloride
verapamil hydrochloride	verapress
verapamil hydrochloride	vera-til
verapamil hydrochloride	vertab
verapamil hydrochloride	zolvera
ACEi/CCB Combination Drugs	
amlodipine besilate/ perindopril erbumine	perindopril erbumine / amlodipine
felodipine/ ramipril	felodipine / ramipril
felodipine/ ramipril	triapin
trandolapril/ verapamil hydrochloride	tarka
trandolapril/ verapamil hydrochloride	verapamil / trandolapril

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
Angina	
1047381000006114	Adverse reaction to Tranguina XL
3637786016	CLASP (Cardiovascular Limitations and Symptoms Profile) angina score
1235225010	Prinzmetal's angina
1235225010	Variant angina pectoris
1576311000006117	Cause of Death- Angina Pectoris
1731551000000112	Angina self management plan commenced
1731571000000115	Angina self management plan completed
3010438013	Frequency of angina
2117311000000111	Angina self-management plan review
2117731000000119	Angina self-management plan agreed
3638316014	Canadian Cardiovascular Society classification of angina
3637787013	Cardiovascular Limitations and Symptoms Profile angina score
2210191000000118	Referral to Angina Plan self-management programme
2210251000000115	Referral to Angina Plan self-management programme declined
251679016	H/O: angina pectoris
2819370013	Preinfarction angina
264492012	Angina control
264493019	Angina control - good
264494013	Angina control - poor
264495014	Angina control - improving
264496010	Angina control - worsening
264492012	Angina control NOS
481684018	Angina pectoris with documented spasm
299757012	Angina pectoris
299758019	Stenocardia
98087016	Angina decubitus NOS
299757012	Angina pectoris NOS
299757012	[X]Other forms of angina pectoris
32122016	Status anginosus
338974012	Ischaemic chest pain
98088014	Anginal chest pain at rest
350348018	Stable angina
350350014	New onset angina
36036010	Syncope anginosa
144818014	Prinzmetal angina
144819018	Variant angina pectoris
1235223015	Variant angina
1235224014	Coronary artery spasm angina
39773018	Coronary artery spasm
442204010	Angina on effort
451370011	H/O: Angina in last year

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
451425016	Antianginal therapy
2986318019	History of angina pectoris
458410010	Post infarct angina
459487012	Refractory angina
3637873018	Euroscore for angina
299755016	Angina
299756015	Cardiac angina
299759010	Anginal syndrome
299760017	AP - Angina pectoris
299761018	Ischemic heart disease - angina
299762013	Ischaemic heart disease - angina
361157010	Angina - abdominal
498328016	Angina at rest
482911000006118	Angina grading (canadian cardiovascular society)
299757012	Angina pectoris NOS
482961000006115	Anginal Control: No attacks
494261017	Worsening angina
498328016	Angina at rest
361155019	Intestinal angina
442203016	Exercise-induced angina
442205011	Exertional angina
442206012	Angina of effort
2986990019	History of angina in last year
59952018	Nocturnal angina
7845011	Unstable angina
7845011	Unstable angina
7847015	Crescendo angina
2967773018	Angina associated with type 2 diabetes mellitus
2967590010	Angina associated with type II diabetes mellitus
2967662015	Diabetic angina pectoris associated with type 2 diabetes mellitus
854491000006113	Unstable angina
855991000006115	Angina control - stable
856011000006116	Angina control - unsatisfactory
856451000006113	Possible angina
905381000006117	[RFC] Angina
960181000006111	Anginal pain
98087016	Angina decubitus
981131000033119	Trangina XI
Atrial Fibrillation	
1569921000000118	Excepted from atrial fibrillation qual indic: Inform dissent
2779681000000117	QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
3032484016	Perc transluminal ablation of atrial wall for atrial flutter
3032484016	Perc translum ablat conduct sys heart for atrial flutter NEC
3620630016	Referral to atrial fibrillation clinic
1823951000006111	Atrial fibrillation confirmed
1824051000006113	Atrial fibrillation clinical pathway protocol followed
1824151000006112	Atrial fibrillation clinical pathway protocol not followed
1854971000006115	Did not attend atrial fibrillation monitoring
1855501000006118	Atrial fibrillation monitoring in primary care
1855511000006115	Atrial fibrillation monitoring in secondary care
1856431000006118	Atrial fibrillation follow-up
1932021000006117	3D study - problems with atrial fibrillation management
216183015	Atrial fibrillation monitoring
2197581000000114	Atrial fibrillation care pathway
2986139019	Provision of written information about atrial fibrillation
256478018	ECG: atrial fibrillation
256479014	ECG: atrial flutter
2587711000000116	High risk of atrial fibrillation
3320796013	Typical atrial flutter
3322864015	Atypical atrial flutter
2675253013	Chronic atrial fibrillation
2675306013	Paroxysmal atrial flutter
2692063011	History of atrial flutter
1569421000000113	Exception reporting: atrial fibrillation quality indicators
294601000000110	Atrial fibrillation resolved
300130013	Atrial fibrillation and flutter
300130013	Atrial fibrillation and flutter NOS
1230726010	AF - Atrial fibrillation
350465014	Non-rheumatic atrial fibrillation
1565041000000112	Atrial fibrillation monitoring administration
406861000000119	Atrial fibrillation annual review
1569761000000112	Atrial fibrillation monitoring first letter
1569531000000111	Atrial fibrillation monitoring second letter
1568741000000115	Atrial fibrillation monitoring third letter
1570401000000119	Atrial fibrillation monitoring verbal invite
1570381000000119	Atrial fibrillation monitoring telephone invite
421235014	Paroxysmal atrial fibrillation
456154015	H/O: atrial fibrillation
3300048013	Electrocardiographic atrial fibrillation
3300081014	Electrocardiographic atrial flutter
3300082019	EKG: atrial flutter
350466010	NRAF - Non-rheumatic atrial fibrillation
421232012	AF - Paroxysmal atrial fibrillation

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
421233019	PAF - Paroxysmal atrial fibrillation
421234013	Intermittent atrial fibrillation
2986292016	History of atrial fibrillation
2793372019	Persistent atrial fibrillation
2793259018	Permanent atrial fibrillation
3320801015	Atrial flutter type I
3320802010	Atrial flutter type 1
271235013	Implant intravenous pacemaker for atrial fibrillation
1569271000000111	Atrial fibrillation monitoring telephone invitation
1569561000000118	Atrial fibrillation monitoring verbal invitation
82343012	Atrial fibrillation
3323015018	Atrial flutter type 2
3323016017	Atrial flutter type II
9988012	Atrial flutter
Diabetes	
1013661000006110	Adverse reaction to Drugs Used In Diabetes
1065811000000118	Discharged from diabetes shared care programme
10928019	Diabetes mellitus associated with genetic syndrome
1139821000000110	Unsuitable for diabetes year of care programme
1139861000000119	Declined consent for diabetes year of care programme
3334354013	Atypical diabetes mellitus
3334355014	ADM - atypical diabetes mellitus
2974927015	Education in self management of diabetes
913591000006110	Insulin dependent diabetes mellitus with ulcer
3315456014	Hypoglycemic coma co-occurrent and due to diabetes mellitus type II
3637539017	Congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischaemic attack score
3637540015	Congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack score
3637564019	CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score
3643834015	Provision of patient held diabetes record declined
3657200017	Diabetes Treatment Satisfaction Questionnaire status version score
3690175010	Clinically significant macular oedema of right eye co-occurrent and due to diabetes mellitus
3690176011	Clinically significant macular edema of right eye due to diabetes mellitus
3690178012	Clinically significant macular edema of right eye co-occurrent and due to diabetes mellitus
3690182014	Clinically significant macular oedema of left eye due to diabetes mellitus
3690179016	Clinically significant macular oedema of left eye co-occurrent and due to diabetes mellitus

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
3690181019	Clinically significant macular edema of left eye co-occurrent and due to diabetes mellitus
3690183016	Clinically significant macular edema of left eye due to diabetes mellitus
3690549019	Maculopathy of right eye due to diabetes mellitus
3690551015	Disorder of right macula co-occurrent and due to diabetes mellitus
3690553017	Maculopathy of left eye due to diabetes mellitus
3690555012	Disorder of left macula co-occurrent and due to diabetes mellitus
2762991000000111	Diabetes structured education programme offered
121589010	Diabetes mellitus
3688791016	Retinopathy co-occurrent and due to diabetes mellitus
3688792011	Retinopathy due to diabetes mellitus
12174801000006114	Eye disorder due to diabetes mellitus
3688437018	Disorder of eye co-occurrent and due to diabetes mellitus
3698324018	Lumbosacral radiculoplexus neuropathy with diabetes mellitus
3698325017	Lumbosacral radiculoplexus neuropathy co-occurrent and due to diabetes mellitus
3686318016	Cataract co-occurrent and due to diabetes mellitus
3688520011	Cataract due to diabetes mellitus
3695673019	Polyneuropathy due to diabetes mellitus
3695674013	Polyneuropathy co-occurrent and due to diabetes mellitus
3698364019	Autonomic neuropathy with diabetes mellitus
3698365018	Autonomic neuropathy co-occurrent and due to diabetes mellitus
3699414017	Proliferative retinopathy with diabetes mellitus
3699416015	Proliferative retinopathy co-occurrent and due to diabetes mellitus
3688487013	Disorder of kidney co-occurrent and due to diabetes mellitus
12218511000006112	Kidney disorder due to diabetes mellitus
3697739017	Mononeuritis multiplex co-occurrent and due to diabetes mellitus
3697740015	Mononeuritis multiplex with diabetes mellitus
3698385019	Asymptomatic neuropathy co-occurrent and due to diabetes mellitus
3698386018	Asymptomatic neuropathy with diabetes mellitus
3689263018	Preproliferative retinopathy co-occurrent and due to diabetes mellitus
3690613011	Advanced maculopathy co-occurrent and due to diabetes mellitus
3698424019	Advanced maculopathy with diabetes mellitus
3686914014	Iritis co-occurrent and due to diabetes mellitus
3688503012	Iritis due to diabetes mellitus
3695486018	Neuropathy co-occurrent and due to diabetes mellitus
3697662013	Mononeuropathy co-occurrent and due to diabetes mellitus
3690138017	Disorder of macula co-occurrent and due to diabetes mellitus
3690525017	Maculopathy due to diabetes mellitus
3698427014	Maculopathy with diabetes mellitus
3698433017	Advanced retinal disease co-occurrent and due to diabetes mellitus
3698434011	Advanced retinal disease with diabetes mellitus

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
3688873019	Severe nonproliferative retinopathy co-occurrent and due to diabetes mellitus
3690140010	Macular oedema co-occurrent and due to diabetes mellitus
3690141014	Macular edema co-occurrent and due to diabetes mellitus
3690600017	Macular edema due to diabetes mellitus
3690601018	Macular oedema due to diabetes mellitus
1223147012	Insulin treated Type II diabetes mellitus
1223148019	Insulin treated non-insulin dependent diabetes mellitus
2575925018	[V]Dietary counselling in diabetes mellitus
265249012	[V]Screening for diabetes mellitus (DM)
3688867015	Nonproliferative retinopathy co-occurrent and due to diabetes mellitus
1230890017	Autonomic neuropathy due to diabetes
1230929011	Secondary pancreatic diabetes mellitus
1231774017	Malnutrition-related diabetes mellitus - protein-deficient
12331051000006112	Mononeuropathy with type 2 diabetes mellitus
3697666011	Mononeuropathy co-occurrent and due to type 2 diabetes mellitus
12331221000006112	Exudative maculopathy with type 1 diabetes mellitus
3698520014	Exudative maculopathy co-occurrent and due to type 1 diabetes mellitus
12332101000006118	Cataract due to diabetes mellitus type 2
3687731016	Cataract co-occurrent and due to diabetes mellitus type 2
12332271000006117	Retinopathy with type 1 diabetes mellitus
3699406011	Retinopathy co-occurrent and due to type 1 diabetes mellitus
12332751000006115	Mononeuropathy with type 1 diabetes mellitus
3698496011	Mononeuropathy co-occurrent and due to type 1 diabetes mellitus
3695405016	Neurological disorder co-occurrent and due to type 2 diabetes mellitus
12334141000006111	Neurological disorder with diabetes type 2
12334611000006115	Neurological disorder with type 1 diabetes mellitus
3695402018	Neurological disorder co-occurrent and due to type 1 diabetes mellitus
12335671000006113	Exudative maculopathy with type 2 diabetes mellitus
3698530017	Exudative maculopathy co-occurrent and due to type 2 diabetes mellitus
3688500010	Peripheral vascular disorder co-occurrent and due to diabetes mellitus
12335991000006117	Peripheral vascular disorder due to diabetes mellitus
12336111000006119	Cataract due to diabetes mellitus type 1
3686884016	Cataract co-occurrent and due to diabetes mellitus type 1
12336531000006116	Retinopathy with type 2 diabetes mellitus
3699409016	Retinopathy co-occurrent and due to type 2 diabetes mellitus
12336851000006113	Nervous system disorder due to diabetes mellitus
3688362017	Disorder of nervous system co-occurrent and due to diabetes mellitus
12336871000006115	Disorder of eye with type 2 diabetes mellitus
3698441017	Disorder of eye co-occurrent and due to type 2 diabetes mellitus
12363661000006113	Gastroparesis with type 1 diabetes mellitus
3698407013	Gastroparesis co-occurrent and due to type 1 diabetes mellitus

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
12363681000006115	Gastroparesis with type 2 diabetes mellitus
3698411019	Gastroparesis co-occurrent and due to type 2 diabetes mellitus
3696383017	Polyneuropathy co-occurrent and due to type 1 diabetes mellitus
3696410013	Polyneuropathy co-occurrent and due to type 2 diabetes mellitus
12370271000006116	Disorder of eye with type 1 diabetes mellitus
3698437016	Disorder of eye co-occurrent and due to type 1 diabetes mellitus
938331000006118	Type II diabetes mellitus with exudative maculopathy
12491551000006119	Radiculoplexoneuropathy due to diabetes mellitus
12491571000006112	Lumbosacral plexopathy co-occurrent and due to diabetes mellitus
12491581000006110	Lumbosacral plexopathy with diabetes mellitus
125705011	Diabetes mellitus due to insulin receptor antibodies
2779821000000117	QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation
2967908016	Diabetic cataract associated with type 1 diabetes mellitus
2623031016	Mononeuropathy associated with type 1 diabetes mellitus
3537386015	Diabetic oculopathy due to type I diabetes mellitus
2967753011	Diabetic cataract associated with type 2 diabetes mellitus
2967756015	Mononeuropathy associated with type 2 diabetes mellitus
84931000006113	Type II diabetes mellitus with neurological complications
12702421000006111	Type II diabetes mellitus with ophthalmic complications
430881000006111	[X]Unspecified diabetes mellitus with renal complications
292667010	Steroid induced diabetes
2618195014	Neurologic disorder associated with diabetes mellitus
2618203015	Peripheral circulatory disorder associated with diabetes mellitus
2623029013	Neurological disorder associated with type 1 diabetes mellitus
2967894011	Diabetic retinopathy associated with type 1 diabetes mellitus
2967746019	Diabetic oculopathy associated with type 2 diabetes mellitus
2623027010	Neurologic disorder associated with type 2 diabetes mellitus
2967760017	Diabetic retinopathy associated with type 2 diabetes mellitus
2967777017	Ketoacidotic coma in type 2 diabetes mellitus
2967767019	Exudative maculopathy associated with type 1 diabetes mellitus
2967775013	Exudative maculopathy associated with type 2 diabetes mellitus
3690177019	Clinically significant macular oedema of right eye due to diabetes mellitus
3297343012	Gastroparesis due to type 1 diabetes mellitus
3297356017	Gastroparesis due to type 2 diabetes mellitus
292616012	Steroid induced diabetes mellitus without complication
1188841000000119	Diabetes mellitus, adult onset, with no mention of complication
1390421000000119	Other specified diabetes mellitus with coma
1445721000000115	Diabetes mellitus with other specified manifestation
1445831000000112	Diabetes mellitus NOS with other specified manifestation
914051000006113	Diabetic oculopathy associated with type 2 diabetes mellitus
760111000000115	Other specified diabetes mellitus with multiple comps

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
2618195014	Other specified diabetes mellitus with neurological comps
42062018	Other specified diabetes mellitus with ophthalmic complicatn
121589010	Other specified diabetes mellitus with other spec comps
2618203015	Other specified diabetes mellitus with periph circ comps
123939015	Other specified diabetes mellitus with unspecified comps
1569461000000117	Exception reporting: diabetes quality indicators
1488441010	Diabetes medication review
1488822019	Urine screening test for diabetes
1488898011	Hyperosmolar non-ketotic state in type 2 diabetes mellitus
1550571000000114	Jamaica type diabetes
15518018	Secondary diabetes mellitus
1564911000000111	Diabetes monitoring admin.NOS
547511000000115	Did not complete DESMOND diabetes structured educat program
547581000000110	Did not complete XPERT diabetes structured education program
548141000000111	Did not attend DESMOND diabetes structured education program
532621000000114	Seen by general practitioner special interest in diabetes
1667891000000113	Hyperosmolar non-ketotic state in type II diabetes mellitus
3698412014	Type II diabetes mellitus with gastroparesis
3698406016	Type I diabetes mellitus with gastroparesis
1690631000000113	Did not attend diabetes foot screening
2157525015	Newly diagnosed diabetes
1230609013	Retinal abnormality - diabetes related
2955926019	Suspected diabetes mellitus
3022978015	Diabetes monitor invitation by SMS (short message service)
1757221000006115	Suspected diabetes mellitus
1759911000000118	Diabetes care plan declined
1763361000006116	Participant in ASCEND(A Study of Cardiovascu.Events in Diabetes)
2576238013	Pre-conception advice for diabetes mellitus
1775381000006118	Referred to Diabetes Service
1775531012	Hypogonadism, diabetes mellitus, alopecia, mental retardation and electrocardiographic abnormalities
1776581000006117	Reason for referral: Diabetes
1780311019	Type 1 diabetes mellitus with persistent microalbuminuria
1786715019	Bronzed diabetes
1803751000006119	DIDMOAD - Diabetes insip, diabetes mell, optic atrophy, deafness
1822191000006112	Diabetes pathway protocol not followed
1823471000006110	Diabetes mellitus high risk review
1823921000006119	Diabetes mellitus confirmed
1824081000006117	Diabetes clinical pathway protocol followed
1824571000006112	Referral to walking away from diabetes programme
1824581000006110	Referral to walking away from diabetes programme declined
1672471000000117	Advised about diabetes and driving

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
1824931000006119	Home visit for diabetes monitoring
1850931000006111	Reason for influenza vaccine - diabetes mellitus
1853141000006111	In-house diabetes foot screening
1853151000006113	In-house diabetes foot screen first appointment
1853161000006110	In-house diabetes foot screen follow-up appointment
1853171000006115	In-house diabetes foot screen discharge
1854821000006113	Diabetes year of care annual review
1856641000006113	Diabetes monitoring in primary care
1856651000006110	Diabetes monitoring in secondary care
1856661000006112	Diabetes treatment type
1858811000006114	AURAS-AF - consider the patient to have diabetes
2262201000000116	Referral to DAFNE diabetes structured educn prog declined
1873301000006114	Care contact service: diabetes
1877371000006111	Diabetes clinical management plan no longer in place
1891061000006117	Participant in Diabetes Aerobic and Resistance Exercise study
189711000000119	Lipoatrophic diabetes mellitus without complication
15518018	Secondary diabetes mellitus without complication
189831000000116	Informed consent for diabetes national audit
189841000000113	Informed dissent for diabetes national audit
1916521000006118	Access to online patient diabetes education given
1918361000006116	Diabetes care planning test results sent to patient
1920661000006119	Unsuitable for DESMOND diabetes structured education programme
1932051000006114	3D study - problems with diabetes management
1935341000006117	Patient in diabetes study
3303627011	Provision of written information about diabetes & hypertensn
3303627011	Provision of written information about diabetes and high BP
3318543018	Provision written information abt diabetes & high HbA1c lev
3304025010	Provsn written information about diabetes & high cholesterol
2439471000000113	Joint consultn pracse nurse & comm diabetes specialist nurse
2439751000000110	Joint consultation GP & community diabetes specialist nurse
1957911000006111	H/O: hypoglycaemic event in diabetes
2485781000000113	Recommendation self-refer for diabetes structured education
2967853015	Maturity onset diabetes of the young type 5
197761014	Type 2 diabetes mellitus
1979691000006117	Liverpool diabetes pilot administration
1979721000006110	Liverpool diabetes pilot - support option 1
1979731000006113	Liverpool diabetes pilot - support option 2
1979741000006115	Liverpool diabetes pilot - support option 3
1979751000006118	Liverpool diabetes pilot - support option 4
1979761000006116	Liverpool diabetes pilot - support option 5
197984010	Type 1 diabetes mellitus
1984081000006115	Manchester triage - Diabetes

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
84990019	Secondary pancreatic diabetes mellitus without complication
2645821000000114	X-PERT First Steps diabetes self-management programme complt
19931010	Brittle diabetes
356181016	Type A insulin resistance without complication
205225016	Diabetic nephropathy
2115761000000117	Diabetes self-management plan review
2116661000000116	Referral to community diabetes service
2117891000000114	Diabetes self-management plan agreed
760131000000111	Pre-existing diabetes mellitus, unspecified
82373015	Polyneuropathy in diabetes
2156000010	Lipodystrophy, partial, with Rieger anomaly, short stature, and insulinopenic diabetes mellitus
2156571000000116	Provision of diabetes clinical summary
2159170012	Patient on maximal tolerated therapy for diabetes
2388971000000113	Diabetes key contact
2159956013	Under care of diabetes specialist nurse
2160090014	Diabetes mellitus induced by non-steroid drugs
364695019	Diabetes care by hospital only
1564911000000111	Diabetes monitoring admin.
2176771000000110	Referral to community diabetes specialist nurse declined
2182651000000118	Referral to community diabetes clinic
2205911000000116	Diabetes clinical pathway
2220161000000117	Provision of written information about diabetes and driving
493774016	Maturity onset diabetes
2243331000000115	Erectile dysfunction due to diabetes mellitus
2262381000000117	Conversion to insulin by diabetes specialist nurse
2990473010	Education about diabetes and driving
2990473010	Advice about diabetes and driving
2283241000000113	Diabetes structured education programme not available
2287311000000111	Diabetes Year of Care annual review
2337981000000116	Diabetes Distress Scale 2 item
2341461000000112	Diabetes Distress Scale 17 item
2369111000000112	Lifestyle education for diabetes
2378231000000112	Discharge from secondary care diabetes service
3316960010	Provision of diabetes identity card
3321867012	Has diabetes identity card
3517021014	Diabetes clinical management plan
2474726011	Pan retinal photocoagulation for diabetes
2474730014	Fibrocalculous pancreatopathy without complication
2475901019	Type A insulin resistance
2967867012	Maturity onset diabetes in youth type 1
251591016	H/O: diabetes mellitus

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED CT Code	Description
1564931000000115	Diabetes clinic administration
2532974016	Transition of diabetes care options discussed
2533102013	Attended diabetes structured education programme
2533106011	Referral to diabetes preconception counselling clinic
1459984016	Patient diabetes education review
2533110014	Referral to diabetes structured education programme
3006793017	Diabetes care plan agreed
2548430017	Discharged from care of diabetes specialist nurse
2549069011	Seen in community diabetes specialist clinic
2762991000000111	Patient offered diabetes structured education programme
3320858019	Seen by diabetes specialist nurse
2586691000000116	Under care of hospital-based diabetes specialist nurse
2586731000000110	Under care of community-based diabetes specialist nurse
2609971000000114	Referred by Diabetes UK roadshow clinician
2622193012	Diabetes mellitus with ketoacidosis
264693010	Has seen dietician - diabetes
264695015	Understands diet - diabetes
264723013	Diabetes: practice programme
264724019	Diabetes: shared care programme
264676010	Diabetes management plan given
16500010	Latent diabetes
16501014	Chemical diabetes
2658852011	Brittle diabetes mellitus
1220208016	Labile diabetes
2871747019	Unstable diabetes mellitus
2693189019	Health education - diabetes
3316336015	Non-insulin dependent diabetes mellitus with hypoglyca coma
3697667019	Non-insulin dependent diabetes mellitus with mononeuropathy
3035432019	Non-insulin dependent diabetes mellitus with nephropathy
3297353013	Non-insulin dependent diabetes mellitus with polyneuropathy
292580015	Non-insulin dependent diabetes mellitus with ulcer
459307013	Non-insulin-dependent d m with peripheral angiopath
493773010	Non-insulin dependent diabetes mellitus
292578014	Non-insulin-dependent diabetes mellitus with multiple comps
3695406015	Non-insulin-dependent diabetes mellitus with neuro comps
3035281015	Non-insulin depend diabetes mellitus with diabetic cataract
2842387018	Non-insulin dependent diabetes mellitus - poor control
459314010	Non-insulin dependent d m with neuropathic arthropathy
2967779019	Non-insulin dependent diabetes mellitus with gangrene
2817479019	Hyperglycaemic crisis in diabetes mellitus
285751016	Attends diabetes monitoring
285752011	Refuses diabetes monitoring

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
285753018	Diabetes monitoring default
285759019	Diabetes monitoring deleted
42064017	Ophthalmic manifestations of diabetes
178796018	Diabetes mellitus with no mention of complication
178796018	Diabetes mellitus NOS with no mention of complication
2616611010	Other specified diabetes mellitus with ketoacidosis
2616611010	Diabetes mellitus NOS with ketoacidosis
2618221017	Diabetes mellitus with hyperosmolar coma
292482014	Diabetes mellitus, juvenile type, with hyperosmolar coma
292483016	Diabetes mellitus, adult onset, with hyperosmolar coma
2618221017	Diabetes mellitus NOS with hyperosmolar coma
2618230013	Other specified diabetes mellitus with coma
2616611010	Diabetes mellitus NOS with ketoacidotic coma
301016	Other specified diabetes mellitus with renal complications
301016	Diabetes mellitus with nephropathy NOS
42062018	Diabetes mellitus NOS with ophthalmic manifestation
2618195014	Diabetes mellitus NOS with neurological manifestation
2618203015	Diabetes mellitus NOS with peripheral circulatory disorder
292538019	Type I diabetes mellitus with ulcer
292540012	Type 1 diabetes mellitus with ulcer
2618207019	Type 1 diabetes mellitus with gangrene
2618207019	Type I diabetes mellitus with gangrene
2872487013	Type 1 diabetes mellitus - poor control
2872487013	Type I diabetes mellitus - poor control
292551012	Type I diabetes mellitus maturity onset
292553010	Type 1 diabetes mellitus maturity onset
760111000000115	Unspecified diabetes mellitus with multiple complications
292576013	Type II diabetes mellitus with multiple complications
292577016	Type 2 diabetes mellitus with multiple complications
292579018	Type 2 diabetes mellitus with ulcer
292581016	Type II diabetes mellitus with ulcer
2618206011	Type II diabetes mellitus with gangrene
2618206011	Type 2 diabetes mellitus with gangrene
2921019012	Type II diabetes mellitus - poor control
2921019012	Type 2 diabetes mellitus - poor control
292606016	Malnutrition-related diabetes mellitus with ketoacidosis
292612014	Malnutrition-related diabetes mellitus without complications
123939015	Diabetes mellitus with other specified manifestation
121589010	Diabetes mellitus NOS with other specified manifestation
123939015	Diabetes mellitus with unspecified complication
123939015	Diabetes mellitus NOS with unspecified complication
121589010	[X]Other specified diabetes mellitus

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
301016	[X]Unspecified diabetes mellitus with renal complications
3698406016	Type 1 diabetes mellitus with gastroparesis
3698412014	Type 2 diabetes mellitus with gastroparesis
303846016	Nephrotic syndrome in diabetes mellitus
55997018	Pineal hyperplasia AND diabetes mellitus syndrome
1228082013	Pineal hyperplasia, insulin-resistant diabetes mellitus and somatic abnormalities
452844015	[X]Glomerular disorders in diabetes mellitus
760131000000111	Pre-existing diabetes mellitus, insulin-dependent
306113018	Pre-existing diabetes mellitus, non-insulin-dependent
306114012	Pre-existing malnutrition-related diabetes mellitus
760131000000111	[X]Pre-existing diabetes mellitus, unspecified
73465010	Diabetes mellitus type II
197763012	Diabetes mellitus type 2
77728011	Diabetes mellitus type I
197985011	Diabetes mellitus type 1
3291658019	Diabetes mellitus caused by insulin receptor antibodies
345487013	Diabetes mellitus with neuropathy
103479010	Pretibial pigmental patches in diabetes
3537388019	Diabetic oculopathy due to type 1 diabetes mellitus
3688488015	Renal diabetes
356077018	Malnutrition-related diabetes mellitus - fibrocalculous
356078011	Secondary endocrine diabetes mellitus
356079015	Metabolic syndrome X
356085010	Maturity onset diabetes in youth type 2
356099014	Photomyoclonus, diabetes mellitus, deafness, nephropathy and cerebral dysfunction
356110010	Megaloblastic anaemia, thiamine-responsive, with diabetes mellitus and sensorineural deafness
356111014	Insulin-dependent diabetes mellitus secretory diarrhoea syndrome
356115017	Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhoea
356119011	Abnormal metabolic state in diabetes mellitus
3636751012	Acute complication with diabetes mellitus
3636752017	Acute complication co-occurrent and due to diabetes mellitus
502372015	DM - Diabetes mellitus
2621161019	Disorder associated with diabetes mellitus
125663012	Lipodystrophic diabetes with partial lipoatrophy
121589010	[X]Diabetes mellitus
505747013	Diabetes mellitus, Addison's disease and myxoedema
505755018	Diabetes mellitus, Addison's disease and myxedema
292611019	[X]Malnutrit-relat diabetes mellitus with other spec comps

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
292611019	[X]Malnutrit-related diabetes mellitus with unspec complics
405057014	Diabetes monitored
3657199015	Diabetes treatment satisfaction questionnaire
19931010	Unstable diabetes
429970018	Unstable type I diabetes mellitus
429971019	Unstable type 1 diabetes mellitus
19931010	Unstable insulin dependent diabetes mellitus
300015	Lipoatrophic diabetes
205214013	Lipodystrophic diabetes
2619011010	Renal disorder associated with diabetes mellitus
3313383012	Diabetes with peripheral circulatory disorder
3313388015	Peripheral angiopathy due to diabetes mellitus
453050019	Education score - diabetes
453100011	H/O: Admission in last year for diabetes foot problem
2820057017	Pre-existing diabetes mellitus
2986596017	History of diabetes mellitus
456646018	Referral to diabetes nurse
456686014	Attending diabetes clinic
457325013	Type I diabetes mellitus without complication
457326014	Type 1 diabetes mellitus without complication
178796018	Insulin-dependent diabetes without complication
457328010	Non-insulin-dependent diabetes mellitus without complication
457329019	Type 2 diabetes mellitus without complication
457330012	Type II diabetes mellitus without complication
459161015	Type 1 diabetes mellitus with hypoglycaemic coma
356141011	Insulin dependent diabetes mellitus with hypoglycaemic coma
459163017	Type I diabetes mellitus with hypoglycaemic coma
3316336015	Type 2 diabetes mellitus with hypoglycaemic coma
3316336015	Type II diabetes mellitus with hypoglycaemic coma
459292011	Type 1 diabetes mellitus with arthropathy
1229552016	Insulin dependent diabetes mellitus with arthropathy
459294012	Type I diabetes mellitus with arthropathy
3010513018	Type I diabetes mellitus with neuropathic arthropathy
3010513018	Type 1 diabetes mellitus with neuropathic arthropathy
459306016	Type II diabetes mellitus with peripheral angiopathy
459308015	Type 2 diabetes mellitus with peripheral angiopathy
459309011	Non-insulin dependent diabetes mellitus with arthropathy
459310018	Type 2 diabetes mellitus with arthropathy
459311019	Type II diabetes mellitus with arthropathy
459312014	Type II diabetes mellitus with neuropathic arthropathy
459313016	Type 2 diabetes mellitus with neuropathic arthropathy
4600881000006113	Glucose tolerance test indicates diabetes mellitus

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
265249012	[V]Screening for diabetes mellitus
264680017	Diet controlled diabetes mellitus
264694016	Has seen dietitian - diabetes
264722015	Diabetes: practice program
264725018	Diabetes: shared care program
2967854014	Type 1 diabetes mellitus with hyperosmolar coma
2967818010	Type 2 diabetes mellitus with hyperosmolar coma
292539010	Insulin-dependent diabetes mellitus with ulcer
292552017	Insulin-dependent diabetes maturity onset
3013381011	Nephrotic syndrome due to diabetes mellitus
479511000000117	Diabetes type 1 review
479571000000110	Diabetes type 2 review
2967812011	Pre-existing type 2 diabetes mellitus
479981000000119	Referral to community diabetes specialist nurse
2967884018	Diabetes mellitus autosomal dominant
2967884018	Maturity onset diabetes in youth
493773010	NIDDM - Non-insulin dependent diabetes mellitus
493774016	Type II diabetes mellitus
494564012	Type I diabetes mellitus
2674608014	Cystic fibrosis related diabetes mellitus
498512013	Genetic syndromes of diabetes mellitus
3037103012	Diabetes type 2 on insulin
2967875018	Maturity onset diabetes of the young, type 2
356083015	Maturity onset diabetes in youth type II
356084014	MODY - Maturity onset diabetes in youth type II
356086011	MODY - Maturity onset diabetes in youth type 2
356087019	MODY - Maturity onset diabetes glucokinase-related
356108013	Megaloblastic anemia, thiamine-responsive, with diabetes mellitus and sensorineural deafness
356112019	Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea
356116016	Insulin-dependent diabetes mellitus secretory diarrhea syndrome
356141011	Hypoglycaemic event in diabetes
356142016	Hypoglycemic event in diabetes
5211000033113	Drugs Used In Diabetes
1662411000000116	Diabetes structured education programme completed
546001000000113	Attended XPERT diabetes structured education programme
546071000000117	Attended DAFNE diabetes structured education programme
546151000000110	DAFNE diabetes structured education programme completed
546221000000114	DESMOND diabetes structured education programme completed
546291000000112	XPERT diabetes structured education programme completed
546471000000114	Diabetes structured education programme declined
546871000000112	Referral to DAFNE diabetes structured education programme

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
546961000000111	Referral to DESMOND diabetes structured education programme
547061000000110	Referral to XPERT diabetes structured education programme
547191000000117	Did not attend diabetes structured education programme
547331000000115	Did not complete diabetes structured education programme
547441000000118	Did not complete DAFNE diabetes structured education program
548121000000116	Did not attend DAFNE diabetes structured education programme
548131000000119	Did not attend XPERT diabetes structured education programme
2920470017	Diabetes mellitus uncontrolled
408813012	DWBQ - Diabetes wellbeing questionnaire
1495355018	Lipoatrophic diabetes mellitus
2872766016	Brittle type 1 diabetes mellitus
2872767013	Brittle type I diabetes mellitus
2872768015	Labile type I diabetes mellitus
3698440016	Non-insulin-dependent diabetes mellitus with ophthalm comps
2615535015	Non-insulin-dependent diabetes mellitus with renal comps
2986907010	History of admission in last year for diabetes foot problem
457327017	Insulin-dependent diabetes without complication
459162010	Insulin dependent diabetes mellitus with hypoglycaemic coma
459164011	Type I diabetes mellitus with hypoglycemic coma
459165012	Insulin dependent diabetes mellitus with hypoglycemic coma
459166013	Type 1 diabetes mellitus with hypoglycemic coma
459293018	Insulin dependent diabetes mellitus with arthropathy
459792010	DIGAMI - diabetes mellitus insulin-glucose infusion in acute myocardial infarction
2923439012	Diabetes mellitus in puerperium - baby previously delivered
306109013	Diabetes mellitus in puerperium - baby delivered
292667010	Diabetes mellitus induced by steroids
265249012	Diabetes mellitus screen
2616612015	Diabetes mellitus with gangrene
44045012	Diabetes mellitus with ketoacidotic coma
3688477014	Diabetes mellitus with neurological manifestation
3688467012	Diabetes mellitus with ophthalmic manifestation
3688501014	Diabetes mellitus with peripheral circulatory disorder
82373015	Diabetes mellitus with polyneuropathy
301016	Diabetes mellitus with renal manifestation
2618196010	Diabetes mellitus, adult onset, + neurological manifestation
2618233010	Diabetes mellitus, adult onset, + ophthalmic manifestation
3013072014	Diabetes mellitus, adult onset, + unspecified complication
457329019	Diabetes mellitus, adult onset, no mention of complication
2618220016	Diabetes mellitus, adult onset, with ketoacidosis
2618218019	Diabetes mellitus, adult onset, with ketoacidotic coma
2615535015	Diabetes mellitus, adult onset, with renal manifestation

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
2618206011	Diabetes mellitus, adult with gangrene
121589010	Diabetes mellitus, adult, + other specified manifestation
2618204014	Diabetes mellitus, adult, + peripheral circulatory disorder
2618205010	Diabetes mellitus, juvenile +peripheral circulatory disorder
3537386015	Diabetes mellitus, juvenile type, + ophthalmic manifestation
3013528019	Diabetes mellitus, juvenile type, + unspecified complication
457326014	Diabetes mellitus, juvenile type, no mention of complication
2618216015	Diabetes mellitus, juvenile type, with ketoacidosis
2618217012	Diabetes mellitus, juvenile type, with ketoacidotic coma
2618211013	Diabetes mellitus, juvenile type, with renal manifestation
2618197018	Diabetes mellitus, juvenile, + neurological manifestation
121589010	Diabetes mellitus, juvenile, + other specified manifestation
405056017	Diabetes monitor. check done
285758010	Diabetes monitor.phone invite
285757017	Diabetes monitor.verbal invite
285754012	Diabetes monitoring 1st letter
285755013	Diabetes monitoring 2nd letter
285756014	Diabetes monitoring 3rd letter
408812019	Diabetes well being questionnaire
2616612015	Diabetes with gangrene
65526011	Diabetic amyotrophy
620171000000113	Referral to diabetes special interest general practitioner
1564381000000115	Diabetes screening administration
3013197011	Diabetes screening invitation
3035295017	Non-insulin-dependent diabetes mellitus with retinopathy
1778601012	Bronze diabetes
2623039019	NIDDM with peripheral circulatory disorder
3290374011	Diabetes mellitus caused by non-steroid drugs
2478684010	Panretinal photocoagulation for diabetes
3290307015	Diabetes mellitus caused by non-steroid drugs without complication
2533101018	Attended diabetes structured education program
2533105010	Referral to diabetes preconception counseling clinic
2533109016	Referral to diabetes structured education program
2618216015	Ketoacidosis in type I diabetes mellitus
3035606019	Diabetes type 1 with ketoacidosis
2623051017	Kidney disorder associated with type 2 diabetes mellitus
2622192019	Ketoacidosis in diabetes mellitus
2618201018	Mononeuropathy associated with type II diabetes mellitus
2618236019	Exudative maculopathy associated with type I diabetes mellitus
2618212018	Persistent proteinuria associated with type I diabetes mellitus
2618198011	Neurological disorder associated with malnutrition-related diabetes mellitus
2618209016	Persistent microalbuminuria associated with type II diabetes mellitus

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
2618240011	Diabetic cataract associated with type II diabetes mellitus
3035281015	Diabetes type 2 with cataract
2618238018	Diabetic retinopathy associated with type I diabetes mellitus
3035448018	Diabetes type 1 with retinopathy
2623046011	Gangrene associated with type 1 diabetes mellitus
2618207019	Gangrene associated with type I diabetes mellitus
3035408014	Diabetes type 1 with gangrene
2618215016	Disorder associated with type I diabetes mellitus
2618199015	Mononeuropathy associated with type I diabetes mellitus
2618229015	Coma associated with malnutrition-related diabetes mellitus
2618217012	Ketoacidotic coma in type I diabetes mellitus
3035596015	Diabetes mellitus type 1 with ketoacidotic coma
2618239014	Ophthalmic complication of malnutrition-related diabetes mellitus
2618196010	Neurologic disorder associated with type II diabetes mellitus
3035455016	Diabetes type 2 with neurological disorder
2967882019	Peripheral circulatory disorder associated with type 1 diabetes mellitus
2618205010	Peripheral circulatory disorder associated with type I diabetes mellitus
2618197018	Neurological disorder associated with type I diabetes mellitus
3035338016	Diabetes type 1 with neurological disorder
6975211000006112	Gangrene associated with type 2 diabetes mellitus
2618206011	Gangrene associated with type II diabetes mellitus
2618220016	Ketoacidosis in type II diabetes mellitus
3035594017	Diabetes type 2 with ketoacidosis
2618237011	Exudative maculopathy associated with type II diabetes mellitus
3035601012	Diabetes mellitus type 2 with ketoacidotic coma
2618211013	Renal disorder associated with type I diabetes mellitus
2623057018	Kidney disorder associated with type 1 diabetes mellitus
2618234016	Diabetic cataract associated with type I diabetes mellitus
3035484013	Diabetes type 1 with cataract
2618222012	Non-ketotic non-hyperosmolar coma associated with diabetes mellitus
2618210014	Persistent proteinuria associated with type II diabetes mellitus
3013092019	Disorder due to type II diabetes mellitus
2618241010	Diabetic retinopathy associated with type II diabetes mellitus
3035295017	Diabetes type 2 with retinopathy
2623025019	Neurologic complication of diabetes mellitus
2618233010	Diabetic oculopathy associated with type II diabetes mellitus
6985001000006110	Peripheral circulatory disorder associated with type 2 diabetes mellitus
2618204014	Peripheral circulatory disorder associated with type II diabetes mellitus
6985421000006113	Skin ulcer associated with diabetes mellitus
2618232017	Multiple complications of type I diabetes mellitus
2616612015	Gangrene associated with diabetes mellitus
3440582013	Diabetes mellitus co-occurrent and due to cystic fibrosis

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
292611019	Malnutrit-related diabetes mellitus with unspec complics
2618239014	Malnutrit-related diabetes mellitus with ophthalmic complicat
125439011	Malnutrition-related diabetes mellitus
2618229015	Malnutrition-related diabetes mellitus with coma
292611019	Malnutrition-related diabetes mellitus with multiple comps
292607013	Malnutrition-related diabetes mellitus with renal complicatn
2618198011	Malnutrition-related diabetes mellitus with neuro complicatns
292610018	Malnutritn-relat diabetes melitus with periph circul complctn
292611019	Malnutrit-relat diabetes mellitus with other spec comps
2817480016	Hyperglycemic crisis in diabetes mellitus
19931010	Unstable insulin dependent diabetes mellitus
429971019	Unstable type 1 diabetes mellitus
429970018	Unstable type I diabetes mellitus
3321322011	Type 2 diabetes mellitus uncontrolled
2967763015	Type 1 diabetes mellitus uncontrolled
2842075017	Type I diabetes mellitus uncontrolled
493773010	Non-insulin dependent diabetes mellitus
178796018	Insulin-dependent diabetes without complication
2967867012	Maturity onset diabetes of the young, type 1
3435008016	MODY5 - maturity-onset diabetes of the young type 5
3435009012	Renal cysts and diabetes syndrome
2714541000000116	RCAD (renal cysts and diabetes) syndrome
417658010	Foot abnormality - diabetes related
417658010	Foot abnormality - diabetes related
3038864015	Gingivitis co-occurrent with diabetes mellitus
3297354019	Gastroparesis due to diabetes mellitus type I
3297368014	Gastroparesis due to diabetes mellitus type II
3297342019	Polyneuropathy due to type 1 diabetes mellitus
3297366013	Polyneuropathy due to diabetes mellitus type II
1229552016	Insulin dependent diabetes mellitus with arthropathy
73294018	Insulin dependent diabetes mellitus with diabetic cataract
2616612015	Insulin dependent diabetes mellitus with gangrene
356141011	Insulin dependent diabetes mellitus with hypoglycaemic coma
345492010	Insulin dependent diabetes mellitus with mononeuropathy
760111000000115	Insulin dependent diabetes mellitus with multiple complicatn
301016	Insulin dependent diabetes mellitus with nephropathy
82373015	Insulin dependent diabetes mellitus with polyneuropathy
9093013	Insulin dependent diabetes mellitus with retinopathy
2623058011	Insulin dependent diabetes mellitus with ulcer
3688477014	Insulin-dependent diabetes mellitus with neurological comps
3688467012	Insulin-dependent diabetes mellitus with ophthalmic comps
301016	Insulin-dependent diabetes mellitus with renal complications

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
309740011	Insulin dependent diab mell with neuropathic arthropathy
2618203015	Insulin dependent diab mell with peripheral angiopathy
121589010	Insulin dependent diabetes maturity onset
121589010	Insulin dependent diabetes mellitus
121589010	Insulin dependent diabetes mellitus
401531012	Insulin dependent diabetes mellitus - poor control
3305694014	Gingival disease co-occurrent with diabetes mellitus
121589010	Insulin dependent diabetes mellitus
7783451000006114	Hypoglycaemic coma co-occurrent and due to diabetes mellitus type II
3318542011	Provision of written information about diabetes and high hemoglobin A1c level
3321053016	Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program
3321057015	Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed programme
3321059017	Not suitable for DESMOND (Diabetes Education and Self Management for Ongoing and Newly Diagnosed) program
3444986010	Radiculoplexoneuropathy due to diabetes mellitus
3436917010	Lumbosacral plexopathy co-occurrent and due to diabetes mellitus
3436918017	Lumbosacral plexopathy with diabetes mellitus
2618203015	IDDM with peripheral circulatory disorder
121589010	IDDM-Insulin dependent diabetes mellitus
2967773018	Angina associated with type 2 diabetes mellitus
2967590010	Angina associated with type II diabetes mellitus
2967662015	Diabetic angina pectoris associated with type 2 diabetes mellitus
3313373013	Peripheral vascular disease due to type I diabetes
3012218016	Neuropathic arthropathy due to type 1 diabetes mellitus
3013379014	Diabetic neuropathic arthropathy due to type 1 diabetes mellitus
3028508015	Diabetes mellitus type 1 with diabetic Charcot's arthropathy
3005790010	Pre-existing diabetes mellitus in mother complicating childbirth
3005777015	Pre-existing diabetes mellitus in childbirth
8059261000006114	Diabetes monitoring lower risk albumin excretion
8059281000006116	Diabetes monitoring higher risk albumin excretion
1676151000000117	Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme
474071000000116	Attended diabetes education and self management for ongoing and newly diagnosed structured programme
1667931000000115	Diabetes type II review
545911000000117	Attended expert patient education versus routine treatment diabetes structured education programme
1678351000000116	Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
546021000000116	Attended dose adjustment for normal eating diabetes structured education programme
1677261000000111	Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme
546101000000114	Dose adjustment for normal eating diabetes structured education programme completed
1678361000000118	DAFNE (dose adjustment for normal eating) diabetes structured education programme completed
546171000000118	Diabetes education and self management for ongoing and newly diagnosed structured programme completed
1678371000000113	DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed
546241000000119	Expert patient education versus routine treatment diabetes structured education programme completed
1678381000000110	XPERT (expert patient education versus routine treatment) diabetes structured education programme completed
546821000000113	Referral to dose adjustment for normal eating diabetes structured education programme
1678391000000112	Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme
546911000000114	Referral to diabetes education and self management for ongoing and newly diagnosed diabetes structured programme
1678421000000118	Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme
546981000000119	Referral to expert patient education versus routine treatment diabetes structured education programme
1678451000000111	Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme
547391000000119	Did not complete dose adjustment for normal eating diabetes structured education programme
1678521000000117	Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme
547461000000117	Did not complete diabetes education and self management for ongoing and newly diagnosed structured programme
1678531000000115	Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme
547531000000111	Did not complete expert patient education versus routine treatment diabetes structured education programme
547951000000111	Did not attend dose adjustment for normal eating diabetes structured education programme
1677601000000114	Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
548011000000114	Did not attend diabetes education and self management for ongoing and newly diagnosed structured programme
1677761000000115	Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme
548071000000116	Did not attend expert patient education versus routine treatment diabetes structured education programme
1677771000000110	Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme
3449586019	Hyperosmolarity co-occurrent and due to drug induced diabetes mellitus
3288475010	Hyperosmolar coma due to secondary diabetes mellitus
1690661000000115	DNA (did not attend) diabetes foot screening
1748431000000112	Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined
2226651000000113	Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined
8323631000006117	Diabetes Distress Scale 2 item score
2338001000000111	DDS2 (Diabetes Distress Scale 2) score
8324991000006112	Diabetes Distress Scale 17 item score
2341481000000115	DDS17 (Diabetes Distress Scale 17) score
2967820013	Insulin treated Type 2 diabetes mellitus
356082013	Diabetes mellitus autosomal dominant type 2
1223147012	Insulin treated Type II diabetes mellitus
2609421000000115	X-PERT (expert patient education versus routine treatment) First Steps diabetes self-management programme completed
197984010	Type 1 diabetes mellitus
2872487013	Type 1 diabetes mellitus - poor control
292553010	Type 1 diabetes mellitus maturity onset
459292011	Type 1 diabetes mellitus with arthropathy
2618234016	Type 1 diabetes mellitus with diabetic cataract
2618207019	Type 1 diabetes mellitus with gangrene
459161015	Type 1 diabetes mellitus with hypoglycaemic coma
2618199015	Type 1 diabetes mellitus with mononeuropathy
2618232017	Type 1 diabetes mellitus with multiple complications
2623054013	Type 1 diabetes mellitus with nephropathy
2618197018	Type 1 diabetes mellitus with neurological complications
3010513018	Type 1 diabetes mellitus with neuropathic arthropathy
3537386015	Type 1 diabetes mellitus with ophthalmic complications
3315042015	Type 1 diabetes mellitus with peripheral angiopathy
3297342019	Type 1 diabetes mellitus with polyneuropathy
2618211013	Type 1 diabetes mellitus with renal complications
3699407019	Type 1 diabetes mellitus with retinopathy
292540012	Type 1 diabetes mellitus with ulcer

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
457326014	Type 1 diabetes mellitus without complication
197761014	Type 2 diabetes mellitus
2921019012	Type 2 diabetes mellitus - poor control
459310018	Type 2 diabetes mellitus with arthropathy
3688522015	Type 2 diabetes mellitus with diabetic cataract
2618206011	Type 2 diabetes mellitus with gangrene
3316336015	Type 2 diabetes mellitus with hypoglycaemic coma
2618201018	Type 2 diabetes mellitus with mononeuropathy
292577016	Type 2 diabetes mellitus with multiple complications
3035432019	Type 2 diabetes mellitus with nephropathy
3695406015	Type 2 diabetes mellitus with neurological complications
459313016	Type 2 diabetes mellitus with neuropathic arthropathy
3698440016	Type 2 diabetes mellitus with ophthalmic complications
459308015	Type 2 diabetes mellitus with peripheral angiopathy
3297353013	Type 2 diabetes mellitus with polyneuropathy
2618208012	Type 2 diabetes mellitus with renal complications
3699410014	Type 2 diabetes mellitus with retinopathy
292579018	Type 2 diabetes mellitus with ulcer
457329019	Type 2 diabetes mellitus without complication
494564012	Type I diabetes mellitus
2872487013	Type I diabetes mellitus - poor control
292551012	Type I diabetes mellitus maturity onset
459294012	Type I diabetes mellitus with arthropathy
3688521010	Type I diabetes mellitus with diabetic cataract
2618207019	Type I diabetes mellitus with gangrene
459163017	Type I diabetes mellitus with hypoglycaemic coma
3697664014	Type I diabetes mellitus with mononeuropathy
2967771016	Type I diabetes mellitus with multiple complications
2623054013	Type I diabetes mellitus with nephropathy
3695401013	Type I diabetes mellitus with neurological complications
3010513018	Type I diabetes mellitus with neuropathic arthropathy
3698438014	Type I diabetes mellitus with ophthalmic complications
3315042015	Type I diabetes mellitus with peripheral angiopathy
3297390014	Type I diabetes mellitus with polyneuropathy
2623054013	Type I diabetes mellitus with renal complications
3699407019	Type I diabetes mellitus with retinopathy
292538019	Type I diabetes mellitus with ulcer
457325013	Type I diabetes mellitus without complication
493774016	Type II diabetes mellitus
2921019012	Type II diabetes mellitus - poor control
459311019	Type II diabetes mellitus with arthropathy
3688522015	Type II diabetes mellitus with diabetic cataract

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
2618206011	Type II diabetes mellitus with gangrene
3316336015	Type II diabetes mellitus with hypoglycaemic coma
3697667019	Type II diabetes mellitus with mononeuropathy
292576013	Type II diabetes mellitus with multiple complications
3013392012	Type II diabetes mellitus with nephropathy
3695406015	Type II diabetes mellitus with neurological complications
459312014	Type II diabetes mellitus with neuropathic arthropathy
3698440016	Type II diabetes mellitus with ophthalmic complications
459306016	Type II diabetes mellitus with peripheral angiopathy
3297353013	Type II diabetes mellitus with polyneuropathy
3013392012	Type II diabetes mellitus with renal complications
3699410014	Type II diabetes mellitus with retinopathy
292581016	Type II diabetes mellitus with ulcer
457330012	Type II diabetes mellitus without complication
1488898011	Hyperosmolar non-ketotic state in type 2 diabetes mellitus
856771000006110	Patient has been told has diabetes
881441000006111	Diabetes mellitus - juvenile
881451000006113	Diabetes mellitus -adult onset
881461000006110	Diabetes+ketoacidosis -no coma
881471000006115	Diabetes with coma
881481000006117	Diabetes + nephropathy
881491000006119	Diabetes + eye manifestation
881501000006110	Diabetes + neuropathy
881511000006113	Diabetes + periph.circulat.dis
881521000006117	Diabetes + other complications
905621000006113	[RFC] Diabetes
908831000006118	[RFC] Diabetes mellitus
301016	Insulin-dependent diabetes mellitus with renal complications
2618211013	Type 1 diabetes mellitus with renal complications
2623054013	Type I diabetes mellitus with renal complications
3688467012	Insulin-dependent diabetes mellitus with ophthalmic comps
3537386015	Type 1 diabetes mellitus with ophthalmic complications
3698438014	Type I diabetes mellitus with ophthalmic complications
3688477014	Insulin-dependent diabetes mellitus with neurological comps
2618197018	Type 1 diabetes mellitus with neurological complications
3695401013	Type I diabetes mellitus with neurological complications
760111000000115	Insulin dependent diabetes mellitus with multiple complicat
2618232017	Type 1 diabetes mellitus with multiple complications
2967771016	Type I diabetes mellitus with multiple complications
2623058011	Insulin dependent diabetes mellitus with ulcer
2616612015	Insulin dependent diabetes mellitus with gangrene
9093013	Insulin dependent diabetes mellitus with retinopathy

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
3699407019	Type 1 diabetes mellitus with retinopathy
3699407019	Type I diabetes mellitus with retinopathy
401531012	Insulin dependent diabetes mellitus - poor control
121589010	Insulin dependent diabetes maturity onset
345492010	Insulin dependent diabetes mellitus with mononeuropathy
2618199015	Type 1 diabetes mellitus with mononeuropathy
3697664014	Type I diabetes mellitus with mononeuropathy
82373015	Insulin dependent diabetes mellitus with polyneuropathy
3297342019	Type 1 diabetes mellitus with polyneuropathy
3297390014	Type I diabetes mellitus with polyneuropathy
301016	Insulin dependent diabetes mellitus with nephropathy
2623054013	Type 1 diabetes mellitus with nephropathy
2623054013	Type I diabetes mellitus with nephropathy
73294018	Insulin dependent diabetes mellitus with diabetic cataract
2618234016	Type 1 diabetes mellitus with diabetic cataract
3688521010	Type I diabetes mellitus with diabetic cataract
2618203015	Insulin dependent diab mell with peripheral angiopathy
3315042015	Type 1 diabetes mellitus with peripheral angiopathy
3315042015	Type I diabetes mellitus with peripheral angiopathy
309740011	Insulin dependent diab mell with neuropathic arthropathy
2618208012	Type 2 diabetes mellitus with renal complications
3013392012	Type II diabetes mellitus with renal complications
3698440016	Type 2 diabetes mellitus with ophthalmic complications
3698440016	Type II diabetes mellitus with ophthalmic complications
3695406015	Type 2 diabetes mellitus with neurological complications
3695406015	Type II diabetes mellitus with neurological complications
3699410014	Type 2 diabetes mellitus with retinopathy
3699410014	Type II diabetes mellitus with retinopathy
2618201018	Type 2 diabetes mellitus with mononeuropathy
3697667019	Type II diabetes mellitus with mononeuropathy
3297353013	Type 2 diabetes mellitus with polyneuropathy
3297353013	Type II diabetes mellitus with polyneuropathy
3035432019	Type 2 diabetes mellitus with nephropathy
3013392012	Type II diabetes mellitus with nephropathy
3688522015	Type 2 diabetes mellitus with diabetic cataract
3688522015	Type II diabetes mellitus with diabetic cataract
2967820013	Insulin treated Type 2 diabetes mellitus
2967914011	Type 1 diabetes mellitus with persistent proteinuria
2967914011	Type I diabetes mellitus with persistent proteinuria
1780311019	Type I diabetes mellitus with persistent microalbuminuria
2967817017	Type 1 diabetes mellitus with ketoacidosis
2967817017	Type I diabetes mellitus with ketoacidosis

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
2967758019	Type 1 diabetes mellitus with ketoacidotic coma
2967758019	Type I diabetes mellitus with ketoacidotic coma
2967751013	Type 2 diabetes mellitus with persistent proteinuria
2967751013	Type II diabetes mellitus with persistent proteinuria
2967769016	Type 2 diabetes mellitus with persistent microalbuminuria
2967769016	Type II diabetes mellitus with persistent microalbuminuria
2967754017	Type 2 diabetes mellitus with ketoacidosis
2967754017	Type II diabetes mellitus with ketoacidosis
2618218019	Type 2 diabetes mellitus with ketoacidotic coma
2618218019	Type II diabetes mellitus with ketoacidotic coma
3004434014	Diabetes mellitus in mother complicating childbirth
3004494012	Diabetes mellitus in childbirth
932641000006116	Diabetes with coma
933211000006112	DM + persist microalbuminuria
933221000006116	DM + persistent proteinuria
933231000006118	Hypo states in diabetes
3698521013	Type 1 diabetes mellitus with exudative maculopathy
2618236019	Type I diabetes mellitus with exudative maculopathy
2618237011	Type 2 diabetes mellitus with exudative maculopathy
3698529010	Type II diabetes mellitus with exudative maculopathy
958001000006111	Diabetes, Heart disease and Stroke(DHDS)prevention pilot project
958071000006117	DNA - Diabetes, Heart disease & Stroke prevention pilot project
958321000006115	DHDS pilot project outcome - new diagnosis Diabetes
96244016	Protein-deficient diabetes mellitus
2474729016	DM induced by non-steroid drugs without complication
5649018	Fibrocalculous pancreatopathy
300015	Lipoatrophic diabetes mellitus
9986011	Drug-induced diabetes mellitus

Heart Failure

1165041000000115	Heart failure resolved
329137013	Failure of sterile precautions during heart catheterization
3637539017	Congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischaemic attack score
3637540015	Congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack score
3637564019	CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score
2549208013	Admit heart failure emergency
2774561000000111	Excepted from heart failure quality indicators - service unavailable
2779841000000112	QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
139475013	Heart failure
139475013	Weak heart
139482012	Cardiac failure
141306010	Left ventricular failure
147247018	Chronic congestive heart failure
1484917012	Heart failure follow-up
1484918019	Heart failure annual review
1488591011	Suspected heart failure
1488804017	Heart failure confirmed
492666016	Pulmonary oedema - acute
119456014	Asthma - cardiac
1539381000006117	Heart failure lifestyle plan commenced
1539391000006119	Heart failure information starter pack provided
1539471000006111	Heart failure monitoring - unstable symptoms
1539481000006114	Heart failure monitoring - specialist clinical needs
1539491000006112	Heart failure monitoring - social issues
1539501000006116	Heart failure monitoring - psychological issues
1539511000006118	Heart failure monitoring - multiple readmissions
1539521000006114	Heart failure monitoring - co-medications
1539531000006112	Heart failure monitoring - co-morbidities
1539541000006119	Heart failure monitoring - palliative care
1570021000000117	Excepted heart failure quality indicators: Patient unsuitabl
1570031000000115	Excepted heart failure quality indicators: Informed dissent
2883808011	Heart failure with normal ejection fraction
1713091000000115	HFNEF - heart failure with normal ejection fraction
1693911000000115	Referral to heart failure education group declined
1705341000000110	Discharge from heart failure nurse service
1728531000006116	Heart failure resolved
3011446018	Referral to heart failure exercise programme declined
3011612011	Referral to heart failure exercise programme not indicated
1746171000000119	Has heart failure management plan
1747691000006119	Emergency heart failure admission since last appointment
1765351000000114	Preferred place of care for next exacerbation heart failure
490972013	Right ventricular failure
1822161000006116	Heart failure pathway protocol not followed
1824091000006119	Heart failure clinical pathway protocol followed
18472010	Acute congestive heart failure
1856361000006116	Heart failure monitoring in primary care
1856371000006111	Heart failure monitoring in secondary care
1856381000006114	Heart failure monitoring default
1861731000006114	AURAS-AF - consider the patient to have heart failure
206703015	Right heart failure

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED CT Code	Description
2115781000000114	Heart failure self-management plan review
2117931000000116	Heart failure self-management plan agreed
2122191000000110	Education about deteriorating heart failure
216184014	Congestive heart failure monitoring
216246012	Referral to heart failure clinic
2205951000000117	Heart failure clinical pathway
2227501000000110	Heart failure with preserved ejection fraction
139482012	Cardiac failure NOS
2256811000000114	Referral to rapid access heart failure clinic
2352391000000117	On optimal heart failure therapy
2405871000000117	Heart failure rehabilitation programme not available
251680018	H/O: heart failure
2548316014	Seen by community heart failure nurse
3082850014	Admit heart failure emergency
2549243014	Seen in heart failure clinic
2549697018	Referral to heart failure nurse
2645623019	Heart failure education
2675255018	Congestive heart failure due to valvular disease
299673010	Hypertensive heart and renal disease with renal failure
300179017	Decompensated cardiac failure
300180019	Compensated cardiac failure
300190010	Acute left ventricular failure
300214014	Post cardiac operation heart failure NOS
303361000000111	Referred by heart failure nurse specialist
303441000000116	Discharge from practice nurse heart failure clinic
303861000000118	Did not attend practice nurse heart failure clinic
2451451000000116	Heart failure information given to patient
3011242019	Referral to heart failure exercise programme
1565031000000115	Heart failure monitoring administration
308261000000111	Heart failure review completed
2253411000000117	Heart failure care plan discussed with patient
311561000000117	Referred to heart failure education group
493289014	CHF - Congestive heart failure
329136016	Failure of sterile precautions during heart catheterisation
350484012	Heart failure as a complication of care
3513892012	Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score
129404019	Benign hypertensive heart disease without congestive heart failure
329136016	[X]Failure sterile precautions during heart catheterisation
137848017	Malignant hypertensive heart disease with congestive heart failure
1234906013	HF - Heart failure
141303019	Left heart failure

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
201199018	Left-sided heart failure
139475013	Heart failure NOS
404741000000119	Heart failure 6 month review
1570071000000118	Heart failure monitoring telephone invite
1570041000000112	Heart failure monitoring verbal invite
1569521000000114	Heart failure monitoring first letter
1569731000000119	Heart failure monitoring second letter
1569171000000116	Heart failure monitoring third letter
407181000000116	Did not attend heart failure clinic
1568511000000111	Exception reporting: heart failure quality indicators
411506018	Impaired left ventricular function
453099015	H/O: Heart failure in last year
2986453013	History of heart failure
329187018	Mechanical failure of instrument or apparatus during heart catheterization
490972013	Right ventricular failure
70653017	Congestive cardiac failure
153058012	Biventricular failure
2986867013	History of heart failure in last year
6895651000006113	Emergency hospital admission for heart failure
70653017	Congestive heart failure
329186010	Mechanical failure of apparatus during heart catheterisation
3496968011	Heart failure with preserved ejection fraction
299672017	Hypertensive heart&renal dis wth (congestive) heart failure
3012159015	Referral to heart failure exercise program
3011502011	Referral to heart failure exercise program not indicated
3010562018	Referral to heart failure exercise program declined
3637504017	New York Heart Assoc classification heart failure symptoms
94251011	Acute heart failure

Hyperlipidemia

108541018	Hurler's syndrome
118479017	Lipodystrophy
125668015	Progressive lipodystrophy
405333015	Steatosis
398872012	Hoffa's Disease
1773186016	Familial hypercholesterolaemia
1784926017	Xanthoma tuberosum
192452016	Disorder of cholesterol metabolism
1232722017	Pseudo - Hurler's disease
201018013	Primary familial xanthomatosis
1232722017	Pseudo - Hurler's disease
398869017	Lipoprotein deficiencies

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
503079012	Barraquer - Simons disease
2475993013	Launois-Bensaude's lipomatosis
26026013	Tangier disease
2642990018	Dyslipidaemia
23283015	Hypercholesterolemia
28183014	Fabry's disease
477884017	Fabry's disease
28195014	Anderson-Fabry disease
293259016	Hyperbetalipoproteinaemia
293262018	Hyperlipidaemia, group A
23283015	Other specified pure hypercholesterolaemia
398852019	Pure hypercholesterolaemia NOS
497411018	Hyperlipidaemia NOS
2901227016	High density lipoid deficiency
293307012	Hypo-beta-lipoproteinaemia
398869017	Lipoprotein deficiency NOS
118479017	Lipodystrophy NOS
293327013	Gaucher's disease
398850010	Other disorders of lipid metabolism
1781793014	Lipomatosis NEC
398850010	Other disorder of lipid metabolism NOS
398851014	Disorder of lipid metabolism NOS
296993015	Cerebral lipidoses NOS
296990017	Cerebral degeneration in Gaucher's disease
296991018	Cerebral degeneration in Niemann-Pick disease
297824010	Hereditary retinal dystrophies in lipidoses
67105019	Chronic idiopathic xanthomatosis
92826017	Hyperlipidemia
497409010	HLD - Hyperlipidemia
3517028015	Hyperlipidemia clinical management plan
108538010	L-iduronidase deficiency, Hurler type
108542013	Hurler-Pfaundler syndrome
500081010	Hurler disease MPS type 1H
356800016	Familial combined hyperlipidaemia
356862010	Xanthomatosis, familial
356867016	Polygenic hypercholesterolaemia
356878012	Familial defective apolipoprotein B-100
356884010	Very low density lipoproteinaemia
356886012	Fredrickson type IV lipidaemia
109253010	Pseudo-Hurler disease
1232722017	Pseudo-Hurler's disease
125665017	Barraquer-Simons syndrome

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
12566016	Hollander-Simons syndrome
503079012	Barraquer-Simons disease
136837016	Wolman's disease
136838014	Primary familial xanthomatosis with adrenal calcification
136839018	Familial visceral xanthomatosis
201017015	Wolman xanthomatosis
398851014	Disorders of lipoid metabolism
398852019	Pure hypercholesterolaemia
398855017	Pure hyperglyceridaemia
398856016	Mixed hyperlipidaemia
398868013	Hyperchylomicronaemia
3010913012	Lipidoses
18656011	Lipidoses NOS
293309010	A-beta-lipoproteinaemia
444854010	Hypertriglyceridaemia
475418015	Hypercholesterolaemia
293261013	Hyperlipidemia, group A
293326016	Gaucher's disease
293331019	Gaucher splenomegaly
293334010	Gaucher syndrome
2841929013	Cerebral degeneration in Gaucher disease
477882018	Alpha-galactosidase A deficiency
477882018	Anderson's disease
477882018	Anderson's disease
293309010	Bassen-Kornzweig disease
505109013	Wolman disease
356799015	Familial combined hyperlipidemia
356802012	FCHL - Familial combined hyperlipidemia
356868014	Sporadic hypercholesterolemia
356870017	Polygenic hypercholesterolemia
398865011	Burger - Grute syndrome
2577873013	Cerebral degeneration in lipidoses EC
24174013	Cerebral lipidoses
178620010	Chemically induced lipidosis
398853012	Pure hypercholesterolemia
398854018	Pure hyperglyceridemia
398858015	Multiple-type hyperlipidemia
398859011	Mixed hyperlipidemia
398860018	Hyperchylomicronemia
398861019	Primary hyperchylomicronemia
398863016	Familial hyperchylomicronemia
2901805016	Hoffa disease

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
458872018	Hyperlipidemia risk assessment with New Zealand table
1774472018	Familial hypercholesterolemia
1784011016	Essential familial hypercholesterolemia
477884017	Fabry's disease
1784050017	Remnant hyperlipidemia
1784057019	Familial hypercholesterolemia with hyperlipemia
1773186016	Familial hypercholesterolaemia
2966571013	Cerebral degeneration in lipidoses
1783622013	Low-density-lipoprotein-type (LDL) hyperlipoproteinaemia
1783622013	Low density lipoproteinaemia
131021010	Lipase deficiency
2956035019	Possible familial hypercholesterolemia
293304017	Hypo-alpha-lipoproteinaemia
356890014	Fredrickson type I lipaemia
1783622013	Fredrickson type IIa lipidaemia
356800016	Fredrickson type IIb lipidaemia
1783671015	Fredrickson type III lipidaemia
1216426013	Fredrickson type V lipaemia
1783622013	Fredrickson's hyperlipoproteinaemia, type IIa
405333015	Hepatic familial steatosis
108541018	Hurler's syndrome
881701000006116	Disorders of lipid metabolism
881711000006118	Other lipid metabolism disord.

Hypertension	
1011861000006110	Adverse reaction to Antihypertensive Drugs
1011871000006115	Adverse reaction to Vasodilator Antihypertensive Drugs
1011881000006117	Adverse reaction to Centrally Acting Antihypertensive Drugs
107545013	Hypertensive heart disease
108730018	Malignant hypertensive renal disease
109700019	Benign hypertensive heart AND renal disease
110659019	Malignant hypertensive heart AND renal disease
1179241000000118	Lifestyle advice regarding hypertension
113392018	Benign intracranial hypertension
3512257015	Renal disease due to hypertension
3638556010	Hypertension monitoring declined
264486018	Hypertensive treatm.changed
264485019	Hypertension treatm. started
264487010	Hypertension treatm.stopped
12496011	Hypertensive retinopathy
2779861000000113	QOF (Quality and Outcomes Framework) hypertension quality indicator-related care invitation

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
1479581000000112	Adverse reaction to other antihypertensives
1479611000000118	Adverse reaction to antihypertensives NOS
131046010	Malignant essential hypertension
132655012	Chronic cor pulmonale
1569851000000118	Exception reporting: hypertension quality indicators
1409014	Benign hypertensive renal disease
143003017	Hypertensive heart AND renal disease
145620019	Chronic pulmonary heart disease
146259010	Secondary pulmonary hypertension
1484957010	DNA - Did not attend hypertension clinic
1488750011	Hypertension monitoring not required
147988014	Secondary malignant hypertension
1529013	Blind hypertensive eye
285265015	Seen in hypertension clinic
53452019	Secondary hypertension NOS
1566291000000115	Hypertension screen admin.
1566291000000115	Hypertension screen admin. NOS
1564881000000111	Hypertens.monitoring admin.NOS
265322010	Risk factors present at hypertension screen
3637565018	Cong heart fail, hypertens, age, diab, stroke 2 risk score
1706551000000114	Hypertension 9 month review
1749291000006113	Thromboembolic pulmonary hypertension
1780252014	Hypertension treatment refused
1780253016	Hypertension six month review
1780318013	Moderate hypertension control
1780319017	Hypertension annual review
1806071000006118	Stage 1 hypertension
1806081000006115	Stage 2 hypertension
1806141000006113	Severe hypertension
1823901000006112	Hypertension confirmed
2189411000000111	Stage 1 hypertension (NICE - Nat Ins for Hth Clin Excl 2011)
2189451000000110	Severe hypertension (Nat Inst for Health Clinical Ex 2011)
2194941000000119	Stage 2 hypertension (NICE - Nat Ins for Hth Clin Excl 2011)
1855781000006115	Hypertension monitoring in primary care
1855791000006117	Hypertension monitoring in secondary care
1858771000006114	AURAS-AF - consider the patient to have hypertension
1858801000006111	AURAS-AF - more time needed to decide on hypertension status
1877391000006112	Hypertension clinical management plan no longer in place
2335801000000114	Stage 1 hyperten (NICE 2011) with evidence end organ damage
3303627011	Provision of written information about diabetes & hypertension
1992471000006116	VTE risk assessment - uncontrolled systolic hypertension
2011000033113	Antihypertensive Drugs

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
2115801000000110	Hypertension self-management plan review
2117971000000119	Hypertension self-management plan agreed
2159168015	Patient on maximal tolerated antihypertensive therapy
1564881000000111	Hypertension monitoring admin.
2193021000000110	Severe hypertension
2193031000000112	Stage 1 hypertension
2193971000000110	Hypertension resistant to drug therapy
2297871000000111	Pulmonary arterial hypertension drugs Band 1
2297911000000113	Pulmonary arterial hypertension drugs Band 2
2297951000000112	Pulmonary arterial hypertension drugs Band 3
2297991000000116	Pulmonary arterial hypertension drugs Band 4
3302075013	Telehealth hypertension monitoring
3517026016	Hypertension clinical management plan
2478822013	Secondary benign renovascular hypertension
251674014	H/O: hypertension
253532015	Hypertension resolved
2548266018	Suspected hypertension
499131018	Cirrhosis-familial with pulmonary hypertension
1564901000000114	Hypertension clinic admin.
262960017	Hypertension induced by oral contraceptive pill
264471012	Good hypertension control
264472017	Poor hypertension control
264473010	Hypertension:follow-up default
2694699015	Hypertension treatm. started
2871342011	Hypertensive treatm.changed
2691941019	Hypertension treatm.stopped
2645973019	Chronic peripheral venous hypertension
19722017	Pulmonary hypertensive arterial disease
19723010	Hypertensive pulmonary arterial disease
28311000033116	Vasodilator Antihypertensive Drugs
284062018	Referral to hypertension clinic
28411000033112	Centrally Acting Antihypertensive Drugs
285265015	Seen in hypertension clinic
90135019	Malignant hypertensive heart disease NOS
60444016	Benign hypertensive heart disease NOS
107545013	Hypertensive heart disease NOS
81984019	Hypertensive renal disease with renal failure
299673010	Hypertensive heart and renal disease with renal failure
143003017	Hypertensive heart and renal disease NOS
299676019	Secondary malignant renovascular hypertension
147988014	Secondary malignant hypertension NOS
299678018	Secondary benign hypertension

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
2470031013	Secondary benign hypertension NOS
299681011	Hypertension secondary to endocrine disorders
53452019	Secondary hypertension NOS
192288012	Secondary renovascular hypertension NOS
299684015	Hypertension secondary to drug
1215744012	Other specified hypertensive disease
1215744012	Hypertensive disease NOS
145620019	Other chronic pulmonary heart disease
145620019	Other chronic pulmonary heart disease NOS
1215744012	[X]Hypertensive diseases
53452019	[X]Other secondary hypertension
53452019	[X]Hypertension secondary to other renal disorders
1228208015	PHT - Portal hypertension
64172013	High blood pressure
64173015	Hypertensive vascular disease
64174014	Hypertensive vascular degeneration
490277011	BP - High blood pressure
490278018	Systemic arterial hypertension
490280012	HBP - High blood pressure
490281011	HT - Hypertension
490282016	High blood pressure disorder
490283014	BP+ - Hypertension
2164904016	HTN - Hypertension
2671386015	Hypertensive disorder, systemic arterial
64285018	Hypertensive nephropathy
3135013	Benign essential hypertension
81984019	Hypertensive renal failure
433712011	Adverse reaction to other antihypertensives
433712011	Adverse reaction to antihypertensives NOS
99044013	Idiopathic hypertension
99046010	Systemic primary arterial hypertension
350517010	Thromboembolic pulmonary hypertension
350601000000116	High cost hypertension drugs
350591000000110	High cost hypertension drugs NOS
350591000000110	Other specified high cost hypertension drugs
351381000000114	Primary pulmonary hypertension drugs Band 1
3513892012	Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score
351401000000114	Primary pulmonary hypertension drugs Band 2
351421000000117	Primary pulmonary hypertension drugs Band 3
351441000000112	Primary pulmonary hypertension drugs Band 4
433712011	[X] Adverse reaction to antihypertensives NOS

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
107547017	Hypertensive cardiopathy
107548010	Hypertensive cardiomegaly
107549019	Hypertensive cardiovascular disease
499930018	HHD - Hypertensive heart disease
433712011	[X] Adverse reaction to other antihypertensives
1233029012	BIH - Benign intracranial hypertension
1233030019	IIH - Idiopathic intracranial hypertension
1233031015	Idiopathic intracranial hypertension
116721012	Malignant hypertension
117919017	Pulmonary hypertension
1233340012	PHT - Pulmonary hypertension
121910014	Benign secondary renovascular hypertension
503982017	Accelerated essential hypertension
137848017	Malignant hypertensive heart disease with congestive heart failure
508416019	Accelerated secondary hypertension
99042012	Essential hypertension NOS
64282015	Hypertensive renal disease NOS
145620019	Chronic pulmonary heart disease NOS
405053013	Hypertension monitored
411508017	Cardiomegaly - hypertensive
411919011	Hypertension monitoring
1220673019	Hypertension due to renovascular disease
473052014	Hypertensive congenital adrenal hyperplasia
2968228010	Primary pulmonary hypertension
443764015	On treatment for hypertension
451424017	Antihypertensive therapy
2987063016	History of hypertension
2667434017	On examination - blood pressure reading very high
3290297011	Hypertension caused by oral contraceptive pill
4634851000006119	Treatment for hypertension started
4634871000006112	Hypertensive treatment changed
4634891000006113	Treatment for hypertension stopped
64282015	Renal hypertension
285723013	Hypertension monitoring deleted
2470030014	Malignant secondary renovascular hypertension
2532161014	Hypertension secondary to endocrine disorder
3290640017	Hypertension caused by drug
285715011	Attends hypertension monitor.
299653017	Benign hypertensive heart disease with CCF
2968345015	Chronic thromboembolic pulmonary hypertension
64168014	BP - hypertensive disease
530161000000111	Trial reduction of antihypertensive therapy

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
530221000000112	Trial withdrawal of antihypertensive therapy
53452019	Secondary hypertension
535591000000118	Trial withdrawal of antihypertensive therapy declined
535651000000113	Trial reduction of antihypertensive therapy declined
64282015	Nephrosclerosis
57989014	Portal hypertension
60444016	Benign hypertensive heart disease
64168014	Hypertensive disease
196353013	High blood pressure
64282015	Hypertensive renal disease
2470344013	Did not attend hypertension clinic
2842455015	Lifestyle education regarding hypertension
1236017010	Malignant hypertensive heart disease with CCF
107545013	Hypertensive heart disease NOS
107545013	Hypertensive heart disease NOS with CCF
299672017	Hypertensive heart&renal dis wth (congestive) heart failure
2968361018	Labile hypertension due to being in a clinical environment
2651741000000110	HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile international normalised ratio, elderly over 65, and drugs and/or alcohol concomitantly) bleeding risk score
3011808015	Hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalised ratio, elderly over 65, and drugs/alcohol concomitantly bleeding risk score
7587431000006113	Hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly over 65, and drugs/alcohol concomitantly bleeding risk score
76126013	Kyphoscoliotic heart disease
299674016	Hyperten heart&renal dis+both(congestv)heart and renal fail
285719017	Hypertens.monitor 2nd letter
285720011	Hypertens.monitor 3rd letter
285723013	Hypertens.monitor deleted
285722015	Hypertens.monitor phone invite
285721010	Hypertens.monitor verbal inv.
285718013	Hypertens.monitor.1st letter
790031000006119	Hypertension annual review
405052015	Hypertension monitor.chck done
411919011	Hypertension monitoring
64176011	Hypertension NOS
253532015	Hypertension resolved
265318017	Hypertension screen
80224019	Diastolic hypertension
1217317016	HELLP - Syndrome haemolysis, elev liver enzyme low platelets

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
2194001000000116	Resistant hypertension
2211211000000110	Stage 2 hypertension
84111015	Hypertensive encephalopathy
84111015	Hypertensive crisis
856971000006112	Hypertensive clinic
884121000006111	Malignant hypertension
884131000006114	Hypertensive renal + heart dis
884191000006113	Chronic pulmonary heart dis.
884201000006111	Pulmonary heart disease NOS
884211000006114	Other pulmonary heart disease
90135019	Malignant hypertensive heart disease
905451000006118	[RFC] Pulmonary embolism/pulmonary hypertension
909441000006118	[RFC] Hypertension
1569371000000118	Excepted from hypertension qual indicators: Patient unsuit
1569321000000117	Excepted from hypertension qual indicators: Informed dissent
93494011	Systolic hypertension
2956303010	Hypertension medication review
99042012	Essential hypertension
99047018	Primary hypertension

Myocardial Infarction	
500341014	Postmyocardial infarction syndrome
116992017	Acute subendocardial infarction
299808017	Subsequent myocardial infarction of unspecified site
1218860015	Acute papillary muscle infarction
3673281015	Hemopericardium due to and following acute myocardial infarction
3673282010	Haemopericardium due to and following acute myocardial infarction
3673273016	Atrial septal defect due to and following acute myocardial infarction
3673278013	Rupture of chordae tendinae due to and following acute myocardial infarction
3673277015	Thrombosis of atrium, auricular appendage, and ventricle due to and following acute myocardial infarction
3673284011	Cardiac rupture due to and following acute myocardial infarction
1229885017	Microinfarction of heart
1234005010	Acute inferoposterior infarction
1234306015	Acute septal infarction
1235655012	Mural thrombosis
1576271000006117	Cause of Death- Myocardial Infarction
1576301000006115	Cause of Death- Acute Myocardial Infarction
2986492018	History of myocardial infarction
1570081000000116	Exception reporting: myocardial infarction quality indicator
1780491019	Acute ST segment elevation myocardial infarction

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
1780501013	Acute non-ST segment elevation myocardial infarction
1786198013	Thrombosis - coronary
208365015	Postoperative myocardial infarction
455418016	Postoperative transmural myocardial infarction anterior wall
455419012	Postoperative transmural myocardial infarction inferior wall
208365015	Postoperative transmural myocardial infarction other sites
208365015	Postoperative transmural myocardial infarction unspec site
37443015	Attack - heart
94884017	MI - acute myocardial infarction
2986492018	Personal history of myocardial infarction
256452010	ECG: myocardial infarction
256454011	ECG: old myocardial infarction
2619484018	MI - Myocardial infarction aborted
37436014	Myocardial infarction
37441018	Infarction of heart
1784872019	MI - Myocardial infarction
1231324017	Other specified anterior myocardial infarction
3038718019	Acute anteroapical infarction
1231324017	Anterior myocardial infarction NOS
350371016	Posterior myocardial infarction NOS
1231860015	Lateral myocardial infarction NOS
299712015	True posterior myocardial infarction
122557015	Inferior myocardial infarction NOS
94884017	Other acute myocardial infarction
299719012	Acute atrial infarction
94884017	Other acute myocardial infarction NOS
94884017	Acute myocardial infarction NOS
299808017	Subsequent myocardial infarction
299811016	Subsequent myocardial infarction of anterior wall
299812011	Subsequent myocardial infarction of inferior wall
299808017	Subsequent myocardial infarction of other sites
299808017	[X]Subsequent myocardial infarction of other sites
299808017	[X]Subsequent myocardial infarction of unspecified site
70952012	Microinfarct of heart
86618010	Acute anteroapical myocardial infarction
90302019	Acute myocardial infarction of anterior wall
1231678011	AMI - Acute myocardial infarction
97399018	Acute myocardial infarction of lateral wall
350376014	Silent myocardial infarction
108912018	Acute myocardial infarction of inferolateral wall
109915012	Postmyocardial infarction syndrome
109917016	Postmyocardial infarction pericarditis

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED CT Code	Description
94884017	[X]Acute transmural myocardial infarction of unspecif site
116613011	Acute myocardial infarction of anterolateral wall
122559017	Acute myocardial infarction of diaphragmatic wall
1233665015	Acute inferior myocardial infarction
37443015	Heart attack
127193015	Acute myocardial infarction of inferoposterior wall
131106018	Acute myocardial infarction of septum
131107010	Acute myocardial infarction of septum alone
4031011	Old myocardial infarction
4032016	Healed myocardial infarction
447324018	Acute Q-wave infarct
450322013	Acute non-Q wave infarction
451369010	H/O: Myocardial infarction in last year
455422014	Postoperative subendocardial myocardial infarction
208365015	Postoperative myocardial infarction, unspecified
1233238016	Acute anterolateral infarction
104192010	Acute anteroseptal infarction
1232697013	Acute inferolateral infarction
3300376010	Electrocardiographic myocardial infarction
3300377018	EKG: myocardial infarction
3300311011	EKG: old myocardial infarction
3300312016	Electrocardiographic old myocardial infarction
94884017	Acute transmural myocardial infarction of unspecif site
265592018	[V]Observation for suspected myocardial infarction
2470032018	Acute myocardial infarction of atrium
2619483012	Aborted myocardial infarction
299817017	Hemopericardium as current complication following acute myocardial infarction
299820013	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction
350377017	MI - Silent myocardial infarction
3333538017	Defect of ventricular septum following myocardial infarction
350432018	Pericarditis following myocardial infarction
350383019	Cardiac rupture following myocardial infarction (MI)
447323012	Acute Q wave myocardial infarction
2986726013	History of myocardial infarction in last year
459792010	DIGAMI - diabetes mellitus insulin-glucose infusion in acute myocardial infarction
6348651000006112	Myocardial infarction with complication
1786753012	Past history of myocardial infarction
545891000000115	Previous myocardial infarction
2840840013	STEMI - ST elevation myocardial infarction

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
2619484018	Myocardial infarction aborted
884151000006119	Myocardial Infarction
905351000006113	[RFC] Myocardial infarction (MI)
932081000006118	First myocardial infarction
94884017	Acute myocardial infarction
27071012	Acute posterolateral myocardial infarction

Renal Disorders	
1569431000000110	Exc chronic kidney disease quality indicators: Inform dissen
102173012	Acute nephritis
108730018	Malignant hypertensive renal disease
109700019	Benign hypertensive heart AND renal disease
110356018	Amyloid nephropathy of Ostertag
110659019	Malignant hypertensive heart AND renal disease
114310015	Lupus nephritis
3082872011	Ischaemic nephropathy
3512257015	Renal disease due to hypertension
11924551000006114	End-stage renal disease
3657946010	ADPKD - autosomal dominant polycystic kidney disease
1221119015	ARF - Acute renal failure
3688487013	Disorder of kidney co-occurrent and due to diabetes mellitus
12218511000006112	Kidney disorder due to diabetes mellitus
1225985011	AIN - Acute interstitial nephritis
1225986012	ATIN - Acute tubulo-interstitial nephritis
1225987015	Acute tubulo-interstitial nephritis
1226060014	Autosomal recessive polycystic kidney disease
1227469014	Hydroureter - congenital
1227911011	Acute drug-induced interstitial nephritis
1230030015	Chronic lithium nephrotoxicity
1230211012	Renal artery atherosclerosis
1230447010	Acute idiopathic interstitial nephritis
1232869016	Acute infective interstitial nephritis
3491804010	Classic distal renal tubular acidosis
12481351000006114	[X]Unspecified nephritic syndrome, dense deposit disease
830021000006113	Hydronephrosis with renal and ureteral calculous obstruction
2220291000000118	eGFR (estimated glomerular filtration rate) using CKD-Epi (Chronic Kidney Disease Epidemiology Collaboration) formula per 1.73 square metres
424761000006119	[X]Renal tubulo-interstitial diseases
3517959016	End-stage renal disease
303862010	Chronic mesangial proliferative glomerulonephritis
354331019	Steroid sensitive nephrotic syndrome
408661000000117	Predicted stage chronic kidney disease

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
303806010	Nephritis, nephrosis and nephrotic syndrome
1370001000000111	Kidney and ureter disease NOS
505127011	Congenital cystic kidney disease
13777018	Radiation nephritis
1409014	Benign hypertensive renal disease
143003017	Hypertensive heart AND renal disease
4074014	Renotubular acidaemia
151534010	Secondary hyperparathyroidism
1591611000006114	Did not attend chronic kidney disease monitoring clinic
303981015	Rpd prog neph syn df mesangial proliferatv glomerulonephritis
170418016	Acquired renal cystic disease
2694055011	Acute renal failure due to urinary obstruction
1757951000006119	Ischaemic nephropathy
304041015	Ren tub-interst disordr/blood dis+disordr inv immune mech
304043017	Ren tub-interstitl disordr/systemic connectv tiss disorder
48036015	Ren tubulo-interstitial disord infect and parasitic dis EC
1770901000006119	Chronic kidney disease diagnosis reviewed
4074014	Renal tubular acidaemia
451122013	Renal tubulo-interstitial disorder in SLE
304040019	Renal tubulo-interstitial disorder/ neoplastic diseases
48036015	Renal tubulo-interstitial disorders in diseases EC
304045012	Renal tubulo-interstitial disorders in transplant rejectn
1229860014	Kidney failure unspecified
1823941000006114	Chronic kidney disease confirmed
1824651000006118	QKidney chronic kidney disease 5 year risk score
1825111000006112	Chronic kidney disease diagnosis discussed with patient
3300550011	Recurrent+persistnt haematuria minor glomerular abnormality
2200341000000110	QKidney disease risk calculator
477144012	Amyloid nephropathy with deafness and urticaria
354342011	Wilms' tumour + nephrotic syndrome + pseudohermaphroditism
2180941000000110	Acute renal failure induced by non-steroid anti-inflamm drug
4074014	Type III renal tubular acidosis
4074014	Mixed renal tubular acidosis
354487011	Inherited renal tubule insuffic with cholestatic jaundice
1850891000006119	Reason for influenza vaccine - chronic kidney disease
1856481000006117	Chronic kidney disease follow-up
3300526014	Recur+persist haematuria difus crescentic glomerulonephritis
3300544018	Recur+persist haematuria difus membranous glomerulonephritis
3300562010	Recur+persist haematuria, focal+segmental glomerular lesions
3300532016	Recur+persist haemuria df endocaply proliferatv glomeruloneph
3300556017	Recur+persist haemuria df mesangial prolifer glomerulonephritis
3300538017	Recur+persist hmuria df mesangiocapillary glomerulonephritis

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
303983017	Rapid prog neph syn df mesangiocapillary glomerulonephritis
303982010	Rapid progres neph syn df endocapillary prolifv glomnephritis
303980019	Rapid progres neph syn diffuse membranous glomerulonephritis
303978013	Rapid progres neph syndrome, minor glomerular abnormality
303985012	Rapid progres nephritic syn df crescentic glomerulonephritis
303979017	Rapid progres nephritic syn focal+segmental glomerulr lesion
303984011	Rapid progressive nephritic syndrome, dense deposit disease
1920821000006112	Hered angiopathy with nephropathy, aneurysms + muscle cramp synd
1932031000006119	3D study - problems with chronic kidney disease management
2002941000006114	Chronic kidney disease monthly review
2002951000006111	Chronic kidney disease 2 monthly review
2002961000006113	Chronic kidney disease 3 monthly review
2002971000006118	Chronic kidney disease 4 monthly review
2002981000006115	Chronic kidney disease six monthly review
205225016	Diabetic nephropathy
2115881000000117	Chronic kidney disease self-management plan review
2117811000000117	Chronic kidney disease self-management plan agreed
2149391000000115	Acute nephropathy induced by heavy metals
76995019	End stage renal failure
2180741000000113	Acute renal failure induced by aminoglycoside
2180861000000117	Acute renal failure induced by cisplatin
2180901000000112	Acute renal failure induced by cyclosporin A
2184271000000115	Acute renal failure due to non-traumatic rhabdomyolysis
2185551000000111	Acute renal failure induced by animal toxin
2185591000000115	Acute renal failure induced by plant toxin
2185631000000115	Acute renal failure induced by heavy metal
2191151000000117	Acute renal failure induced by poison
2191301000000116	Acute renal failure induced by radiographic contrast media
2191381000000114	Acute renal failure induced by solvent
2198081000000118	Acute renal failure due to traumatic rhabdomyolysis
2204191000000110	Acute kidney injury
2206791000000119	Acute kidney injury stage 1
2206811000000118	Acute kidney injury stage 2
2206831000000114	Acute kidney injury stage 3
2214211000000112	Acute renal failure induced by toxin
2214231000000116	Acute uric acid nephropathy
2323001000000115	Chronic kidney disease laboratory study
23676016	Sickle cell nephropathy
487930011	Haemorrhagic nephrosonephritis
12812019	Other obstructive and reflux uropathy
251763010	H/O: nephritis
7243014	Diffuse endocapillary proliferative glomerulonephritis

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
7689013	Lithium nephropathy
12995019	Hepatorenal glycogen storage disease
2645796013	Acute renal failure due to ACE inhibitor
12812019	Obstructive and reflux uropathy, unspecified
25678018	Familial amyloid nephropathy with urticaria AND deafness
206986018	Other kidney and ureteric disorders
1221328013	Primary hydronephrosis
27586014	Congenital hydronephrosis
477916012	Renal bone disease
477917015	ROD - Renal osteodystrophy
2767154014	Chronic kidney disease stage 5
2767383018	Chronic kidney disease stage 1
2767384012	Chronic kidney disease stage 2
2767385013	Chronic kidney disease stage 4
477998012	Vascular disorder of kidney
3036750018	Chronic kidney disease
2773184015	Chronic kidney disease stage 3
3035432019	Non-insulin dependent diabetes mellitus with nephropathy
195975011	Acute exudative glomerulonephritis
28321015	Renal osteodystrophy
28322010	Renal rickets
1222585013	CGN - Chronic glomerulonephritis
3320160019	Tuberculous nephropathy
287143014	Plasmodium malariae malaria with nephropathy
301016	Diabetes mellitus with nephropathy NOS
293394013	Gouty nephropathy
293393019	Gouty nephropathy unspecified
293393019	Gouty nephropathy NOS
48040012	Tubulointerstitial nephropathy
2961101000006113	Renal tubulo-interstitial disease
48176011	Polycystic kidney disease, infantile type
48177019	Autosomal recessive infantile polycystic kidney disease
1226061013	Infantile polycystic kidney disease
1226062018	ARPKD - Autosomal recessive polycystic kidney disease
1226063011	IPKD - Infantile polycystic kidney disease
81984019	Hypertensive renal disease with renal failure
299673010	Hypertensive heart and renal disease with renal failure
143003017	Hypertensive heart and renal disease NOS
52329010	Congenital hydroureter
53631019	Acute drug-induced tubulointerstitial nephritis
53632014	Acute tubulointerstitial nephritis due to hypersensitivity to drugs
303806010	Nephritis, nephrosis and nephrotic syndrome

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
303812017	Acute proliferative glomerulonephritis
303814016	Acute nephritis with lesions of necrotising glomerulitis
32619017	Other acute glomerulonephritis
303816019	Acute glomerulonephritis in diseases EC
303817011	Acute exudative nephritis
303818018	Acute focal nephritis
303819014	Acute diffuse nephritis
32619017	Other acute glomerulonephritis NOS
32619017	Acute glomerulonephritis NOS
303825013	Nephrotic syndrome with proliferative glomerulonephritis
303826014	Nephrotic syndrome with membranous glomerulonephritis
303832016	Nephrotic syndrome, minor glomerular abnormality
303833014	Nephrotic syndrome, focal and segmental glomerular lesions
303834015	Nephrotic syndrome, diffuse membranous glomerulonephritis
303838017	Nephrotic syndrome, dense deposit disease
303839013	Nephrotic syndrome, diffuse crescentic glomerulonephritis
303842019	Congenital Finnish nephrosis
81307015	Congenital nephrotic syndrome NOS
303844018	Nephrotic syndrome in diseases EC
303845017	Nephrotic syndrome in amyloidosis
303846016	Nephrotic syndrome in diabetes mellitus
303847013	Kimmelstiel - Wilson disease
303848015	Nephrotic syndrome in malaria
303849011	Nephrotic syndrome in polyarteritis nodosa
2575708013	Nephrotic syndrome in diseases EC NOS
86957016	Nephrotic syndrome with other pathological kidney lesions
86957016	Nephrotic syndrome NOS
354352010	Chronic rapidly progressive glomerulonephritis
35171019	Other chronic glomerulonephritis
303866013	Chronic exudative glomerulonephritis
303867016	Chronic focal glomerulonephritis
303868014	Chronic diffuse glomerulonephritis
35171019	Other chronic glomerulonephritis NOS
35171019	Chronic glomerulonephritis NOS
87940013	Proliferative nephritis unspecified
128137019	Membranous nephritis unspecified
87940013	Membranoproliferative nephritis unspecified
303877019	Focal membranoproliferative glomerulonephritis
303881019	Anaphylactoid glomerulonephritis
1778791010	Other familial glomerulonephritis
303884010	Berger's IgA or IgG nephropathy
354352010	Rapidly progressive nephritis unspecified

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
2692740012	Renal cortical necrosis unspecified
354421010	Renal medullary necrosis unspecified
150315015	Other nephritis and nephrosis unspecified
150315015	Other nephritis and nephrosis in diseases EC
3013482017	Other exudative nephritis
48036015	Other interstitial nephritis
150315015	Other nephritis and nephrosis NOS
60355017	Unspecified glomerulonephritis NOS
2920634011	Other acute renal failure
2920634011	Acute renal failure NOS
303938018	Renal sclerosis unspecified
303935015	Atrophy of kidney
303937011	Renal fibrosis
303938018	Glomerulosclerosis
303938018	Renal sclerosis NOS
303943013	Impaired renal function disorder
303944019	Phosphate-losing tubular disorders
28321015	Renal infantilism
28321015	Renal osteodystrophy NOS
303943013	Other impaired renal function disorder
3491803016	Albright's renal tubular acidosis
303951011	Renal function impairment with growth failure
303943013	Impaired renal function disorder NOS
303967017	Glomerular disease
303969019	Acute nephritic syndrome, minor glomerular abnormality
303975011	Acute nephritic syndrome, dense deposit disease
303977015	Rapidly progressive nephritic syndrome
304004016	Chronic nephritic syndrome
304005015	Chronic nephritic syndrome, minor glomerular abnormality
304011017	Chronic nephritic syndrome, dense deposit disease
304013019	Isolated proteinuria with specified morphological lesion
354545012	Hereditary nephropathy not elsewhere classified
2767383018	Chronic kidney disease stage 1
304036011	Glomerular disorders in neoplastic diseases
304042010	Renal tubulo-interstitial disorders in metabolic diseases
2767384012	Chronic kidney disease stage 2
304053016	Nephropathy induced by heavy metals
354531018	Toxic nephropathy, not elsewhere classified
150315015	Other specified nephritis, nephrosis or nephrotic syndrome
150315015	Nephritis, nephrosis and nephrotic syndrome NOS
2773184015	Chronic kidney disease stage 3
2767385013	Chronic kidney disease stage 4

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
3520573015	Hydronephrosis with renal and ureteral calculous obstruction
71850014	Hydronephrosis NOS
2767154014	Chronic kidney disease stage 5
2841622019	Kidney and ureter disease NOS
303967017	[X]Rapidly progressive nephritic syndrome, other
891521000000111	[X]Unspecified nephritic syndrome, dense deposit disease
101225013	[X]Other chronic tubulo-interstitial nephritis
71850014	[X]Other and unspecified hydronephrosis
12812019	[X]Other obstructive and reflux uropathy
12812019	[X]Obstructive and reflux uropathy, unspecified
48036015	[X]Other specified renal tubulo-interstitial diseases
71850014	[X]Hydronephrosis with ureteral stricture NEC
2841622019	[X]Other disorders of kidney and ureter
2841622019	[X]Other specified disorders of kidney and ureter
1228363011	GN - Glomerulonephritis
64285018	Hypertensive nephropathy
136885015	Other specified congenital cystic kidney disease
136885015	Other congenital cystic kidney disease NOS
136885015	Congenital cystic kidney disease NOS
3037469017	[X]Other cystic kidney diseases
1230130017	MCGN - Minimal change glomerulonephritis
1230131018	Minimal change nephrotic syndrome
1230132013	Idiopathic nephrotic syndrome
1230133015	Minimal change nephropathy
1230134014	Light negative glomerulonephritis
1230135010	Minimal change glomerulonephritis
1230136011	MCNS - Minimal change nephrotic syndrome
1230137019	MCN - Minimal change nephropathy
75487016	Atherosclerosis of renal artery
2923323018	Atherosclerosis renal artery
76996018	End stage kidney disease
1230316017	ESRD - End stage renal disease
324973015	Kidney transplant failure and rejection
32619017	Acute glomerulonephritis
78912011	Idiopathic acute interstitial nephritis
81162018	Amyloid nephropathy
81308013	Familial nephrotic syndrome
84263015	Hemorrhagic pneumonia AND glomerulonephritis
84266011	Lung purpura with nephritis syndrome
84267019	Pulmonary hemorrhage with glomerulonephritis
84269016	Pulmonary hemosiderosis with glomerulonephritis
84270015	Anti-GBM nephritis with pulmonary hemorrhage

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
495714011	Pulmonary haemorrhage with glomerulonephritis
495715012	Pulmonary haemosiderosis with glomerulonephritis
495716013	Haemorrhagic pneumonia AND glomerulonephritis
495717016	Anti-GBM nephritis with pulmonary haemorrhage
1231098019	NS - Nephrotic syndrome
91212019	Hypokalemic nephropathy
101225013	Chronic interstitial nephritis
101230012	Chronic tubulointerstitial nephritis
1232149011	CTIN - Chronic tubulo-interstitial nephritis
1232150011	Chronic tubulo-interstitial nephritis
1232151010	CIN - Chronic interstitial nephritis
35171019	Chronic glomerulonephritis
11668001000006115	Hydronephrosis co-occurrent and due to calculus of kidney and ureter
3520574014	Hydronephrosis with renal and ureteral calculus
3528309015	MCKD - Multicystic kidney disease
150315015	Other kidney disorders
354318012	Renal acidaemia
150322011	Nephropathy, unspecified
354324018	Chronic infective interstitial nephritis
354340015	Congenital nephrotic syndrome with focal glomerulosclerosis
354341016	Nephrotic syndrome with pseudohermaphroditism
354343018	Drash syndrome
87940013	Mixed membranous and proliferative glomerulonephritis NEC
303860019	Mesangioproliferative glomerulonephritis NEC
87940013	Lobular glomerulonephritis NEC
303860019	Hypocomplementaemic persistent glomerulonephritis NEC
354352010	Rapidly progressive glomerulonephritis
354363013	Crescentic glomerulonephritis
354364019	CGN - Crescentic glomerulonephritis
354379014	IgA nephropathy
133280014	Mesangiocapillary glomerulonephritis NEC
354399015	Thin basement membrane disease
354406016	Renal impairment
354407013	Impaired renal function
354413016	Acute drug-induced renal failure
354417015	Acute-on-chronic renal failure
106739010	Diffuse crescentic glomerulonephritis
354441017	Chronic interstitial nephritis due to heavy metals
354442012	Chronic lead nephropathy
354443019	Saturnine nephropathy
354444013	Chronic cadmium nephropathy
354445014	Chronic mercury nephropathy

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
354451016	Distal renal tubular acidosis
354457017	Type IV renal tubular acidosis
354458010	Hyperkalaemic renal tubular acidosis
354470014	Specific renal tubule transport defect
354480013	Familial renal hypouricaemia
354485015	Acquired magnesium-losing nephropathy
354486019	Renal tubule insufficiency with biliary malformation
354501012	Urate nephropathy
354502017	Uric acid nephropathy
354503010	Acute urate nephropathy
354505015	Renal disorders in systemic disease
354508018	Clinical diabetic nephropathy
354509014	Proteinuric diabetic nephropathy
354512012	Renal involvement in scleroderma
354513019	Acute scleroderma renal crisis
354514013	Henoch-Schonlein nephritis
354516010	Cryoglobulinaemic glomerulonephritis
354521013	Renal involvement in malignant disease
354534014	Acute lead nephropathy
354535010	Acute cadmium nephropathy
354536011	Acute mercury nephropathy
354537019	Chronic drug-induced renal disease
354543017	Acute radiation nephritis
354544011	Chronic radiation nephritis
354547016	Diffuse mesangial sclerosis with ocular abnormalities
354552014	Renal tubular acidosis with progressive nerve deafness
354621016	Chronic transplant nephropathy
354632016	De novo glomerulonephritis
354636018	Cytomegalovirus-induced glomerulonephritis
356099014	Photomyoclonus, diabetes mellitus, deafness, nephropathy and cerebral dysfunction
111280012	Acute infectious tubulointerstitial nephritis
114307010	SLE glomerulonephritis syndrome
2621068010	Systemic lupus erythematosus glomerulonephritis syndrome
1234073016	MGN - Membranous glomerulonephritis
354423013	Cystic kidney disease NEC
200856017	Lobular glomerulonephritis
504397015	MCGN - Mesangiocapillary glomerulonephritis
504398013	MPGN - Membranoproliferative glomerulonephritis
136888018	Congenital polycystic kidney disease
505125015	PKD - Polycystic kidney disease
505129014	PCK - Polycystic kidney disease

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
303967017	[X]Hereditary nephropathy, unspecif morphological changes
354545012	[X]Heredtry nephrpthy NEC difus mesangiocapilry glomneph
143006013	Cardiorenal disease
64282015	Hypertensive renal disease NOS
396706011	Nephrotic syndrome with minimal change glomerulonephritis
87940013	Nephritis and nephropathy unspecified
1229860014	Renal failure unspecified
303943013	Other impaired renal function disorder NOS
206986018	Other kidney and ureter disorders
2841622019	Other kidney and ureteric disorders NOS
150323018	Renal disease
201547011	Disease of kidney
1235600014	Disorder of kidney
48036015	[X]Nephropathy induced by other drugs+biological substances
505126019	Polycystic kidney disease NOS
400871016	Fibrocystic kidney disease
403110014	Kidney failure as a complication of care
2841622019	[X]Oth disorders/kidney+ureter/infests+parasitic diseases CE
405116017	Acute renal medullary necrosis
405115018	Acute necrotising papillitis
1565051000000110	Chronic kidney disease monitoring administration
4074014	Renal tubular acidosis
407481000000111	Chronic kidney disease monitoring
1569201000000115	Chronic kidney disease monitoring first letter
1570281000000111	Chronic kidney disease monitoring second letter
1570001000000114	Chronic kidney disease monitoring third letter
1570441000000116	Chronic kidney disease monitoring verbal invite
1570451000000118	Chronic kidney disease monitoring telephone invite
408381000000119	Chronic kidney disease annual review
408661000000117	Predicted stage chronic kidney disease
2841622019	[X]Other disorders of kidney+ureter in other diseases CE
354421010	[X]Other disorders resulting/impaired renal tubular function
411547015	H/O: kidney disease
41542016	Proximal renal tubular acidosis
483950014	[X]Renal tubulo-interstitial diseases
48036015	[X]Renal tubulo-interstitial disorders in other diseases CE
48036015	[X]Renal tubulo-interstitial disorders/metabolic diseases CE
48036015	[X]Renal tubulo-interstitial disorders/neoplastic diseases CE
354531018	[X]Toxic nephropathy, not elsewhere classified
2694843016	[X]Tubulo-interstit nephritis, not specif as acute or chron
7243014	[X]Unsp nephrit synd, diff endocap prolif glomerulonephritis
303967017	[X]Unsp nephrit synd, diff mesang prolif glomerulonephritis

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
106739010	[X]Unspecif nephr synd, diff concentric glomerulonephritis
43768016	Balkan nephropathy
303973016	Ac neph syn difus endocaplyr proliferative glomerulonephritis
2986715019	History of nephritis
454284017	Hydronephrosis with pelviureteric junction obstruction
454285016	Hydronephrosis with ureteropelvic junction obstruction
303972014	Acute neph syn, diffuse mesangial proliferative glomerulonephritis
303974010	Acute neph syn, diffuse mesangiocapillary glomerulonephritis
303971019	Acute nephritic syn, diffuse membranous glomerulonephritis
303970018	Acute nephritic syndrome, focal+segmental glomerular lesions
303976012	Acute nephrotic syndrome diffuse crescentic glomerulonephritis
2873011015	Acute renal cortical necrosis
2920634011	Acute renal failure
481694011	Acute renal tubular necrosis
293393019	Chronic gouty nephropathy
293395014	Chronic urate nephropathy
477999016	Renal vascular disease
303811012	PGN - Acute proliferative glomerulonephritis
303813010	Acute nephritis with lesions of necrotizing glomerulonephritis
2575722013	Acute glomerulonephritis associated with another disorder
303841014	CNF - Finnish congenital nephrotic syndrome
3013381011	Nephrotic syndrome due to diabetes mellitus
303860019	PGN - Chronic mesangial proliferative glomerulonephritis
2575711014	Chronic glomerulonephritis associated with another disorder
2842506014	Berger IgA or IgG nephropathy
2968772014	Berger's immunoglobulin A or immunoglobulin G nephropathy
3037323018	Nephropathy due to heavy metals
3290279015	Nephropathy caused by heavy metals
2535862011	Nephropathy associated with vesicoureteral reflux
2535863018	RN - Reflux nephropathy
2535864012	Reflux nephropathy
479396010	AGN - Acute glomerulonephritis
47940012	Acute interstitial nephritis
59152019	ATN - Acute tubular necrosis
482017019	Type II renal tubular acidosis
314289012	Medullary cystic disease of the kidney
3036989017	Medullary cystic kidney disease
314292011	Familial juvenile medullary cystic kidney disease
3657945014	Autosomal dominant polycystic kidney disease
303935015	Atrophy of kidney
499033018	Acute nephritic syndrome
505126019	Polycystic kidney disease

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
405115018	Necrotising renal papillitis
509108014	Chronic uraemia
509111010	Chronic renal failure
354332014	Steroid-responsive nephrotic syndrome
354333016	SSNS - Steroid-sensitive nephrotic syndrome
354344012	Wilms' tumor and nephrotic syndrome with pseudohermaphroditism
354353017	RPGN - Rapidly progressive glomerulonephritis
354362015	Idiopathic crescentic glomerulonephritis
3029375014	Proliferative crescentic glomerulonephritis
354378018	IgAN - IgA nephropathy
2881692013	IgA glomerulonephritis
2969517019	Immunoglobulin A nephropathy
354398011	Thin basement membrane nephropathy
3293130015	Chronic interstitial nephritis caused by heavy metals
2817685018	Henoch-Schönlein nephritis
354517018	Cryoglobulinemic glomerulonephritis
354545012	Renal disorders in inherited disease
354620015	Chronic allograft nephropathy
354622011	Mild chronic transplant nephropathy
354625013	Moderate chronic transplant nephropathy
354626014	Severe chronic transplant nephropathy
354637010	CMV - Cytomegalovirus-induced glomerulonephritis
115874017	Hydroureter
526441000000118	Did not attend chronic kidney disease monitoring clinic
2965903012	Foetal or neonatal effect of maternal renal or urinary disease
303861015	Chron neph syn difus mesangial prolifrtiv glomerulonephritis
304009014	Chron neph syn difuse endocap prolifrativ glomerulonephritis
1234074010	Chron nephritic syndrom difuse membranous glomerulonephritis
303865012	Chronic glomerulonephritis + diseases EC
133282018	Chronic membranoproliferative glomerulonephritis
128137019	Chronic membranous glomerulonephritis
304010016	Chronic neph syn difus mesangiocapillary glomerulonephritis
304012012	Chronic nephritic syn diffuse crescentic glomerulonephritis
304006019	Chronic nephritic syndrm focal+segmental glomerular lesions
303862010	Chronic proliferative glomerulonephritis
2986603012	History of renal disease
2986680013	History of kidney disease
2990386017	Chronic kidney disease stage 3A
2990361014	Chronic kidney disease stage 3B
505127011	Congenital cystic renal disease
595541000000119	Chronic kidney disease stage 1 with proteinuria
595601000000118	Chronic kidney disease stage 1 without proteinuria

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
595661000000119	Chronic kidney disease stage 2 with proteinuria
595721000000116	Chronic kidney disease stage 2 without proteinuria
595811000000117	Chronic kidney disease stage 3 with proteinuria
595871000000110	Chronic kidney disease stage 3 without proteinuria
595931000000116	Chronic kidney disease stage 3A with proteinuria
595991000000115	Chronic kidney disease stage 3A without proteinuria
596051000000115	Chronic kidney disease stage 3B with proteinuria
596131000000114	Chronic kidney disease stage 3B without proteinuria
596191000000110	Chronic kidney disease stage 4 with proteinuria
596261000000111	Chronic kidney disease stage 4 without proteinuria
596321000000110	Chronic kidney disease stage 5 with proteinuria
596401000000111	Chronic kidney disease stage 5 without proteinuria
61575019	Renal dwarfism
61863019	Shunt nephritis
487930011	Puumala virus nephropathy
304049018	Drug/heavy-metal-induced tubulo-interstitial and tub conditn
76995019	End stage renal failure
76996018	End-stage renal disease
64282015	Hypertensive renal disease
477998012	Vascular disorders of kidney
1778791010	Hereditary nephritis
1786827012	GN - Hereditary glomerulonephritis
1786828019	Hereditary glomerulonephritis
1786829010	Familial glomerulonephritis in Alport's syndrome
66749015	Hydroureteronephrosis
303835019	Nephrotic syn difus mesangial proliferativ glomerulonephritis
303837010	Nephrotic syn,diffuse mesangiocapillary glomerulonephritis
303836018	Nephrotic syn,difus endocapillary proliftrv glomerulonephritis
114310015	Nephrotic syndrome in systemic lupus erythematosus
303827017	Nephrotic syndrome+membranoproliferative glomerulonephritis
304004016	Nephritis - chronic
87940013	Nephritis and nephropathy unspecified
87940013	Nephritis unsp+membranoprolif glomerulonephritis lesion NOS
87940013	Nephritis unsp+OS membranoprolif glomerulonephritis lesion
150322011	Nephropathy - chronic
150315015	Nephropathy induced by other drugs meds and biologl substncs
354531018	Nephropathy induced by unspec drug medicament or biol subs
2623051017	Kidney disorder associated with type 2 diabetes mellitus
2623057018	Kidney disorder associated with type 1 diabetes mellitus
304022018	Isol proteinur specfd morph lesion df crescentic glomneph
303840010	Microcystic type congenital nephrotic syndrome
304021013	Isolatd proteinur spcfd morph lesion dense deposit diseas

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
2694182017	Tubulo-interstitial nephritis
303840010	Finnish nephrosis syndrome
304014013	Isolatd proteinur specfd morphlgcl lesion min glom abnrm
304017018	Isolatd proteinur/specfd morphlgcl les df membrn glomneph
404234016	Mechanical failure of apparatus during kidney dialysis
304016010	Isolatd proteinur/specifd morphlgcl les foc+seg glom lesn
71850014	Hydronephrosis
494005015	Uraemia NOS
303967017	Isolated proteinuria, with oth specif morpholog changes
891551000000118	Isolated proteinuria, with unspecified morpholog changes
304019015	Isolt prteinur/spcfd morph les df endocap prolif glomneph
304018011	Isoldt prteinur/spcfd morph lesn df mesngl prolf glomneph
3491803016	Lightwood - Albright syndrome
304020014	Isoldt prteinur+specfd morph les df mesangiocap glomneph
74720014	Lipoid nephrosis
2995590017	HANAC - hereditary angiopathy with nephropathy, aneurysms, and muscle cramps
2995072011	Hereditary angiopathy with nephropathy, aneurysms, and muscle cramps syndrome
60355017	Focal glomerulon + focal recurr macroscop glomerulonephritis
3037959015	CKD - chronic kidney disease
3038200016	Chronic renal disease
3044790019	Nephropathy due to ischaemia
3044841012	Nephropathy due to ischemia
3082908010	Ischemic nephropathy
301016	Insulin dependent diabetes mellitus with nephropathy
3300525013	Recurrent hematuria co-occurrent and due to diffuse crescentic glomerulonephritis
3300531011	Recurrent hematuria co-occurrent and due to diffuse endocapillary proliferative glomerulonephritis
3300537010	Recurrent hematuria co-occurrent and due to diffuse mesangiocapillary glomerulonephritis
3300543012	Recurrent hematuria co-occurrent and due to diffuse membranous glomerulonephritis
3300555018	Recurrent hematuria co-occurrent and due to diffuse mesangial proliferative glomerulonephritis
891521000000111	Unspecified nephritic syndrome, dense deposit disease
304037019	Glom disordr in blood diseas+disordr invlvg imun mechansm
1677051000000115	CKD (chronic kidney disease stage) 1 with proteinuria
1677041000000118	CKD (chronic kidney disease) stage 1 without proteinuria
1677031000000110	CKD (chronic kidney disease) stage 2 with proteinuria
1676881000000118	CKD (chronic kidney disease) stage 2 without proteinuria

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
1676871000000115	CKD (chronic kidney disease) stage 3 with proteinuria
1676861000000110	CKD (chronic kidney disease) stage 3 without proteinuria
1692921000000118	CKD (chronic kidney disease) stage 3A with proteinuria
1692931000000116	CKD (chronic kidney disease) stage 3A without proteinuria
1692941000000113	CKD (chronic kidney disease) stage 3B with proteinuria
1692951000000111	CKD (chronic kidney disease) stage 3B without proteinuria
1693001000000116	CKD (chronic kidney disease) stage 4 with proteinuria
1693051000000115	CKD (chronic kidney disease) stage 4 without proteinuria
1693061000000117	CKD (chronic kidney disease) stage 5 with proteinuria
1692911000000112	CKD (chronic kidney disease) stage 5 without proteinuria
411547015	H/O: renal disease
7243014	Unsp nephrit synd, diff endocap prolif glomerulonephritis
303967017	Unsp nephrit synd, diff mesang prolif glomerulonephritis
81307015	Congenital nephrotic syndrome
106739010	Unspecif nephr synd, diff concentric glomerulonephritis
354545012	Hereditary nephropathy NEC, minor glomerular abnormality
354545012	Hereditary nephropathy NEC,focal+segmnt glomerular lesion
354545012	Hereditary nephropathy, NEC, dense deposit disease
303967017	Hereditary nephropathy, unspecif morphological changes
354545012	Hereditary nephropathy,NEC,difus crescentic glomnephritis
354545012	Hereditry nephropathy NEC,difus membran glomerulnephritis
354545012	Hereditry nephropthy NEC difus endocapil prolif glomnephrit
354545012	Hereditry nephropthy NEC difus mesangial prolif glomnephrit
1569771000000117	Chronic kidney disease monitoring verbal invitation
1570051000000110	Chronic kidney disease monitoring telephone invitation
8294801000006111	Estimated glomerular filtration rate using Chronic Kidney Disease Epidemiology Collaboration formula
2221401000000117	eGFR (estimated glomerular filtration rate) using CKD-Epi (Chronic Kidney Disease Epidemiology Collaboration) formula
71850014	Hydronephrosis with ureteral stricture NEC
2694843016	Tubulo-interstit nephritis, not specif as acute or chron
2426361000000116	Chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A1
2426411000000110	Chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A2
2426541000000110	Chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A3
2426671000000115	Chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A1
2426801000000110	Chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A2

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
2426851000000111	Chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A3
2427351000000116	Chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A1
2427431000000116	Chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A2
2427481000000117	Chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A3
2427781000000111	Chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A1
2427831000000118	Chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A2
2427881000000119	Chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A3
2428071000000110	Chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A1
2428121000000110	Chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A2
2428171000000114	Chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A3
2428261000000114	Chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A1
2428311000000119	Chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A2
2428361000000117	Chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A3
2623054013	Type 1 diabetes mellitus with nephropathy
3035432019	Type 2 diabetes mellitus with nephropathy
2623054013	Type I diabetes mellitus with nephropathy
3013392012	Type II diabetes mellitus with nephropathy
86957016	Nephrotic syndrome
881481000006117	Diabetes + nephropathy
886611000006116	Nephritis/nephrosis/neph syndr
886621000006112	Nephritis NOS
886631000006110	Renal failure NOS
886641000006117	Other kidney/urinary diseases
886681000006111	Kidney/ureter disorder NOS
886721000006116	Renal disease NOS
886871000006112	Kidney/urinary disease NOS
893231000006117	Cystic kidney disease
91216016	Hypokalaemic nephropathy
301016	Insulin dependent diabetes mellitus with nephropathy

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
2623054013	Type 1 diabetes mellitus with nephropathy
2623054013	Type I diabetes mellitus with nephropathy
3035432019	Type 2 diabetes mellitus with nephropathy
3013392012	Type II diabetes mellitus with nephropathy
98667016	Analgesic nephropathy
994391000006115	Chronic kidney disease stage
994401000006118	Chronic kidney disease stage 1
994411000006115	Chronic kidney disease stage 2
994421000006111	Chronic kidney disease stage 3
994431000006114	Chronic kidney disease stage 4
994441000006116	Chronic kidney disease stage 5
1569901000000110	Exception reporting: chronic kidney disease quality indicato
1569441000000118	Except chronic kidney disease qual indic: Patient unsuitable
Stroke	
104563015	Cerebrovascular disease
2842187014	Small vessel cerebrovascular disease
1160471000000111	Stroke 6 month review
118689010	Cerebral thrombosis
11903571000006110	Stroke due to intracerebral haemorrhage
1212072018	Occlusive stroke
3673216015	Intracerebral hemorrhage
3673218019	ICH - intracerebral hemorrhage
1222398015	Cerebral arterial occlusion
345638019	Stroke due to cerebral arterial occlusion
409860011	Stroke due to intracerebral haemorrhage
345637012	Stroke unspecified
2476091017	[V]Personal history of stroke
125470015	Cerebral embolism
2779941000000115	QOF (Quality and Outcomes Framework) stroke and transient ischaemic attack quality indicator-related care invitation
1495311000000117	Cerebral infarction NOS
1501361000000113	Stroke and cerebrovascular accident unspecified
2475363012	Traumatic intracerebral hemorrhage
130375018	Lateral medullary syndrome
1568881000000119	Exception reporting: stroke quality indicators
1569131000000118	Excepted from stroke quality indicators: Patient unsuitable
1568581000000116	Excepted from stroke quality indicators: Informed dissent
300403014	Sequelae of stroke,not specfd as h'morrhage or infarction
300403014	Sequelae/other + unspecified cerebrovascular diseases
1569781000000115	Stroke/transient ischaemic attack monitoring telephone invte
1573101000006112	Cerebral infarction with haemorrhagic transformation

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
158118014	Cerebellar infarction
137901000000116	DNA - Did not attend stroke clinic
300277011	Right sided intracerebral haemorrhage, unspecified
1726581000006116	Central post-stroke pain
2983515011	Stroke/CVA annual review
1747751000000110	Ref multidisciplinary stroke function improvement declined
1809201000006113	At risk of cerebrovascular disease
1855541000006116	Cerebrovascular disease monitoring admin.
1855551000006119	Cerebrovascular disease monitoring in primary care
1855561000006117	Cerebrovascular disease monitoring in secondary care
1855571000006112	Cerebrovascular disease monitoring default
1857051000006118	Cerebrovascular disease management
1863321000006113	Referral by stroke nurse specialist
1992451000006114	VTE risk assessment - acute stroke
1994761000006112	Referral to stroke rehabilitation service
2008521000006110	Referral to community stroke service
2008601000006116	Discharge from community stroke service
2115821000000118	Stroke self-management plan review
2118011000000114	Stroke self-management plan agreed
2983500010	Stroke annual review
2127781000000110	Stroke initial post discharge review
216645017	Stroke risk
2770034014	Infarction - cerebral
2185361000000119	Provision of written information about stroke
1565011000000111	Stroke/transient ischaemic attack monitoring administration
2436731000000112	Old cerebral infarction on imaging
2469365010	Stroke / transient ischaemic attack referral
2474330011	Referral to stroke clinic
2474651019	Infarction of basal ganglia
2474668015	Stroke group member
2476091017	H/O: stroke
2534196010	Stroke/transient ischaemic attack monitoring third letter
2534212018	Stroke/transient ischaemic attack monitoring second letter
2534253014	Stroke/transient ischaemic attack monitoring first letter
2548554013	Haemorrhagic stroke monitoring
264499015	Stroke monitoring
297013012	Cerebral degeneration due to cerebrovascular disease
300276019	External capsule haemorrhage
300277011	Intracerebral haemorrhage, intraventricular
2819959010	Intracerebral haemorrhage NOS
300313017	Cerebral infarction due to embolism of precerebral arteries
300321011	Cerebral infarction due to thrombosis of cerebral arteries

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
300322016	Cerebral infarction due to embolism of cerebral arteries
300362017	Middle cerebral artery syndrome
300363010	Anterior cerebral artery syndrome
300364016	Posterior cerebral artery syndrome
300366019	Cerebellar stroke syndrome
300370010	Left sided CVA
300371014	Right sided CVA
104563015	Other cerebrovascular disease
444905019	Generalised ischaemic cerebrovascular disease NOS
104563015	Other cerebrovascular disease OS
104563015	Other cerebrovascular disease NOS
300403014	Late effects of cerebrovascular disease
300411016	Sequelae of cerebral infarction
104563015	Other specified cerebrovascular disease
104563015	Cerebrovascular disease NOS
2770034014	[X]Other cerebral infarction
104563015	[X]Other specified cerebrovascular diseases
306621000000116	Seen in stroke clinic
66510015	Juvenile myopathy, encephalopathy, lactic acidosis AND stroke
345639010	Infarction - precerebral
158113017	Brainstem infarction NOS
345655015	Pure motor lacunar syndrome
345658018	Pure sensory lacunar syndrome
345675012	Lobar cerebral haemorrhage
499414018	CVD - Cerebrovascular disease
104563015	[X]Cerebrovascular diseases
371641000000112	Delivery of rehabilitation for stroke
2770034014	Cerebral infarction NOS
345637012	Stroke and cerebrovascular accident unspecified
2966556014	Brain stem stroke
104563015	[X]Other cerebrovascular disorders in diseases CE
411416011	Stroke in the puerperium
413750011	Central post-stroke pain
300403014	[X]Sequelae of stroke, not spec'd as h'morrhage or infarction
300403014	[X]Sequelae/other + unspecified cerebrovascular diseases
449935012	Admission to stroke unit
451133011	Left sided cerebral infarction
451134017	Right sided cerebral infarction
451368019	H/O: cerebrovascular disease
451371010	H/O: Stroke in last year
300278018	Intracerebral hemorrhage, intraventricular
2916313015	Intracerebral hemorrhage with intraventricular hemorrhage

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
300279014	Intracerebral hemorrhage, multiple localized
300404015	Sequelae of cerebrovascular disease
300408017	Sequelae of intracerebral hemorrhage
3467313018	Bulbar haemorrhage
495394013	Cortical haemorrhage
496232015	Internal capsule haemorrhage
345636015	Stroke
345652017	Lacunar stroke
502878012	Cerebellar haemorrhage
503469016	Pontine haemorrhage
300272017	Basal nucleus haemorrhage
300365015	Brain stem stroke syndrome
158113017	Brainstem infarction
125470015	Cerebral embolus
2819960017	Intracerebral hemorrhage (ICH)
413749011	CPSP - Central post-stroke pain
130374019	Wallenberg syndrome
449934011	Referral to stroke service
2986639018	History of cerebrovascular disease
2986393012	History of stroke in last year
345638019	CVA - cerebral artery occlusion
409859018	CVA - cerebrovascular accid due to intracerebral haemorrhage
345635016	CVA - Cerebrovascular accident unspecified
345637012	CVA unspecified
2966612019	Basal ganglion stroke
2469839018	Stroke / transient ischemic attack referral
2694676019	Stroke/transient ischemic attack referral
2534252016	Stroke/transient ischemic attack monitoring first letter
2534211013	Stroke/transient ischemic attack monitoring second letter
2534195014	Stroke/transient ischemic attack monitoring third letter
2549606015	Stroke/transient ischemic attack monitoring verbal invitation
2548553019	Hemorrhagic stroke monitoring
2915288012	Traumatic intracerebral hemorrhage
2819959010	Intracerebral haemorrhage
409860011	Intracerebral haemorrhage in hemisphere, unspecified
300280012	Intracerebral haemorrhage, multiple localized
409859018	Left sided intracerebral haemorrhage, unspecified
444905019	Generalised ischaemic cerebrovascular disease NOS
1681231000000118	DNA (did not attend) stroke clinic
2986886017	H/O: CVA/stroke
1550221000000113	Stroke/cerebrovascular accident 6 month review

Appendix D. List of Systemized Nomenclature for Medicine, Clinical Terms (SNOMED-CT) Codes Used to Define Baseline Characteristics in this Request

SNOMED_CT Code	Description
2350741000000110	SCPE (Surveillance of Cerebral Palsy in Europe) predominant pattern classification B.2 - sequelae of intraventricular haemorrhage or periventricular infarction
884501000006113	Cerebral A. occlusion NOS
884521000006115	Stroke/CVA - undefined
884531000006117	Stroke
907581000006119	[RFC] Stroke/CVA
907591000006116	[RFC] Stroke
908801000006114	[RFC] Stroke
940051000006114	Stroke monitoring administration
940061000006111	Stroke monitoring invite 1
940071000006116	Stroke monitoring invite 2
940081000006118	Stroke monitoring invite 3
199461000000113	Ref to multidisciplinary stroke function improvement service
2549607012	Stroke/transient ischaemic attack monitoring verbal invitati
989201000006117	Cerebral haemorrhage
989211000006119	Cerebral haemorrhage NOS

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

Query period: January 1, 2014 - August 25, 2020
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 183 days
Post-index enrollment requirement: 0 days
Enrollment gap: 45 days
Age groups: 18-44, 45-64, 65+ years
Sex groups: Male, Female
Censor output categorization: 1-183, 184-365, 366-730, 731+ days
Stratified output: Age group
Year*month
Year*quarter
Envelope macro: No reclassification
Freeze data: No
Additional programming: Episodes that cross multiple quarters will be counted in each quarter
Notes: Stockpile by custom-defined generic name

Drug/Exposure

	Primary Cohort 1 All ARB Incident Cohort	Primary Cohort 2 Azilsartan	Primary Cohort 3 Candesartan	Primary Cohort 4 Eprosartan	Primary Cohort 5 Irbesartan
Exposure	Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)	Azilsartan	Candesartan	Eprosartan	Irbesartan
Care Setting	N/A	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

Drug/Exposure		Primary Cohort 1	Primary Cohort 2	Primary Cohort 3	Primary Cohort 4	Primary Cohort 5
		All ARB Incident Cohort	Azilsartan	Candesartan	Eprosartan	Irbesartan
	Incident with respect to:	Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)	Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)	Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)	Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)	Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)
	Washout (days)	183 days	183 days	183 days	183 days	183 days
	Cohort Definition	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)
	Exposure Episode Truncation Criteria	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation
	Exposure Episode Gap	30 days	30 days	30 days	30 days	30 days
	Exposure Extension Period	30 days	30 days	30 days	30 days	30 days
	Minimum Episode Duration	1 day	1 day	1 day	1 day	1 day
	Minimum Days Supplied	1 day	1 day	1 day	1 day	1 day
	Intention-to-Treat Days	N/A	N/A	N/A	N/A	N/A
	Prevalent Cohort creation?	Yes	Yes	Yes	Yes	Yes

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Primary Cohort 1	Primary Cohort 2	Primary Cohort 3	Primary Cohort 4	Primary Cohort 5
		All ARB Incident Cohort	Azilsartan	Candesartan	Eprosartan	Irbesartan
Stockpiling	Same Day Dispensing (Days Supplied)	Sum	Sum	Sum	Sum	Sum
	Same Day Dispensing (Amount Supplied)	Sum	Sum	Sum	Sum	Sum
	Range of Allowable Days Supplied	Any	Any	Any	Any	Any
	Range of Allowable Amount Supplied	Any	Any	Any	Any	Any
	Overlap Percentage Processing	33% overlap	33% overlap	33% overlap	33% overlap	33% overlap
Baseline Covariates	Output Baseline Table?	Yes	Yes	Yes	Yes	Yes
	Covariates	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke
	Care Setting/PDX	N/A	N/A	N/A	N/A	N/A
	Covariate evaluation window (days)	(-183, 0)	(-183, 0)	(-183, 0)	(-183, 0)	(-183, 0)

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 1	Multiple Events Group 1	Multiple Events Group 1	Multiple Events Group 1	Multiple Events Group 1
		All ARB Incident Cohort	Azilsartan exposure with candesartan switch	Candesartan exposure with azilsartan switch	Eprosartan exposure with azilsartan switch	Irbesartan exposure with azilsartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 2	Multiple Events Group 2	Multiple Events Group 2	Multiple Events Group 2
		Azilsartan exposure with eprosartan switch	Candesartan exposure with eprosartan switch	Eprosartan exposure with candesartan switch	Irbesartan exposure with candesartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 3	Multiple Events Group 3	Multiple Events Group 3	Multiple Events Group 3
		Azilsartan exposure with irbesartan switch	Candesartan exposure with irbesartan switch	Eprosartan exposure with irbesartan switch	Irbesartan exposure with eprosartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 4	Multiple Events Group 4	Multiple Events Group 4	Multiple Events Group 4
		Azilsartan exposure with losartan switch	Candesartan exposure with losartan switch	Eprosartan exposure with losartan switch	Irbesartan exposure with losartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 5	Multiple Events Group 5	Multiple Events Group 5	Multiple Events Group 5
		Azilsartan exposure with olmesartan switch	Candesartan exposure with olmesartan switch	Eprosartan exposure with olmesartan switch	Irbesartan exposure with olmesartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 6	Multiple Events Group 6	Multiple Events Group 6	Multiple Events Group 6
		Azilsartan exposure with telmisartan switch	Candesartan exposure with telmisartan switch	Eprosartan exposure with telmisartan switch	Irbesartan exposure with telmisartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 7	Multiple Events Group 7	Multiple Events Group 7	Multiple Events Group 7
		Azilsartan exposure with valsartan switch	Candesartan exposure with valsartan switch	Eprosartan exposure with valsartan switch	Irbesartan exposure with valsartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

			Multiple Events Group 8	Multiple Events Group 8	Multiple Events Group 8	Multiple Events Group 8
			Azilsartan exposure with any ARB switch (except azilsartan)	Candesartan exposure with any ARB switch (except candesartan)	Eprosartan exposure with any ARB switch (except eprosartan)	Irbesartan exposure with any ARB switch (except irbesartan)
Multiple Events	Observation window around primary episode		(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics		First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent		N/A	N/A	N/A	N/A
	Categories for length of primary episode		N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 9	Multiple Events Group 9	Multiple Events Group 9	Multiple Events Group 9
		Azilsartan exposure with ACEi or calcium channel blockers (CCB) switch	Candesartan exposure with ACEi or CCB switch	Eprosartan exposure with ACEi or CCB switch	Irbesartan exposure with ACEi or CCB switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 10	Multiple Events Group 10	Multiple Events Group 10	Multiple Events Group 10
		Azilsartan exposure with any ACEi switch	Candesartan exposure with any ACEi switch	Eprosartan exposure with any ACEi switch	Irbesartan exposure with any ACEi switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 11	Multiple Events Group 11	Multiple Events Group 11	Multiple Events Group 11
		Azilsartan exposure with any CCB switch	Candesartan exposure with any CCB switch	Eprosartan exposure with any CCB switch	Irbesartan exposure with any CCB switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 12	Multiple Events Group 12	Multiple Events Group 12	Multiple Events Group 12
		Azilsartan exposure with any ACEi/CCB combination drug switch	Candesartan exposure with any ACEi/CCB combination drug switch	Eprosartan exposure with any ACEi/CCB combination drug switch	Irbesartan exposure with any ACEi/CCB combination drug switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Primary Cohort 6	Primary Cohort 7	Primary Cohort 8	Primary Cohort 9
		Losartan	Olmesartan	Telmisartan	Valsartan
Drug/Exposure	Exposure	Losartan	Olmesartan	Telmisartan	Valsartan
	Care Setting	N/A	N/A	N/A	N/A
	Incident with respect to:	Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)	Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)	Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)	Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)
	Washout (days)	183 days	183 days	183 days	183 days
	Cohort Definition	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)
	Exposure Episode Truncation Criteria	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation
	Exposure Episode Gap	30 days	30 days	30 days	30 days
	Exposure Extension Period	30 days	30 days	30 days	30 days
	Minimum Episode Duration	1 day	1 day	1 day	1 day
	Minimum Days Supplied	1 day	1 day	1 day	1 day
	Intention-to-Treat Days	N/A	N/A	N/A	N/A
	Prevalent Cohort creation?	Yes	Yes	Yes	Yes

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Primary Cohort 6	Primary Cohort 7	Primary Cohort 8	Primary Cohort 9
		Losartan	Olmesartan	Telmisartan	Valsartan
Stockpiling	Same Day Dispensing (Days Supplied)	Sum	Sum	Sum	Sum
	Same Day Dispensing (Amount Supplied)	Sum	Sum	Sum	Sum
	Range of Allowable Days Supplied	Any	Any	Any	Any
	Range of Allowable Amount Supplied	Any	Any	Any	Any
	Overlap Percentage Processing	33% overlap	33% overlap	33% overlap	33% overlap
Baseline Covariates	Output Baseline Table?	Yes	Yes	Yes	Yes
	Covariates	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke
	Care Setting/PDX	N/A	N/A	N/A	N/A
	Covariate evaluation window (days)	(-183, 0)	(-183, 0)	(-183, 0)	(-183, 0)

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 1	Multiple Events Group 1	Multiple Events Group 1	Multiple Events Group 1
		Losartan exposure with azilsartan switch	Olmesartan exposure with azilsartan switch	Telmisartan exposure with azilsartan switch	Valsartan exposure with azilsartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 2	Multiple Events Group 2	Multiple Events Group 2	Multiple Events Group 2
		Losartan exposure with candesartan switch	Olmesartan exposure with candesartan switch	Telmisartan exposure with candesartan switch	Valsartan exposure with candesartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 3	Multiple Events Group 3	Multiple Events Group 3	Multiple Events Group 3
		Losartan exposure with eprosartan switch	Olmесartan exposure with eprosartan switch	Telmisartan exposure with eprosartan switch	Valsartan exposure with eprosartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 4	Multiple Events Group 4	Multiple Events Group 4	Multiple Events Group 4
		Losartan exposure with irbesartan switch	Olmесartan exposure with irbesartan switch	Telmisartan exposure with irbesartan switch	Valsartan exposure with irbesartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 5	Multiple Events Group 5	Multiple Events Group 5	Multiple Events Group 5
		Losartan exposure with olmesartan switch	Olmesartan exposure with losartan switch	Telmisartan exposure with losartan switch	Valsartan exposure with losartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 6	Multiple Events Group 6	Multiple Events Group 6	Multiple Events Group 6
		Losartan exposure with telmisartan switch	Olmesartan exposure with telmisartan switch	Telmisartan exposure with olmesartan switch	Valsartan exposure with olmesartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 7	Multiple Events Group 7	Multiple Events Group 7	Multiple Events Group 7
		Losartan exposure with valsartan switch	Olmesartan exposure with valsartan switch	Telmisartan exposure with valsartan switch	Valsartan exposure with telmisartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 8	Multiple Events Group 8	Multiple Events Group 8	Multiple Events Group 8
		Losartan exposure with any ARB switch (except losartan)	Olmесartan exposure with any ARB switch (except olmesartan)	Telmisartan exposure with any ARB switch (except telmisartan)	Valsartan exposure with any ARB switch (except valsartan)
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 9	Multiple Events Group 9	Multiple Events Group 9	Multiple Events Group 9
		Losartan exposure with ACEi or CCB switch	Olmesartan exposure with ACEi or CCB switch	Telmisartan exposure with ACEi or CCB switch	Valsartan exposure with ACEi or CCB switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 10	Multiple Events Group 10	Multiple Events Group 10	Multiple Events Group 10
		Losartan exposure with any ACEi switch	Olmesartan exposure with any ACEi switch	Telmisartan exposure with any ACEi switch	Valsartan exposure with any ACEi switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 11	Multiple Events Group 11	Multiple Events Group 11	Multiple Events Group 11
		Losartan exposure with any CCB switch	Olmесartan exposure with any CCB switch	Telmisartan exposure with any CCB switch	Valsartan exposure with any CCB switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

Multiple Events		Multiple Events Group 12	Multiple Events Group 12	Multiple Events Group 12	Multiple Events Group 12
		Losartan exposure with any ACEi/CCB combination drug switch	Olmesartan exposure with any ACEi/CCB combination drug switch	Telmisartan exposure with any ACEi/CCB combination drug switch	Valsartan exposure with any ACEi/CCB combination drug switch
		Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
		Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
		Minimum cutoff to be considered adherent	N/A	N/A	N/A
		Categories for length of primary episode	N/A	N/A	N/A

Appendix F. Specifications Defining Parameters for this Request (Cohorts used to Define Switches)

		Secondary Cohort 1	Secondary Cohort 2	Secondary Cohort 3	Secondary Cohort 4
		Azilsartan	Candesartan	Eprosartan	Irbesartan
Drug/Exposure	Exposure	Azilsartan (forced days supply of 1 day)	Candesartan (forced days supply of 1 day)	Eprosartan (forced days supply of 1 day)	Irbesartan (forced days supply of 1 day)
	Care Setting	N/A	N/A	N/A	N/A
	Incident with respect to:	N/A	N/A	N/A	N/A
	Washout (days)	N/A	N/A	N/A	N/A
	Cohort Definition	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)
	Exposure Episode Truncation Criteria	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation
	Exposure Episode Gap	0 days	0 days	0 days	0 days
	Exposure Extension Period	0 days	0 days	0 days	0 days
	Minimum Episode Duration	1 day	1 day	1 day	1 day
	Minimum Days Supplied	1 day	1 day	1 day	1 day
	Intention-to-Treat Days	N/A	N/A	N/A	N/A
	Prevalent Cohort creation?	No	No	No	No

Appendix F. Specifications Defining Parameters for this Request (Cohorts used to Define Switches)

		Secondary Cohort 1	Secondary Cohort 2	Secondary Cohort 3	Secondary Cohort 4
		Azilsartan	Candesartan	Eprosartan	Irbesartan
Stockpiling	Same Day Dispensing (Days Supplied)	Sum	Sum	Sum	Sum
	Same Day Dispensing (Amount Supplied)	Sum	Sum	Sum	Sum
	Range of Allowable Days Supplied	Any	Any	Any	Any
	Range of Allowable Amount Supplied	Any	Any	Any	Any
	Overlap Percentage Processing	33% overlap	33% overlap	33% overlap	33% overlap
Baseline Covariates	Output Baseline Table?	No	No	No	No
	Covariates	N/A	N/A	N/A	N/A
	Care Setting/PDX	N/A	N/A	N/A	N/A
	Covariate evaluation window (days)	N/A	N/A	N/A	N/A

Drug/Exposure

Appendix F. Specifications Defining Parameters for this Request (Cohorts used to Define Switches) (Continued)

		Secondary Cohort 5	Secondary Cohort 6	Secondary Cohort 7	Secondary Cohort 8
		Losartan	Olmesartan	Telmisartan	Valsartan
Stockpiling	Same Day Dispensing (Days Supplied)	Sum	Sum	Sum	Sum
	Same Day Dispensing (Amount Supplied)	Sum	Sum	Sum	Sum
	Range of Allowable Days Supplied	Any	Any	Any	Any
	Range of Allowable Amount Supplied	Any	Any	Any	Any
	Overlap Percentage Processing	33% overlap	33% overlap	33% overlap	33% overlap
Baseline Covariates	Output Baseline Table?	No	No	No	No
	Covariates	N/A	N/A	N/A	N/A
	Care Setting/PDX	N/A	N/A	N/A	N/A
	Covariate evaluation window (days)	N/A	N/A	N/A	N/A

Appendix F. Specifications Defining Parameters for this Request (Cohorts used to Define Switches) (Continued)

Drug/Exposure		Secondary Cohort 9	Secondary Cohort 10	Secondary Cohort 11
		ACE inhibitors	CCB	Combinations
	Exposure	Angiotensin-converting-enzyme inhibitors (ACEi) (forced days supply of 1 day)	Calcium channel blockers (CCB) (forced days supply of 1 day)	ACEi/CCB combination drugs (forced days supply of 1 day)
	Care Setting	N/A	N/A	N/A
	Incident with respect to:	N/A	N/A	N/A
	Washout (days)	N/A	N/A	N/A
	Cohort Definition	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)
	Exposure Episode Truncation Criteria	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation
	Exposure Episode Gap	0 days	0 days	0 days
	Exposure Extension Period	0 days	0 days	0 days
	Minimum Episode Duration	1 day	1 day	1 day
	Minimum Days Supplied	1 day	1 day	1 day
	Intention-to-Treat Days	N/A	N/A	N/A
Prevalent Cohort creation?	No	No	No	

Appendix F. Specifications Defining Parameters for this Request (Cohorts used to Define Switches) (Continued)

Stockpiling	Same Day Dispensing (Days Supplied)	Sum	Sum	Sum
	Same Day Dispensing (Amount Supplied)	Sum	Sum	Sum
	Range of Allowable Days Supplied	Any	Any	Any
	Range of Allowable Amount Supplied	Any	Any	Any
	Overlap Percentage Processing	33% overlap	33% overlap	33% overlap
Baseline Covariates	Output Baseline Table?	No	No	No
	Covariates	N/A	N/A	N/A
	Care Setting/PDX	N/A	N/A	N/A
	Covariate evaluation window (days)	N/A	N/A	N/A